U.S. patent application number 17/118204 was filed with the patent office on 2021-06-03 for novel cryptophycin compounds and conjugates, their preparation and their therapeutic use.
The applicant listed for this patent is SANOFI. Invention is credited to Antony BIGOT, Herve BOUCHARD, Marie-Priscille BRUN, Francois CLERC, Jidong ZHANG.
Application Number | 20210163458 17/118204 |
Document ID | / |
Family ID | 1000005387636 |
Filed Date | 2021-06-03 |
United States Patent
Application |
20210163458 |
Kind Code |
A1 |
BIGOT; Antony ; et
al. |
June 3, 2021 |
NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATES, THEIR PREPARATION AND
THEIR THERAPEUTIC USE
Abstract
The present invention relates to cryptophycin compounds of
formula (I): ##STR00001## The invention also relates to
cryptophycin payloads, to cryptophycin conjugates, to compositions
containing them and to their therapeutic use, especially as
anticancer agents. The invention also relates to the process for
preparing these conjugates.
Inventors: |
BIGOT; Antony; (Paris,
FR) ; BOUCHARD; Herve; (Paris, FR) ; BRUN;
Marie-Priscille; (Paris, FR) ; CLERC; Francois;
(Paris, FR) ; ZHANG; Jidong; (Paris, FR) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
SANOFI |
Paris |
|
FR |
|
|
Family ID: |
1000005387636 |
Appl. No.: |
17/118204 |
Filed: |
December 10, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15768792 |
Apr 16, 2018 |
10941139 |
|
|
PCT/EP2016/076603 |
Nov 3, 2016 |
|
|
|
17118204 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 35/00 20180101;
C07D 413/06 20130101; C07D 413/14 20130101 |
International
Class: |
C07D 413/06 20060101
C07D413/06; A61P 35/00 20060101 A61P035/00; C07D 413/14 20060101
C07D413/14 |
Foreign Application Data
Date |
Code |
Application Number |
Nov 5, 2015 |
EP |
15306751.7 |
Claims
1. A Cryptophycin compound of formula (I): ##STR00759## wherein:
R.sub.1 represents a (C.sub.1-C.sub.6)alkyl group; R.sub.2 and
R.sub.3 represent, independently of each other, a hydrogen atom or
a (C.sub.1-C.sub.6)alkyl group, or alternatively R.sub.2 and
R.sub.3 form together with the carbon atom to which they are
attached a (C.sub.3-C.sub.6)cycloalkyl or a
(C.sub.3-C.sub.6)heterocycloalkyl group; R.sub.4 and R.sub.5
represent, independently of each other, a hydrogen atom or a
(C.sub.1-C.sub.6)alkyl group or a
(C.sub.1-C.sub.6)alkyl-NH(R.sub.2) group or a
(C.sub.1-C.sub.6)alkyl-OH group or a (C.sub.1-C.sub.6)alkyl-SH
group or a (C.sub.1-C.sub.6)alkyl-CO.sub.2H group, or alternatively
R.sub.4 and R.sub.5 form together with the carbon atom to which
they are attached a (C.sub.3-C.sub.6)cycloalkyl or a
(C.sub.3-C.sub.6)heterocycloalkyl group; R.sub.6 represents a
hydrogen atom or a (C.sub.1-C.sub.6)alkyl group; R.sub.7 and
R.sub.8 represent, independently of each other, a hydrogen atom or
a (C.sub.1-C.sub.6)alkyl group or a
(C.sub.1-C.sub.6)alkyl-CO.sub.2H group or a
(C.sub.1-C.sub.6)alkyl-N(C.sub.1-C.sub.6)alkyl.sub.2 group or
alternatively R.sub.7 and R.sub.8 form together with the carbon
atom to which they are attached a (C.sub.3-C.sub.6)cycloalkyl group
or a (C.sub.3-C.sub.6)heterocycloalkyl group; R.sub.9 represents
one or more substituents of the phenyl nucleus chosen,
independently of each other, from: a hydrogen atom, --OH,
(C.sub.1-C.sub.4)alkoxy, a halogen atom, --NH.sub.2,
--NH(C.sub.1-C.sub.6)alkyl or --N(C.sub.1-C.sub.6)alkyl.sub.2 or
--NH(C.sub.1-C.sub.6)cycloalkyl or
(C.sub.3-C.sub.6)heterocycloalkyl; R.sub.10 represents at least one
substituent of the phenyl nucleus chosen from a hydrogen atom and
(C.sub.1-C.sub.4)alkyl; W represents
(C.sub.1-C.sub.6)alkyl-NH(R.sub.11), (C.sub.1-C.sub.6)alkyl-OH,
(C.sub.1-C.sub.6)alkyl-SH, CO.sub.2H or C(.dbd.O)NH.sub.2,
(C.sub.1-C.sub.6)alkyl-CO.sub.2H or
(C.sub.1-C.sub.6)alkyl-C(.dbd.O)NH.sub.2, or
(C.sub.1-C.sub.6)alkyl-N.sub.3; and R.sub.11 and R.sub.12
represent, independently of each other, a hydrogen atom or a
(C.sub.1-C.sub.6)alkyl group.
2-3. (canceled)
4. The Cryptophycin compound of formula (I) according to claim 1,
wherein: each of R.sub.2 and R.sub.3 represents a hydrogen atom, or
one of R.sub.2 and R.sub.3 represents a methyl group and the other
one represents a hydrogen atom, or R.sub.2 and R.sub.3 form
together with the carbon atom to which they are attached a
cyclopropyl group.
5-6. (canceled)
7. The Cryptophycin compound of formula (I) according to claim 1,
wherein each of R.sub.4 and R.sub.5 represents a methyl group.
8. (canceled)
9. The Cryptophycin compound of formula (I) according to claim 1,
wherein R.sub.7 and R.sub.8 represent, independently of each other,
a hydrogen atom or a (C.sub.1-C.sub.6)alkyl group.
10. The Cryptophycin compound of formula (I) according to claim 1,
wherein R.sub.9 represents two substituents selected from a methoxy
group and a chlorine atom.
11-13. (canceled)
14. The Cryptophycin compound of formula (I) according to claim 1,
wherein W is selected from (C.sub.1-C.sub.6)alkyl-NHR.sub.11,
(C.sub.1-C.sub.6)alkyl-OH, (C.sub.1-C.sub.6)alkyl-SH and
(C.sub.1-C.sub.6)alkyl-CO.sub.2H.
15. The Cryptophycin compound of formula (I) according to claim 1,
wherein W represents a CH.sub.2--NH.sub.2 or a CH.sub.2--OH
group.
16. (canceled)
17. A Cryptophycin payload of formula (II): ##STR00760## wherein
R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7,
R.sub.8, R.sub.9 and R.sub.10 are as defined in claim 1; Y is
selected from (C.sub.1-C.sub.6)alkyl-NR.sub.11,
(C.sub.1-C.sub.6)alkyl-O, (C.sub.1-C.sub.6)alkyl-S, C(.dbd.O)O,
C(.dbd.O)NH, (C.sub.1-C.sub.6)alkyl-C(.dbd.O)O,
(C.sub.1-C.sub.6)alkyl-C(.dbd.O)NH or
(C.sub.1-C.sub.6)alkyl-triazole group; R.sub.1 represents a
hydrogen atom or a (C.sub.1-C.sub.6)alkyl group; L represents a
linker; and RCG.sub.1 represents a reactive chemical group present
at the end of the linker.
18. (canceled)
19. The Cryptophycin payload of formula (II) according to claim 17,
wherein Y represents (C.sub.1-C.sub.6)alkyl-NR.sub.11.
20. (canceled)
21. The Cryptophycin payload of formula (II) according to claim 17,
wherein L is of formula (IV): ##STR00761## wherein: L1 represents a
single bond or a
NR.sub.16(hetero)aryl-CR.sub.15R.sub.14--O--C(.dbd.O) group if
Y.dbd.(C.sub.1-C.sub.6)alkyl-N(R.sub.11), or L1 represents a
NR.sub.18--(C.sub.2-C.sub.6)alkyl-NR.sub.17--C(.dbd.O) group or a
NR.sub.16(hetero)aryl-CR.sub.15R.sub.14--O--C(.dbd.O)--NR.sub.18--(C.sub.-
2-C.sub.6)alkyl-NR.sub.17--C(.dbd.O) group if Y is
(C.sub.1-C.sub.6)alkyl-O or (C.sub.1-C.sub.6)alkyl-S, or L1
represents a NR.sub.16(hetero)aryl-CR.sub.15R.sub.14-- group if Y
is C(.dbd.O)O, C(.dbd.O)NH, (C.sub.1-C.sub.6)alkyl-C(.dbd.O)O or
(C.sub.1-C.sub.6)alkyl-C(.dbd.O)NH; R.sub.11, R.sub.14, R.sub.15,
R.sub.16, R.sub.17 and R.sub.18 each represent, independently of
each other, a hydrogen atom or a (C.sub.1-C.sub.6)alkyl group;
(AA).sub.w represents a sequence of w amino acids AA connected
together via peptide bonds; w represents an integer ranging from 1
to 12; L2 represents a single bond, a (C.sub.1-C.sub.6)alkyl group,
a (C.sub.1-C.sub.6)alkyl-(OCH.sub.2CH.sub.2).sub.i group, a
(C.sub.1-C.sub.6)alkyl-(OCH.sub.2CH.sub.2).sub.i--O(C.sub.1-C.sub.6)alkyl
group, a (CH.sub.2CH.sub.2O).sub.i(C.sub.1-C.sub.6)alkyl group, a
CH(SO.sub.3H)--(C.sub.1-C.sub.6)alkyl group, a
(C.sub.1-C.sub.6)alkyl-CH(SO.sub.3H) group, a
(C.sub.1-C.sub.6)alkyl-cyclohexyl group, a
NR.sub.19--(C.sub.1-C.sub.6)alkyl group, a
NR.sub.20--(CH.sub.2CH.sub.2O).sub.i(C.sub.1-C.sub.6)alkyl group, a
NR.sub.21-aryl group, a NR.sub.21-heteroaryl group, a
(C.sub.1-C.sub.6)alkyl-NR.sub.22C(.dbd.O)--(C.sub.1-C.sub.6)alkyl
group or a
(C.sub.1-C.sub.6)alkyl-NR.sub.22C(.dbd.O)--(C.sub.1-C.sub.6)alkyl-(O-
CH.sub.2CH.sub.2).sub.i group; R.sub.9, R.sub.20, R.sub.21 and
R.sub.22 each represent, independently of each other, a hydrogen
atom or a (C.sub.1-C.sub.6)alkyl group; i represents an integer
between 1 and 50; and AA denotes a natural or unnatural amino acid,
of configuration D or L, selected from: alanine (Ala),
.beta.-alanine, .gamma.-aminobutyric acid,
2-amino-2-cyclohexylacetic acid, 2-amino-2-phenylacetic acid,
arginine (Arg), asparagine (Asn), aspartic acid (Asp), citrulline
(Cit), cysteine (Cys),
.alpha.,.alpha.-dimethyl-.gamma.-aminobutyric acid,
.beta.,.beta.-dimethyl-.gamma.-aminobutyric acid, glutamine (Gln),
glutamic acid (Glu), glycine (Gly), histidine (His), isoleucine
(Ile), leucine (Leu), lysine (Lys), .epsilon.-acetyl-lysine
(AcLys), methionine (Met), ornithine (Orn), phenylalanine (Phe),
proline (Pro), serine (Ser), threonine (Thr), tryptophan (Trp),
tyrosine (Tyr), valine (Val).
22. The Cryptophycin payload of formula (II) according to claim 21,
wherein the sequence (AA).sub.w has the formula: ##STR00762## in
which R.sub.23 represents the side chain of AA.
23-24. (canceled)
25. The Cryptophycin payload of formula (II) according to claim 21,
wherein L2 represents a (C.sub.1-C.sub.6)alkyl group or a
(C.sub.1-C.sub.6)alkyl-(OCH.sub.2CH.sub.2).sub.i group or a
CH(SO.sub.3H)--(C.sub.1-C.sub.6)alkyl group.
26. (canceled)
27. A Conjugate of formula (III): ##STR00763## wherein R.sub.1,
R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8,
R.sub.9 and R.sub.10 are as defined in claim 1; Y is selected from
(C.sub.1-C.sub.6)alkyl-NR.sub.11, (C.sub.1-C.sub.6)alkyl-O,
(C.sub.1-C.sub.6)alkyl-S, C(.dbd.O)O, C(.dbd.O)NH,
(C.sub.1-C.sub.6)alkyl-C(.dbd.O)O,
(C.sub.1-C.sub.6)alkyl-C(.dbd.O)NH or
(C.sub.1-C.sub.6)alkyl-triazole group; L represents a linker G
represents the product of reaction between RCG1, a reactive group
present at the end of the linker and RCG2, an orthogonal reactive
group present on Ab; and Ab represents an antibody.
28. (canceled)
29. The Conjugate of formula (III) according to claim 27, wherein
RCG2 is selected from: .epsilon.-amino groups of lysines borne by
the side chains of the lysine residues that are present at the
surface of an antibody, .alpha.-amino groups of N-terminal amino
acids of antibody heavy and light chains, saccharide groups of the
hinge region, thiols of cysteines generated by reducing intra-chain
disulfide bonds or the thiols of engineered cysteines amide groups
borne by the side chains of some glutamine residues that are
present at the surface of an antibody, or aldehyde groups
introduced using formylglycine generating enzyme.
30-31. (canceled)
32. A Process for preparing the cryptophycin compound of formula
(I) comprising the step: ##STR00764## wherein: Step (i) is a
peptidic coupling between fragments AD3 and alternative BC in the
presence of coupling reagents; Step (ii) is a macrocyclization by
ring closing metathesis in the presence of a catalyst; Step (iii)
is a deprotection of the p-methoxybenzyl ether in acidic
conditions; Step (iv) is an oxidation of the alcohol using an
oxidizing agent; Step (v) is an introduction of the epoxide by
asymmetric Corey-Chaykovsky reaction using appropriately
substituted isothiocineole-derived chiral sulfonium in the presence
of a base; and Step (vi) is a reduction of the azido group.
33. The Process for preparing a conjugate of formula (III)
comprising the steps of: (i) placing in contact and leaving to
react: an optionally buffered aqueous solution of an antibody,
optionally modified by means of a odifying agent, and a solution of
a cryptophycin payload of formula (II) as defined in claim 17,
wherein the chemical group RCG1 of the cryptophycin payload of
formula (II) is reactive towards the chemical group RCG2 present on
the antibody especially towards the amino groups present on
antibodies, the said chemical groups RCG2 having been introduced,
where appropriate, by the modifying agent, so as to attach the
cryptophycin payload of formula (II) to the antibody by formation
of a covalent bond; and (ii) optionally separating the conjugate
formed in step (i) from the cryptophycin payload of formula (II)
and/or from the unreacted antibody and/or from any aggregates that
may have formed.
34. A medicament, wherein the medicament comprises a conjugate of
formula (III).
35. A pharmaceutical composition, wherein the composition comprises
a conjugate of formula (III) and a pharmaceutically acceptable
excipient.
36-37. (canceled)
38. A method of treating cancer in a patient in need thereof,
comprising ad mistering a therapeutically effect amount of a
compound of formula (I).
39. A method of treating cancer in a patient in need thereof,
comprising administering a therapeutically effect amount of a
compound of formula (III).
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 15/768,792, filed Apr. 16, 2018, which is a 35
U.S.C. .sctn. 371 filing of International Patent Application No.
PCT/EP2016/076603, filed Nov. 3, 2016, which claims priority to
European Patent Application No. 15306751.7, filed Nov. 5, 2015, the
entire contents of which are incorporated herein by reference.
[0002] The present invention relates to new cryptophycin compounds,
to new cryptophycin payloads, to new cryptophycin conjugates, to
compositions containing them and to their therapeutic use,
especially as anticancer agents. The invention also relates to the
process for preparing these conjugates.
[0003] Cryptophycins are secondary metabolites belonging to the
class of depsipeptide macrocycles produced by cyanobacteria of the
genus Nostoc. The first representative of this class of molecules,
cryptophycin-1 (C-1), was isolated in 1990 from cyanobacterium
Nostoc sp (ATCC 53789; see Ei ler S., et al., Synthesis 2006, 22,
3747-3789). Cryptophycins C-1 and C-52, which are characterized by
an epoxide function, were discovered to have in vitro and in vivo
antitumor activity in the early 1990s. The chlorohydrins of these,
C-8 and C-55, were markedly more active but could not be formulated
as stable solutions (Bionpally R. R., et al., Cancer Chemother
Pharmacol 2003, 52, 25-33). Their higher activity was correlated by
their putative ability to generate the corresponding epoxides in
cells. With no method to adequately stabilize the chlorohydrins at
the time, cryptophycin C-52 (LY355703) entered clinical trials,
produced marginal antitumor activity in two phase II lung cancer
trials with 30-40% stable disease and was thus discontinued
(Edelman M. J., et al., Lung Cancer 2003, 39, 197-99 and Sessa C.,
et al., Eur J Cancer 2002, 38, 2388-96).
##STR00002##
Considering their high potency and common mechanism of action with
maytansinoids and auristatins, the two cytotoxic molecules
validated in the clinic for antibody-drug conjugates (ADC), this
series was considered as a potential tubulin binder for ADC.
Therefore conjugates in the cryptophycin series were developed
starting from derivatization at the para-benzylic position of the
macrocycle (A-Awar R. S., et al., J Med Chem 2003, 46,
2985-3007).
[0004] WO2011/001052 describes cryptophycin antibody-drug
conjugates for which the cytotoxic moiety is linked to the antibody
through the para-benzylic position using various kinds of linkers.
They might be cleavable, disulfide or protease-sensitive, or
non-cleavable.
[0005] Further optimization of cryptophycin antibody-drug
conjugates described in WO2011/001052 led to potent cryptophycin
conjugates which displayed promising antitumor activity but were
found unstable in the plasma of mice while being stable in the
plasma of non-rodent species. Therefore, there was a need for
cryptophycin conjugates exhibiting improved stability
properties.
[0006] The purpose of this invention is that of proposing new
cryptophycin macrocycles which once conjugated to an antibody are
stable in mice plasma and new cryptophycin conjugates composed of
those stable macrocycles.
SUMMARY OF THE INVENTION
[0007] In this respect, the invention relates to cryptophycin
compounds of formula (I):
##STR00003##
wherein: [0008] R.sub.1 represents a (C.sub.1-C.sub.6)alkyl group;
[0009] R.sub.2 and R.sub.3 represent, independently of each other,
a hydrogen atom or a (C.sub.1-C.sub.6)alkyl group; or alternatively
R.sub.2 and R.sub.3 form together with the carbon atom to which
they are attached a (C.sub.3-C.sub.6)cycloalkyl or a
(C.sub.3-C.sub.6)heterocycloalkyl group; [0010] R.sub.4 and R.sub.5
represent, independently of each other, a hydrogen atom or a
(C.sub.1-C.sub.6)alkyl group or a
(C.sub.1-C.sub.6)alkyl-NH(R.sub.12) group or a
(C.sub.1-C.sub.6)alkyl-OH group or a (C.sub.1-C.sub.6)alkyl-SH
group or a (C.sub.1-C.sub.6)alkyl-CO.sub.2H group; [0011] or
alternatively R.sub.4 and R.sub.5 form together with the carbon
atom to which they are attached a (C.sub.3-C.sub.6)cycloalkyl or a
(C.sub.3-C.sub.6)heterocycloalkyl group; [0012] R.sub.6 represents
a hydrogen atom or a (C.sub.1-C.sub.6)alkyl group; [0013] R.sub.7
and Ra represent, independently of each other, a hydrogen atom or a
(C.sub.1-C.sub.6)alkyl group or a (C.sub.1-C.sub.6)alkyl-CO.sub.2H
group or a (C.sub.1-C.sub.6)alkyl-N(C.sub.1-C.sub.6)alkyl.sub.2
group; or alternatively R.sub.7 and Ra form together with the
carbon atom to which they are attached a
(C.sub.3-C.sub.6)cycloalkyl group or a
(C.sub.3-C.sub.6)heterocycloalkyl group; [0014] R.sub.9 represents
one or more substituents of the phenyl nucleus chosen,
independently of each other, from: a hydrogen atom, --OH,
(C.sub.1-C.sub.4)alkoxy, a halogen atom, --NH.sub.2,
--NH(C.sub.1-C.sub.6)alkyl, --N(C.sub.1-C.sub.6)alkyl.sub.2,
--NH(C.sub.1-C.sub.6)cycloalkyl or
(C.sub.3-C.sub.6)heterocycloalkyl; [0015] R.sub.10 represents at
least one substituent of the phenyl nucleus chosen from a hydrogen
atom and a group (C.sub.1-C.sub.4)alkyl; [0016] W represents [0017]
(C.sub.1-C.sub.6)alkyl-NH(R.sub.11), more particularly
(CH.sub.2).sub.nNHR.sub.11; [0018] (C.sub.1-C.sub.6)alkyl-OH, more
particularly (CH.sub.2).sub.nOH; [0019] (C.sub.1-C.sub.6)alkyl-SH,
more particularly (CH.sub.2).sub.nSH; [0020] CO.sub.2H or
C(.dbd.O)NH.sub.2; [0021] (C.sub.1-C.sub.6)alkyl-CO.sub.2H or
(C.sub.1-C.sub.6)alkyl-C(.dbd.O)NH.sub.2; or [0022]
(C.sub.1-C.sub.6)alkyl-N.sub.3. [0023] W being positioned in an
ortho (o), meta (m) or para (p) position of the phenyl nucleus;
[0024] R.sub.11 and R.sub.12 represent, independently of each
other, a hydrogen atom or (C.sub.1-C.sub.6)alkyl, more particularly
a methyl group; [0025] n represents an integer between 1 and 6.
[0026] The invention further relates to cryptophycin payloads of
formula (II):
##STR00004##
wherein: [0027] R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5,
R.sub.6, R.sub.6, R.sub.8, R.sub.9 and R.sub.10 are as defined in
formula (I); [0028] Y represents (C.sub.1-C.sub.6)alkyl-NR.sub.11
or (C.sub.1-C.sub.6)alkyl-O or (C.sub.1-C.sub.6)alkyl-S; [0029] or
alternatively Y represents C(.dbd.O)O, C(.dbd.O)NH,
(C.sub.1-C.sub.6)alkyl-C(.dbd.O)O or
(C.sub.1-C.sub.6)alkyl-C(.dbd.O)NH; or alternatively Y represents
(C.sub.1-C.sub.6)alkyl-triazole-like
##STR00005##
[0029] Y being positioned in an ortho (o), meta (m) or para (p)
position of the phenyl nucleus; [0030] R.sub.11 represents a
hydrogen atom or a (C.sub.1-C.sub.6)alkyl group; [0031] L
represents a linker; [0032] RCG1 represents a reactive chemical
group present at the end of the linker, RCG1 being reactive towards
a reactive chemical group present on an antibody.
[0033] The invention also relates to conjugates of formula
(III):
##STR00006##
wherein: [0034] R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5,
R.sub.6, R.sub.7, R.sub.8, R.sub.9 and R.sub.10 are as defined in
formula (I); [0035] Y and L are as defined in formula (II); [0036]
G represents the product of reaction between RCG1, a reactive
chemical group present at the end of the linker and RCG2, an
orthogonal reactive chemical group present on the antibody (Ab);
[0037] Ab represents an antibody.
[0038] Each substituent R.sub.1 to R.sub.11 may also adopt one of
the spatial configurations (e.g. R or S or alternatively Z or E) as
described in the examples.
[0039] The compounds of formula (I), (II) and (III) may contain one
or more asymetric carbon atoms. They may therefore exist in the
form of enantiomers or diastereoisomers. These enantiomers and
diastereoisomers, and also mixtures thereof, including racemic
mixtures, form part of the invention.
[0040] The compounds of formula (I), including those that are
illustrated, may exist in the form of bases or of acid-addition
salts, especially of pharmaceutically acceptable acids.
Definitions
[0041] In the context of the present invention, certain terms have
the following definitions: [0042] alkenyl group: a hydrocarbon
group obtained by removing one hydrogen atom from an alkene. The
alkenyl group may be linear or branched. Examples that may be
mentioned include ethenyl (--CH.dbd.CH.sub.2, also named vinyl) and
propenyl (--CH.sub.2--CH.dbd.CH.sub.2, also named allyl). [0043]
alkoxy group: a group --O-alkyl, in which the alkyl group is as
defined below; [0044] alkyl group: a linear or branched saturated
aliphatic hydrocarbon-based group obtained by removing a hydrogen
atom from an alkane. Examples that may be mentioned include methyl,
ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl,
neopentyl, 2,2-dimethylpropyl and hexyl groups; [0045] alkylene
group: a saturated divalent group of empirical formula
--C.sub.nH.sub.2n--, obtained by removing two hydrogen atoms from
an alkane. The alkylene group may be linear or branched. Examples
that may be mentioned include methylene (--CH.sub.2--), ethylene
(--CH.sub.2CH.sub.2--), propylene (--CH.sub.2CH.sub.2CH.sub.2--),
butylene (--CH.sub.2CH.sub.2CH.sub.2CH.sub.2--) and hexylene
(--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.sub.2--) groups or
the following branched groups
##STR00007##
[0045] preferably, the alkylene group is of the formula
--(CH.sub.2).sub.n--, n representing an integer; in the ranges of
values, the limits are included (e.g. a range of the type "n
ranging from 1 to 6" or "between 1 and 6" includes limits 1 and 6);
[0046] antibody: an antibody with affinity for a biological target,
more particularly a monoclonal antibody. The function of the
antibody is to direct the biologically active compound as a
cytotoxic compound towards the biological target. The antibody may
be monoclonal, polyclonal or multispecific; it may also be an
antibody fragment; it may also be a murine, chimeric, humanized or
human antibody. An "antibody" may be a natural or conventional
antibody in which two heavy chains are linked to each other by
disulfide bonds and each heavy chain is linked to a light chain by
a disulfide bond (also referred to as a "full-length antibody").
The terms "conventional (or full-length) antibody" refers both to
an antibody comprising the signal peptide (or pro-peptide, if any),
and to the mature form obtained upon secretion and proteolytic
processing of the chain(s). There are two types of light chain,
lambda (l) and kappa (k). There are five main heavy chain classes
(or isotypes) which determine the functional activity of an
antibody molecule: IgM, IgD, IgG, IgA and IgE. Each chain contains
distinct sequence domains. The light chain includes two domains or
regions, a variable domain (VL) and a constant domain (CL). The
heavy chain includes four domains, a variable domain (VH) and three
constant domains (CH1, CH2 and CH3, collectively referred to as
CH). The variable regions of both light (VL) and heavy (VH) chains
determine binding recognition and specificity to the antigen. The
constant region domains of the light (CL) and heavy (CH) chains
confer important biological properties such as antibody chain
association, secretion, trans-placental mobility, complement
binding, and binding to Fc receptors (FcR). The Fv fragment is the
N-terminal part of the Fab fragment of an immunoglobulin and
consists of the variable portions of one light chain and one heavy
chain. The specificity of the antibody resides in the structural
complementarity between the antibody combining site and the
antigenic determinant. Antibody combining sites are made up of
residues that are primarily from the hypervariable or
complementarity determining regions (CDRs). Occasionally, residues
from nonhypervariable or framework regions (FR) influence the
overall domain structure and hence the combining site.
Complementarity Determining Regions or CDRs refer to amino acid
sequences which together define the binding affinity and
specificity of the natural Fv region of a native immunoglobulin
binding site. The light and heavy chains of an immunoglobulin each
have three CDRs, designated CDR1-L, CDR2-L, CDR3-L and CDR1-H,
CDR2-H, CDR3-H, respectively. A conventional antibody
antigen-binding site, therefore, includes six CDRs, comprising the
CDR set from each of a heavy and a light chain V region. As used
herein, the term "antibody" denotes both conventional (full-length)
antibodies and fragments thereof, as well as single domain
antibodies and fragments thereof, in particular variable heavy
chain of single domain antibodies. Fragments of (conventional)
antibodies typically comprise a portion of an intact antibody, in
particular the antigen binding region or variable region of the
intact antibody, and retain the biological function of the
conventional antibody. Examples of such fragments include Fv, Fab,
F(ab')2, Fab', dsFv, (dsFv)2, scFv, sc(Fv)2 and diabodies.
[0047] The function of the antibody is to direct the biologically
active compound as a cytotoxic compound towards the biological
target. [0048] aryl group: a cyclic aromatic group containing
between 5 to 10 carbon atoms. Examples of aryl groups include
phenyl, tolyl, xylyl, naphtyl; [0049] biological target: an antigen
(or group of antigens) preferably located at the surface of cancer
cells or stromal cells associated with this tumour; these antigens
may be, for example, a growth factor receptor, an oncogene product
or a mutated "tumor suppressant" gene product, an
angiogenesis-related molecule or an adhesion molecule; [0050]
conjugate: an antibody-drug conjugate or ADC, i.e. an antibody to
which is covalently attached via a linker at least one molecule of
a cytotoxic compound; [0051] cycloalkyl group: a cyclic alkyl group
comprising between 3 and 6 carbon atoms engaged in the cyclic
structure. Examples that may be mentioned include cyclopropyl,
cyclobutyl, cyclopentyl and cyclohexyl groups; [0052] DAR
(drug-to-antibody ratio): an average number of cytotoxic molecules
attached via a linker to an antibody; [0053] halogen: any of the
four elements fluorine, chlorine, bromine and iodine; [0054]
heteroaryl group: an aryl group containing between 2 to 10 carbon
atoms and between 1 to 5 heteroatoms such as nitrogen, oxygen or
sulphur engaged in the ring and connected to the carbon atoms
forming the ring. Examples of heteroaryl groups include pyridyl,
pyrimidyl, thienyl, imidazolyl, triazolyl, indolyl,
imidazo-pyridyl, pyrazolyl; [0055] heterocycloalkyl group: a
cycloalkyl group containing between 2 to 8 carbon atoms and between
1 to 3 heteroatoms, such as nitrogen, oxygen or sulphur engaged in
the ring and connected to the carbon atoms forming the ring.
Examples include aziridinyl, pyrrolidinyl, piperidinyl,
piperazinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl,
tetrahydrothiofuranyl, tetrahydropyranyl, azetidinyl, oxetanyl and
pyranyl; [0056] linker: a group of atoms or a single bond that can
covalently attach a cytotoxic compound to an antibody in order to
form a conjugate; [0057] fragment: simpler molecules that allow the
total synthesis of cryptophycin compounds; [0058] payload: a
cytotoxic compound to which is covalently attached a linker; [0059]
reactive chemical group: group of atoms that can promote or undergo
a chemical reaction.
Abbreviations
[0060] ADC: antibody-drug conjugate; AcOH: acetic acid; AIBN:
azobisisobutyronitrile; ALK: (C.sub.1-C.sub.12)alkylene group, more
particularly (C.sub.1-C.sub.6)alkylene, more particularly of the
form --(CH.sub.2).sub.n--, n being an integer from 1 to 12 and
preferably from 1 to 6; aq.: aqueous; Ar: argon; AUC: area under
the curve; BEMP:
2-tert-butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diazaphosphor-
ine; BF.sub.3: boron trifluoride; Boc.sub.2O:
di-tert-butyl-dicarbonate; BuLi: butyl lithium; CAN: ceric ammonium
nitrate; Cbz: carboxybenzyl; CHCl.sub.3: chloroform; CH.sub.3CN:
acetonitrile; CH.sub.3I: methyl iodide; CO.sub.2: carbon dioxide;
CL: clearance; m-CPBA: m-chloroperbenzoic acid; CR: complete
response; crypto denotes the unit of formula
##STR00008##
crypto especially denoting one of the D.sub.1-D.sub.19 cryptophycin
compounds described later or a cryptophycin compound of an example;
D1 refers to an ADC with a DAR of 1, D2 to an ADC with a DAR of 2,
etc.; d: day; DAR: drug-to-antibody ratio; DBU:
8-diazabycyclo[5.4.0]undec-7-ene; DCC:
N,N'-dicyclohexylcarbodiimide; DCE: dichloroethane; DCM:
dichloromethane; DDQ: 2,3-dichloro-5,6-dicyano-1,4-benzoquinone;
DIC: N,N'-diisopropylcarbodiimide; DIAD:
diisopropylazodicarboxylate; DIEA: N,N-diisopropylethylamine; DMA:
dimethylacetamide; DMAP: 4-(dimethylamino)pyridine; DME:
dimethoxyethane; DMEM: Dulbecco's Modified Eagle Medium; DMEM/F12:
Dulbecco's Modified Eagle Medium Nutrient Mixture F-12; DMF:
dimethylformamide; DMSO: dimethylsulfoxide; DPBS: Dulbecco's
phosphate-buffered saline; DPPA: diphenylphosphorazide
(PhO).sub.2P(.dbd.O)N.sub.3; DSC: N,N'-disuccinimidyl carbonate;
EDA: ethylenediamine; EDC:
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide; EDTA:
ethylenediaminetetraacetic acid; EEDQ:
N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline; ELSD: evaporating
light scattering detector; eq.: equivalent; ES: electrospray;
EtOAc: ethyl acetate; Et.sub.2O: diethyl ether; EtOH: ethanol; Ex.:
example; FCS: foetal calf serum; Fmoc: 9-fluorenylmethoxycarbonyl;
FmocOSu: N-(9-fluorenylmethoxycarbonyloxy) succinimide; GI:
electroinductive group; Grubbs I:
benzylidene-bis(tricyclohexylphosphine)dichlororuthenium; Grubbs
II:
(1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene)dichloro(phenylmeth-
ylene)(tricyclohexylphosphine)ruthenium; h: hour; H.sub.2O: water;
Hal: halogen; HATU:
1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium
3-oxid hexafluorophosphate; HCl: chlorohydric acid; HEPES:
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; HIC:
hydrophobic interaction chromatography; HOAt:
1-hydroxy-7-azabenzotriazole; HOBt: 1-hydroxy-benzotriazole; HPLC:
high performance liquid chromtography; HRMS: high resolution mass
spectrometry; IC.sub.50: median inhibitory concentration; i.e.: id
est meaning that is; IEC: ion exchange chromatography; iPrOH:
2-propanol; iPr.sub.2O: diisopropyl ether; i.v.: intravenous;
K.sub.2CO.sub.3: potassium carbonate; LDA: lithium
diisopropylamide; LiOH: lithium hydroxide; marg.: marginally; MeOH:
methanol; MeTHF: 2-methyl-tetrahydrofuran; MgSO.sub.4: magnesium
sulfate; min: minute; MNBA: 2-methyl-6-nitrobenzoic anhydride;
MTBE: methyl tert-butyl ether; MTD: maximum tolerated dose; NaH:
sodium hydride; NaHSO.sub.4: sodium bisulfate; Na.sub.2S2.sub.3:
sodium thiosulfate; NaCl: sodium chloride; NaHCO.sub.3: sodium
hydrogen carbonate; NaHSO.sub.3: sodium bisulfite; NaHSO.sub.4:
sodium hydrogen sulfate; NaOH: sodium hydroxide; NH.sub.4Cl:
ammonium chloride; NHS: N-hydroxysuccinimide; NMP:
1-methyl-2-pyrrolidone; NMR: nuclear magnetic resonance;
P.sub.2-Et:
1-ethyl-2,2,4,4,4-pentakis(dimethylamino)-2.lamda.5,4.lamda.5-catenadi(ph-
osphazene); PBS: phosphate-buffered saline; PEG: polyethylene
glycol; PK: pharmacokinetics; PMB: para-methoxybenzyl; PNGase F:
Peptide-N-Glycosidase F; PPh.sub.3: triphenylphosphine; ppm: parts
per million; PR: partial response; QS: quantum satis meaning the
amount what is needed; Q-Tof: quadrupole time-of-flight; quant.:
quantitative yield; RCG: reactive chemical group; RT: room
temperature; sat.: saturated; s.c.: subcutaneously; SCID: severe
combined immunodeficiency; SEC: size exclusion chromatography;
TBAF: tetrabutylammonium fluoride; tBuOK: potassium tert-butoxide;
TCEP: tris(2-carboxyethyl)phosphine hydrochloride; TEA:
triethylamine; TEMPO: (2,2,6,6-tetramethylpiperidin-1-yl)oxyl; TFA:
trifluoroacetic acid; TFS: tumor-free survivor; THF:
tetrahydrofuran; THP: tetrahydropyran; TLC: thin layer
chromatography; t.sub.1/2: half-life; t.sub.R: retention time;
p-TsOH: para-toluenesulfonic acid; UPLC: Ultra Performance Liquid
Chromatography; UV: ultra-violet; V.sub.ss: apparent volume of
distribution at steady state.
FIGURES
[0061] FIG. 1: High resolution mass spectrum of Ex.3
[0062] FIG. 2: High resolution mass spectrum of Ex.7
[0063] FIG. 3: High resolution mass spectrum of Ex.10
[0064] FIG. 4: High resolution mass spectrum of Ex.14
[0065] FIG. 5: High resolution mass spectrum of Ex.20
[0066] FIG. 6: High resolution mass spectrum of Ex.23
[0067] FIG. 7: In vivo efficacy of Ex.3 against MDA-MB-231
xenograft in SCID mice
[0068] FIG. 8: In vivo efficacy of Ex.7 against MDA-MB-231
xenograft in SCID mice
[0069] FIG. 9: In vivo efficacy of Ex.10 against MDA-MB-231
xenograft in SCID mice
[0070] FIG. 10: In vivo efficacy of Ex.14 against MDA-MB-231
xenograft in SCID mice
[0071] FIG. 11: In vivo efficacy of Ex.20 against MDA-MB-231
xenograft in SCID mice
[0072] FIG. 12: In vivo efficacy of Ex.23 against MDA-MB-231
xenograft in SCID mice
[0073] FIG. 13: In vivo PK profile of ADC1 following a single i.v.
administration in SCID mice
[0074] FIG. 14: In vivo PK profile of ADC1 following a single i.v.
administration in non-rodent species
[0075] FIG. 15: In vivo PK profile of Ex.3 following a single i.v.
administration in SCID mice
[0076] FIG. 16: In vivo PK profile of Ex.7 following a single i.v.
administration in SCID mice
[0077] FIG. 17: HRMS spectrum of deglycosylated ADC1 at 96 h
following a single i.v. administration in SCID mice
[0078] FIG. 18: HRMS spectrum of ADC2 light chain at 96 h following
a single i.v. administration in SCID mice
[0079] FIG. 19: HRMS spectrum of deglycosylated ADC1 at 6 d
following a single i.v. administration in non-rodent species
[0080] FIG. 20: HRMS spectrum of Ex.3 at 96 h following a single
i.v. administration in SCID mice
[0081] FIG. 21: HRMS spectrum of Ex.7 at 96 h following a single
i.v. administration in SCID mice
[0082] FIG. 22: HRMS spectrum of Ex.10 at 96 h following a single
i.v. administration in SCID mice
[0083] FIG. 23: HRMS spectrum of Ex.14 at 96 h following a single
i.v. administration in SCID mice
[0084] FIG. 24: HRMS spectrum of Ex.20 at 96 h following a single
i.v. administration in SCID mice
[0085] FIG. 25: HRMS spectrum of Ex.23 at 96 h following a single
i.v. administration in SCID mice
DETAILED DESCRIPTION OF THE INVENTION
[0086] The invention relates to cryptophycin compounds of formula
(I):
##STR00009##
wherein: [0087] R.sub.1 represents a (C.sub.1-C.sub.6)alkyl group;
[0088] R.sub.2 and R.sub.3 represent, independently of each other,
a hydrogen atom or a (C.sub.1-C.sub.6)alkyl group; or alternatively
R.sub.2 and R.sub.3 form together with the carbon atom to which
they are attached a (C.sub.3-C.sub.6)cycloalkyl or a
(C.sub.3-C.sub.6)heterocycloalkyl group; [0089] R.sub.4 and R.sub.5
represent, independently of each other, a hydrogen atom or a
(C.sub.1-C.sub.6)alkyl group or a
(C.sub.1-C.sub.6)alkyl-NH(R.sub.12) group or a
(C.sub.1-C.sub.6)alkyl-OH group or a (C.sub.1-C.sub.6)alkyl-SH
group or a (C.sub.1-C.sub.6)alkyl-CO.sub.2H group; [0090] or
alternatively R.sub.4 and R.sub.5 form together with the carbon
atom to which they are attached a (C.sub.3-C.sub.6)cycloalkyl or a
(C.sub.3-C.sub.6)heterocycloalkyl group; [0091] R.sub.6 represents
a hydrogen atom or a (C.sub.1-C.sub.6)alkyl group; [0092] R.sub.7
and Ra represent, independently of each other, a hydrogen atom or a
(C.sub.1-C.sub.6)alkyl group or a (C.sub.1-C.sub.6)alkyl-CO.sub.2H
group or a (C.sub.1-C.sub.6)alkyl-N(C.sub.1-C.sub.6)alkyl.sub.2
group; [0093] or alternatively R.sub.7 and Ra form together with
the carbon atom to which they are attached a
(C.sub.3-C.sub.6)cycloalkyl group or a
(C.sub.3-C.sub.6)heterocycloalkyl group; [0094] R.sub.9 represents
one or more substituents of the phenyl nucleus chosen,
independently of each other, from: a hydrogen atom, --OH,
(C.sub.1-C.sub.4)alkoxy, a halogen atom, --NH.sub.2,
--NH(C.sub.1-C.sub.6)alkyl or --N(C.sub.1-C.sub.6)alkyl.sub.2 or
--NH(C.sub.1-C.sub.6)cycloalkyl or
(C.sub.3-C.sub.6)heterocycloalkyl group; [0095] R.sub.10 represents
at least one substituent of the phenyl nucleus chosen from a
hydrogen atom and a group (C.sub.1-C.sub.4)alkyl; [0096] W
represents [0097] (C.sub.1-C.sub.6)alkyl-NH(R.sub.11), more
particularly (CH.sub.2).sub.nNHR.sub.11; [0098]
(C.sub.1-C.sub.6)alkyl-OH, more particularly (CH.sub.2).sub.nOH;
[0099] (C.sub.1-C.sub.6)alkyl-SH, more particularly
(CH.sub.2).sub.nSH; [0100] CO.sub.2H or C(.dbd.O)NH.sub.2; [0101]
(C.sub.1-C.sub.6)alkyl-CO.sub.2H or
(C.sub.1-C.sub.6)alkyl-C(.dbd.O)NH.sub.2; or [0102]
(C.sub.1-C.sub.6)alkyl-N.sub.3. [0103] W is positioned in an ortho
(o), meta (m) or para (p) position of the phenyl nucleus; [0104]
R.sub.11 and R.sub.12 represent, independently of each other, a
hydrogen atom or a group (C.sub.1-C.sub.6)alkyl, more particularly
a methyl group; [0105] n represents an integer between 1 and 6.
[0106] The cryptophycin compound may be one of the following
D.sub.1-D.sub.1:
##STR00010## ##STR00011## ##STR00012## ##STR00013##
wherein: [0107] W and R.sub.12 are as defined in formula (I);
[0108] Or the cryptophycin compound may bean equivalent unit
described in one of the examples.
[0109] Among the compounds of formula (I) that are subject matter
of the invention, a first group of compounds is composed of the
compounds for which R.sub.1 represents a (C.sub.1-C.sub.6)alkyl, in
particular a methyl group.
[0110] Among the compounds of formula (I) that are subject matter
of the invention, a second group of compounds is composed of the
compounds for which each of R.sub.2 and R.sub.3 represents a
hydrogen atom.
[0111] Among the compounds of formula (I) that are subject matter
of the invention, a third group of compounds is composed of the
compounds for which one of R.sub.2 and R.sub.3 represents a
(C.sub.1-C.sub.6)alkyl, in particular a methyl group, and the other
one represents a hydrogen atom.
[0112] Among the compounds of formula (I) that are subject matter
of the invention, a fourth group of compounds is composed of the
compounds for which R.sub.2 and R.sub.3 form together with the
carbon atom to which they are attached a
(C.sub.3-C.sub.6)cycloalkyl group, in particular a cyclopropyl
group.
[0113] Among the compounds of formula (I) that are subject matter
of the invention, a fifth group of compounds is composed of the
compounds for which each of R.sub.4 and R.sub.5 represents a
(C.sub.1-C.sub.6)alkyl, in particular a methyl group.
[0114] Among the compounds of formula (I) that are subject matter
of the invention, a sixth group of compounds is composed of the
compounds for which R.sub.6 represents a hydrogen atom.
[0115] Among the compounds of formula (I) that are subject matter
of the invention, a seventh group of compounds is composed of the
compounds for which R.sub.7 and Ra represent independently of each
other an hydrogen atom or a (C.sub.1-C.sub.6)alkyl group.
[0116] Among the compounds of formula (I) that are subject matter
of the invention, an eighth group of compounds is composed of the
compounds for which R.sub.9 represents two substituents selected
from a methoxy group and a chlorine atom. More particularly, the
phenyl nucleus comprises two substituents in positions 3 and 4 on
the phenyl nucleus. Preferably, it is 3-Cl and 4-methoxy.
[0117] Among the compounds of formula (I) that are subject matter
of the invention, a ninth group of compounds is composed of the
compounds for which R.sub.10 represents a hydrogen atom.
[0118] Among the compounds of formula (I) that are subject matter
of the invention, a tenth group of compounds is composed of the
compounds for which W is positioned in the para position of the
phenyl nucleus.
[0119] Among the compounds of formula (I) that are subject matter
of the invention, a eleventh group of compounds is composed of the
compounds for which W is selected from
(C.sub.1-C.sub.6)alkyl-NHR.sub.11, in particular
(C.sub.1-C.sub.3)alkyl-NHR.sub.11, particularly a
CH.sub.2--NH.sub.2 group, (C.sub.1-C.sub.6)alkyl-OH, in particular
(C.sub.1-C.sub.3)alkyl-OH, particularly a CH.sub.2--OH group,
(C.sub.1-C.sub.6)alkyl-SH, in particular (C.sub.1-C.sub.3)alkyl-SH
and (C.sub.1-C.sub.6)alkyl-CO.sub.2H, in particular
(C.sub.1-C.sub.3)alkyl-CO.sub.2H.
[0120] Among the compounds of formula (I) that are subject matter
of the invention, a twelfth group of compounds is composed of the
compounds for which R.sub.1 represents a (C.sub.1-C.sub.6)alkyl, in
particular a methyl group, each of R.sub.2 and R.sub.3 represents a
hydrogen atom, R.sub.6 represents a hydrogen atom, R.sub.9
represents two substituents selected from a methoxy group and a
chlorine atom, more particularly, the phenyl nucleus comprises two
substituents in positions 3 and 4 on the phenyl nucleus,
preferably, it is 3-Cl and 4-methoxy and R.sub.10 represents a
hydrogen atom.
[0121] Among the compounds of formula (I) that are subject matter
of the invention, a thirteenth group of compounds is composed of
the compounds for which R.sub.1 represents a
(C.sub.1-C.sub.6)alkyl, in particular a methyl group, R.sub.2 and
R.sub.3 represents a (C.sub.1-C.sub.6)alkyl, in particular a methyl
group, and the other one represents a hydrogen atom, R.sub.6
represents a hydrogen atom, R.sub.9 represents two substituents
selected from a methoxy group and a chlorine atom, more
particularly, the phenyl nucleus comprises two substituents in
positions 3 and 4 on the phenyl nucleus, preferably, it is 3-Cl and
4-methoxy and R.sub.10 represents a hydrogen atom.
[0122] Alternatively, W is selected from
(CH.sub.2).sub.nNHR.sub.11, (CH.sub.2).sub.nSH from
(CH.sub.2).sub.nOH, wherein n represents an integer between 1 and
6.
[0123] Among the compounds of formula (I) that are subject matter
of the invention, a fourteenth group of compounds is composed of
the compounds of the following structure (beta epoxide
configuration):
##STR00014##
[0124] All these sub-groups taken alone or in combination are part
of the invention.
[0125] Among the compounds of formula (I) that are the subject
matter of the invention, mention may be made in particular of the
following compounds:
##STR00015## ##STR00016## ##STR00017## ##STR00018##
[0126] The invention further relates to cryptophycin payloads of
formula (II):
##STR00019##
wherein: [0127] R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5,
R.sub.6, R.sub.7, R.sub.8, R.sub.9 and R.sub.10 are as defined in
formula (I); [0128] Y represents (C.sub.1-C.sub.6)alkyl-NR.sub.11
or (C.sub.1-C.sub.6)alkyl-O or (C.sub.1-C.sub.6)alkyl-S; [0129] or
alternatively Y represents C(.dbd.O)O, C(.dbd.O)NH,
(C.sub.1-C.sub.6)alkyl-C(.dbd.O)O or
(C.sub.1-C.sub.6)alkyl-C(.dbd.O)NH; [0130] or alternatively Y
represents (C.sub.1-C.sub.6)alkyl-triazole-like;
[0130] ##STR00020## [0131] Y is positioned in an ortho (o), meta
(m) or para (p) position of the phenyl nucleus; [0132] R.sub.11
represents a hydrogen atom or a (C.sub.1-C.sub.6)alkyl group;
[0133] L represents a linker; [0134] RCG1 represents a reactive
chemical group present at the end of the linker, RCG1 being
reactive towards a reactive chemical group present on an
antibody.
[0135] Among the compounds of formula (II) that are subject matter
of the invention, a first group of compounds is composed of the
compounds for which R.sub.1 represents a (C.sub.1-C.sub.6)alkyl, in
particular a methyl group.
[0136] Among the compounds of formula (II) that are subject matter
of the invention, a second group of compounds is composed of the
compounds for which each of R.sub.2 and R.sub.3 represents a
hydrogen atom.
[0137] Among the compounds of formula (II) that are subject matter
of the invention, a third group of compounds is composed of the
compounds for which one of R.sub.2 and R.sub.3 represents a
(C.sub.1-C.sub.6)alkyl group, in particular a methyl group and the
other one represents a hydrogen atom.
[0138] Among the compounds of formula (II) that are subject matter
of the invention, a fourth group of compounds is composed of the
compounds for which R.sub.2 and R.sub.3 form together with the
carbon atom to which they are attached a
(C.sub.3-C.sub.6)cycloalkyl group, in particular a cyclopropyl
group.
[0139] Among the compounds of formula (II) that are subject matter
of the invention, a fifth group of compounds is composed of the
compounds for which each of R.sub.4 and R.sub.5 represents a
(C.sub.1-C.sub.6)alkyl group, in particular a methyl group.
[0140] Among the compounds of formula (II) that are subject matter
of the invention, a sixth group of compounds is composed of the
compounds for which R.sub.6 represents a hydrogen atom.
[0141] Among the compounds of formula (II) that are subject matter
of the invention, a seventh group of compounds is composed of the
compounds for which R.sub.7 and Ra represent independently of each
other an hydrogen atom or a (C.sub.1-C.sub.6)alkyl group.
[0142] Among the compounds of formula (II) that are subject matter
of the invention, an eighth group of compounds is composed of the
compounds for which R.sub.9 represents two substituents selected
from a methoxy group and a chlorine atom. More particularly, the
phenyl nucleus comprises two substituents in positions 3 and 4 on
the phenyl nucleus. Preferably, it is 3-Cl and 4-methoxy.
[0143] Among the compounds of formula (II) that are subject matter
of the invention, a ninth group of compounds is composed of the
compounds for which R.sub.10 represents a hydrogen atom.
[0144] Among the compounds of formula (II) that are subject matter
of the invention, a tenth group of compounds is composed of the
compounds for which Y is positioned in the para position of the
phenyl nucleus.
[0145] Among the compounds of formula (II) that are subject matter
of the invention, an eleventh group of compounds is composed of the
compounds for which Y represents (C.sub.1-C.sub.6)alkyl-NR.sub.11
in particular (C.sub.1-C.sub.3)alkyl-NR.sub.11 more particularly
CH.sub.2--NH.
[0146] Among the compounds of formula (I) that are subject matter
of the invention, a twelfth group of compounds is composed of the
compounds for which R.sub.1 represents a (C.sub.1-C.sub.6)alkyl, in
particular a methyl group, each of R.sub.2 and R.sub.3 represents a
hydrogen atom, R.sub.6 represents a hydrogen atom, R.sub.9
represents two substituents selected from a methoxy group and a
chlorine atom, more particularly, the phenyl nucleus comprises two
substituents in positions 3 and 4 on the phenyl nucleus,
preferably, it is 3-Cl and 4-methoxy and R.sub.10 represents a
hydrogen atom.
[0147] Among the compounds of formula (I) that are subject matter
of the invention, a thirteenth group of compounds is composed of
the compounds for which R.sub.1 represents a
(C.sub.1-C.sub.6)alkyl, in particular a methyl group, R.sub.2 and
R.sub.3 represents a (C.sub.1-C.sub.6)alkyl, in particular a methyl
group, and the other one represents a hydrogen atom, R.sub.6
represents a hydrogen atom, R.sub.9 represents two substituents
selected from a methoxy group and a chlorine atom, more
particularly, the phenyl nucleus comprises two substituents in
positions 3 and 4 on the phenyl nucleus, preferably, it is 3-Cl and
4-methoxy and R.sub.10 represents a hydrogen atom.
[0148] Among the compounds of formula (II) that are subject matter
of the invention, a fourteenth group of compounds is composed of
the compounds of the following structure (beta epoxide
configuration):
##STR00021##
[0149] All these sub-groups taken alone or in combination are part
of the invention.
[0150] Among the compounds of formula (II) that are the subject
matter of the invention, mention may be made in particular of the
following compounds:
##STR00022## ##STR00023##
[0151] The invention also relates to conjugates of formula
(III):
##STR00024##
wherein: [0152] R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5,
R.sub.6, R.sub.7, R.sub.8, R.sub.9, and R.sub.10 are as defined in
formula (I); [0153] Y and L are as defined in formula (II); [0154]
G represents the product of reaction between RCG1, a reactive
chemical group present at the end of the linker and RCG2, an
orthogonal reactive chemical group present on the antibody (Ab);
[0155] Ab represents an antibody.
[0156] Among the compounds of formula (III) that are subject matter
of the invention, a first group of compounds is composed of the
compounds for which R.sub.1 represents a (C.sub.1-C.sub.6)alkyl, in
particular a methyl group.
[0157] Among the compounds of formula (III) that are subject matter
of the invention, a second group of compounds is composed of the
compounds for which each of R.sub.2 and R.sub.3 represents a
hydrogen atom.
[0158] Among the compounds of formula (III) that are subject matter
of the invention, a third group of compounds is composed of the
compounds for which one of R.sub.2 and R.sub.3 represents a
(C.sub.1-C.sub.6)alkyl group, in particular a methyl group and the
other one represents a hydrogen atom.
[0159] Among the compounds of formula (III) that are subject matter
of the invention, a fourth group of compounds is composed of the
compounds for which R.sub.2 and R.sub.3 form together with the
carbon atom to which they are attached a
(C.sub.3-C.sub.6)cycloalkyl group, in particular a cyclopropyl
group.
[0160] Among the compounds of formula (III) that are subject matter
of the invention, a fifth group of compounds is composed of the
compounds for which each of R.sub.4 and R.sub.5 represents a
(C.sub.1-C.sub.6)alkyl group, in particular a methyl group.
[0161] Among the compounds of formula (III) that are subject matter
of the invention, a sixth group of compounds is composed of the
compounds for which R.sub.6 represents a hydrogen atom.
[0162] Among the compounds of formula (III) that are subject matter
of the invention, a seventh group of compounds is composed of the
compounds for which R.sub.7 and Ra represent independently of each
other an hydrogen atom or a (C.sub.1-C.sub.6)alkyl group.
[0163] Among the compounds of formula (III) that are subject matter
of the invention, an eighth group of compounds is composed of the
compounds for which R.sub.9 represents two substituents selected
from a methoxy group and a chlorine atom. More particularly, the
phenyl nucleus comprises two substituents in positions 3 and 4 on
the phenyl nucleus. Preferably, it is 3-Cl and 4-methoxy.
[0164] Among the compounds of formula (III) that are subject matter
of the invention, a ninth group of compounds is composed of the
compounds for which R.sub.10 represents a hydrogen atom.
[0165] Among the compounds of formula (II) that are subject matter
of the invention, a tenth group of compounds is composed of the
compounds for which Y is positioned in the para position of the
phenyl nucleus.
[0166] Among the compounds of formula (III) that are subject matter
of the invention, an eleventh group of compounds is composed of the
compounds for which Y represents (C.sub.1-C.sub.6)alkyl-NR.sub.11
in particular (C.sub.1-C.sub.3)alkyl-NR.sub.11 more particularly
CH.sub.2--NH.
[0167] Among the compounds of formula (I) that are subject matter
of the invention, a twelfth group of compounds is composed of the
compounds of the following structure (beta epoxide
configuration):
##STR00025##
[0168] All these sub-groups taken alone or in combination are part
of the invention.
[0169] Among the compounds of formula (III) that are the subject
matter of the invention, mention may be made in particular of the
following compounds:
##STR00026## ##STR00027##
[0170] The attachment between the cryptophycin payload of formula
(II) and the antibody, in order to obtain the conjugate of formula
(III), is produced by means of a reactive chemical group RCG1
present on the payload that is reactive towards a reactive group
RCG2 present on the antibody.
[0171] The reaction between RCG1 and RCG2 ensures the attachment of
the compound of formula (II) to the antibody by formation of a
covalent bond. In the conjugate of formula (III), parts of RCG1 and
RCG2 can remain forming the attachment between the linker and the
antibody.
[0172] Examples of RCG1 that may be mentioned include: [0173] (i)
the --C(.dbd.O)--Z.sub.aR.sub.a reactive group for which Z.sub.a
represents a single bond, O or NH, more particularly O, and R.sub.a
represents a hydrogen atom or a (C.sub.1-C.sub.6)alkyl,
(C.sub.3-C.sub.7)cycloalkyl, alkenyl, aryl, heteroaryl or
(C.sub.3-C.sub.7)heterocycloalkyl group. The aryl group may be
substituted by 1 to 5 groups chosen from halogen, in particular F,
alkyl, alkoxy, nitro and cyano groups; [0174] (ii) one of the
following reactive groups: the maleimido
##STR00028##
[0174] group; the haloacetamido
##STR00029##
group with R.sub.13 representing a hydrogen atom or a
(C.sub.1-C.sub.6)alkyl group, more particularly Me; --Cl;
--N.sub.3; --OH; --SH; --NH.sub.2; --C.ident.CH or an activated
C.ident.C such as a cyclooctyne moiety like
##STR00030##
an O-alkyl hydroxylamine or a Pictet-Spengler reaction substrate
such as
##STR00031##
described in Agarwal P., et al., Bioconjugate Chem 2013, 24,
846-851.
[0175] More particularly, --Z.sub.aR.sub.a may represent --OH,
--OCH.sub.3, --OCH.sub.2CH.dbd.CH.sub.2,
##STR00032##
(O--NHS) or
##STR00033##
[0176] where cation represents for example sodium, potassium or
cesium or
##STR00034##
or the
##STR00035##
group in which GI represents at least one electroinductive group
such as --NO.sub.2 or -Hal, especially --F. They may be, for
example, the following groups:
##STR00036##
Another type of --C(.dbd.O)Z.sub.aR.sub.a group is the
following:
##STR00037##
More particularly, RCG1 may be chosen from one of those described
in the examples.
[0177] Examples of RCG2 that may be mentioned include (Garnett M.
C., et al., Advanced Drug Delivery Reviews 2001, 53, 171-216):
[0178] (i) .epsilon.-amino groups of lysines borne by the side
chains of the lysine residues that are present at the surface of an
antibody; [0179] (ii) .alpha.-amino groups of N-terminal amino
acids of antibody heavy and light chains; (iii) the saccharide
groups of the hinge region; [0180] (iv) the thiols of cysteines
generated by reducing intra-chain disulfide bonds or the thiols of
engineered cysteines; [0181] (v) amide groups borne by the side
chains of some glutamine residues that are present at the surface
of an antibody; [0182] (vi) aldehyde groups introduced using
formylglycine generating enzyme.
[0183] More recently, other conjugation approaches have been
considered, for instance the introduction of cysteines by mutation
(Junutula J. R., et al., Nature Biotechnology 2008, 26, 925-932),
the introduction of unnatural amino acids allowing other types of
chemistry (Axup J. Y., et al., PNAS 2012, 109, 40, 16101-16106) or
the conjugation on antibody glycans (Zhou Q., et al., Bioconjugate
Chem. 2014, 25, 510-520). Another approach for site-specific
modifications of antibodies is based on enzymatic labeling using
for example bacterial transglutaminase (Jeger S., et al., Angew.
Chem. nt. Ed. 2010, 49, 9995-9997; Strop P., et al., Chem. Biol.
2013, 20, 161-167) or formylglycine generating enzyme (Hudak J. E.,
et al., Angew. Chem. Int. Ed. 2012, 51, 4161-4165). For a review of
site-specific conjugation strategies, see Agarwal P. and Bertozzi
C. R., Bioconjugate Chem 2015, 26, 176-192. These conjugation
technologies may also be applied to cryptophycin payloads described
in the present invention.
[0184] It is also possible to chemically modify the antibody so as
to introduce novel reactive chemical groups RCG2. Thus, it is well
known to those skilled in the art how to modify an antibody with
the aid of a modifying agent introducing for example activated
disulfide, thiol, maleimido or haloacetamido groups (see especially
WO2005/077090 page 14 and WO2011/001052). The modification makes it
possible to improve the conjugation reaction and to use a wider
variety of groups RCG1.
[0185] More particularly, in the case where RCG1 is of the type
(ii) above, it is possible to chemically modify the antibody using
an adequate modifying agent or to introduce one or more unnatural
amino acids so as to introduce the adequate functions RCG2. For
example: [0186] when RCG1 represents a N-hydroxysuccinimidyl ester,
RCG2 represents a --NH2 group; [0187] when RCG1 represents a
maleimido or haloacetamido function or a --Cl group, RCG2 may be a
--SH group; [0188] when RCG1 represents a --N.sub.3 group, RCG2 may
be a --C.ident.CH group or an activated C.ident.C such as a
cyclooctyne moiety; [0189] when RCG1 represents a --OH or
--NH.sub.2 group, RCG2 may be a carboxylic acid or amide function;
[0190] when RCG1 represents a --SH group, RCG2 may be a maleimido
or haloacetamido function; [0191] when RCG1 represents a
--C.ident.CH function or an activated C.ident.C, RCG2 may be a
--N.sub.3 group; [0192] when RCG1 represents a --O-alkyl
hydroxylamine function or a Pictet-Spengler reaction substrate,
RCG2 may be an aldehyde or ketone function.
[0193] Examples of G that may be mentioned include:
##STR00038##
[0194] The invention relates to cryptophycin payloads of formula
(II) and to conjugates of formula (II):
##STR00039##
in which the linker L is of formula (IV):
##STR00040##
in which: [0195] L1 represents [0196] a single bond or a
NR.sub.16(hetero)aryl-CR.sub.15R.sub.14--O--C(.dbd.O) group if
Y.dbd.(C.sub.1-C.sub.6)alkyl-N(R.sub.11); [0197] a
NR.sub.18--(C.sub.2-C.sub.6)alkyl-NR.sub.17--C(.dbd.O) group or a
NR.sub.16(hetero)aryl-CR.sub.15R.sub.14--O--C(.dbd.O)NR.sub.18--(C.sub.2--
C.sub.6)alkyl-NR.sub.17--C(.dbd.O) group if
Y.dbd.(C.sub.1-C.sub.6)alkyl-O-- or (C.sub.1-C.sub.6)alkyl-S;
[0198] a NR.sub.16(hetero)aryl-CR.sub.15R.sub.14 group if
Y.dbd.C(.dbd.O)O, C(.dbd.O)NH, (C.sub.1-C.sub.6)alkyl-C(.dbd.O)O or
(C.sub.1-C.sub.6)alkyl-C(.dbd.O)NH; [0199] R.sub.11, R.sub.14,
R.sub.15, R.sub.16, R.sub.17 and R.sub.18 represent, independently
of each other, H or a (C.sub.1-C.sub.6)alkyl group; [0200]
(AA).sub.w represents a sequence of w amino acids AA connected
together via peptide bonds; [0201] w represents an integer ranging
from 1 to 12, preferably from 1 to 6 and more particularly 2 or 3;
[0202] L2 represents a single bond or a (C.sub.1-C.sub.6)alkyl
group or a (C.sub.1-C.sub.6)alkyl-(OCH.sub.2CH.sub.2).sub.i group
or a
(C.sub.1-C.sub.6)alkyl-(OCH.sub.2CH.sub.2).sub.i--O(C.sub.1-C.sub.6)alkyl
group or a (CH.sub.2CH.sub.2O)(C.sub.1-C.sub.6)alkyl group or a
CH(SO.sub.3H)--(C.sub.1-C.sub.6)alkyl group or a
(C.sub.1-C.sub.6)alkyl-CH(SO.sub.3H) group or a
(C.sub.1-C.sub.6)alkyl-cyclohexyl group or a
NR.sub.19--(C.sub.1-C.sub.6)alkyl group or a
NR.sub.2O--(CH.sub.2CH.sub.2O).sub.i(C.sub.1-C.sub.6)alkyl group or
a NR.sub.21-aryl group or a NR.sub.21-heteroaryl group or a
(C.sub.1-C.sub.6)alkyl-NR.sub.22C(.dbd.O)--(C.sub.1-C.sub.6)alkyl
group or a
(C.sub.1-C.sub.6)alkyl-NR.sub.22C(.dbd.O)--(C.sub.1-C.sub.6)alkyl-(O-
CH.sub.2CH.sub.2).sub.i group. More particularly L2 represents a
(C.sub.1-C.sub.6)alkyl group or a
(C.sub.1-C.sub.6)alkyl-(OCH.sub.2CH.sub.2).sub.i group or a
CH(SO.sub.3H)--(C.sub.1-C.sub.6)alkyl group; [0203] R.sub.19,
R.sub.20, R.sub.21 and R.sub.22 represent, independently of each
other, H or a (C.sub.1-C.sub.6)alkyl group; [0204] i represents an
integer between 1 and 50 and preferably between 1 and 10 (i may
take all the values between 1 and 50).
[0205] AA denotes a natural or unnatural amino acid, of
configuration D or L, more particularly chosen from: alanine (Ala),
.beta.-alanine, .gamma.-aminobutyric acid,
2-amino-2-cyclohexylacetic acid, 2-amino-2-phenylacetic acid,
arginine (Arg), asparagine (Asn), aspartic acid (Asp), citrulline
(Cit), cysteine (Cys),
.alpha.,.alpha.-dimethyl-.gamma.-aminobutyric acid,
.beta.,.beta.-dimethyl-.gamma.-aminobutyric acid, glutamine (Gln),
glutamic acid (Glu), glycine (Gly), histidine (His), isoleucine
(Ile), leucine (Leu), lysine (Lys), .epsilon.-acetyl-lysine
(AcLys), methionine (Met), ornithine (Orn), phenylalanine (Phe),
proline (Pro), serine (Ser), threonine (Thr), tryptophan (Trp),
tyrosine (Tyr), valine (Val). More particularly, AA is chosen from
alanine (Ala), citrulline (Cit), glutamine (Gln), glycine (Gly),
.epsilon.-acetyl-lysine (AcLys), valine (Val).
[0206] The sequence (AA), has the formula:
##STR00041##
R.sub.23 in which R.sub.23 represents the side chain of one of the
amino acids described above. Examples of sequences are as follows:
Gly-Gly, Phe-Lys, Val-Lys, Val-AcLys, Val-Cit, Phe-Phe-Lys,
D-Phe-Phe-Lys, Gly-Phe-Lys, Ala-Lys, Val-Ala, Phe-Cit, Leu-Cit,
Ile-Cit, Trp-Cit, Phe-Ala, Ala-Phe, Gly-Gly-Gly, Gly-Ala-Phe,
Gly-Val-Cit, Gly-Phe-Leu-Cit, Gly-Phe-Leu-Gly, Ala-Leu-Ala-Leu.
[0207] For Y.dbd.(C.sub.1-C.sub.6)alkyl-N(R.sub.11) and more
particularly CH.sub.2NH, RCG1-L may be one of the following
(IV1-17):
TABLE-US-00001 RCG1 Examples of RCG1-L ##STR00042## ##STR00043##
##STR00044## ##STR00045## ##STR00046## ##STR00047## ##STR00048##
##STR00049## ##STR00050## ##STR00051## ##STR00052## ##STR00053##
##STR00054## ##STR00055## --NH.sub.2 ##STR00056## ##STR00057##
--N.sub.3 ##STR00058## ##STR00059## ##STR00060## ##STR00061##
##STR00062##
in which: [0208] (AA).sub.w represents a sequence of w amino acids
AA connected together via peptide bonds as described above; [0209]
w represents an integer ranging from 1 to 12, preferably from 1 to
6 and more particularly 2 or 3; [0210] i represents an integer
between 1 and 50 and preferably between 1 and 10 (i may take all
the values between 1 and 50); [0211] M1, M2, M3 and M4 are chosen,
independently of each other, from CR.sub.24 and N; [0212] R.sub.19,
R.sub.20, R.sub.21, R.sub.22 and R.sub.24 represent, independently
of each other, a hydrogen atom or a (C.sub.1-C.sub.6)alkyl group,
more particularly a hydrogen atom or a methyl group.
[0213] For Y.dbd.(C.sub.1-C.sub.6)alkyl- or
(C.sub.1-C.sub.6)alkyl-S and more particularly CH.sub.2 or
CH.sub.2S, RCG1-L may be one of the following (IV18-34):
TABLE-US-00002 RCG1 Examples of RCG1-L ##STR00063## ##STR00064##
##STR00065## ##STR00066## ##STR00067## ##STR00068## ##STR00069##
##STR00070## ##STR00071## ##STR00072## ##STR00073## ##STR00074##
##STR00075## ##STR00076## --NH.sub.2 ##STR00077## ##STR00078##
--N.sub.3 ##STR00079## ##STR00080## ##STR00081## ##STR00082##
##STR00083##
in which: [0214] (AA).sub.w represents a sequence of w amino acids
AA connected together via peptide bonds as described above; [0215]
w represents an integer ranging from 1 to 12, preferably from 1 to
6 and more particularly 2 or 3; [0216] i represents an integer
between 1 and 50 and preferably between 1 and 10 (i may take all
the values between 1 and 50); [0217] M.sub.1, M2, M3 and M4 are
chosen, independently of each other, from CR.sub.24 and N; [0218]
R.sub.17, R.sub.18, R.sub.19, R.sub.20, R.sub.21, R.sub.22 and
R.sub.24 represent, independently of each other, hydrogen atom or a
(C.sub.1-C.sub.6)alkyl group, more particularly a hydrogen atom or
a methyl group.
[0219] For Y.dbd.(C.sub.1-C.sub.6)alkyl-N(R.sub.11) and more
particularl yCH.sub.2NH, RCG-L may also be one of the following
(IV35-51):
TABLE-US-00003 RCG1 Examples of RCG1-L ##STR00084## ##STR00085##
##STR00086## ##STR00087## ##STR00088## ##STR00089## ##STR00090##
##STR00091## ##STR00092## ##STR00093## ##STR00094## ##STR00095##
##STR00096## ##STR00097## --NH.sub.2 ##STR00098## ##STR00099##
--N.sub.3 ##STR00100## ##STR00101## ##STR00102## ##STR00103##
##STR00104##
in which: [0220] (AA).sub.w represents a sequence of w amino acids
AA connected together via peptide bonds as described above; [0221]
w represents an integer ranging from 1 to 12, preferably from 1 to
6 and more particularly 2 or 3; [0222] i represents an integer
between 1 and 50 and preferably between 1 and 10 (i may take all
the values between 1 and 50); [0223] J.sub.1, J.sub.2, J.sub.3 and
J.sub.4 are chosen, independently of each other, from CR.sub.24 and
N; [0224] M.sub.1, M.sub.2, M.sub.3 and M.sub.4 are chosen,
independently of each other, from CR.sub.24 and N; [0225] R.sub.14,
R.sub.15, R.sub.16, R.sub.19, R.sub.20, R.sub.21, R.sub.22 and
R.sub.24 represent, independently of each other, a hydrogen atom or
a (C.sub.1-C.sub.6)alkyl group, more particularly a hydrogen atom
or a methyl group.
[0226] For Y.dbd.(C.sub.1-C.sub.6)alkyl- or
(C.sub.1-C.sub.6)alkyl-S and more particularly CH.sub.2 or
CH.sub.2S, RCG1-L may also be one of the following (IV52-68):
TABLE-US-00004 RCG1 Examples of RCG1-L ##STR00105## ##STR00106##
##STR00107## ##STR00108## ##STR00109## ##STR00110## ##STR00111##
##STR00112## ##STR00113## ##STR00114## ##STR00115## ##STR00116##
##STR00117## ##STR00118## --NH.sub.2 ##STR00119## ##STR00120##
--N.sub.3 ##STR00121## ##STR00122## ##STR00123## ##STR00124##
##STR00125##
in which: [0227] (AA).sub.w represents a sequence of w amino acids
AA connected together via peptide bonds as described above; [0228]
w represents an integer ranging from 1 to 12, preferably from 1 to
6 and more particularly 2 or 3; [0229] i represents an integer
between 1 and 50 and preferably between 1 and 10 (i may take all
the values between 1 and 50); [0230] J.sub.1, J.sub.2, J.sub.3 and
J.sub.4 are chosen, independently of each other, from CR.sub.24 and
N; [0231] M.sub.1, M.sub.2, M.sub.3 and M.sub.4 are chosen,
independently of each other, from CR.sub.24 and N; [0232] R.sub.14,
R.sub.15, R.sub.16, R.sub.17, R.sub.18, R.sub.19, R.sub.20,
R.sub.21, R.sub.22 and R.sub.24 represent, independently of each
other, a hydrogen atom or a (C.sub.1-C.sub.6)alkyl group, more
particularly a hydrogen atom or a methyl group.
[0233] For Y.dbd.C(.dbd.O)O, C(.dbd.O)NH,
(C.sub.1-C.sub.6)alkyl-C(.dbd.O)O or
(C.sub.1-C.sub.6)alkyl-C(.dbd.O)NH and more particularly C(.dbd.O)O
or CH.sub.2--C(.dbd.O)O, RCG1-L may be one of the following
(IV69-85):
TABLE-US-00005 RCG1 Examples of RCG1-L ##STR00126## ##STR00127##
##STR00128## ##STR00129## ##STR00130## ##STR00131## ##STR00132##
##STR00133## ##STR00134## ##STR00135## ##STR00136## ##STR00137##
##STR00138## ##STR00139## --NH.sub.2 ##STR00140## ##STR00141##
--N.sub.3 ##STR00142## ##STR00143## ##STR00144## ##STR00145##
##STR00146##
in which: [0234] (AA).sub.w represents a sequence of w amino acids
AA connected together via peptide bonds as described above; [0235]
w represents an integer ranging from 1 to 12, preferably from 1 to
6 and more particularly 2 or 3; [0236] i represents an integer
between 1 and 50 and preferably between 1 and 10 (i may take all
the values between 1 and 50); [0237] J.sub.1, J.sub.2, J.sub.3 and
J.sub.4 are chosen, independently of each other, from CR.sub.24 and
N; [0238] M.sub.1, M.sub.2, M.sub.3 and M.sub.4 are chosen,
independently of each other, from CR.sub.24 and N; [0239] R.sub.14,
R.sub.15, R.sub.16, R.sub.19, R.sub.20, R.sub.21, R.sub.22 and
R.sub.24 represent, independently of each other, a hydrogen atom or
a (C.sub.1-C.sub.6)alkyl group, more particularly a hydrogen atom
or a methyl group.
[0240] For Y.dbd.C(.dbd.O) or (C.sub.1-C.sub.6)alkyl-C(.dbd.O), the
invention also relates to cryptophycin payloads of formula (II) and
to conjugates of formula (III):
##STR00147##
in which the linker L is of formula (V):
##STR00148##
in which: [0241] (AA)'.sub.w represents a sequence of w amino acids
AA connected together via peptide bonds; [0242] w represents an
integer ranging from 1 to 12, preferably from 1 to 6 and more
particularly 2 or 3; [0243] R.sub.25 represents a hydrogen atom or
a (C.sub.1-C.sub.6)alkyl group; [0244] L3 represents a
(C.sub.1-C.sub.6)alkyl group or a
(CH.sub.2CH.sub.2O).sub.i--(C.sub.1-C.sub.6)alkyl group or a
(C.sub.1-C.sub.6)alkyl-(OCH.sub.2CH.sub.2).sub.i group or a
CH(SO.sub.3H)--(C.sub.1-C.sub.6)alkyl group or or a
(C.sub.1-C.sub.6)alkyl-(OCH.sub.2CH.sub.2).sub.i--O(C.sub.1-C.sub.6)alkyl
group or a NR.sub.19--(C.sub.1-C.sub.6)alkyl group or a
NR.sub.20--(CH.sub.2CH.sub.2O).sub.iCH.sub.2CH.sub.2 group or a
(C.sub.1-C.sub.6)alkyl-cyclohexyl-C(.dbd.O)NR.sub.19--(C.sub.1-C.sub.6)al-
kyl group or a
(C.sub.1-C.sub.6)alkyl-cyclohexyl-C(.dbd.O)NR.sub.20--(CH.sub.2CH.sub.2O)-
.sub.i--CH.sub.2CH.sub.2 group or a
NR.sub.21-aryl-C(.dbd.O)NR.sub.19--(C.sub.1-C.sub.6)alkyl group or
a NR.sub.21-heteroaryl-C(.dbd.O)NR.sub.19--(C.sub.1-C.sub.6)alkyl
group or a
(C.sub.1-C.sub.6)alkyl-NR.sub.22C(.dbd.O)(CH.sub.2CH.sub.2O).sub.i--(C.-
sub.1-C.sub.6)alkyl group; [0245] R.sub.19, R.sub.20, R.sub.21,
R.sub.22 and R.sub.25 represents a hydrogen atom or a
(C.sub.1-C.sub.6)alkyl group; [0246] RCG1 represents a reactive
chemical group that is reactive towards a reactive chemical group
present on the antibody, as defined above; [0247] R.sub.1, R.sub.2,
R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and
R.sub.10 are as defined above.
[0248] AA denotes a natural or unnatural amino acid, of
configuration D or L, more particularly chosen from: alanine (Ala),
.beta.-alanine, .gamma.-aminobutyric acid,
2-amino-2-cyclohexylacetic acid, 2-amino-2-phenylacetic acid,
arginine (Arg), asparagine (Asn), aspartic acid (Asp), citrulline
(Cit), cysteine (Cys),
.alpha.,.alpha.-dimethyl-.gamma.-aminobutyric acid,
.beta.,.beta.-dimethyl-.gamma.-aminobutyric acid, glutamine (Gln),
glutamic acid (Glu), glycine (Gly), histidine (His), isoleucine
(Ile), leucine (Leu), lysine (Lys), .epsilon.-acetyl-lysine
(AcLys), methionine (Met), ornithine (Orn), phenylalanine (Phe),
proline (Pro), serine (Ser), threonine (Thr), tryptophan (Trp),
tyrosine (Tyr), valine (Val). More particularly, AA is chosen from
alanine (Ala), citruline (Cit), gutamine (Gn), glycine (Gly),
.epsilon.-acetyl-ylsine (AcLys), valine (Val)
[0249] The sequence (AA)'.sub.w has the formula:
##STR00149##
R.sub.6 in which R.sub.26 represents the side chain of one of the
amino acids described above. Examples of sequences areas follows:
Gly-Gly, Lys-Phe, Lys-Val, AcLys-Val, Cit-Val, Lys-Phe-Phe,
Lys-Phe-DPhe, Lys-Phe-Gly, Lys-Ala, Ala-Val, Cit-Phe, Cit-Leu,
Cit-Ile, Cit-Trp, Ala-Phe, Phe-Ala, Gly-Gly-Gly, Phe-Ala-Gly,
Cit-Val-Gly, Cit-Leu-Phe-Gly, Gly-Leu-Phe-Gly, Leu-Ala-Leu-Ala.
[0250] For Y.dbd.C(.dbd.O) or (C.sub.1-C.sub.6)alkyl-C(.dbd.O) and
more particularly C(.dbd.O) or CH.sub.2--C(.dbd.O), RCG1-L may be
one of the following (V86-101):
TABLE-US-00006 RCG1 Examples of RCG1-L ##STR00150## ##STR00151##
##STR00152## ##STR00153## ##STR00154## ##STR00155## ##STR00156##
##STR00157## ##STR00158## ##STR00159## ##STR00160## ##STR00161##
##STR00162## --NH.sub.2 H.sub.2N--ALK--NR.sub.25--(AA)'w-- (V96)
##STR00163## --N.sub.3 N.sub.3--ALK--NR.sub.25--(AA)'w-- (V98)
##STR00164## ##STR00165## ##STR00166## ##STR00167##
in which: [0251] (AA)'.sub.W represents a sequence of w amino acids
AA connected together via peptide bonds as described above; [0252]
w represents an integer ranging from 1 to 12, preferably from 1 to
6 and more particularly 2 or 3; [0253] i represents an integer
between 1 and 50 and preferably between 1 and 10 (i may take all
the values between 1 and 50); [0254] M.sub.1, M.sub.2, M.sub.3 and
M.sub.4 are chosen, independently of each other, from CR.sub.24 and
N; [0255] R.sub.19, R.sub.20, R.sub.21, R.sub.22, R.sub.24 and
R.sub.25 represent, independently of each other, a hydrogen atom or
a (C.sub.1-C.sub.6)alkyl group, more particularly ahydrogen atom or
amethyl group.
[0256] The linker L may also be chosen from the illustrated
compounds.
[0257] In accordance with the invention, the compounds of general
formula (I), (II) and (II) can be prepared by the following
processes.
Process for Preparing the cryptophycin Compounds General Route a
for the Preparation of the Compounds of Formula (I) in the Case
where W.dbd.CH.sub.2N.sub.3 or CH.sub.2NH.sub.2
##STR00168##
[0258] Fragments A, B, C and D allow the preparation of
cryptophycin compounds P.sub.1 to P.sub.3 with the aid of the steps
detailed below:
[0259] Step (i): peptidic coupling between fragments AD1 and BC in
the presence of coupling reagents such as, for example, HOAt and
HATU;
[0260] Step (ii): deprotection in acidic conditions using for
example TFA and macrocyclization in the presence of coupling
reagents such as, for example, HOAt and HATU;
[0261] Step (iii): oxidation of the olefine to form the epoxide
using, for example, m-CPBA;
[0262] Step (v): reduction of the azido group using, for example,
TCEP.
[0263] Fragments A and B were prepared according to the synthesis
described below. Fragments C protected as methyl esters are
commercially available for R.sub.4.dbd.H, R.sub.5=Me (R),
R.sub.2.dbd.R.sub.3.dbd.H (CAS number [92535-26-7]); R.sub.4.dbd.H,
R.sub.5=Me (S), R.sub.2.dbd.R.sub.3.dbd.H (CAS number
[118138-56-0]); R.sub.4.dbd.R.sub.5=Me, R.sub.2.dbd.R.sub.3.dbd.H
(CAS number [25307-82-8]); R.sub.2.dbd.H, R.sub.3=Me (R),
R.sub.4.dbd.H, R.sub.5=Me (R) (CAS number [86544-92-5]);
R.sub.2.dbd.H, R.sub.3=Me (S), R.sub.4.dbd.H, R.sub.5=Me (R) (CAS
number [86544-93-6]); R.sub.2.dbd.H, R.sub.3=Me (R),
R.sub.4.dbd.R.sub.5=Me (CAS number [1315052-25-5]); R.sub.2.dbd.H,
R.sub.3=Me (S), R.sub.4.dbd.R.sub.5=Me (CAS number [1315050-96-4]);
R.sub.2.dbd.H, R.sub.3.dbd.iPr (R), R.sub.4.dbd.R.sub.5=Me (CAS
number [1314999-06-8]); R.sub.2.dbd.H, R.sub.3.dbd.iPr (S),
R.sub.4.dbd.R.sub.5=Me (CAS number [1315054-33-1]);
R.sub.2.dbd.R.sub.3.dbd.R.sub.4.dbd.R.sub.5=Me (CAS number
[90886-53-6]); R.sub.4 and R.sub.5 form together with the carbon
atom to which they are attached a cyclopropyl group (CAS number
[914226-26-9]). They may also be prepared as described in the
examples. Non-commercially available fragments C were prepared as
described in the examples. All fragments D are commercially
available: L-Fmoc-Ala-OH (CAS number [35661-39-3]); L-Fmoc-Val-OH
(CAS number [68858-20-8]); L-Fmoc-tert-Leu-OH (CAS number
[132684-60-7]); L-Fmoc-Leu-OH (CAS number [35661-60-0]);
L-Fmoc-NMe-Leu-OH (CAS number [103478-62-2]);
L-Fmoc-3-dimethylamino-Ala-OH (CAS number [587880-86-2]);
L-Fmoc-(Oallyl)Asp-OH (CAS number [146982-24-3]);
L-Fmoc-4-methyl-Leu-OH (CAS number [139551-74-9]). Building blocks
AD1 and BC were prepared according to the synthesis described
below.
General Route B for the Preparation of the Compounds of Formula (I)
in the Case where W.dbd.CH.sub.2OH or CH.sub.2N.sub.3 or
CH.sub.2NH.sub.2
##STR00169##
[0264] Fragments A, B, C and D allow the preparation of
cryptophycin compounds P2 to P4 with the aid of the steps detailed
below:
[0265] Step (i): peptidic coupling between fragments AD1 and BC in
the presence of coupling reagents such as, for example, HOAt and
HATU;
[0266] Step (ii): deprotection in acidic conditions using for
example TFA, macrocyclization in the presence of coupling reagents
such as, for example, HOAt and HATU and acetate hydrolysis at pH
6-7 using for example NaOH in a mixture of water and AcOEt;
[0267] Step (iii): benzylic alcohol protection as a silyl ether
using for example chlorotriisopropylsilane in the presence of a
base such as, for example, imidazole; oxidation of the olefine to
form the epoxide using, for example, m-CPBA; deprotection of the
silyl ether using, for example, a TBAF solution.
[0268] Step (iv): azidation in the presence of DPPA and a base such
as, for example, DBU;
[0269] Step (v): reduction of the azido group using, for example,
TCEP.
[0270] Fragments A and B were prepared according to the synthesis
described below. Fragments C were either commercially available as
reported in the previous section or prepared as described in the
examples. All fragments D are commercially available as reported in
the previous section. Building blocks AD2 and BC were prepared
according to the synthesis described below.
General Route C for the Preparation of the Compounds of Formula (I)
in the Case where W.dbd.CH.sub.2OH or CH.sub.2N.sub.3 or
CH.sub.2NH.sub.2
##STR00170##
[0271] Sakurai alcohol and fragments B, C and D allow the
preparation of cryptophycin compounds P.sub.2 to P.sub.4 with the
aid of the steps detailed below:
[0272] Step (i): peptidic coupling between fragments AD3 and
alternative BC in the presence of coupling reagents such as, for
example, HOAt and HATU;
[0273] Step (ii): macrocyclization by ring closing metathesis in
the presence of a catalyst such as, for example, Grubbs I
catalyst;
[0274] Step (iii): deprotection of the p-methoxybenzyl ether in
acidic conditions such as, for example, 10% TFA;
[0275] Step (iv): oxidation of the alcohol using an oxidizing agent
such as, for example, TEMPO in the presence of sodium
hypochlorite;
[0276] Step (v): introduction of the epoxide by asymmetric
Corey-Chaykovsky reaction using appropriately substituted
isothiocineole-derived chiral sulfonium in the presence of a base
such as, for example, phosphazene base P.sub.2-Et;
[0277] Step (vi): reduction of the azido group using, for example,
TCEP.
[0278] Sakurai alcohol and fragment B were prepared according to
the synthesis described below. Fragments C were either commercially
available as reported in the previous section or prepared as
described in the examples. All fragments D are commercially
available as reported in the previous section. Building blocks AD3
and alternative BC were prepared according to the synthesis
described below.
Preparation of the Compounds of Formula (I) in the Case where
W.dbd.CH.sub.2SH
##STR00171##
[0279] P.sub.4 allows the preparation of other cryptophycin
compounds P.sub.5 and P.sub.6 with the aid of the steps detailed
below:
[0280] Step (i): introduction of the chloro group using
methanesulfonyl chloride in the presence of a base such as, for
example, DIEA;
[0281] Step (ii): functionalization using tetrabutylammonium
trimethylsilylthiolate prepared in situ from TBAF and
hexamethyldisilathiane according to Hu J., et al., J. Org. Chem.
1999, 64, 4959-496: in the course of this reaction, the
intermediate dimer depicted in Scheme 3 is usually formed;
[0282] Step (iii): reduction of the dimer using a phosphine such
as, for example, TCEP.
[0283] Schemes 1, 2, 3 and 4 describe the cases n=1 but may also
apply for the preparation of compounds of formula (I) in the case
where n>1 starting from P.sub.2, P.sub.3 or P.sub.4 with the aid
of the steps detailed below and described in Scheme 2 of
WO2011/001052:
##STR00172##
[0284] Step (i): opening of the epoxide ring in acidic medium so as
to obtain the diol function; concentrated perchloric acid may be
used, for example;
[0285] Step (ii): oxidative cleavage of the diol using, for
example, sodium periodate;
[0286] Step (iii): Wittig reaction using a suitable phosphonium
halide, for example a bromide, and a strong base, for instance
BuLi;
[0287] Step (iv): oxidation of the olefine to form the epoxide
using, for example, m-CPBA;
[0288] Step (v): deprotection of the silyl ether using, for
example, a TBAF solution.
Preparation of the Compounds of Formula (I) in the Case where
W.dbd.CO.sub.2H
##STR00173##
[0289] P.sub.4 allows the preparation of other cryptophycin
compounds P.sub.7 and P.sub.8 with the aid of the steps detailed
below:
[0290] Step (i): oxidation using the Dess-Martin reagent;
[0291] Step (ii): oxidation of Pinnick type in the presence of 2
methyl-2-butene (Pinnick H. W., Tetrahedron 1981, 37,
2091-2096).
[0292] Scheme 6 describes the case n=0 but may also apply for the
preparation of compounds of formula (I) in the case where
W.dbd.(CH.sub.2).sub.nCO.sub.2H starting from an analog of P.sub.4
bearing a (CH.sub.2).sub.n+1OH group. Schemes 1, 2, 3, 4, 5 and 6
are given for a linker in the para position, but may identically
apply for the ortho or meta positions. Similarly, they are given
for a cryptophycin compound, but may also apply to the preparation
of other compounds of formula (I), especially D.sub.1-D.sub.19.
Process for Preparing the Cryptophycin Payloads
[0293] The compounds of formula (II) might be prepared according to
Scheme 7 starting with a cryptophycin compound of formula (I) and a
linker precursor (LP);
##STR00174##
[0294] W represents [0295] (C.sub.1-C.sub.6)alkyl-NH(R.sub.11),
more particularly (CH.sub.2).sub.nNHR.sub.11; [0296]
(C.sub.1-C.sub.6)alkyl-OH, more particularly (CH.sub.2).sub.nOH;
[0297] (C.sub.1-C.sub.6)alkyl-SH, more particularly
(CH.sub.2).sub.nSH; [0298] CO.sub.2H; [0299]
(C.sub.1-C.sub.6)alkyl-CO.sub.2H, more particularly
(CH.sub.2).sub.nCO.sub.2H; or [0300]
(C.sub.1-C.sub.6)alkyl-N.sub.3. in which R.sub.11 represents a
hydrogen atom or a group (C.sub.1-C.sub.6)alkyl, more particularly
a methyl group.
[0301] The linker precursor LP has the function of introducing a
precursor of the linker L into the cryptophycin compound after
reaction between the group W and a chemical function present on
LP.
[0302] In Scheme 7, several steps and/or reactions may be necessary
to prepare the cryptophycin payload (II) starting from the
cryptophycin compound (I). For example, in the case where
Z.sub.aR.sub.a=--O--NHS, a linker L for which
Z.sub.aR.sub.a=--O-allyl may be introduced using the corresponding
linker precursor, followed by deprotecting the ester function and
introducing --O--NHS. Deprotection may be performed by treatment
with a palladium catalyst, for example Pd(PPh.sub.3).sub.4 in the
presence of a scavenger amine, for example morpholine; the
activation may be performed with DSC in the presence of a base such
as, for example, DIEA or with NHS in the presence of a coupling
agent such as, for example, DCC. This conversion of a group
Z.sub.aR.sub.a into another group Z.sub.aR.sub.a (e.g.
--O-allyl.fwdarw.--O--NHS) may be applied to obtain other groups
Z.sub.aR.sub.a, especially those described previously.
[0303] Scheme 7' similarly illustrates the preparation of a
cryptophycin compound comprising a linker bearing respectively, a
maleimido, a haloacetamido, an amino or an azido group (L*
represents a fragment of a linker such that L=-L*-maleimido or
L=-L*-haloacetamido or L=-L*--NH.sub.2-- or L=-L*--N.sub.3).
##STR00175##
[0304] These compounds are obtained by reaction between a
cryptophycin compound comprising a linker L' comprising an amino
group and a modifying agent for introducing, respectively, a
maleimido, a haloacetamido, an amino or an azido group.
[0305] The compounds of formula (II) might alternatively be
prepared according to Scheme 8 starting with the same cryptophycin
compound of formula (I) and another linker precursor (LP'):
##STR00176##
[0306] In Scheme 8, several steps and/or reactions may be necessary
to arrive at the cryptophycin payload (II) starting from the
cryptophycin compound (I). For example, in the case where
Z.sub.aR.sub.a.dbd.--O--NHS, a protected linker precursor L' may be
introduced, followed by deprotection and coupling to a linker
precursor L'' to introduce the carboxylic acid function that may be
directly activated to Z.sub.aR.sub.a=--O--NHS or first deprotected
and subsequently activated (L' and L'' represent fragments of
linker such that L=L'-L''). Deprotection may be performed by
treatment with a base, for example, piperidine; coupling to a
linker L'' may proceed through opening of a cyclic anhydride, for
example, glutaric anhydride; the activation may be performed with
DSC in the presence of a base such as, for example, DIEA or with
NHS in the presence of a coupling agent such as, for example,
DCC.
[0307] An example of reaction between the group W and a chemical
function present on LP is an amidation either between a linker
precursor LP bearing a carboxylic acid function and
W.dbd.(CH.sub.2).sub.nNH.sub.2 or between a linker precursor LP
bearing an amine function and W.dbd.CO.sub.2H or
(CH.sub.2).sub.nCO.sub.2H: this reaction may be performed in the
presence of a coupling agent such as, for example, EDCI or HOBt. It
is also possible to react a linker precursor LP bearing an amine
function and W'.dbd.(CH.sub.2).sub.nO--C(.dbd.O)--O-(4-nitrophenyl)
obtained from W.dbd.(CH.sub.2).sub.nOH and p-nitrophenyl
chloroformate (activation of the alcohol in the form of carbonate)
according to the scheme below (R.sub.17.dbd.H or
(C.sub.1-C.sub.6)alkyl):
--NHR.sub.17+crypto-(CH.sub.2).sub.nO--C(.dbd.O)--O-(4-nitrophenyl).fwda-
rw.crypto-(CH.sub.2).sub.nO--C(.dbd.O)--NR.sub.17--
[0308] The same kind of reaction can also be performed between a
linker precursor LP bearing an alcohol function activated as a
carbonate and W.dbd.(CH.sub.2).sub.nNH.sub.2. Another example of
reaction is an esterification between a linker precursor bearing an
alcohol function and W.dbd.CO.sub.2H or (CH.sub.2).sub.nCO.sub.2H:
this reaction may be performed in the presence of a coupling agent
such as, for example, MNBA. Another example of reaction is a
copper-catalyzed azide-alkyne cycloaddition between a linker
precursor bearing an alkyne function and W.dbd.(CH.sub.2)N.sub.3:
this reaction may be performed in the presence of copper sulfate
and sodium ascorbate.
Preparation of the Compounds of Formula (II) in the Case where
W.dbd.(CH.sub.2).sub.nNH.sub.2 and L=(IV1) with n=1, R.sub.15.dbd.H
and ALK=(CH.sub.2).sub.3 Based on Scheme 7
##STR00177##
[0309] Step (i): peptidic coupling in the presence of coupling
reagents such as, for example, EDC and HOBt, and a base such as,
for example, DIEA;
[0310] Step (ii): deprotection of the allyl ester in the presence
of a catalyst such as, for example,
tetrakis-(triphenylphosphine)palladium;
[0311] Step (iii): activation of the carboxylic acid as a NHS ester
by treatment with DSC in the presence of a base such as, for
example, DIEA.
Preparation of the Compounds of Formula (II) in the Case where
W.dbd.(CH.sub.2).sub.nNH.sub.2 and L=(IV1) with n=1, R.sub.11.dbd.H
and ALK=(CH.sub.2).sub.3 Based on Scheme 8
##STR00178##
[0312] Step (i): peptidic coupling in the presence of coupling
reagents such as, for example, EDC and HOBt and a base such as, for
example, DIEA;
[0313] Step (ii): deprotection of the Fmoc amine in the presence of
a base such as, for example, piperidine;
[0314] Step (iii): coupling to glutaric anhydride;
[0315] Step (iv): activation of the carboxylic acid as a NHS ester
by treatment with DSC in the presence of a base such as, for
example, DIEA.
[0316] Schemes 9 and 10 describe the case L(IV1) with n=1,
R.sub.11.dbd.H and ALK=(CH.sub.2).sub.3 but they may also apply to
other linkers L with RCG1=C(.dbd.O)ONHS, namely the case L(IV1)
with n.noteq.1 and/or R.sub.11.noteq.H and/or
ALK.noteq.(CH.sub.2).sub.3 and the cases L(IV2) and L(IV3). They
are given for a linker in the para position, but may identically
apply for the ortho or meta positions. Similarly, they are given
for a cryptophycin compound, but may also apply to the preparation
of other compounds of formula (I), especially D.sub.1-D.sub.19.
Preparation of the Compounds of Formula (II) in the Case where
W.dbd.(CH.sub.2).sub.nNH.sub.2 with n=1, R.sub.11.dbd.H and
RCG1=Maleimido, Haloacetamido, NH.sub.2, N.sub.3 or Cyclooctyne
Namely Linkers L(IV4) to L(IV17)
##STR00179##
[0317] Step (i):peptidic coupling in the presence of coupling
reagents such as, for example, EDC and HOBt and abase such as, for
example, DIEA;
[0318] Step (ii): deprotection of the Fmoc amine in the presence of
abase such as, for example, piperidine.
[0319] Scheme 11 describes the cases L(IV4) with n=1,
R.sub.11.dbd.H and ALK=(CH.sub.2).sub.5, L(IV8) with n=1 and
R.sub.11.dbd.H, L(IV12) with n=1, R.sub.11.dbd.H and
ALK=(CH.sub.2).sub.4, L(IV14) with n=1, R.sub.11.dbd.H and
ALK=(CH.sub.2).sub.3 and L(IV16) with n=1, R.sub.11.dbd.H,
ALK=(CH.sub.2).sub.3 and ALK'=(CH.sub.2).sub.2 but it may also
apply to other linkers L(IV4) to L(IV17) with RCG1=maleimido,
iodoacetamido, NH.sub.2, N.sub.3 or cyclooctyne. It is depicted for
an iodoacetamido reactive group but may identically apply for a
bromoacetamido reactive group. It is given for a linker in the para
position, but may identically apply for the ortho or meta
positions. Similarly, it is given for a cryptophycin compound, but
may also apply to the preparation of other compounds of formula
(I), especially D.sub.1-D.sub.19.
Preparation of the Compounds of Formula (II) in the Case where
W.dbd.(CH.sub.2).sub.nX with X.dbd.O or S and L=(IV18) with n=1,
R.sub.17 and R.sub.18.dbd.H and ALK=(CH.sub.2).sub.3 based on
Scheme 7
##STR00180##
[0320] Step (i): activation of the benzylic alcohol or benzylic
thiol as a p-nitrophenyl-(thio)carbonate by treatment with
p-nitrophenyl-chloroformate in the presence of a base such as, for
example, DIEA;
[0321] Step (ii): formation of the (thio)carbamate by reacting with
an amine in the presence of a base such as, for example, DIEA;
[0322] Step (iii): deprotection of the allyl ester in the presence
of a catalyst such as, for example,
tetrakis(triphenylphosphine)palladium;
[0323] Step (iv): activation of the carboxylic acid as a NHS ester
by treatment with DSC in the presence of a base such as, for
example, DIEA.
Preparation of the Compounds of Formula (II) in the Case where
W.dbd.(CH.sub.2).sub.nX with X.dbd.O or S and L=(IV18) with n=1,
R.sub.17 and R.sub.18.dbd.H and ALK=(CH.sub.2).sub.3 Based on
Scheme 8
##STR00181##
[0324] Step (i): formation of the (thio)carbamate by reacting with
an amine in the presence of abase such as, for example, DIEA;
[0325] Step (ii): deprotection of the Fmoc amine in the presence of
abase such as, for example, piperidine;
[0326] Step (iii): coupling to glutaric anhydride;
[0327] Step (iv): activation of the carboxylic acid as a NHS ester
by treatment with DSC in the presence of abase such as, for
example, DIEA.
[0328] Schemes 12 and 13 describe the case L(V18) with n=1,
R.sub.17 and R.sub.18.dbd.H and ALK=(CH.sub.2).sub.3 but they may
also apply to other linkers L with RCG1=C(.dbd.O)ONHS, namely the
case L(IV18) with n.noteq.1 and/or R.sub.17, R.sub.18.noteq.H
and/or ALK.noteq.(CH.sub.2).sub.3 and the cases L(IV19) and
L(IV20). They are given for a linker in the para position, but may
identically apply for the ortho or meta positions. Similarly, they
are given for a cryptophycin compound, but may also apply to the
preparation of other compounds of formula (I), especially
D.sub.1-D.sub.19.
Preparation of the Compounds of Formula (II) in the Case where
W.dbd.(CH.sub.2).sub.nX with X.dbd.O or S and RCG1=Maleimido,
Haloacetamido, NH.sub.2, N.sub.3 or Cyclooctyne Namely Linkers
L(IV21) to (IV34)
##STR00182##
[0329] Step (i): formation of the (thio)carbamate, the reaction is
performed in the presence of abase such as, for example, DIEA;
[0330] Step (ii): deprotection of the Fmoc amine in the presence of
a base such as, for example, piperidine.
[0331] Scheme 14 describes the case L(IV21) with n=1, R.sub.17 and
R.sub.18.dbd.H and ALK=(CH.sub.2).sub.5, the case L(IV25) with n=1
and R.sub.17 and R.sub.18.dbd.H, the case L(IV29) with n=1,
R.sub.17 and R.sub.18.dbd.H and ALK=(CH.sub.2).sub.4, the case
L(IV31) with n=1, R.sub.17 and R.sub.18.dbd.H and
ALK=(CH.sub.2).sub.3 and the case L(IV33) with n=1, R.sub.17,
R.sub.18 and R.sub.22.dbd.H, ALK=(CH.sub.2).sub.3 and
ALK'.dbd.(CH.sub.2).sub.2 but it may also apply to other linkers
L(IV21 to 34) with RCG1=maleimido, iodoacetamido, NH.sub.2, N.sub.3
or cyclooctyne. It is depicted for an iodoacetamido reactive group
but may identically apply for a bromoacetamido reactive group. It
is given for a linker in the para position, but may identically
apply for the ortho or meta positions. Similarly, it is given for a
cryptophycin compound, but may also apply to the preparation of
other compounds of formula (I), especially D.sub.1-D.sub.19.
Preparation of the Compounds of Formula (II) in the Case where
W.dbd.(CH.sub.2).sub.nNH.sub.2 and L=(IV35) with n=1,
R.sub.11.dbd.R.sub.14.dbd.R.sub.15.dbd.R.sub.16.dbd.H,
J.sub.1=J.sub.2=J.sub.3=J.sub.4=CH and ALK=(CH.sub.2).sub.3 Based
on Scheme 7
##STR00183##
[0332] Step (i): formation of the carbamate, the reaction is
performed in the presence of a base such as, for example, DIEA;
[0333] Step (ii): deprotection of the allyl ester in the presence
of a catalyst such as, for example,
tetrakis-(triphenylphosphine)palladium;
[0334] Step (iii): activation of the carboxylic acid as a NHS ester
by treatment with DSC in the presence of a base such as, for
example, DIEA.
Preparation of the Compounds of Formula (II) in the Case where
W.dbd.(CH.sub.2).sub.nNH.sub.2 and L=(IV35) with n=1,
R.sub.11.dbd.R.sub.14.dbd.R.sub.15.dbd.R.sub.16.dbd.H,
J.sub.1=J.sub.2=J.sub.3=J.sub.4=CH and ALK=(CH.sub.2).sub.3 Based
on Scheme 8
##STR00184##
[0335] Step (i): formation of the carbamate, the reaction is
performed in the presence of a base such as, for example, DIEA in
the presence of a suitable p-nitrophenylcarbonate reagent;
[0336] Step (ii): deprotection of the Fmoc amine in the presence of
a base such as, for example, piperidine;
[0337] Step (iii): coupling to glutaric anhydride;
[0338] Step (iv): activation of the carboxylic acid as a NHS ester
by treatment with DSC in the presence of a base such as, for
example, DIEA.
[0339] Schemes 15 and 16 describe the case L(IV35) with n=1,
R.sub.11.dbd.R.sub.14.dbd.R.sub.15.dbd.R.sub.16.dbd.H,
J.sub.1=J.sub.2=J.sub.3=J.sub.4=CH, a para-benzylic alcohol and
ALK=(CH.sub.2).sub.3 but they may also apply to other linkers L
with RCG1=C(.dbd.O)ONHS, namely the case L(IV35) with n.noteq.1
and/or R.sub.11, R.sub.14, R.sub.15, R.sub.16.noteq.H and/or
J.sub.1, J.sub.2, J.sub.3, J.sub.4.noteq.CH and/or an
ortho-benzylic alcohol and/or ALK.noteq.(CH.sub.2).sub.3 and the
cases L(IV36) and L(IV37). They are given for a linker in the para
position, but may identically apply for the ortho or meta
positions. Similarly, they are given for a cryptophycin compound,
but may also apply to the preparation of other compounds of formula
(I), especially D.sub.1-D.sub.19.
Preparation of the Compounds of Formula (II) in the Case where
W.dbd.(CH.sub.2).sub.nNH.sub.2 with n=1,
R.sub.11.dbd.R.sub.14.dbd.R.sub.15.dbd.R.sub.16.dbd.H,
J.sub.1=J.sub.2=J.sub.3=J.sub.4=CH and RCG1=Maleimido,
Haloacetamido, NH.sub.2, N.sub.3 or Cyclooctyne Namely Linkers
L(IV38) to L(IV151)
##STR00185##
[0340] Step (i): formation of the carbamate, the reaction is
performed in the presence of abase such as, for example, DIEA in
the presence of a suitable p-nitrophenylcarbonate reagent;
[0341] Step (ii): deprotection of the Fmoc amine in the presence of
a base such as, for example, piperidine.
[0342] Scheme 17 describes the cases L(IV38) with n=1,
R.sub.11.dbd.R.sub.14.dbd.R.sub.15.dbd.R.sub.16.dbd.H,
J.sub.1=J.sub.2=J.sub.3=J.sub.4=CH, a para-benzylic alcohol and
ALK=(CH.sub.2), L(IV42) with n=1,
R.sub.11.dbd.R.sub.14.dbd.R.sub.15.dbd.R.sub.16.dbd.H and
J.sub.1=J.sub.2=J.sub.3=J.sub.4=CH and a para-benzylic alcohol,
L(IV46) with n=1,
R.sub.11.dbd.R.sub.14.dbd.R.sub.15.dbd.R.sub.16.dbd.H,
J.sub.1=J.sub.2=J.sub.3=J.sub.4=CH, a para-benzylic alcohol and
ALK=(CH.sub.2).sub.4, L(IV48) with n=1,
R.sub.11.dbd.R.sub.14.dbd.R.sub.15.dbd.R.sub.16.dbd.H,
J.sub.1=J.sub.2=J.sub.3=J.sub.4=CH, a para-benzylic alcohol and
ALK=(CH.sub.2).sub.3 and L(IV50) with n=1,
R.sub.11.dbd.R.sub.14.dbd.R.sub.15.dbd.R.sub.16.dbd.R.sub.22.dbd.H,
J.sub.1=J.sub.2=J.sub.3=J.sub.4=CH, a para-benzylic alcohol,
ALK=(CH.sub.2).sub.3 and ALK'=(CH.sub.2).sub.2 but it may also
apply to other linkers L(IV38) to L(IV51) with RCG1=maleimido,
iodoacetamido, NH.sub.2, N.sub.3 or cyclooctyne. It is given with a
para-benzylic alcohol but it may also apply to an ortho-benzylic
alcohol. It is depicted for an iodoacetamido reactive group but may
identically apply for a bromoacetamido reactive group. It is given
for a linker in the para position, but may identically apply for
the ortho or meta positions. Similarly, it is given for a
cryptophycin compound, but may also apply to the preparation of
other compounds of formula (I), especially D.sub.1-D.sub.19.
Preparation of the Compounds of Formula (II) in the Case where
W.dbd.(CH.sub.2).sub.nX with X.dbd.O or S and L=(IV52) with n=1,
R.sub.14.dbd.R.sub.15.dbd.R.sub.16.dbd.R.sub.17.dbd.R.sub.18.dbd.H,
J.sub.1=J.sub.2=J.sub.3=J.sub.4=CH and ALK=(CH.sub.2).sub.3 Based
on Scheme 7
##STR00186##
[0343] Step (i): formation of the (thio)carbamate by reacting with
an amine in the presence of a base such as, for example, DIEA;
[0344] Step (ii): deprotection of the allyl ester in the presence
of a catalyst such as, for example,
tetrakis(triphenylphosphine)palladium;
[0345] Step (iii): activation of the carboxylic acid as a NHS ester
by treatment with DSC in the presence of a base such as, for
example, DIEA.
Preparation of the Compounds of Formula (II) in the Case where
W.dbd.(CH.sub.2).sub.nX with X.dbd.O or S and L=(IV52) with n=1,
R.sub.14.dbd.R.sub.15.dbd.R.sub.16.dbd.R.sub.17.dbd.R.sub.18.dbd.H,
J.sub.1=J.sub.2=J.sub.3=J.sub.4=CH and ALK=(CH.sub.2).sub.3 Based
on Scheme 8
##STR00187##
[0346] Step (i): formation of the (thio)carbamate by reacting with
an amine in the presence of abase such as, for example, DIEA;
[0347] Step (ii): deprotection of the Fmoc amine in the presence of
a base such as, for example, piperidine;
[0348] Step (iii): coupling to glutaric anhydride;
[0349] Step (iv): activation of the carboxylicacid as a NHS ester
by treatment with DSC in the presence such as, for example,
DIEA.
[0350] Schemes 18 and 19 describe the case L(IV52) with n=1,
R.sub.14.dbd.R.sub.15.dbd.R.sub.16.dbd.R.sub.17.dbd.R.sub.18.dbd.H,
J.sub.1=J.sub.2=J.sub.3=J.sub.4=CH, a para-benzylic alcohol and
ALK=(CH.sub.2).sub.3 but they may also apply to other linkers L
with RCG1=C(.dbd.O)ONHS, namely the case L(IV52) with n1 and/or
R.sub.14, R.sub.15, R.sub.16, R.sub.17, R.sub.18.noteq.H and/or
J.sub.1, J.sub.2, J.sub.3, J.sub.4.noteq.CH and/or an
ortho-benzylic alcohol and/or ALK.noteq.(CH.sub.2).sub.3 and the
cases L(IV53) and L(IV54). They are given for a linker in the para
position, but may identically apply for the ortho or meta
positions. Similarly, they are given for a cryptophycin compound,
but may also apply to the preparation of other compounds of formula
(I), especially D.sub.1-D.sub.19.
Preparation of the Compounds of Formula (II) in the Case where
W.dbd.(CH.sub.2).sub.nX with X.dbd.O or S and RCG1=Maleimido,
Haloacetamido, NH.sub.2, N.sub.3 or Cyclooctyne Namely Linkers
L(IV55) to (IV68)
##STR00188##
[0351] Step (i): formation of the (thio)carbamate by reacting with
an amine in the presence of abase such as, for example, DIEA;
[0352] Step (ii): deprotection of the Fmoc amine in the presence of
abase such as, for example, piperidine.
[0353] Scheme 20 describes the case L(V55) with
n=1,R.sub.14.dbd.R.sub.15.dbd.R.sub.16.dbd.R.sub.17.dbd.R.sub.18.dbd.H,
J.sub.1=J.sub.2=J.sub.3=J.sub.4=CH, a para-benzylic alcohol,
ALK=(CH.sub.2).sub.2 and ALK'=(CH.sub.2).sub.5, the case L(IV59)
with n=1,
R.sub.14.dbd.R.sub.15.dbd.R.sub.16.dbd.R.sub.17.dbd.R.sub.18.dbd.H,
J.sub.1=J.sub.2=J.sub.3=J.sub.4=CH, a para-benzylic alcohol and
ALK=(CH.sub.2).sub.2, the case L(IV63) with n=1,
R.sub.14.dbd.R.sub.15.dbd.R.sub.16.dbd.R.sub.17.dbd.R.sub.18.dbd.H,
J.sub.1=J.sub.2=J.sub.3=J.sub.4=CH, a para-benzylic alcohol,
ALK=(CH.sub.2).sub.2 and ALK'=(CH.sub.2).sub.4, the case L(IV65)
with n=1,
R.sub.14.dbd.R.sub.15.dbd.R.sub.16.dbd.R.sub.17.dbd.R.sub.18.dbd.H,
J.sub.1=J.sub.2=J.sub.3=J.sub.4=CH, a para-benzylic alcohol,
ALK=(CH.sub.2).sub.2 and ALK'=(CH.sub.2).sub.3 and the case L(IV67)
with n=1,
R.sub.14.dbd.R.sub.15.dbd.R.sub.16.dbd.R.sub.17.dbd.R.sub.18.dbd.R.s-
ub.22.dbd.H, J.sub.1=J.sub.2=J.sub.3=J.sub.4=CH, a para-benzylic
alcohol, ALK=(CH.sub.2).sub.2, ALK'=(CH.sub.2) and
ALK''=(CH.sub.2).sub.2 but it may also apply to other linkers
L(IV55 to 68) with RCG1=maleimido, iodoacetamido, NH.sub.2, N.sub.3
or cyclooctyne. It is depicted for an iodoacetamido reactive group
but may identically apply for a bromoacetamido reactive group. It
is given for a linker in the para position, but may identically
apply for the ortho or meta positions. Similarly, it is given for a
cryptophycin compound, but may also apply to the preparation of
other compounds of formula (I), especially D.sub.1-D.sub.19.
Preparation of the Compounds of Formula (II) in the Case where
W.dbd.C(.dbd.O)O and L=(IV69) with
R.sub.14.dbd.R.sub.15.dbd.R.sub.16.dbd.H,
J.sub.1=J.sub.2=J.sub.3=J.sub.4=CH and ALK=(CH.sub.2).sub.3 Based
on Scheme 7
##STR00189##
[0354] Step (i): esterification in the presence of a coupling
reagent such as, for example, MNBA and a base such as, for example,
DMAP and DIEA;
[0355] Step (ii): deprotection of the allyl ester in the presence
of a catalyst such as, for example,
tetrakis-(triphenylphosphine)palladium;
[0356] Step (iii): activation of the carboxylic acid as a NHS ester
by treatment with DSC in the presence of a base such as, for
example, DIEA.
Preparation of the Compounds of Formula (II) in the Case where
W.dbd.C(.dbd.O)O and L=(IV69) with
R.sub.14.dbd.R.sub.15.dbd.R.sub.16.dbd.H,
J.sub.1=J.sub.2=J.sub.3=J.sub.4=CH and ALK=(CH.sub.2).sub.3 based
on Scheme 8
##STR00190##
[0357] Step (i): esterification in the presence of a coupling
reagent such as, for example, MNBA and a base such as, for example,
DMAP and DIEA;
[0358] Step (ii): deprotection of the Fmoc amine in the presence of
a base such as, for example, piperidine;
[0359] Step (iii): coupling to glutaric anhydride;
[0360] Step (iv): activation of the carboxylic acid as a NHS ester
by treatment with DSC in the presence of a base such as, for
example, DIEA.
[0361] Schemes 21 and 22 describe the case L(IV69) with
R.sub.14.dbd.R.sub.15.dbd.R.sub.16.dbd.H,
J.sub.1=J.sub.2=J.sub.3=J.sub.4=CH, a para-benzylic alcohol and
ALK=(CH.sub.2).sub.3 but they may also apply to other linkers L
with RCG1=C(.dbd.O)ONHS, namely the case L(IV69) with R.sub.14,
R.sub.15, R.sub.16.dbd.H and/or J.sub.1, J.sub.2, J.sub.3,
J.sub.4=CH and/or an ortho-benzylic alcohol and/or
ALK.noteq.(CH.sub.2).sub.3 and the cases L(IV70) and L(IV71). They
are given for a linker in the para position, but may identically
apply for the ortho or meta positions. Similarly, they are given
for a cryptophycin compound, but may also apply to the preparation
of other compounds of formula (I), especially D.sub.1-D.sub.19.
Preparation of the Compounds of Formula (II) in the Case where
W.dbd.C(.dbd.O)O with R.sub.14.dbd.R.sub.15.dbd.R.sub.16.dbd.H,
J.sub.1=J.sub.2=J.sub.3=J.sub.4=CH and RCG1=Maleimido,
Haloacetamido, NH.sub.2, N.sub.3 or Cyclooctyne Namely Linkers
L(IV72) to L(IV85)
##STR00191##
[0362] Step (i): esterification in the presence of a coupling
reagent such as, for example, MNBA and a base such as, for example,
DMAP and DIEA;
[0363] Step (ii): deprotection of the Fmoc amine in the presence of
abase such as, for example, piperidine.
[0364] Scheme 23 describes the cases L(IV72) with n=1,
R.sub.14.dbd.R.sub.15.dbd.R.sub.16.dbd.H,
J.sub.1=J.sub.2=J.sub.3=J.sub.4=CH, a para-benzylic alcohol and
ALK=(CH.sub.2).sub.5, L(IV76) with n=1,
R.sub.14.dbd.R.sub.15.dbd.R.sub.16.dbd.H and
J.sub.1=J.sub.2=J.sub.3=J.sub.4=CH and a para-benzylic alcohol,
L(IV80) with n=1, R.sub.14.dbd.R.sub.15.dbd.R.sub.16.dbd.H,
J.sub.1=J.sub.2=J.sub.3=J.sub.4=CH, a para-benzylic alcohol and
ALK=(CH.sub.2).sub.4, L(IV82) with n=1,
R.sub.14.dbd.R.sub.15.dbd.R.sub.16.dbd.H,
J.sub.1=J.sub.2=J.sub.3=J.sub.4=CH, a para-benzylic alcohol and
ALK=(CH.sub.2).sub.3 and L(IV84) with n=1,
R.sub.14.dbd.R.sub.15.dbd.R.sub.16.dbd.R.sub.22.dbd.H,
J.sub.1=J.sub.2=J.sub.3=J.sub.4=CH, a para-benzylic alcohol,
ALK=(CH.sub.2).sub.3 and ALK'=(CH.sub.2).sub.2 but it may also
apply to other linkers L(IV72) to L(IV85) with RCG1=maleimido,
iodoacetamido, NH.sub.2, N.sub.3 or cyclooctyne. It is given with a
para-benzylic alcohol but it may also apply to an ortho-benzylic
alcohol. It is depicted for an iodoacetamido reactive group but may
identically apply for a bromoacetamido reactive group. It is given
for a linker in the para position, but may identically apply for
the ortho or meta positions. Similarly, it is given for a
cryptophycin compound, but may also apply to the preparation of
other compounds of formula (I), especially D.sub.1-D.sub.19.
Preparation of the Compounds of Formula (II) in the Case where
W.dbd.C(.dbd.O)O and L=(V86) with R.sub.25.dbd.H and
ALK=(CH.sub.2).sub.7
##STR00192##
[0365] Step (i): activation of the carboxylic acid as a NHS ester
by treatment with DSC in the presence of a base such as, for
example, DIEA;
[0366] Step (ii): peptidic coupling in the presence of a base such
as, for example, DIEA;
[0367] Step (iii): activation of the carboxylic acid as a NHS ester
by treatment with DSC in the presence of a base such as, for
example, DIEA.
[0368] Scheme 24 describes the case L(V86) with R.sub.25.dbd.H and
ALK=(CH.sub.2).sub.7 but they may also apply to other linkers L
with RCG1=C(.dbd.O)ONHS, namely the case L(V86) with
R.sub.25.noteq.H and/or ALK.noteq.(CH.sub.2).sub.7 and the cases
L(V87) and L(V88). They are given for a linker in the para
position, but may identically apply for the ortho or meta
positions. Similarly, they are given for a cryptophycin compound,
but may also apply to the preparation of other compounds of formula
(I), especially D.sub.1-D.sub.19.
Preparation of the Compounds of Formula (II) in the Case where
W.dbd.C(.dbd.O)O with R.sub.30.dbd.H and RCG1=maleimido,
haloacetamido, NH.sub.2, N.sub.3 or cyclooctyne namely linkers
L(V89) to L(V101)
##STR00193##
[0369] Step (i): peptidic coupling in the presence of a base such
as, for example, DIEA;
[0370] Step (ii): reduction of the azido by treatment with a
reducing agent such as, for example, TCEP.
[0371] Scheme 25 describes the cases L(V89) with R.sub.25.dbd.H and
ALK=(CH.sub.2), L(V93) with R.sub.25.dbd.H and
ALK=(CH.sub.2).sub.3, L(V96) with R.sub.25.dbd.H and
ALK=(CH.sub.2).sub.4, L(V98) with R.sub.25.dbd.H and
ALK=(CH.sub.2).sub.3 and L(V100) with R.sub.22.dbd.R.sub.25.dbd.H,
ALK=(CH.sub.2).sub.3 and ALK'=(CH.sub.2).sub.2 but it may also
apply to other linkers L(V89) to L(V101) with RCG1=maleimido,
iodoacetamido, NH.sub.2, N.sub.3 or cyclooctyne. It is depicted for
an iodoacetamido reactive group but may identically apply for a
bromoacetamido reactive group. It is given for a linker in the para
position, but may identically apply for the ortho or meta
positions. Similarly, it is given for a cryptophycin compound, but
may also apply to the preparation of other compounds of formula
(I), especially D.sub.1-D.sub.19.
Process for Preparing the Cryptophycin Conjugates
[0372] The compounds of formula (III) might be prepared according
to Scheme 26 starting with a cryptophycin payload of formula (II)
and an antibody (Ab):
##STR00194##
in which: [0373] Y represents (C.sub.1-C.sub.6)alkyl-NR.sub.11 or
(C.sub.1-C.sub.6)alkyl-O or (C.sub.1-C.sub.6)alkyl-S; [0374] or
alternatively Y represents C(.dbd.O)O or
O(C.sub.1-C.sub.6)alkyl-C(.dbd.O)O; [0375] or alternatively Y
represents (C.sub.1-C.sub.6)alkyl-triazole-like
[0375] ##STR00195## [0376] Y is positioned in an ortho (o), meta
(m) or para (p) position of the phenyl nucleus; [0377] R.sub.11
represents a hydrogen atom or a (C.sub.1-C.sub.6)alkyl group;
[0378] L represents a linker positioned in an ortho (o), meta (m)
or para (p) position of the phenyl nucleus, as defined above;
[0379] RCG1 represents a reactive chemical group that is reactive
towards a reactive chemical group present on the antibody, as
defined above; [0380] Ab represents an antibody.
Process for Preparing the Building Blocks for the Synthesis of
Cryptophycin Compounds of Formula (I)
General Synthesis of Fragment A
##STR00196##
[0382] Fragment A may be prepared in 12 steps starting from
appropriate hydroxy esters with the aid of the steps detailed
below:
[0383] Step (i): protection of the alcohol as a p-methoxybenzyl
ether using p-methoxybenzyl alcohol activated as a
trichloroacetimidate in the presence of a catalytic amount of acid
such as, for example, p-TsOH;
[0384] Step (ii): reduction of the ester using a reducing agent
such as, for example, lithium borohydride;
[0385] Step (iii): oxidation of the alcohol using an oxidizing
agent such as, for example, TEMPO in the presence of sodium
hypochlorite;
[0386] Step (iv): diastereoselective allylation using
allyltributyltin in the presence of tin tetrachloride;
[0387] Step (v): cross metathesis using tert-butylacrylate in the
presence of a catalyst such as, for example, Grubbs II
catalyst;
[0388] Step (vi): deprotection of the p-methoxybenzyl ether using
CAN and subsequent treatment with ethanedithiol in the presence of
a catalytic amount of acid such as, for example, p-TsOH;
[0389] Step (vii): protection of the alcohols as silyl ethers using
chlorotriethylsilane in the presence of a base such as, for
example, imidazole;
[0390] Step (viii): Swern oxidation using DMSO and oxalyl chloride
in the presence of a base such as, for example, DIEA;
[0391] Step (ix): Wittig reaction using a suitable phosphonium
halide, for example a bromide, and a strong base such as, for
example, BuLi;
[0392] Step (x): deprotection of the silyl ether using, for
example, a TBAF solution.
[0393] Step (xi): oxidation of the benzylic alcohol using an
oxidizing agent such as, for example, manganese oxide;
[0394] Step (xii): isomerization of the double bond using AIBN in
the presence of benzenethiol.
[0395] Hydroxy esters are commercially available for R.sub.1=Me
(CAS number [72657-23-9]), Et (CAS number [72604-81-0]) and iPr
(CAS number [72604-82-1]). Preparation of phosphonium halides is
described in WO2011/001052.
General Synthesis of Fragment B
##STR00197##
[0397] Fragment B may be prepared in 2 steps starting from
appropriate amino acids with the aid of the steps detailed
below:
[0398] Step (i): protection of the amine by treatment with
Boc.sub.2O in the presence of a base such as, for example, TEA;
[0399] Step (ii): saponification of the methyl ester using a base
such as, for example, LiOH.
[0400] Amino acids protected as methyl esters are commercially
available for R.sub.9=3-Cl, 4-OMe (CAS number [704870-54-2]); 3-Cl,
4-OEt (CAS number [1256963-00-9]); 3-Cl, 4-OPr (CAS number
[1259709-59-9]); 3-Cl, 4-OMe, 5-F (CAS number [1213670-98-4]);
3-Cl, 4-OMe, 5-Cl (CAS number [1259701-42-2]); 3-Cl, 4-OMe, 5-OMe
(CAS number [1212820-34-2]); 3-Cl, 4-OH, 5-OMe (CAS number
[1213426-93-7]); 3-Cl, 4-NH.sub.2 (CAS number [1213672-64-0]);
2-Cl, 3-Cl, 4-NH.sub.2 (CAS number [1213607-49-8]); 3-Cl,
4-NH.sub.2, 5-F (CAS number [1213400-66-8]); 3-Cl, 4-NH.sub.2, 5-Cl
(CAS number [1213480-30-8]).
General Synthesis of Building Block AD1
##STR00198##
[0402] Fragments A and D allow the preparation of building block
AD1 with the aid of the steps detailed below:
[0403] Step (i): esterification of fragment D with fragment A in
the presence of a coupling reagent such as, for example, MNBA and a
base such as, for example, DMAP and DIEA;
[0404] Step (ii): reduction of the aldehyde into an alcohol using a
reducing agent such as, for example, sodium
trimethoxyborohydride;
[0405] Step (iii): activation of the alcohol as a mesylate by
treatment with methanesulfonyl chloride in the presence of a base
such as, for example, TEA; substitution of the mesylate by an azido
group by treatment with sodium azide;
[0406] Step (iv): deprotection of the amine by treatment with a
base such as, for example, piperidine.
General Synthesis of Building Block AD2
##STR00199##
[0408] Fragments A and D allow the preparation of building block
AD2 with the aid of the steps detailed below:
[0409] Step (i): esterification of fragment D with fragment A in
the presence of a coupling reagent such as, for example, MNBA and a
base such as, for example, DMAP and DIEA;
[0410] Step (ii): reduction of the aldehyde into an alcohol using a
reducing agent such as, for example, sodium
trimethoxyborohydride;
[0411] Step (iii): deprotection of the amine by treatment with a
base such as, for example, piperidine.
General Synthesis of Building Block AD3
##STR00200##
[0413] Step (i): esterification of fragment D with Sakurai alcohol
in the presence of a coupling reagent such as, for example, MNBA
and a base such as, for example, DMAP and DIEA;
[0414] Step (ii): deprotection of the amine by treatment with a
base such as, for example, piperidine.
General Synthesis of Building Block BC
##STR00201##
[0416] Fragments B and C allow the preparation of building block BC
with the aid of the steps detailed below:
[0417] Step (i): peptidic coupling of fragment B with fragment C in
the presence of coupling reagents such as, for example, HOBt and
EDC and a base such as, for example, DIEA;
[0418] Step (ii): saponification of the methyl ester using a base
such as, for example, LiOH.
General Synthesis of an Alternative Building Block BC
##STR00202##
[0420] Fragments B and C allow the preparation of an alternative
building block BC with the aid of the steps detailed below:
[0421] Step (i): peptidic coupling of fragment B with fragment C in
the presence of coupling reagents such as, for example, HOBt and
EDC and a base such as, for example, DIEA;
[0422] Step (ii): deprotection of the Boc group in acidic
conditions using, for example, TFA;
[0423] Step (iii): formation of the acrylamide by treatment with
acryloyle chloride in the presence of a base such as, for example,
DIEA;
[0424] Step (iv): saponification of the methyl ester using a base
such as, for example, tBuOK.
Preparation of the Linker Precursors LP
[0425] LP may be one of the following; LP.sub.1 to LP.sub.10 are
described using L amino acids but may also apply to D amino acids.
They are given for w=2 but may similarly apply to w>2 by
repeating as many times as required the peptide coupling step.
##STR00203##
prepared according to the scheme below:
##STR00204##
[0426] Step (i): peptide coupling between Fmoc-L-amino acid-ONHS
and L-amino acid; the reaction is performed in a polar solvent such
as a DME/THF/H.sub.2O mixture in the presence of a base such as,
for example, sodium bicarbonate;
[0427] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0428] Step (iii): activation of the carboxylic acid as a NHS
ester; the reaction is performed in a polar aprotic solvent such as
DCM by treatment with NHS in the presence of a coupling agent such
as, for example, EDC;
[0429] Step (iv): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed at RT in a polar aprotic
solvent such as a DCM/CHCN mixture.
[0430] NHS esters of Fmoc-L-amino acids are commercially available;
the diacids monoprotected as allyl esters are commercially
available for n=2 (monoallyl succinate) or may be prepared by
transesterification of the methyl or tert-butyl monoesters, which
are commercially available for n=2 to 6.
##STR00205##
prepared according to the scheme below:
##STR00206##
[0431] Step (1: peptide coupling between Fmoc-L-amino acid-ONHS and
L-amino acid; the reaction is performed in a polar solvent such as
a DME/THF/H.sub.2O mixture in the presence of a base such as, for
example, sodium bicarbonate;
[0432] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0433] Step (iii): activation of the carboxylic acid as a NHS
ester; the reaction is performed in a polar aprotic solvent such as
DCM by treatment with NHS in the presence of a coupling agent such
as, for example, supported DCC;
[0434] Step (iv): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed in a polar aprotic solvent
such as a DCM/CHCN mixture.
[0435] NHS esters of Fmoc-L-amino acids are commercially available;
the PEG diacids monoprotected as allyl esters may be prepared
according to the scheme below: [0436] when ALK=CH.sub.2CH.sub.2
[0436] ##STR00207## [0437] when ALK.noteq.CH.sub.2CH.sub.2
##STR00208##
[0438] Step (i): elongation of the PEG chain; the reaction is
performed in an anhydrous polar aprotic solvent such as THF or DMF
by treatment of an unsaturated protected acid with the alkoxyde
generated by the action of sodium in catalytic amount;
[0439] Step (ii): deprotection using a solution of hydrochloric
acid (for example solution in dioxane) or of trifluoroacetic acid.
In the latter case, trifluoroacetate of the alcohol function
present on the structure may be formed. This trifluoroacetate is
cleaved during the following step (iii);
[0440] Step (iii): protection of the carboxylic acid as a methyl
ester; the reaction is performed in a polar aprotic solvent such as
MeOH, by treatment with trimethylsilyldiazomethane;
[0441] Step (iv): saponification of the methyl ester; the reaction
is performed in a mixture of polar solvents such as a THF/H.sub.2O
mixture in the presence of LiOH;
[0442] Step (v): protection of the carboxylic acid as an allyl
ester; the reaction is performed in a polar aprotic solvent such as
DCM in the presence of allyl alcohol, a coupling agent such as, for
example, EDC and a base such as, for example, DMAP;
[0443] Step (vi): elongation of the PEG chain; the reaction is
performed in an anhydrous polar aprotic solvent such as THE or DMF
by treatment of a halogenated ester with the alkoxyde of the PEG
diol monoprotected as a THP ether. The preparation of this type of
monoprotected PEG diol is well described in the literature: see,
for example, Richard A., et al., Chem. Eur. J. 2005, 11, 7315-7321
or Sakellariou E. G., et al., Tetrahedron 2003, 59, 9083-9090.
[0444] The starting PEG diols are commercially available for i=3 to
12.
##STR00209##
prepared according to the scheme below:
##STR00210##
[0445] Step (i): peptide coupling between Fmoc-L-amino acid-ONHS
and L-amino acid; the reaction is performed in a polar solvent such
as a DME/THF/H.sub.2O mixture in the presence of a base such as,
for example, sodium bicarbonate;
[0446] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0447] Step (iii): activation of the carboxylic acid as a NHS
ester; the reaction is performed in a polar solvent such as a
mixture DMF/H.sub.2O by treatment with N,N'-disuccinimidyl
carbonate in the presence of a base such as, for example, DIEA;
[0448] Step (iv): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed at RT in a polar aprotic
solvent such as a DCM/CH.sub.3CN mixture.
[0449] NHS esters of Fmoc-L-amino acids are commercially available;
the sulfo diacids monoprotected as allyl ester may be prepared
according to the scheme below:
##STR00211##
alternative when ALK=CH.sub.2CH.sub.2
##STR00212##
[0450] Step (i): protection of the carboxylic acid as an allyl
ester; the reaction is performed in a polar aprotic solvent such as
DCM in the presence of allyl alcohol, a coupling agent such as, for
example, EDC and a base such as, for example, DMAP;
[0451] Step (ii): .alpha.-sulfonation of the carboxylic acid; the
reaction is performed at 75.degree. C. in a polar aprotic solvent
like DCE by treatment with chlorosulfonic acid in the presence of a
base such as, for example, DIEA.
[0452] Step (iii): formation of the carboxylic acid moiety; the
reaction is performed by treatment with sodium hydroxide;
[0453] Step (iv): substitution of the bromide by a thioacetyle; the
reaction is performed at -20.degree. C. in a polar aprotic solvent
such as THE using thioacetic acid in the presence of a base such
as, for example, DIEA;
[0454] Step (v): formation of the sulfonic acid moiety; the
reaction is performed at RT by treatment with hydrogen peroxide and
acetic acid.
[0455] Cyano carboxylic acids are commercially available for n=1 to
12.
##STR00213##
prepared according to the scheme below:
##STR00214##
[0456] Step (i): peptide coupling between Fmoc-L-amino acid-ONHS
and L-amino acid; the reaction is performed in a polar solvent such
as a DME/THF/H.sub.2O mixture in the presence of a base such as,
for example, sodium bicarbonate;
[0457] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0458] Step (iii): activation of the carboxylic acid as a NHS
ester; the reaction is performed in a polar aprotic solvent such as
DCM by treatment with NHS in the presence of a coupling agent such
as, for example, EDC;
[0459] Step (iv): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed in a polar aprotic solvent
such as a DCM/CHCN mixture.
[0460] NHS esters of Fmoc-L-amino acids are commercially available;
the maleimido carboxylic acids are commercially available for n=1
to 12.
##STR00215##
prepared according to the scheme below:
##STR00216##
[0461] Step (i): peptide coupling between Fmoc-L-amino acid-ONHS
and L-amino acid; the reaction is performed in a polar solvent such
as a DME/THF/H.sub.2O mixture in the presence of a base such as,
for example, sodium bicarbonate;
[0462] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0463] Step (iii): activation of the carboxylic acid as a NHS
ester; the reaction is performed in a polar aprotic solvent such as
DCM by treatment with NHS in the presence of a coupling agent such
as, for example, supported DCC;
[0464] Step (iv): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed in a polar aprotic solvent
such as a DCM/CHCN mixture.
[0465] NHS esters of Fmoc-L-amino acids are commercially available;
the maleimido acids are commercially available for
ALK=ALK'=CH.sub.2CH.sub.2 and i=1 to 7 and may be otherwise
prepared according to the scheme below: [0466] when
ALK=ALK'=CH.sub.2CH.sub.2 and i>7
[0466] ##STR00217## [0467] when ALK.noteq.CH.sub.2CH.sub.2 and
ALK'=CH.sub.2CH.sub.2
##STR00218##
[0467] when ALK=CH.sub.2CH.sub.2 and
ALK'.noteq.CH.sub.2CH.sub.2
##STR00219##
when ALK and ALK'.noteq.CH.sub.2CH.sub.2
##STR00220##
[0468] Step (i): elongation of the PEG chain; the reaction is
performed in an anhydrous polar aprotic solvent such as THE or DMF
by treatment of an unsaturated protected acid with the alkoxyde
generated by the action of sodium in catalytic amount;
[0469] Step (ii): Mitsunobu reaction on maleimide; the reaction is
performed in a polar aprotic solvent such as THE by treatment of
maleimide by the PEG hydroxy acid in the presence of PPh.sub.3 and
DIAD;
[0470] Step (iii): deprotection using a solution of hydrochloric
acid (for example solution in dioxane) or of trifluoroacetic
acid;
[0471] Step (iv): elongation of the PEG chain; the reaction is
performed in an anhydrous polar aprotic solvent such as THE or DMF
by treatment of a halogenated ester with the alkoxyde of the PEG
diol monoprotected as the THP ether. The preparation of this type
of monoprotected PEG diol is well described in the literature: see,
for example, Richard A., et al., Chem. Eur. J. 2005, 11, 7315-7321
or Sakellariou E. G., et al., Tetrahedron 2003, 59, 9083-9090;
[0472] Step (v): selective deprotection of THP ether; the reaction
is performed in a polar protic solvent such as MeOH using a
catalytic amount of acetyl chloride;
[0473] Step (vi): activation of the alcohol as a mesylate; the
reaction is performed in a polar aprotic solvent such as DCM by
treatment with methanesulfonyl chloride in the presence of a base
such as, for example, TEA;
[0474] Step (vii): nucleophilic substitution; the reaction is
performed in a polar aprotic solvent such as DMF in the presence of
a base such as, for example, sodium hydride;
[0475] Step (viii): protection of the alcohol as a benzyl ether;
the reaction is performed in a polar aprotic solvent such as THE by
treatment with benzyl bromide in the presence of a base such as,
for example, sodium hydride;
[0476] Step (ix): deprotection of the alcohol using a solution of
hydrochloric acid (for example solution in dioxane);
[0477] Step (x): deprotection of the alcohol by hydrogenolysis in
the presence of a catalyst such as, for example, palladium on
carbon.
[0478] The starting PEG diols are commercially available for i=3 to
12. The starting ALK diols are commercially available for n=1 to
12.
##STR00221##
prepared according to the scheme below:
##STR00222##
[0479] Step (i): peptide coupling between Fmoc-L-amino acid-ONHS
and L-amino acid; the reaction is performed in a polar solvent such
as a DME/THF/H.sub.2O mixture in the presence of abase such as, for
example, sodium bicarbonate;
[0480] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0481] Step (iii): activation of the carboxylic acid as a NHS
ester; the reaction is performed in a polar solvent such as a
mixture DMF/H.sub.2O by treatment with N,N'-disuccinimidyl
carbonate in the presence of a base such as, for example, DIEA;
[0482] Step (iv): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed in a polar aprotic solvent
such as a DCM/CH.sub.3CN mixture.
[0483] NHS esters of Fmoc-L-amino acids are commercially available;
the maleimido cyclohexanecarboxylic acid is commercially available
for ALK=CH.sub.2 and may be otherwise prepared according to the
scheme below:
[0484] When n=2 to 4
##STR00223##
[0485] When n>4
##STR00224##
[0486] Step (i): hydrogenation; the reaction is performed at
60.degree. C. in acetic acid in the presence of a catalyst such as
platinum oxide under pressure of hydrogen, for example 60 psi;
[0487] Step (ii): protection of the amine; the reaction is
performed in a polar protic solvent such as a dioxane/H.sub.2O
mixture by treatment with benzylchloroformate in the presence of a
base such as, for example, NaOH;
[0488] Step (iii): protection of the carboxylic acid; the reaction
is performed in a polar aprotic solvent such as DCM by treatment
with tert-butanol in the presence of a coupling reagent such as,
for example, EDC and a base such as, for example, DMAP;
[0489] Step (iv): deprotection of the amine; the reaction is
performed by hydrogenolysis in a polar protic solvent such as MeOH
in the presence of a catalyst such as, for example, palladium;
[0490] Step (v): introduction of the maleimido moeity; the reaction
is performed in a polar aprotic solvent such as DMF by treatment
with maleic anhydride in the presence of NHS and a coupling reagent
such as, for example, EDC;
[0491] Step (vi): deprotection using a solution of hydrochloric
acid (for example solution in dioxane) or of trifluoroacetic
acid;
[0492] Step (vii): palladium-catalyzed coupling; the reaction is
performed in a polar aprotic solvent such as THE by treatment with
the bromo-ALK-cyano derivative in the presence of lithium chloride,
zinc and trimethylchlorosilane and a catalyst such as, for example,
tetrakis(triphenylphosphine)palladium.
[0493] The suitable bromo-ALK-cyano derivatives are commercially
available for n=1 to 12.
##STR00225##
prepared according to the scheme below:
##STR00226##
[0494] Step (i): peptide coupling between Fmoc-L-amino acid-ONHS
and L-amino acid; the reaction is performed in a polar solvent such
as a DME/THF/H.sub.2O mixture in the presence of a base such as,
for example, sodium bicarbonate;
[0495] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0496] Step (iii): .alpha.-sulfonation of the carboxylic acid; the
reaction is performed at 75.degree. C. in a polar aprotic solvent
like DCE by treatment with chlorosulfonic acid in the presence of a
base such as, for example, DIEA;
[0497] Step (iv): activation of the carboxylic acid as a NHS ester;
the reaction is performed at RT in a polar solvent such as a
mixture DMF/H.sub.2O by treatment with N,N'-disuccinimidyl
carbonate in the presence of a base such as, for example, DIEA;
[0498] Step (v): peptide coupling between the dipeptide and the NHS
ester; the reaction is performed at RT in a polar aprotic solvent
such as a DCM/CHCN mixture.
[0499] NHS esters of Fmoc-L-amino acids are commercially available;
the maleimido acids are commercially available for n=1 to 12.
##STR00227##
prepared according to the scheme below:
##STR00228##
[0500] Step (i): peptide coupling between Fmoc-L-amino acid-ONHS
and L-amino acid; the reaction is performed in a polar solvent such
as a DME/THF/H.sub.2O mixture in the presence of a base such as,
for example, sodium bicarbonate;
[0501] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0502] Step (iii): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed in a polar aprotic solvent
such as a DCM/CHCN mixture.
[0503] NHS esters of Fmoc-L-amino acids are commercially available;
N-succinimidyl bromo- and iodo-acetates are commercially
available.
##STR00229##
prepared according to the scheme below:
##STR00230##
[0504] Step (i): peptide coupling between Fmoc-L-amino acid-ONHS
and L-amino acid; the reaction is performed in a polar solvent such
as a DME/THF/H.sub.2O mixture in the presence of a base such as,
for example, sodium bicarbonate;
[0505] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0506] Step (iii): coupling and activation of the carboxylic acid
as a NHS ester; the coupling of N-succinimidyl bromo- and
iodo-acetate with the amino carboxylic acid is performed at RT in a
polar aprotic solvent such as a DCM/DMF mixture followed by the
addition of N,N'-disuccinimidyl carbonate and a base, such as, for
example, DIEA;
[0507] Step (iv): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed in a polar aprotic solvent
such as a DCM/CHCN mixture.
[0508] NHS esters of Fmoc-L-amino acids are commercially available;
N-succinimidyl bromo- and iodo-acetates are commercially available,
the amino carboxylic acids also for n=1 to 12 and the N-methylated
amino carboxylic acids for n=1 to 7.
##STR00231##
prepared according to the scheme below:
##STR00232##
[0509] Step (i): peptide coupling between Fmoc-L-amino acid-ONHS
and L-amino acid; the reaction is performed in a polar solvent such
as a DME/THF/H.sub.2 mixture in the presence of a base such as, for
example, sodium bicarbonate;
[0510] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0511] Step (iii): coupling and activation of the carboxylic acid
as a NHS ester; the coupling of N-succinimidyl bromo- and
iodo-acetate with the amino carboxylic acid is performed in a polar
aprotic solvent such as a DCM/DMF mixture followed by the addition
of N,N'-disuccinimidyl carbonate and a base such as, for example,
DIEA;
[0512] Step (iv): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed in a polar aprotic solvent
such as a DCM/CHCN mixture.
[0513] NHS esters of Fmoc-L-amino acids are commercially available;
N-succinimidyl bromo- and iodo-acetate are commercially available;
in the case where ALK=CH.sub.2CH.sub.2 and R.sub.20.dbd.H, the
amino PEG carboxylic acids are commercially available for i=1 to 6
and otherwise may be prepared from tert-butyl acrylate and the
corresponding amino-PEG-alcohol; in the case where
ALK.noteq.CH.sub.2CH.sub.2, they may be prepared according to the
schemes below: [0514] in the case where ALK=CH.sub.2CH.sub.2 and
R.sub.20.noteq.H
##STR00233##
[0514] in the case where ALK.noteq.CH.sub.2CH.sub.2
[0515] in the case where R.sub.20.dbd.H
##STR00234##
[0516] in the case where R.sub.20.noteq.H
##STR00235##
[0517] Step (i): protection of the amine; the reaction is performed
in a polar aprotic solvent such as DCM by treating the amine with
di-tert-butyl dicarbonate in the presence of a base such as, for
example, TEA;
[0518] Step (ii): protection of the carboxylic acid; the reaction
is performed in a polar aprotic solvent such as DCM by treatment
with tert-butanol in the presence of a coupling reagent such as,
for example, EDC and a base such as, for example, DMAP;
[0519] Step (iii): alkylation of the nitrogen atom; the reaction is
performed in an anhydrous polar aprotic solvent such as THE by
treatment with a base such as sodium hydride in the presence of a
reagent bearing a leaving group such as a halide;
[0520] Step (iv): deprotection using a solution of hydrochloric
acid (for example solution in dioxane) or of trifluoroacetic
acid;
[0521] Step (v): elongation of the PEG chain; the reaction is
performed in an anhydrous polar aprotic solvent such as THE or DMF
by treatment of a halogenated ester with the alkoxyde of a
benzophenone-imine-PEG-alcohol generated via the action of sodium
hydride or potassium naphthalenide as described in
WO2007/127440;
[0522] Step (vi): saponification of the ester; the reaction is
performed by reacting the ester with LiOH in the presence of
H.sub.2O.
[0523] The amino-PEG-alcohols are commercially available, for
example for i=3, 4, 7, 8 or may be prepared from the PEG diols,
which are commercially available for i=3 to 12, according to the
procedure described in U.S. Pat. No. 7,230,101. The protection of
the amine function with benzophenone may be performed by azeotropic
dehydration in the presence of a Lewis acid such as BF3
etherate.
##STR00236##
prepared according to the scheme below:
##STR00237##
[0524] Step (i): peptide coupling between Fmoc-L-amino acid-NHS and
L-amino acid; the reaction is performed in a polar solvent such as
a DME/THF/H.sub.2O mixture in the presence of a base such as, for
example, sodium bicarbonate;
[0525] Step (ii): deprotection of the amine Fmoc; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0526] Step (iii): coupling and activation of the carboxylic acid
as a NHS ester; the coupling of N-succinimidyl bromo- and
iodo-acetate with the amino carboxylic acid is performed at RT in a
polar aprotic solvent such as a DCM/DMF mixture followed by the
addition of N,N'-disuccinimidyl carbonate and a base such as, for
example, DIEA;
[0527] Step (iv): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed at RT in a polar aprotic
solvent such as a DCM/CH.sub.3CN mixture.
[0528] NHS esters of Fmoc-L-amino acids are commercially available;
N-succinimidyl bromo- and iodo-acetate are commercially available;
the amino-(hetero)aryl-carboxylic acids are commercially available,
like for example 4-amino-2-benzoic acid, 6-amino-3-pyridine
carboxylic acid, 5-amino-2-pyrazine carboxylic acid,
2-amino-5-pyrimidine carboxylic acid or 6-amino-1,2,4,5-tetrazine
carboxylic acid.
##STR00238##
prepared according to the scheme below:
##STR00239##
[0529] Step (i): peptide coupling between Fmoc-L-amino acid-ONHS
and L-amino acid; the reaction is performed in a polar solvent such
as a DME/THF/H.sub.2O mixture in the presence of a base such as,
for example, sodium bicarbonate;
[0530] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0531] Step (iii): activation of the carboxylic acid as a NHS
ester; the reaction is performed in a polar aprotic solvent such as
DCM by treatment with NHS in the presence of a coupling agent such
as, for example, EDC;
[0532] Step (iv): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed in a polar aprotic solvent
such as a DCM/CHCN mixture.
[0533] NHS esters of Fmoc-L-amino acids are commercially available;
the amino carboxylic acids are commercially available for n=1 to
11.
##STR00240##
prepared according to the scheme below:
##STR00241##
[0534] Step (i): peptide coupling between Fmoc-L-amino acid-ONHS
and L-amino acid; the reaction is performed in a polar solvent such
as a DME/THF/H.sub.2O mixture in the presence of a base such as,
for example, sodium bicarbonate;
[0535] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0536] Step (iii): activation of the carboxylic acid as a NHS
ester; the reaction is performed in a polar aprotic solvent such as
DCM by treatment with NHS in the presence of a coupling agent such
as, for example, supported DCC;
[0537] Step (iv): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed in a polar aprotic solvent
such as a DCM/CHCN mixture.
[0538] NHS ester of Fmoc-L-amino acids are commercially available;
in the case where ALK=CH.sub.2CH.sub.2, Fmoc-protected amino PEG
carboxylic acids are commercially available for i=1 to 6 and
otherwise may be prepared from tert-butyl acrylate and the
corresponding amino-PEG-alcohol; in the case where
ALK.noteq.CH.sub.2CH.sub.2, they may be prepared according to the
schemes described for linker precursor LP.sub.10. Protection of the
amine function with a Fmoc group may be realized by treatment with
FmocOSu (CAS number [82911-69-1]) in the presence of a base such
as, for example, DIEA.
##STR00242##
prepared according to the scheme below:
##STR00243##
[0539] Step (i): peptide coupling between Fmoc-L-amino acid-ONHS
and L-amino acid; the reaction is performed in a polar solvent such
as a DME/THF/H.sub.2O mixture in the presence of a base such as,
for example, sodium bicarbonate;
[0540] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0541] Step (iii): introduction of the azido group; the reaction is
performed in a polar solvent such as an acetone/H.sub.2O mixture by
treatment with sodium azide;
[0542] Step (iv): activation of the carboxylic acid as a NHS ester;
the reaction is performed in a polar aprotic solvent such as DCM by
treatment with NHS in the presence of a coupling agent such as, for
example, EDC;
[0543] Step (v): peptide coupling between the dipeptide and the NHS
ester; the reaction is performed in a polar aprotic solvent such as
a DCM/CHCN mixture.
[0544] NHS esters of Fmoc-L-amino acids are commercially available;
bromo carboxylic acids are commercially available for n=1 to
11.
##STR00244##
prepared according to the scheme below:
##STR00245##
[0545] Step (i): peptide coupling between Fmoc-L-amino acid-ONHS
and L-amino acid; the reaction is performed in a polar solvent such
as a DME/THF/H.sub.2O mixture in the presence of a base such as,
for example, sodium bicarbonate;
[0546] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0547] Step (iii): activation of the carboxylic acid as a NHS
ester; the reaction is performed in a polar aprotic solvent such as
DCM by treatment with NHS in the presence of a coupling agent such
as, for example, supported DCC;
[0548] Step (iv): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed in a polar aprotic solvent
such as a DCM/CH.sub.3CN mixture.
[0549] NHS esters of Fmoc-L-amino acids are commercially available;
azido PEG acids may be prepared according to the schemes below:
[0550] when ALK=CH.sub.2CH.sub.2
[0550] ##STR00246## [0551] when ALK.noteq.CH.sub.2CH.sub.2
##STR00247##
[0552] Step (i): elongation of the PEG chain; the reaction is
performed in an anhydrous polar aprotic solvent such as THE or DMF
by treatment of an unsaturated protected acid with the alkoxyde
generated by the action of sodium in catalytic amount;
[0553] Step (ii): activation of the alcohol function; the reaction
is performed in a polar solvent such as DCM using methanesulfonyl
chloride in the presence of a base such as, for example, TEA;
[0554] Step (iii): substitution of the mesylate by an azido group;
the reaction is performed in a polar solvent such as an
acetone/H.sub.2O mixture by treatment with sodium azide;
[0555] Step (iv): deprotection using a solution of hydrochloric
acid (for example solution in dioxane);
[0556] Step (v): elongation of the PEG chain; the reaction is
performed in an anhydrous polar aprotic solvent such as THE or DMF
by treatment of a halogenated ester with the alkoxyde of the PEG
diol monoprotected as a THP ether, alkoxyde generated for example
with sodium hydride. The preparation of this type of monoprotected
PEG diol is well described in the literature: see, for example,
Richard A. et al. Chem. Eur. J. 2005, 11, 7315-7321 or Sakellariou
E. G., et al. Tetrahedron 2003, 59, 9083-9090;
[0557] Step (vi): saponification of the methyl ester; the reaction
is performed at RT in a mixture of polar solvents such as a
THF/H.sub.2O mixture in the presence of LiOH.
[0558] The starting PEG diols are commercially available for i=3 to
12; the bromo methyl esters are commercially available for n=1 to
12.
##STR00248##
prepared according to the scheme below:
##STR00249##
[0559] Step (i): peptide coupling between Fmoc-L-amino acid-ONHS
and L-amino acid; the reaction is performed in a polar solvent such
as a DME/THF/H.sub.2O mixture in the presence of a base such as,
for example, sodium bicarbonate;
[0560] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0561] Step (iii): cyclooctyne coupling; the reaction is performed
in a polar solvent such as DCM;
[0562] Step (iv): activation of the carboxylic acid as a NHS ester;
the reaction is performed in a polar aprotic solvent such as DCM by
treatment with NHS in the presence of a coupling agent such as, for
example, EDC;
[0563] Step (v): peptide coupling between the dipeptide and the NHS
ester; the reaction is performed in a polar aprotic solvent such as
DCM.
[0564] NHS esters of Fmoc-L-amino acids are commercially available;
cyclooctynes are commercially available for n'=1, 2, 3 and 5;
diacids monoactivated as NHS ester are commercially available for
n=1 to 3 and for n=4 to 10 they may be prepared by activating
commercially available diacids with NHS in the presence of a
coupling agent such as, for example, DCC and a base such as, for
example, DMAP.
##STR00250##
Prepared according to the scheme below:
##STR00251##
[0565] Step (i): peptide coupling between Fmoc-L-amino acid-ONHS
and L-amino acid; the reaction is performed in a polar solvent such
as a DME/THF/H.sub.2O mixture in the presence of a base such as,
for example, sodium bicarbonate;
[0566] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0567] Step (iii): cyclooctyne coupling; the reaction is performed
in a polar solvent such as DCM;
[0568] Step (iv): deprotection using a solution of hydrochloric
acid (for example solution in dioxane);
[0569] Step (v): activation of the cyclooctyne-PEG carboxylic acid
as a NHS ester; the reaction is performed in a polar aprotic
solvent such as DCM by treatment with NHS in the presence of a
coupling agent such as, for example, EDC;
[0570] Step (vi): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed in a polar aprotic solvent
such as DCM.
[0571] NHS esters of Fmoc-L-amino acids are commercially available;
cyclooctynes are commercially available for n'=1, 2, 3 and 5; the
PEG diacids mono-activated as NHS ester are prepared according to
the scheme below: [0572] when ALK=CH.sub.2CH.sub.2
##STR00252##
[0572] when ALK.noteq.CH.sub.2CH.sub.2
##STR00253##
[0573] Step (i): elongation of the PEG chain; the reaction is
performed in an anhydrous polar aprotic solvent such as THE or DMF
by treatment of an unsaturated protected acid with the alkoxyde
generated by the action of sodium in catalytic amount;
[0574] Step (ii): deprotection using a solution of hydrochloric
acid (for example solution in dioxane) or of trifluoroacetic
acid;
[0575] Step (iii): mono-activation of one acid as a NHS ester; the
reaction is performed in a polar solvent such as THE using NHS in
the presence of a coupling agent such as, for example, DCC and a
base such as, for example, DMAP;
[0576] Step (iv): elongation of the PEG chain; the reaction is
performed in an anhydrous polar aprotic solvent such as THE or DMF
by treatment of a halogenated ester with the alkoxyde of the PEG
diol monoprotected as a THP ether. The preparation of this type of
monoprotected PEG diol is well described in the literature: see,
for example, Richard A., et al., Chem. Eur. J. 2005, 11, 7315-7321
or Sakellariou E. G., et al., Tetrahedron 2003, 59, 9083-9090;
[0577] Step (v): protection of the carboxylic acid as a methyl
ester; the reaction is performed in a polar aprotic solvent such as
MeOH, by treatment with trimethylsilyldiazomethane;
[0578] Step (vi): saponification of the methyl ester; the reaction
is performed in a mixture of polar solvents such as a THF/H.sub.2O
mixture in the presence of LiOH;
[0579] Step (vii): activation of the acid as a NHS ester; the
reaction is performed in a polar solvent such as THE using NHS in
the presence of a coupling agent such as, for example, DCC and a
base such as, for example, DMAP.
[0580] The starting PEG diols are commercially available for i=3 to
12.
##STR00254##
prepared according to the scheme below:
##STR00255##
[0581] Step (i): peptide coupling; the reaction is performed in a
polar solvent such as a DME/THF/H.sub.2O mixture in the presence of
a base such as sodium bicarbonate or in a polar solvent such as DCM
in the presence of a coupling reagent such as propylphosphonic
anhydride and a base such as, for example, TEA;
[0582] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0583] Step (iii): activation of the carboxylic acid as a NHS
ester; the reaction is performed in a polar aprotic solvent such as
DCM by treatment with NHS in the presence of a coupling agent such
as, for example, EDC;
[0584] Step (iv): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed in a polar aprotic solvent
such as a DCM/CHCN mixture;
[0585] Step (v): deprotection using a solution of hydrochloric acid
(for example solution in dioxane) or of trifluoroacetic acid.
[0586] NHS esters of Fmoc-L-amino acids are commercially available;
the mono-protected diamines are commercially available for n=2 to 4
and R.sub.17 and R.sub.18.dbd.H or Me independently of each other.
The diacids monoprotected as allyl esters are commercially
available for n=2 (monoallyl succinate) or may be prepared by
transesterification of the methyl or tert-butyl monoesters, which
are commercially available for n'=2 to 6.
##STR00256##
prepared according to the scheme below:
##STR00257##
[0587] Step (i): peptide coupling; the reaction is performed in a
polar solvent such as a DME/THF/H.sub.2O mixture in the presence of
a base such as sodium bicarbonate or in a polar solvent such as DCM
in the presence of a coupling reagent such as propylphosphonic
anhydride and a base such as, for example, TEA;
[0588] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0589] Step (iii): activation of the carboxylic acid as a NHS
ester; the reaction is performed in a polar aprotic solvent such as
DCM by treatment with NHS in the presence of a coupling agent such
as, for example, EDC;
[0590] Step (iv): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed in a polar aprotic solvent
such as a DCM/CH.sub.3CN mixture;
[0591] Step (v): deprotection using a solution of hydrochloric acid
(for example solution in dioxane) or of trifluoroacetic acid.
[0592] NHS esters of Fmoc-L-amino acids are commercially available;
the mono-protected diamines are commercially available for n=2 to 4
and R.sub.17 and R.sub.18.dbd.H or Me independently of each other;
the PEG diacids monoprotected as allyl esters are prepared
according to the schemes described for linker precursor
LP.sub.2.
##STR00258##
prepared according to the scheme below:
##STR00259##
[0593] Step (i): peptide coupling; the reaction is performed in a
polar solvent such as a DME/THF/H.sub.2O mixture in the presence of
a base such as sodium bicarbonate or in a polar solvent such as DCM
in the presence of a coupling reagent such as propylphosphonic
anhydride and a base such as, for example, TEA;
[0594] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0595] Step (iii): activation of the carboxylic acid as a NHS
ester; the reaction is performed in a polar aprotic solvent such as
DCM by treatment with NHS in the presence of a coupling agent such
as, for example, EDC;
[0596] Step (iv): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed in a polar aprotic solvent
such as a DCM/CHCN mixture;
[0597] Step (v): deprotection using a solution of hydrochloric acid
(for example solution in dioxane) or of trifluoroacetic acid.
[0598] NHS esters of Fmoc-L-amino acids are commercially available;
the mono-protected diamines are commercially available for n=2 to 4
and R.sub.17 and R.sub.18.dbd.H or Me independently of each other;
the sulfo diacids monoprotected as allyl ester are prepared
according to the schemes described for linker precursor
LP.sub.3.
##STR00260##
prepared according to the scheme below:
##STR00261##
[0599] Step (i): peptide coupling; the reaction is performed in a
polar solvent such as a DME/THF/H.sub.2O mixture in the presence of
a base such as sodium bicarbonate or in a polar solvent such as DCM
in the presence of a coupling reagent such as propylphosphonic
anhydride and a base such as, for example, TEA.
[0600] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0601] Step (iii): activation of the carboxylic acid as a NHS
ester; the reaction is performed in a polar aprotic solvent such as
DCM by treatment with NHS in the presence of a coupling agent such
as, for example, EDC;
[0602] Step (iv): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed in a polar aprotic solvent
such as a DCM/CHCN mixture;
[0603] Step (v): deprotection using a solution of hydrochloric acid
(for example solution in dioxane) or of trifluoroacetic acid.
[0604] NHS esters of Fmoc-L-amino acids are commercially available;
the mono-protected diamines are commercially available for n=2 to 4
and R.sub.17 and R.sub.18.dbd.H or Me independently of each other;
the maleimido carboxylic acids are commercially available for n=1
to 12.
##STR00262##
prepared according to the scheme below:
##STR00263##
[0605] Step (i): peptide coupling; the reaction is performed in a
polar solvent such as a DME/THF/H.sub.2O mixture in the presence of
a base such as sodium bicarbonate or in a polar solvent such as DCM
in the presence of a coupling reagent such as propylphosphonic
anhydride and a base such as, for example, TEA;
[0606] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0607] Step (iii): activation of the carboxylic acid as a NHS
ester; the reaction is performed in a polar aprotic solvent such as
DCM by treatment with NHS in the presence of a coupling agent such
as, for example, supported DCC;
[0608] Step (iv): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed in a polar aprotic solvent
such as a DCM/CHCN mixture;
[0609] Step (v): deprotection using a solution of hydrochloric acid
(for example solution in dioxane) or of trifluoroacetic acid.
[0610] NHS esters of Fmoc-L-amino acids are commercially available;
the mono-protected diamines are commercially available for n=2 to 4
and R.sub.17 and R.sub.18.dbd.H or Me independently of each other;
the maleimido PEG acids are commercially available for
ALK=ALK'=CH.sub.2CH.sub.2 and i=1 to 7 and are otherwise prepared
according to the schemes described for linker precursor
LP.sub.5.
##STR00264##
prepared according to the scheme below:
##STR00265##
[0611] Step (i): peptide coupling; the reaction is performed in a
polar solvent such as a DME/THF/H.sub.2O mixture in the presence of
a base such as sodium bicarbonate or in a polar solvent such as DCM
in the presence of a coupling reagent such as propylphosphonic
anhydride and a base such as, for example, TEA;
[0612] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0613] Step (iii): activation of the carboxylic acid as a NHS
ester; the reaction is performed in a polar aprotic solvent such as
DCM by treatment with NHS in the presence of a coupling agent such
as, for example, EDC;
[0614] Step (iv): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed in a polar aprotic solvent
such as a DCM/CHCN mixture;
[0615] Step (v): deprotection using a solution of hydrochloric acid
(for example solution in dioxane) or of trifluoroacetic acid.
[0616] NHS esters of Fmoc-L-amino acids are commercially available;
the mono-protected diamines are commercially available for n=2 to 4
and R.sub.17 and R.sub.18.dbd.H or Me independently of each other;
the maleimido cyclohexanecarboxylic acid is commercially available
for ALK=CH.sub.2 and may otherwise be prepared according to the
schemes described for linker precursor LP.sub.6.
##STR00266##
Prepared according to the scheme below:
##STR00267##
[0617] Step (i): peptide coupling; the reaction is performed in a
polar solvent such as a DME/THF/H.sub.2O mixture in the presence of
a base such as sodium bicarbonate or in a polar solvent such as DCM
in the presence of a coupling reagent such as propylphosphonic
anhydride and a base such as, for example, TEA;
[0618] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0619] Step (iii): .alpha.-sulfonation of the carboxylic acid; the
reaction is performed at 75.degree. C. in a polar aprotic solvent
like DCE by treatment with chlorosulfonic acid in the presence of a
base such as, for example, DIEA;
[0620] Step (iv): activation of the carboxylic acid as a NHS ester;
the reaction is performed in a polar aprotic solvent such as DCM by
treatment with NHS in the presence of a coupling agent such as, for
example, EDC;
[0621] Step (v): peptide coupling between the dipeptide and the NHS
ester; the reaction is performed in a polar aprotic solvent such as
a DCM/CHCN mixture;
[0622] Step (vi): deprotection using a solution of hydrochloric
acid (for example solution in dioxane) or of trifluoroacetic
acid.
[0623] NHS esters of Fmoc-L-amino acids are commercially available;
the mono-protected diamines are commercially available for n=2 to 4
and R.sub.17 and R.sub.18.dbd.H or Me independently of each other;
the maleimido acids are commercially available for n=1 to 12.
##STR00268##
prepared according to the scheme below:
##STR00269##
[0624] Step (i): peptide coupling; the reaction is performed in a
polar solvent such as a DME/THF/H.sub.2O mixture in the presence of
a base such as sodium bicarbonate or in a polar solvent such as DCM
in the presence of a coupling reagent such as propylphosphonic
anhydride and a base such as, for example, TEA;
[0625] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0626] Step (iii): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed in a polar aprotic solvent
such as a DCM/CHCN mixture;
[0627] Step (iv): deprotection using a solution of hydrochloric
acid (for example solution in dioxane) or of trifluoroacetic
acid.
[0628] NHS esters of Fmoc-L-amino acids are commercially available;
the mono-protected diamines are commercially available for n=2 to 4
and R.sub.17 and R.sub.18.dbd.H or Me independently of each other;
N-succinimidyl bromo- and iodo-acetates are commercially
available.
##STR00270##
prepared according to the scheme below:
##STR00271##
[0629] Step (i): peptide coupling; the reaction is performed in a
polar solvent such as a DME/THF/H.sub.2O mixture in the presence of
a base such as sodium bicarbonate or in a polar solvent such as DCM
in the presence of a coupling reagent such as propylphosphonic
anhydride and a base such as, for example, TEA;
[0630] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0631] Step (iii): coupling and activation of the carboxylic acid
as a NHS ester; the coupling of N-succinimidyl bromo- and
iodo-acetate with the amino carboxylic acid is performed in a polar
aprotic solvent such as a DCM/DMF mixture followed by the addition
of N,N'-disuccinimidyl carbonate and a base such as, for example,
DIEA;
[0632] Step (iv): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed in a polar aprotic solvent
such as a DCM/CHCN mixture;
[0633] Step (v): deprotection using a solution of hydrochloric acid
(for example solution in dioxane) or of trifluoroacetic acid.
[0634] NHS esters of Fmoc-L-amino acids are commercially available;
the mono-protected diamines are commercially available for n=2 to 4
and R.sub.17 and R.sub.18.dbd.H or Me independently of each other;
N-succinimidyl bromo- and iodo-acetates are commercially available;
the amino carboxylic acids are commercially available for n=1 to 12
and the N-methylated amino carboxylic acids for n=1 to 7.
##STR00272##
prepared according to the scheme below:
##STR00273##
[0635] Step (i): peptide coupling; the reaction is performed in a
polar solvent such as a DME/THF/H.sub.2O mixture in the presence of
a base such as sodium bicarbonate or in a polar solvent such as DCM
in the presence of a coupling reagent such as propylphosphonic
anhydride and a base such as, for example, TEA;
[0636] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0637] Step (iii): coupling and activation of the carboxylic acid
as NHS ester; the coupling of N-succinimidyl bromo- and
iodo-acetate with the amino carboxylic acid is performed in a polar
aprotic solvent such as a DCM/DMF mixture followed by the addition
of N,N'-disuccinimidyl carbonate and a base such as, for example,
DIEA;
[0638] Step (iv): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed in a polar aprotic solvent
such as a DCM/CHCN mixture;
[0639] Step (v): deprotection using a solution of hydrochloric acid
(for example solution in dioxane) or of trifluoroacetic acid.
[0640] NHS esters of Fmoc-L-amino acids are commercially available;
the mono-protected diamines are commercially available for n=2 to 4
and R.sub.17 and R.sub.18.dbd.H or Me independently of each other;
N-succinimidyl bromo- and iodo-acetate are commercially available;
in the case where ALK=CH.sub.2CH.sub.2 and R.sub.20.dbd.H, the
amino PEG carboxylic acids are commercially available for and i=1
to 6 and otherwise may be prepared from tert-butyl acrylate and the
corresponding amino-PEG-alcohol; in the case where
ALK.noteq.CH.sub.2CH.sub.2, they may be prepared according to the
schemes described for linker precursor LP.sub.10.
##STR00274##
prepared according to the scheme below:
##STR00275##
[0641] Step (i): peptide coupling; the reaction is performed in a
polar solvent such as a DME/THF/H.sub.2O mixture in the presence of
a base such as sodium bicarbonate or in a polar solvent such as DCM
in the presence of a coupling reagent such as propylphosphonic
anhydride and a base such as, for example, TEA;
[0642] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0643] Step (iii): coupling and activation of the carboxylic acid
as a NHS ester; the coupling of N-succinimidyl bromo- and
iodo-acetate with the amino carboxylic acid is performed in a polar
aprotic solvent such as a DCM/DMF mixture followed by the addition
of N,N'-disuccinimidyl carbonate and a base such as, for example,
DIEA;
[0644] Step (iv): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed in a polar aprotic solvent
such as a DCM/CH.sub.3CN mixture;
[0645] Step (v): deprotection using a solution of hydrochloric acid
(for example solution in dioxane) or of trifluoroacetic acid.
[0646] NHS esters of Fmoc-L-amino acids are commercially available;
the mono-protected diamines are commercially available for n=2 to 4
and R.sub.17 and R.sub.18.dbd.H or Me independently of each other;
N-succinimidyl bromo- and iodo-acetate are commercially available;
the amino-(hetero)aryl-carboxylic acids are commercially available,
like for example 4-amino-2-benzoic acid, 6-amino-3-pyridine
carboxylic acid, 5-amino-2-pyrazine carboxylic acid,
2-amino-5-pyrimidine carboxylic acid or 6-amino-1,2,4,5-tetrazine
carboxylic acid.
##STR00276##
prepared according to the scheme below:
##STR00277##
[0647] Step (i): peptide coupling; the reaction is performed in a
polar solvent such as a DME/THF/H.sub.2O mixture in the presence of
a base such as sodium bicarbonate or in a polar solvent such as DCM
in the presence of a coupling reagent such as propylphosphonic
anhydride and a base such as, for example, TEA;
[0648] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0649] Step (iii): activation of the carboxylic acid as a NHS
ester; the reaction is performed in a polar aprotic solvent such as
DCM by treatment with NHS in the presence of a coupling agent such
as, for example, EDC;
[0650] Step (iv): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed in a polar aprotic solvent
such as a DCM/CH.sub.3CN mixture;
[0651] Step (v): deprotection using a solution of hydrochloric acid
(for example solution in dioxane) or of trifluoroacetic acid.
[0652] NHS esters of Fmoc-L-amino acids are commercially available;
the mono-protected diamines are commercially available for n=2 to 4
and R.sub.17 and R.sub.18.dbd.H or Me independently of each other;
the amino carboxylic acids are commercially available for n=1 to
12.
##STR00278##
prepared according to the scheme below:
##STR00279##
[0653] Step (i): peptide coupling; the reaction is performed in a
polar solvent such as a DME/THF/H.sub.2O mixture in the presence of
a base such as sodium bicarbonate or in a polar solvent such as DCM
in the presence of a coupling reagent such as propylphosphonic
anhydride and a base such as, for example, TEA;
[0654] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0655] Step (iii): activation of the carboxylic acid as a NHS
ester; the reaction is performed in a polar aprotic solvent such as
DCM by treatment with NHS in the presence of a coupling agent such
as, for example, supported DCC;
[0656] Step (iv): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed in a polar aprotic solvent
such as a DCM/CHCN mixture;
[0657] Step (v): deprotection using a solution of hydrochloric acid
(for example solution in dioxane) or of trifluoroacetic acid.
[0658] NHS esters of Fmoc-L-amino acids are commercially available;
the mono-protected diamines are commercially available for n=2 to 4
and R.sub.17 and R.sub.18.dbd.H or Me independently of each other;
Fmoc-protected amino PEG carboxylic acids are commercially
available for and i=1 to 6 and otherwise may be prepared from
tert-butyl acrylate and the corresponding amino-PEG-alcohol; in the
case where ALK.noteq.CH.sub.2CH.sub.2, they may be prepared
according to the schemes for linker precursor LP.sub.10. Protection
of the amine function with a Fmoc group may be realized by
treatment with FmocOSu (CAS number [82911-69-1]) in the presence of
a base such as, for example, DIEA.
##STR00280##
prepared according to the scheme below:
##STR00281##
[0659] Step (i): peptide coupling; the reaction is performed in a
polar solvent such as a DME/THF/H.sub.2O mixture in the presence of
a base such as sodium bicarbonate or in a polar solvent such as DCM
in the presence of a coupling reagent such as propylphosphonic
anhydride and a base such as, for example, TEA;
[0660] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0661] Step (iii): activation of the carboxylic acid as a NHS
ester; the reaction is performed in a polar aprotic solvent such as
DCM by treatment with NHS in the presence of a coupling agent such
as, for example, EDC;
[0662] Step (iv): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed in a polar aprotic solvent
such as a DCM/CH.sub.3CN mixture;
[0663] Step (v): deprotection using a solution of hydrochloric acid
(for example solution in dioxane) or of trifluoroacetic acid.
[0664] NHS esters of Fmoc-L-amino acids are commercially available;
the mono-protected diamines are commercially available for n=2 to 4
and R.sub.17 and R.sub.18.dbd.H or Me independently of each other;
the azido carboxylic acids may be prepared according to the schemes
described for linker precursor
##STR00282##
prepared according to the scheme below:
##STR00283##
[0665] Step (i): peptide coupling; the reaction is performed in a
polar solvent such as a DME/THF/H.sub.2O mixture in the presence of
a base such as sodium bicarbonate or in a polar solvent such as DCM
in the presence of a coupling reagent such as propylphosphonic
anhydride and a base such as, for example, TEA;
[0666] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0667] Step (iii): activation of the carboxylic acid as a NHS
ester; the reaction is performed in a polar aprotic solvent such as
DCM by treatment with NHS in the presence of a coupling agent such
as, for example, supported DCC;
[0668] Step (iv): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed in a polar aprotic solvent
such as a DCM/CHCN mixture;
[0669] Step (v): deprotection using a solution of hydrochloric acid
(for example solution in dioxane) or of trifluoroacetic acid.
[0670] NHS esters of Fmoc-L-amino acids are commercially available;
the mono-protected diamines are commercially available for n=2 to 4
and R.sub.17 and R.sub.18.dbd.H or Me independently of each other;
azido PEG carboxylic acids may be prepared according to the schemes
described for linker precursor LP.sub.15.
##STR00284##
prepared according to the scheme below:
##STR00285##
[0671] Step (i): peptide coupling; the reaction is performed in a
polar solvent such as a DME/THF/H.sub.2O mixture in the presence of
a base such as sodium bicarbonate or in a polar solvent such as DCM
in the presence of a coupling reagent such as propylphosphonic
anhydride and a base such as, for example, TEA;
[0672] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0673] Step (iii): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed in a polar aprotic solvent
such as a DCM/CHCN mixture;
[0674] Step (iv): deprotection using a solution of hydrochloric
acid (for example solution in dioxane) or of trifluoroacetic
acid.
[0675] NHS esters of Fmoc-L-amino acids are commercially available;
the mono-protected diamines are commercially available for n=2 to 4
and R.sub.17 and R.sub.18.dbd.H or Me independently of each other;
cyclooctyne linkers activated as NHS esters may be prepared
according to the schemes described for linker precursor
LP.sub.16.
##STR00286##
prepared according to the scheme below:
##STR00287##
[0676] Step (i): peptide coupling; the reaction is performed in a
polar solvent such as a DME/THF/H.sub.2O mixture in the presence of
a base such as sodium bicarbonate or in a polar solvent such as DCM
in the presence of a coupling reagent such as propylphosphonic
anhydride and a base such as, for example, TEA;
[0677] Step (ii): deprotection of the amine; the reaction is
performed in a polar solvent such as a DCM/MeOH mixture in the
presence of a base such as, for example, piperidine;
[0678] Step (iii): peptide coupling between the dipeptide and the
NHS ester; the reaction is performed in a polar aprotic solvent
such as a DCM/CHCN mixture;
[0679] Step (iv): deprotection using a solution of hydrochloric
acid (for example solution in dioxane) or of trifluoroacetic
acid.
[0680] NHS esters of Fmoc-L-amino acids are commercially available;
the mono-protected diamines are commercially available for n=2 to 4
and R.sub.17 and R.sub.18.dbd.H or Me independently of each other;
cyclooctyne linkers activated as NHS esters may be prepared
according to the schemes described for linker precursor
LP.sub.17.
##STR00288##
prepared according to the scheme below:
##STR00289##
[0681] Step (i): peptide coupling between the linker precursor LP1
and an aniline derivative; the reaction is performed in a polar
solvent such as a DCM/MeOH mixture in the presence of a coupling
agent such as, for example, EEDQ;
[0682] Step (ii): activation of the benzylic alcohol as a
p-nitrophenyl-carbonate by treatment with
p-nitrophenyl-chloroformate in the presence of a base such as, for
example, DIEA.
[0683] Many aniline derivatives are commercially available such as,
for example, 4-(hydroxymethyl)-aniline (CAS number [623-04-1]),
4-(1-hydroxyethyl)-aniline (racemic (CAS number [14572-89-5]) or
enantiopure (R) (CAS number [210754-25-9]) or (S) (CAS number
[500229-84-5])), 4-amino-.alpha.,.alpha.-dimethyl-benzene-methanol
(CAS number [23243-04-1]),
4-amino-.alpha.-methoxy-.alpha.-methyl-benzenemethanol (CAS number
[1379318-81-6]),
4-amino-.alpha.-methyl-.alpha.-trifluoromethyl-benzenemethanol (CAS
number [851652-56-7]), 2-amino-benzenemethanol (CAS number
[5344-90-1]), 2-amino-.alpha.-methyl-benzenemethanol (racemic (CAS
number [10517-50-7]) or enantiopure (R) (CAS number [3205-21-8]) or
(S) (CAS number [3205-21-8])), 6-amino-3-pyridinemethanol (CAS
number [113293-71-3]), 6-amino-.alpha.-methyl-3-pyridinemethanol
(CAS number [1335054-83-5]),
6-amino-.alpha.-ethyl-3-pyridinemethanol (CAS number
[1355225-85-2]),
6-amino-.alpha.,.alpha.-dimethyl-3-pyridinemethanol (CAS number
[843646-03-8]), 5-amino-3-pyridinemethanol (CAS number
[873651-92-4]), 2-amino-3-pyridinemethanol (CAS number
[23612-57-9]), 2-amino-.alpha.-methyl-3-pyridinemethanol (racemic
(CAS number [869567-91-9]) or enantiopure (R) (CAS number
[936718-01-3]) or (S) (CAS number [936718-00-2])),
2-amino-.alpha.-ethyl-3-pyridinemethanol (CAS number
[914223-90-8]), 2-amino-.alpha.,.alpha.-dimethyl-3-pyridinemethanol
(CAS number [213666-96-7]), 3-amino-4-pyridinemethanol (CAS number
[152398-05-5]), 3-amino-.alpha.-methyl-4-pyridinemethanol (CAS
number [1242470-88-7]),
3-amino-.alpha.,.alpha.-methyl-4-pyridinemethanol (CAS number
[13357-81-8]), 4-amino-3-pyridinemethanol (CAS number
[138116-34-4]), 4-amino-.alpha.-methyl-3-pyridinemethanol (CAS
number [741223-49-4]),
4-amino-.alpha.,.alpha.-methyl-3-pyridinemethanol (CAS number
[1339013-26-1]), 3-amino-2-pyridinemethanol (CAS number
[52378-63-9]), 3-amino-.alpha.-methyl-2-pyridinemethanol (CAS
number [954240-54-1]),
3-amino-.alpha.,.alpha.-methyl-2-pyridinemethanol (CAS number
[899438-57-4]).
##STR00290##
prepared according to the scheme below:
##STR00291##
[0684] Step (i): peptide coupling between the linker precursor LP2
and an aniline derivative; the reaction is performed in a polar
solvent such as a DCM/MeOH mixture in the presence of a coupling
agent such as, for example, EEDQ;
[0685] Step (ii): activation of the benzylic alcohol as a
p-nitrophenyl-carbonate by treatment with
p-nitrophenyl-chloroformate in the presence of a base such as, for
example, DIEA.
[0686] Many aniline derivatives are commercially available such as,
for example, those listed for LPas.
##STR00292##
prepared according to the scheme below:
##STR00293##
[0687] Step (i): peptide coupling between the linker precursor
LP.sub.3 and an aniline derivative; the reaction is performed in a
polar solvent such as a DCM/MeOH mixture in the presence of a
coupling agent such as, for example, EEDQ;
[0688] Step (ii): activation of the benzylic alcohol as a
p-nitrophenyl-carbonate by treatment with
p-nitrophenyl-chloroformate in the presence of a base such as, for
example, DIEA.
[0689] Many aniline derivatives are commercially available such as,
for example, those listed for LPas.
##STR00294##
prepared according to the scheme below:
##STR00295##
[0690] Step (i): peptide coupling between the linker precursor LP4
and an aniline derivative; the reaction is performed in a polar
solvent such as a DCM/MeOH mixture in the presence of a coupling
agent such as, for example, EEDQ;
[0691] Step (ii): activation of the benzylic alcohol as a
p-nitrophenyl-carbonate by treatment with
p-nitrophenyl-chloroformate in the presence of a base such as, for
example, DIEA.
[0692] Many aniline derivatives are commercially available such as,
for example, those listed for LPas.
##STR00296##
prepared according to the scheme below:
##STR00297##
[0693] Step (i): peptide coupling between the linker precursor LP
and an aniline derivative; the reaction is performed in a polar
solvent such as a DCM/MeOH mixture in the presence of a coupling
agent such as, for example, EEDQ;
[0694] Step (ii): activation of the benzylic alcohol as
ap-nitrophenyl-carbonate by treatment with
p-nitrophenyl-chloroformate in the presence of abase such as, for
example, DIEA.
[0695] Many aniline derivatives are commercially available such as,
for example, those listed for LP.sub.35.
##STR00298##
prepared according to the scheme below:
##STR00299##
[0696] Step (i): peptide coupling between the linker precursor
LP.sub.6 and an aniline derivative; the reaction is performed in a
polar solvent such as a DCM/MeOH mixture in the presence of a
coupling agent such as, for example, EEDQ;
[0697] Step (ii): activation of the benzylic alcohol as a
p-nitrophenyl-carbonate by treatment with
p-nitrophenyl-chloroformate in the presence of a base such as, for
example, DIEA.
[0698] Many aniline derivatives are commercially available such as,
for example, those listed for LP.sub.35.
##STR00300##
prepared according to the scheme below:
##STR00301##
[0699] Step (i): peptide coupling between the linker precursor
LP.sub.7 and an aniline derivative; the reaction is performed in a
polar solvent such as a DCM/MeOH mixture in the presence of a
coupling agent such as, for example, EEDQ;
[0700] Step (ii): activation of the benzylic alcohol as a
p-nitrophenyl-carbonate by treatment with
p-nitrophenyl-chloroformate in the presence of a base such as, for
example, DIEA.
[0701] Many aniline derivatives are commercially available such as,
for example, those listed for LP.sub.35.
##STR00302##
prepared according to the scheme below:
##STR00303##
[0702] Step (i): peptide coupling between the linker precursor
LP.sub.8 and an aniline derivative; the reaction is performed in a
polar solvent such as a DCM/MeOH mixture in the presence of a
coupling agent such as, for example, EEDQ;
[0703] Step (ii): activation of the benzylic alcohol as a
p-nitrophenyl-carbonate by treatment with
p-nitrophenyl-chloroformate in the presence of a base such as, for
example, DIEA.
[0704] Many aniline derivatives are commercially available such as,
for example, those listed for LP.sub.35.
##STR00304##
prepared according to the scheme below:
##STR00305##
[0705] Step (i): peptide coupling between the linker precursor
LP.sub.9 and an aniline derivative; the reaction is performed in a
polar solvent such as a DCM/MeOH mixture in the presence of a
coupling agent such as, for example, EEDQ;
[0706] Step (ii): activation of the benzylic alcohol as a
p-nitrophenyl-carbonate by treatment with
p-nitrophenyl-chloroformate in the presence of a base such as, for
example, DIEA.
[0707] Many aniline derivatives are commercially available such as,
for example, those listed for LP.sub.35.
##STR00306##
prepared according to the scheme below:
##STR00307##
[0708] Step (i): peptide coupling between the linker precursor
LP.sub.10 and an aniline derivative; the reaction is performed in a
polar solvent such as a DCM/MeOH mixture in the presence of a
coupling agent such as, for example, EEDQ;
[0709] Step (ii): activation of the benzylic alcohol as a
p-nitrophenyl-carbonate by treatment with
p-nitrophenyl-chloroformate in the presence of a base such as, for
example, DIEA.
[0710] Many aniline derivatives are commercially available such as,
for example, those listed for LP.sub.35.
##STR00308##
prepared according to the scheme below:
##STR00309##
[0711] Step (i): peptide coupling between the linker precursor
LP.sub.11 and an aniline derivative; the reaction is performed in a
polar solvent such as a DCM/MeOH mixture in the presence of a
coupling agent such as, for example, EEDQ;
[0712] Step (ii): activation of the benzylic alcohol as a
p-nitrophenyl-carbonate by treatment with
p-nitrophenyl-chloroformate in the presence of a base such as, for
example, DIEA.
[0713] Many aniline derivatives are commercially available such as,
for example, those listed for LP.sub.35.
##STR00310##
prepared according to the scheme below:
##STR00311##
[0714] Step (i): peptide coupling between the linker precursor
LP.sub.12 and an aniline derivative; the reaction is performed in a
polar solvent such as a DCM/MeOH mixture in the presence of a
coupling agent such as, for example, EEDQ;
[0715] Step (ii): activation of the benzylic alcohol as a
p-nitrophenyl-carbonate by treatment with
p-nitrophenyl-chloroformate in the presence of a base such as, for
example, DIEA.
[0716] Many aniline derivatives are commercially available such as,
for example, those listed for LP.sub.35.
##STR00312##
prepared according to the scheme below:
##STR00313##
[0717] Step (i): peptide coupling between the linker precursor
LP.sub.13 and an aniline derivative; the reaction is performed in a
polar solvent such as a DCM/MeOH mixture in the presence of a
coupling agent such as, for example, EEDQ;
[0718] Step (ii): activation of the benzylic alcohol as a
p-nitrophenyl-carbonate by treatment with
p-nitrophenyl-chloroformate in the presence of a base such as, for
example, DIEA.
[0719] Many aniline derivatives are commercially available such as,
for example, those listed for LPas.
##STR00314##
prepared according to the scheme below:
##STR00315##
[0720] Step (i): peptide coupling between the linker precursor
LP.sub.14 and an aniline derivative; the reaction is performed in a
polar solvent such as a DCM/MeOH mixture in the presence of a
coupling agent such as, for example, EEDQ;
[0721] Step (ii): activation of the benzylic alcohol as a
p-nitrophenyl-carbonate by treatment with
p-nitrophenyl-chloroformate in the presence of a base such as, for
example, DIEA.
[0722] Many aniline derivatives are commercially available such as,
for example, those listed for LPas.
##STR00316##
prepared according to the scheme below:
##STR00317##
[0723] Step (i): peptide coupling between the linker precursor
LP.sub.15 and an aniline derivative; the reaction is performed in a
polar solvent such as a DCM/MeOH mixture in the presence of a
coupling agents such as, for example, EEDQ;
[0724] Step (ii): activation of the benzylic alcohol as a
p-nitrophenyl-carbonate by treatment with
p-nitrophenyl-chloroformate in the presence of a base such as, for
example, DIEA.
##STR00318##
prepared according to the scheme below:
##STR00319##
[0725] Step (i): peptide coupling between the linker precursor
LP.sub.16 and an aniline derivative; the reaction is performed in a
polar solvent such as a DCM/MeOH mixture in the presence of a
coupling agent such as, for example, EEDQ;
[0726] Step (ii): activation of the benzylic alcohol as a
p-nitrophenyl-carbonate by treatment with
p-nitrophenyl-chloroformate in the presence of a base such as, for
example, DIEA.
[0727] Many aniline derivatives are commercially available such as,
for example, those listed for LP.sub.35.
##STR00320##
prepared according to the scheme below:
##STR00321##
[0728] Step (i): peptide coupling between the linker precursor
LP.sub.17 and an aniline derivative; the reaction is performed in a
polar solvent such as a DCM/MeOH mixture in the presence of a
coupling agent such as, for example, EEDQ;
[0729] Step (ii): activation of the benzylic alcohol as a
p-nitrophenyl-carbonate by treatment with
p-nitrophenyl-chloroformate in the presence of a base such as, for
example, DIEA.
[0730] Many aniline derivatives are commercially available such as,
for example, those listed for LP.sub.35.
##STR00322##
prepared according to the scheme below:
##STR00323##
[0731] Step (i): formation of the carbamate between the linker
precursor LP.sub.35 and a monoprotected diamine; the reaction is
performed in a polar solvent such as CH.sub.3CN in the presence of
a base such as, for example, DIEA; deprotection using a solution of
hydrochloric acid (for example solution in dioxane) or of
trifluoroacetic acid.
##STR00324##
prepared according to the scheme below:
##STR00325##
[0732] Step (i): formation of the carbamate between the linker
precursor LP.sub.36 and a monoprotected diamine; the reaction is
performed in a polar solvent such as CH.sub.3CN in the presence of
a base such as, for example, DIEA; deprotection using a solution of
hydrochloric acid (for example solution in dioxane) or of
trifluoroacetic acid.
##STR00326##
prepared according to the scheme below:
##STR00327##
[0733] Step (i): formation of the carbamate between the linker
precursor LP.sub.37 and a monoprotected diamine; the reaction is
performed in a polar solvent such as CH.sub.3CN in the presence of
a base such as, for example, DIEA; deprotection using a solution of
hydrochloric acid (for example solution in dioxane) or of
trifluoroacetic acid.
##STR00328##
prepared according to the scheme below:
##STR00329##
[0734] Step (i): formation of the carbamate between the linker
precursor LP.sub.38 and a monoprotected diamine; the reaction is
performed in a polar solvent such as CH.sub.3CN in the presence of
a base such as, for example, DIEA; deprotection using a solution of
hydrochloric acid (for example solution in dioxane) or of
trifluoroacetic acid.
##STR00330##
prepared according to the scheme below:
##STR00331##
[0735] Step (i): formation of the carbamate between the linker
precursor LP.sub.39 and a monoprotected diamine; the reaction is
performed in a polar solvent such as CH.sub.3CN in the presence of
a base such as, for example, DIEA; deprotection using a solution of
hydrochloric acid (for example solution in dioxane) or of
trifluoroacetic acid.
##STR00332##
prepared according to the scheme below:
##STR00333##
[0736] Step (i): formation of the carbamate between the linker
precursor LP.sub.40 and a monoprotected diamine; the reaction is
performed in a polar solvent such as CH.sub.3CN in the presence of
a base such as, for example, DIEA; deprotection using a solution of
hydrochloric acid (for example solution in dioxane) or of
trifluoroacetic acid.
##STR00334##
prepared according to the scheme below:
##STR00335##
[0737] Step (i): formation of the carbamate between the linker
precursor LP.sub.41 and a monoprotected diamine; the reaction is
performed in a polar solvent such as CH.sub.3CN in the presence of
a base such as, for example, DIEA; deprotection using a solution of
hydrochloric acid (for example solution in dioxane) or of
trifluoroacetic acid.
##STR00336##
prepared according to the scheme below:
##STR00337##
[0738] Step (i): formation of the carbamate between the linker
precursor LP.sub.42 and a monoprotected diamine; the reaction is
performed in a polar solvent such as CH.sub.3CN in the presence of
a base such as, for example, DIEA; deprotection using a solution of
hydrochloric acid (for example solution in dioxane) or of
trifluoroacetic acid.
##STR00338##
prepared according to the scheme below:
##STR00339##
[0739] Step (i): formation of the carbamate between the linker
precursor LP.sub.43 and a monoprotected diamine; the reaction is
performed in a polar solvent such as CH.sub.3CN in the presence of
a base such as, for example, DIEA; deprotection using a solution of
hydrochloric acid (for example solution in dioxane) or of
trifluoroacetic acid.
##STR00340##
prepared according to the scheme below:
##STR00341##
[0740] Step (i): formation of the carbamate between the linker
precursor LP.sub.44 and a monoprotected diamine; the reaction is
performed in a polar solvent such as CH.sub.3CN in the presence of
a base such as, for example, DIEA; deprotection using a solution of
hydrochloric acid (for example solution in dioxane) or of
trifluoroacetic acid.
##STR00342##
prepared according to the scheme below:
##STR00343##
[0741] Step (i): formation of the carbamate between the linker
precursor LP.sub.45 and a monoprotected diamine; the reaction is
performed in a polar solvent such as CH.sub.3CN in the presence of
a base such as, for example, DIEA; deprotection using a solution of
hydrochloric acid (for example solution in dioxane) or of
trifluoroacetic acid.
##STR00344##
prepared according to the scheme below:
##STR00345##
[0742] Step (i): formation of the carbamate between the linker
precursor LP.sub.46 and a monoprotected diamine; the reaction is
performed in a polar solvent such as CH.sub.3CN in the presence of
a base such as, for example, DIEA; deprotection using a solution of
hydrochloric acid (for example solution in dioxane) or of
trifluoroacetic acid.
##STR00346##
prepared according to the scheme below:
##STR00347##
[0743] Step (i): formation of the carbamate between the linker
precursor LP.sub.47 and a monoprotected diamine; the reaction is
performed in a polar solvent such as CH.sub.3CN in the presence of
a base such as, for example, DIEA; deprotection using a solution of
hydrochloric acid (for example solution in dioxane) or of
trifluoroacetic acid.
##STR00348##
prepared according to the scheme below:
##STR00349##
[0744] Step (i): formation of the carbamate between the linker
precursor LP.sub.48 and a monoprotected diamine; the reaction is
performed in a polar solvent such as CH.sub.3CN in the presence of
a base such as, for example, DIEA; deprotection using a solution of
hydrochloric acid (for example solution in dioxane) or of
trifluoroacetic acid.
##STR00350##
prepared according to the scheme below:
##STR00351##
[0745] Step (i): formation of the carbamate between the linker
precursor LP.sub.49 and a monoprotected diamine; the reaction is
performed in a polar solvent such as CH.sub.3CN in the presence of
a base such as, for example, DIEA; deprotection using a solution of
hydrochloric acid (for example solution in dioxane) or of
trifluoroacetic acid.
##STR00352##
prepared according to the scheme below:
##STR00353##
[0746] Step (i): formation of the carbamate between the linker
precursor LP.sub.50 and a monoprotected diamine; the reaction is
performed in a polar solvent such as CH.sub.3CN in the presence of
a base such as, for example, DIEA; deprotection using a solution of
hydrochloric acid (for example solution in dioxane) or of
trifluoroacetic acid.
##STR00354##
prepared according to the scheme below:
##STR00355##
[0747] Step (i): formation of the carbamate; the reaction is
performed in a polar solvent such as CHCN in the presence of a base
such as, for example, DIEA; deprotection using a solution of
hydrochloric acid (for example solution in dioxane) or of
trifluoroacetic acid.
##STR00356##
prepared according to the 1.sup.st step described for linker
precursor LP.sub.35.
##STR00357##
prepared according to the 1.sup.st step described for linker
precursor LP.sub.36.
##STR00358##
prepared according to the 1.sup.st step described for linker
precursor LP.sub.37.
##STR00359##
prepared according to the 1.sup.st step described for linker
precursor LP.sub.38.
##STR00360##
prepared according to the 1.sup.st step described for linker
precursor LP.sub.69.
##STR00361##
prepared according to the 1.sup.st step described for linker
precursor LP.sub.40.
##STR00362##
prepared according to the 1.sup.st step described for linker
precursor LP.sub.41.
##STR00363##
prepared according to the 1.sup.st step described for linker
precursor LP.sub.42.
##STR00364##
prepared according to the 1.sup.st step described for linker
precursor LP.sub.43.
##STR00365##
prepared according to the 1.sup.st step described for linker
precursor LP.sub.44.
##STR00366##
prepared according to the 1.sup.st step described for linker
precursor LP.sub.45.
##STR00367##
prepared according to the 1.sup.st step described for linker
precursor LP.sub.46.
##STR00368##
prepared according to the 1.sup.st step described for linker
precursor LP.sub.47.
##STR00369##
prepared according to the 1.sup.st step described for linker
precursor LP.sub.48.
##STR00370##
prepared according to the 1.sup.st step described for linker
precursor LP.sub.49.
##STR00371##
prepared according to the 1.sup.st step described for linker
precursor LP.sub.50.
##STR00372##
prepared according to the 1.sup.st step described for linker
precursor LP.sub.51.
##STR00373##
prepared according to the scheme below:
##STR00374##
[0748] Step (i): coupling of the acid on Wang resin by
esterification; the reaction is performed in a polar solvent such
as DCM in the presence of a coupling reagent such as, for example,
DIC and a base such as, for example, DMAP;
[0749] Step (ii): deprotection of the Fmoc group; the reaction is
performed in a polar solvent such as DMF by treatment with a base
such as, for example, piperidine;
[0750] Step (iii): peptidic coupling; the reaction is performed in
a polar solvent such as DMF in the presence of coupling reagents
such as, for example, HOBt and HATU and a base such as, for
example, DIEA;
[0751] Step (iv): cleavage of the resin; the reaction is performed
in a polar solvent such as a DCM/H.sub.2O mixture in the presence
of an acid such as, for example, TFA.
[0752] Fmoc protected alkyl-amino acids are commercially available
for n=1 to 9; Fmoc L-amino acids are commercially available.
##STR00375##
prepared according to the scheme below:
##STR00376##
[0753] Step (i): coupling of the acid on Wang resin by
esterification; the reaction is performed in polar solvent such as
DCM in the presence of a coupling reagent such as, for example, DIC
and a base such as, for example, DMAP;
[0754] Step (ii):deprotection of the Fmoc group; the reaction is
performed in polar solvent such as DMF by treatment with abase such
as, for example, piperidine;
[0755] Step (iii): peptidic coupling; the reaction is performed in
a polar solvent such as DMF in the presence of coupling reagents
such as, for example, HOBt and HATU and abase such as, for example,
DIEA;
[0756] Step iv: cleavage of the resin; the reaction is performed in
a polar solvent such as a DCM/H.sub.2O mixture in the presence of
an acid such as, for example, TA.
[0757] Fmoc-protected amino PEG carboxylic acids are commercially
available for i=1 to 6 and otherwise may be prepared from
tert-butyl acrylate and the corresponding amino-PEG-alcohol; in the
case where ALK CH.sub.2CH.sub.2, they may be prepared according to
the schemes described for linker precursor LP.sub.10. Protection of
the amine function with a Fmoc group may be realized by treatment
with FmocOSu (CAS number [82911-69-1]) in the presence of abase
such as, for example, DIEA; Fmoc L-amino acids are commercially
available.
##STR00377##
prepared according to the scheme below:
##STR00378##
[0758] Step (i): peptidic coupling between Boc-L-amino acid-ONHS
and L-amino acid; the reaction is performed in a polar solvent such
as a DME/THF/H.sub.2O mixture in the presence of a base such as,
for example, sodium bicarbonate;
[0759] Step (ii): peptidic coupling with sulfo amino acids; the
reaction is performed in a polar solvent such as CH.sub.3CN in the
presence of coupling reagents such as, for example, DCC and HOBt
and a base such as, for example, DIEA;
[0760] Step (iii): deprotection of the Boc group using a solution
of hydrochloric acid (for example solution in dioxane).
[0761] L-amino acids are commercially available; NHS esters of
Boc-protected L-amino acids are commercially available; sulfo amino
acids are commercially available for n=1 and 2 or otherwise may be
prepared according to the scheme below:
##STR00379## [0762] Step (i): substitution of the bromide by a
thioacetyle; the reaction is performed in a polar aprotic solvent
such as, for example, THE using thioacetic acid in the presence of
a base such as, for example, DIEA; [0763] Step (ii): formation of
the sulfonic acid moiety; the reaction is performed by treatment
with hydrogen peroxide and acetic acid; [0764] Step (iii):
substitution of the bromide by an azido; the reaction is performed
in a polar solvent such as, for example, DMA by treatment with
sodium azide; [0765] Step (iv): methyl ester deprotection; the
reaction is performed in acidic conditions such as, for example, a
mixture of HCl and AcOH; [0766] Step (v): reduction of the azido;
the reaction is performed by hydrogenolysis in a polar solvent such
as H.sub.2O in the presence of a catalyst such as palladium on
carbon. [0767] Dibromo derivatives are commercially available for
n=3, 4 and 9.
[0767] ##STR00380## prepared according to the scheme below:
##STR00381##
[0768] Step (i): peptidic coupling between Boc-L-amino acid-ONHS
and L-amino acid; the reaction is performed in a polar solvent such
as a DME/THF/H.sub.2O mixture in the presence of a base such as,
for example, sodium bicarbonate;
[0769] Step (ii): peptidic coupling with maleimido amines; the
reaction is performed in a polar solvent such as CH.sub.3CN in the
presence of coupling reagents such as, for example, DCC and HOBt
and a base such as, for example, DIEA;
[0770] Step (iii): deprotection of the Boc group using a solution
of hydrochloric acid (for example solution in dioxane).
[0771] L-amino acids are commercially available; NHS esters of
Boc-protected L-amino acids are commercially available; maleimido
amines are commercially available for n=2 to 6.
##STR00382##
prepared according to the scheme below:
##STR00383##
[0772] Step (i): peptidic coupling between Boc-L-amino acid-ONHS
and L-amino acid; the reaction is performed in a polar solvent such
as a DME/THF/H.sub.2O mixture in the presence of a base such as,
for example, sodium bicarbonate;
[0773] Step (ii): peptidic coupling with maleimido PEG amines; the
reaction is performed in a polar solvent such as CH.sub.3CN in the
presence of coupling reagents such as, for example, DCC and HOBt
and a base such as, for example, DIEA;
[0774] Step (iii): deprotection of the Boc group using a solution
of hydrochloric acid (for example solution in dioxane).
[0775] L-amino acids are commercially available; NHS esters of
Boc-protected L-amino acids are commercially available; maleimido
PEG amines are commercially available for ALK=ALK'=CH.sub.2CH.sub.2
and i=0 and 1 or otherwise may be prepared according to the scheme
below: [0776] when ALK=ALK'=CH.sub.2CH.sub.2 and i>1
[0776] ##STR00384## [0777] when ALK.noteq.CH.sub.2CH.sub.2 and
ALK'=CH.sub.2CH.sub.2
[0777] ##STR00385## [0778] when ALK=CH.sub.2CH.sub.2 and
ALK'.noteq.CH.sub.2CH.sub.2
[0778] ##STR00386## [0779] when ALK and
ALK'.noteq.CH.sub.2CH.sub.2
##STR00387##
[0780] Step (i): Mitsunobu reaction on maleimide; the reaction is
performed in a polar aprotic solvent such as, for example, THE by
treatment of malemide by the PEG hydroxy acid in the presence of
PPh.sub.3 and DIAD;
[0781] Step (ii): deprotection using a solution of hydrochloric
acid (for example solution in dioxane) or of trifluoroacetic
acid;
[0782] Step (iii): activation of the alcohol as a tosylate; the
reaction is performed in a polar aprotic solvent such as, for
example, DCM by treatment with tosyl chloride in the presence of a
base such as, for example, TEA;
[0783] Step (iv): substitution of the tosyl group; the reaction is
performed in a polar aprotic solvent such as, for example, THF, in
the presence of a base such as, for example, sodium hydride.
[0784] Step (v): deprotection of the benzyl group; the reaction is
performed by hydrogenolysis in a polar solvent such as, for
example, MeOH, in the presence of a catalytic amount of catalyst,
such as, for example, palladium on carbon;
[0785] Step (vi): activation of the alcohol as a mesylate; the
reaction is performed in a polar aprotic solvent such as, for
example, DCM by treatment with methanesulfonyl chloride in the
presence of a base such as, for example, TEA;
[0786] Step (vii): nucleophilic substitution; the reaction is
performed in a polar aprotic solvent such as, for example, DMF in
the presence of a base such as sodium hydride;
[0787] The starting Boc-protected PEG amino alcohols are
commercially available for i=2 to 4 or can be prepared by treating
commercially available PEG amino alcohols by Boc.sub.2O for i=5 to
8; the starting ALK amino alcohols are commercially available for
n=1 and 3 to 10; the starting PEG diols monoprotected with a benzyl
group are commercially available for i=1 to 9; the starting ALK'
diols are commercially available for n=1 to 12.
##STR00388##
prepared according to the scheme below:
##STR00389##
[0788] Step (i): peptidic coupling between Boc-L-amino acid-ONHS
and L-amino acid; the reaction is performed in a polar solvent such
as a DME/THF/H.sub.2O mixture in the presence of a base such as,
for example, sodium bicarbonate;
[0789] Step (ii): peptidic coupling with maleimido amines; the
reaction is performed in a polar solvent such as CH.sub.3CN in the
presence of coupling reagents such as, for example, DCC and HOBt
and a base such as, for example, DIEA;
[0790] Step (iii): deprotection of the Boc group using a solution
of hydrochloric acid (for example solution in dioxane).
[0791] L-amino acids are commercially available; NHS esters of
Boc-protected L-amino acids are commercially available; maleimido
amines may be prepared according to the scheme below:
##STR00390##
[0792] Step (i): activation of the carboxylic acid as a NHS ester;
the reaction is performed in a polar solvent such as a mixture
DMF/H.sub.2O by treatment with N,N'-disuccinimidyl carbonate in the
presence of a base such as, for example, DIEA;
[0793] Step (ii): peptide coupling; the reaction is performed in a
polar aprotic solvent such as a DCM/CH.sub.3CN mixture;
[0794] Step (iii): deprotection of the Boc group using a solution
of hydrochloric acid (for example solution in dioxane).
[0795] The maleimido cyclohexanecarboxylic acid is commercially
available for ALK=CH.sub.2 or otherwise may be prepared according
to the schemes described for LP.sub.6; the diamines monoprotected
with a Boc group are commercially available for n=1 to 10.
##STR00391##
prepared according to the scheme below:
##STR00392##
[0796] Step (i): peptidic coupling between Boc-L-amino acid-ONHS
and L-amino acid; the reaction is performed in a polar solvent such
as a DME/THF/H.sub.2O mixture in the presence of a base such as,
for example, sodium bicarbonate;
[0797] Step (ii): peptidic coupling with maleimido PEG amines; the
reaction is performed in a polar solvent such as CH.sub.3CN in the
presence of coupling reagents such as, for example, DCC and HOBt
and a base such as, for example, DIEA;
[0798] Step (iii): deprotection of the Boc group using a solution
of hydrochloric acid (for example solution in dioxane).
[0799] L-amino acids are commercially available; NHS esters of
Boc-protected L-amino acids are commercially available; maleimido
PEG amines may be prepared according to the scheme below:
##STR00393##
[0800] Step (i): activation of the carboxylic acid as a NHS ester;
the reaction is performed in a polar solvent such as a mixture
DMF/H.sub.2O by treatment with N,N'-disuccinimidyl carbonate in the
presence of a base such as, for example, DIEA;
[0801] Step (ii): peptide coupling; the reaction is performed in a
polar aprotic solvent such as a DCM/CH.sub.3CN mixture;
[0802] Step (iii): deprotection of the Boc group using a solution
of hydrochloric acid (for example solution in dioxane).
[0803] The maleimido cyclohexanecarboxylic acid is commercially
available for ALK=CH.sub.2 or otherwise may be prepared according
to the schemes described for LP.sub.6; the PEG diamines
monoprotected with a Boc group are commercially available for i=1
to 9.
##STR00394##
prepared according to the scheme below:
##STR00395##
[0804] Step (i): peptidic coupling between Boc-L-amino acid-ONHS
and L-amino acid; the reaction is performed in a polar solvent such
as a DME/THF/H.sub.2O mixture in the presence of a base such as,
for example, sodium bicarbonate;
[0805] Step (ii): peptidic coupling with halogenoacetamido PEG
amines; the reaction is performed in a polar solvent such as
CH.sub.3CN in the presence of coupling reagents such as, for
example, DCC and HOBt and a base such as, for example, DIEA;
[0806] Step (iii): deprotection of the Boc group using a solution
of hydrochloric acid (for example solution in dioxane).
[0807] L-amino acids are commercially available; NHS esters of
Boc-protected L-amino acids are commercially available;
halogenoacetamido amines are commercially available for n=2 to 4
and 8 or may be prepared according to the scheme below:
##STR00396##
[0808] Step (ii): peptide coupling; the reaction is performed in a
polar aprotic solvent such as a DCM/CH.sub.3CN mixture;
[0809] Step (iii): deprotection of the Boc group using a solution
of hydrochloric acid (for example solution in dioxane).
[0810] N-succinimidyl bromo- and iodo-acetates are commercially
available; the diamines monoprotected with a Boc group are
commercially available for n=1 to 10.
##STR00397##
prepared according to the scheme below:
##STR00398##
[0811] Step (i): peptidic coupling between Boc-L-amino acid-ONHS
and L-amino acid; the reaction is performed in a polar solvent such
as a DME/THF/H.sub.2O mixture in the presence of a base such as,
for example, sodium bicarbonate;
[0812] Step (ii): peptidic coupling with halogenoacetamido PEG
amines; the reaction is performed in a polar solvent such as
CH.sub.3CN in the presence of coupling reagents such as, for
example, DCC and HOBt and a base such as, for example, DIEA;
[0813] Step (iii): deprotection of the Boc group using a solution
of hydrochloric acid (for example solution in dioxane).
[0814] L-amino acids are commercially available; NHS esters of
Boc-protected L-amino acids are commercially available;
halogenoacetamido amines are commercially available for n=2 to 4
and 8 or may be prepared according to the scheme below:
##STR00399## [0815] Step (ii): peptide coupling; the reaction is
performed in a polar aprotic solvent such as a DCM/CH.sub.3CN
mixture; [0816] Step (iii): deprotection of the Boc group using a
solution of hydrochloric acid (for example solution in dioxane).
[0817] N-succinimidyl bromo- and iodo-acetates are commercially
available; the PEG diamines monoprotected with a Boc group are
commercially available for i=1 to 9.
##STR00400##
[0817] prepared according to the scheme below:
##STR00401##
[0818] Step (i): peptidic coupling between Boc-L-amino acid-ONHS
and L-amino acid; the reaction is performed in a polar solvent such
as a DME/THF/H.sub.2O mixture in the presence of a base such as,
for example, sodium bicarbonate;
[0819] Step (ii): peptidic coupling with halogenoacetamido amines;
the reaction is performed in a polar solvent such as CH.sub.3CN in
the presence of coupling reagents such as, for example, DCC and
HOBt and a base such as, for example, DIEA;
[0820] Step (iii): deprotection of the Boc group using a solution
of hydrochloric acid (for example solution in dioxane).
[0821] L-amino acids are commercially available; NHS esters of
Boc-protected L-amino acids are commercially available;
halogenoacetamido amines can be prepared according to the scheme
below:
##STR00402## [0822] Step (ii): peptide coupling; the reaction is
performed in a polar aprotic solvent such as a DCM/CH.sub.3CN
mixture; [0823] Step (iii): deprotection of the Boc group using a
solution of hydrochloric acid (for example solution in dioxane).
[0824] NHS esters of halogenoacetamides may be prepared as
described for linker precursor LP.sub.11; the diamines
monoprotected with a Boc group are commercially available for n=1
to 10.
##STR00403##
[0824] prepared according to the scheme below:
##STR00404##
[0825] Step (i): peptidic coupling between Boc-L-amino acid-ONHS
and L-amino acid; the reaction is performed in a polar solvent such
as a DME/THF/H.sub.2O mixture in the presence of a base such as,
for example, sodium bicarbonate;
[0826] Step (ii): peptidic coupling with azido amines; the reaction
is performed in a polar solvent such as CH.sub.3CN in the presence
of coupling reagents such as, for example, DCC and HOBt and a base
such as, for example, DIEA;
[0827] Step (iii): deprotection of the Boc group using a solution
of hydrochloric acid (for example solution in dioxane).
[0828] L-amino acids are commercially available; NHS esters of
Boc-protected L-amino acids are commercially available; azido
amines are commercially available for n=2 to 8 and 10.
##STR00405##
prepared according to the scheme below:
##STR00406##
[0829] Step (i): peptidic coupling between Boc-L-amino acid-ONHS
and L-amino acid; the reaction is performed in a polar solvent such
as a DME/THF/H.sub.2O mixture in the presence of a base such as,
for example, sodium bicarbonate;
[0830] Step (ii): peptidic coupling with azido PEG amines; the
reaction is performed in a polar solvent such as CH.sub.3CN in the
presence of coupling reagents such as, for example, DCC and HOBt
and a base such as, for example, DIEA;
[0831] Step (iii): deprotection of the Boc group using a solution
of hydrochloric acid (for example solution in dioxane).
[0832] L-amino acids are commercially available; NHS esters of
Boc-protected L-amino acids are commercially available; for
ALK=CH.sub.2CH.sub.2, azido PEG amines are commercially available
for i=1 to 8 and 10, for ALK.noteq.CH.sub.2CH.sub.2, azido PEG
amines may be prepared according to the scheme below:
##STR00407##
[0833] Step (i): activation of the alcohol as a mesylate; the
reaction is performed in a polar aprotic solvent such as, for
example, DCM by treatment with methanesulfonyl chloride in the
presence of a base such as, for example, TEA;
[0834] Step (ii): substitution of the mesylate by an azido group;
the reaction is performed in a polar solvent such as an
acetone/H.sub.2O mixture by treatment with sodium azide;
[0835] Step (iii): deprotection of the Boc group using a solution
of hydrochloric acid (for example solution in dioxane).
[0836] The starting PEG amino alcohols may be prepared as described
for linker precursor LP.sub.90.
##STR00408##
prepared according to the scheme below:
##STR00409##
[0837] Step (i): peptidic coupling between Boc-L-amino acid-ONHS
and L-amino acid; the reaction is performed in a polar solvent such
as a DME/THF/H.sub.2O mixture in the presence of a base such as,
for example, sodium bicarbonate;
[0838] Step (ii): peptidic coupling with cyclooctyne amines; the
reaction is performed in a polar solvent such as CH.sub.3CN in the
presence of coupling reagents such as, for example, DCC and HOBt
and a base such as, for example, DIEA;
[0839] Step (iii): deprotection of the Boc group using a solution
of hydrochloric acid (for example solution in dioxane).
[0840] Cyclooctyne amines are commercially available for n=1, 2, 3
and 5.
##STR00410##
prepared according to the scheme below:
##STR00411##
[0841] Step (i): peptidic coupling between Boc-L-amino acid-ONHS
and L-amino acid; the reaction is performed in a polar solvent such
as a DME/THF/H.sub.2O mixture in the presence of a base such as,
for example, sodium bicarbonate;
[0842] Step (ii): peptidic coupling with cyclooctyne PEG amines;
the reaction is performed in a polar solvent such as CH.sub.3CN in
the presence of coupling reagents such as, for example, DCC and
HOBt and a base such as, for example, DIEA;
[0843] Step (iii): deprotection of the Boc group using a solution
of hydrochloric acid (for example solution in dioxane).
[0844] Cyclooctyne PEG amines may be prepared according to the
scheme below:
##STR00412## [0845] Step (i): activation of the alcohol as a
mesylate; the reaction is performed in a polar aprotic solvent such
as, for example, DCM by treatment with methanesulfonyl chloride in
the presence of a base such as, for example, TEA; [0846] Step (ii):
nucleophilic substitution; the reaction is performed in a polar
aprotic solvent such as, for example, DMF in the presence of a base
such as sodium hydride; [0847] Step (iii): deprotection using a
solution of hydrochloric acid (for example solution in dioxane) or
of trifluoroacetic acid; [0848] Step (iv): protection of the amine
with a Boc group; the reaction is performed in a polar solvent such
as, for example, DCM, by treatment with Boc.sub.2O in the presence
of a base such as, for example, TEA; [0849] Step (v): peptidic
coupling; the reaction is performed in a polar solvent such as, for
example, DCM, in the presence of coupling reagents such as, for
example, HOBt and EDC. The starting ALK amino alcohols are
commercially available for n=1 to 10; cyclooctynes are commercially
available for n=1, 2, 3 and 5.
TABLE-US-00007 [0849] TABLE 1 Linker precursor Cryptophycin
payloads of formula (II).sup.1,2 LP Examples of LP RCG1-family
derived from the precursor LP LP.sub.1 ##STR00413## L.sub.1
##STR00414## LP.sub.2 ##STR00415## L.sub.2 ##STR00416## LP.sub.3
##STR00417## L.sub.3 ##STR00418## LP.sub.4 ##STR00419## L.sub.4
##STR00420## LP.sub.5 ##STR00421## L.sub.5 ##STR00422## LP.sub.6
##STR00423## L.sub.6 ##STR00424## LP.sub.7 ##STR00425## L.sub.7
##STR00426## LP.sub.8 ##STR00427## L.sub.8 ##STR00428## LP.sub.9
##STR00429## L.sub.9 ##STR00430## LP.sub.10 ##STR00431## L.sub.10
##STR00432## LP.sub.11 ##STR00433## L.sub.11 ##STR00434## LP.sub.12
##STR00435## L.sub.12 ##STR00436## LP.sub.13 ##STR00437## L.sub.13
##STR00438## LP.sub.14 ##STR00439## L.sub.14 ##STR00440## LP.sub.15
##STR00441## L.sub.15 ##STR00442## LP.sub.16 ##STR00443## L.sub.16
##STR00444## LP.sub.17 ##STR00445## L.sub.17 ##STR00446## LP.sub.18
##STR00447## L.sub.18 ##STR00448## LP.sub.19 ##STR00449## L.sub.19
##STR00450## LP.sub.20 ##STR00451## L.sub.20 ##STR00452## LP.sub.21
##STR00453## L.sub.21 ##STR00454## LP.sub.22 ##STR00455## L.sub.22
##STR00456## LP.sub.23 ##STR00457## L.sub.23 ##STR00458## LP.sub.24
##STR00459## L.sub.24 ##STR00460## LP.sub.25 ##STR00461## L.sub.25
##STR00462## LP.sub.26 ##STR00463## L.sub.26 ##STR00464## LP.sub.27
##STR00465## L.sub.27 ##STR00466## LP.sub.28 ##STR00467## L.sub.28
##STR00468## LP.sub.29 ##STR00469## L.sub.29 ##STR00470## LP.sub.30
##STR00471## L.sub.30 ##STR00472## LP.sub.31 ##STR00473## L.sub.31
##STR00474## LP.sub.32 ##STR00475## L.sub.32 ##STR00476## LP.sub.33
##STR00477## L.sub.33 ##STR00478## LP.sub.34 ##STR00479## L.sub.34
##STR00480## LP.sub.35 ##STR00481## L.sub.35 ##STR00482## LP.sub.36
##STR00483## L.sub.36 ##STR00484## LP.sub.37 ##STR00485## L.sub.37
##STR00486## LP.sub.38 ##STR00487## L.sub.38 ##STR00488## LP.sub.39
##STR00489## L.sub.39 ##STR00490## LP.sub.40 ##STR00491## L.sub.40
##STR00492## LP.sub.41 ##STR00493## L.sub.41 ##STR00494## LP.sub.42
##STR00495## L.sub.42 ##STR00496## LP.sub.43 ##STR00497## L.sub.43
##STR00498## LP.sub.44 ##STR00499## L.sub.44 ##STR00500## LP.sub.45
##STR00501## L.sub.45 ##STR00502## LP.sub.46 ##STR00503## L.sub.46
##STR00504## LP.sub.47 ##STR00505## L.sub.47 ##STR00506## LP.sub.48
##STR00507## L.sub.48 ##STR00508## LP.sub.49 ##STR00509## L.sub.49
##STR00510## LP.sub.50 ##STR00511## L.sub.50 ##STR00512## LP.sub.51
##STR00513## L.sub.51 ##STR00514## LP.sub.52 ##STR00515## L.sub.52
##STR00516## LP.sub.53 ##STR00517## L.sub.53 ##STR00518## LP.sub.54
##STR00519## L.sub.54 ##STR00520## LP.sub.55 ##STR00521## L.sub.55
##STR00522## LP.sub.56 ##STR00523## L.sub.56 ##STR00524## LP.sub.57
##STR00525## L.sub.57 ##STR00526## LP.sub.58 ##STR00527## L.sub.58
##STR00528## LP.sub.59 ##STR00529## L.sub.59 ##STR00530## LP.sub.60
##STR00531## L.sub.60 ##STR00532## LP.sub.61 ##STR00533## L.sub.61
##STR00534## LP.sub.62 ##STR00535## L.sub.62 ##STR00536## LP.sub.63
##STR00537## L.sub.63 ##STR00538## LP.sub.64 ##STR00539## L.sub.64
##STR00540## LP.sub.65 ##STR00541## L.sub.65 ##STR00542## LP.sub.66
##STR00543## L.sub.66 ##STR00544## LP.sub.67 ##STR00545## L.sub.67
##STR00546## LP.sub.68 ##STR00547## L.sub.68 ##STR00548## LP.sub.69
##STR00549## L.sub.69 ##STR00550## LP.sub.70 ##STR00551## L.sub.70
##STR00552## LP.sub.71 ##STR00553## L.sub.71 ##STR00554## LP.sub.72
##STR00555## L.sub.72 ##STR00556## LP.sub.73 ##STR00557## L.sub.73
##STR00558## LP.sub.74 ##STR00559## L.sub.74 ##STR00560## LP.sub.75
##STR00561## L.sub.75 ##STR00562## LP.sub.76 ##STR00563## L.sub.76
##STR00564## LP.sub.77 ##STR00565## L.sub.77 ##STR00566## LP.sub.78
##STR00567## L.sub.78 ##STR00568## LP.sub.79 ##STR00569## L.sub.79
##STR00570## LP.sub.80 ##STR00571## L.sub.80 ##STR00572## LP.sub.81
##STR00573## L.sub.81 ##STR00574## LP.sub.82 ##STR00575## L.sub.82
##STR00576## LP.sub.83 ##STR00577## L.sub.83 ##STR00578## LP.sub.84
##STR00579## L.sub.84 ##STR00580## LP.sub.85 ##STR00581## L.sub.85
##STR00582## LP.sub.86 ##STR00583## L.sub.86 ##STR00584## LP.sub.87
##STR00585## L.sub.87 ##STR00586## LP.sub.88 ##STR00587## L.sub.88
##STR00588## LP.sub.89 ##STR00589## L.sub.89 ##STR00590## LP.sub.90
##STR00591## L.sub.90 ##STR00592## LP.sub.91 ##STR00593## L.sub.91
##STR00594## LP.sub.92 ##STR00595## L.sub.92 ##STR00596## LP.sub.93
##STR00597## L.sub.93 ##STR00598## LP.sub.94 ##STR00599## L.sub.94
##STR00600## LP.sub.95 ##STR00601## L.sub.95 ##STR00602## LP.sub.96
& LP.sub.98 ##STR00603## L.sub.96 ##STR00604## L.sub.98
##STR00605## LP.sub.97 & LP.sub.99 ##STR00606## L.sub.97
##STR00607## L.sub.99 ##STR00608## LP.sub.100 ##STR00609##
L.sub.100 ##STR00610## LP.sub.101 ##STR00611## L.sub.101
##STR00612## Cryptophycin payloads of formula (II).sup.1,2
##STR00613## ##STR00614## ##STR00615## ##STR00616## ##STR00617##
##STR00618## ##STR00619## ##STR00620## ##STR00621## ##STR00622##
##STR00623## ##STR00624## ##STR00625## ##STR00626## ##STR00627##
##STR00628## ##STR00629## ##STR00630## ##STR00631## ##STR00632##
##STR00633##
##STR00634## ##STR00635## ##STR00636## ##STR00637## ##STR00638##
##STR00639## ##STR00640## ##STR00641## ##STR00642## ##STR00643##
##STR00644## ##STR00645## ##STR00646## ##STR00647## ##STR00648##
##STR00649## ##STR00650## ##STR00651## ##STR00652## ##STR00653##
##STR00654## ##STR00655## ##STR00656## ##STR00657## ##STR00658##
##STR00659## ##STR00660## ##STR00661## ##STR00662## ##STR00663##
##STR00664## ##STR00665## ##STR00666## ##STR00667## ##STR00668##
##STR00669## ##STR00670## ##STR00671## ##STR00672## ##STR00673##
##STR00674## ##STR00675## ##STR00676## ##STR00677## ##STR00678##
##STR00679## ##STR00680## ##STR00681## ##STR00682## ##STR00683##
##STR00684## ##STR00685## ##STR00686## ##STR00687## ##STR00688##
##STR00689## ##STR00690## ##STR00691## ##STR00692## ##STR00693##
##STR00694## ##STR00695## ##STR00696## ##STR00697## ##STR00698##
##STR00699## ##STR00700## ##STR00701## ##STR00702## ##STR00703##
##STR00704## ##STR00705## ##STR00706## ##STR00707## ##STR00708##
##STR00709## ##STR00710## ##STR00711## ##STR00712## ##STR00713##
##STR00714## .sup.1the examples are given for a particular
cryptophycin compound, but may apply to any cryptophycin compound
of formula (I), especially D.sub.1-D.sub.19. .sup.2in Table I, L is
given here in the para position, but it is possible to obtain
compounds in a similar manner with L in an ortho or meta
position.
Process for Preparing the Conjugates of Formula (III)
[0850] The conjugates of the present invention can obtained via the
process comprising the steps that consist in: [0851] (i) placing in
contact and leaving to react an optionally buffered aqueous
solution of an antibody, optionally first modified by means of a
modifying agent, and a solution of the cryptophycin payload of
formula (II), the chemical group RCG1 of the compound of formula
(II) being reactive towards the chemical groups RCG2 present on the
antibody especially towards the amino groups present on antibodies,
the said chemical groups RCG2 having been introduced, where
appropriate, by the modifying agent, so as to attach the compound
of formula (II) to the antibody by formation of a covalent bond;
[0852] (ii) and then in optionally separating the conjugate formed
in step (i) from the cryptophycin payload and/or from the unreacted
antibody and/or from any aggregates formed.
[0853] According to one variant and more particularly, in step (ii)
the conjugate from step (i) is separated only from the unreacted
cryptophycin payload and from any aggregates formed, and any
unreacted antibody is left in the solution.
[0854] The function of the placing in contact is to react the
chemical groups RCG1 and RCG2 in order to ensure attachment of the
cryptophycin payload to the antibody by formation of a covalent
bond; preferably, [0855] when RCG1 represents
--C(.dbd.O)--Z.sub.aR.sub.a, the reaction preferably takes place on
the amino functions of the antibody, especially the .epsilon.-amino
groups borne by the side chains of the lysine (Lys) residues of the
antibody and the .alpha.-amino groups of N-terminal amino acids of
antibody heavy and light chains. A conjugate of the following
formula is obtained in this case:
mAb-[NH--C(.dbd.O)-L*-Crypto].sub.d with L*=fragment of a linker L
comprising RCG1=--C(.dbd.O)--Z.sub.aR.sub.a and such that
L=-L*C(.dbd.O)--Z.sub.aR.sub.a and d representing the
drug-to-antibody ratio or DAR; [0856] when RCG1 represents --Cl or
a maleimido or haloacetamido group, the antibody may comprise thiol
chemical groups; [0857] when RCG1 represents an azido group, the
antibody may comprise a --C.ident.CH moiety or an activated triple
bond such as a cyclooctyne; [0858] when RCG1 represents --NH.sub.2,
the reaction may take place on amide function of the antibody using
an enzymatic catalysis, especially the amide groups borne by the
side chains of glutamine (Gln) residues of an antibody. A conjugate
of the following formula is obtained in this case:
mAb-[C(.dbd.O)--NH-L*-Crypto].sub.d with L*=fragment of a linker L
comprising RCG1=--NH.sub.2 and such that L=-L*NH.sub.2 and d
representing the drug-to-antibody ratio or DAR; [0859] when RCG1
represents --C.ident.CH or an activated C.ident.C such as a
cyclooctyne moiety, the antibody may comprises azido groups.
[0860] The term "aggregates" means associations that may form
between two or more antibodies, the antibodies possibly having been
modified by conjugation. Aggregates are liable to form under the
influence of a wide variety of parameters such as a high
concentration of antibody in the solution, the pH of the solution,
high shear forces, the number of grafted drugs and their
hydrophobic nature, the temperature (see the references cited in
the introduction of J. Membrane Sci. 2008, 318, 311-316), the
influence of some of them, however, having not been clearly
elucidated. In the case of proteins or antibodies, reference may be
made to AAPS Journal, "Protein Aggregation and Bioprocessing" 2006,
8(3), E572-E579. The aggregate content may be determined via known
techniques such as SEC (see in this respect Analytical Biochemistry
1993, 212 (2), 469-480).
[0861] The aqueous solution of the antibody may be buffered with
buffers such as, for example, potassium phosphate or HEPES or a
mixture of buffers such as buffer A described later. The buffer
depends on the nature of the antibody. The cryptophycin payload is
dissolved in a polar organic solvent such as, for example, DMSO or
DMA.
[0862] The reaction takes place at a temperature generally of
between 20.degree. C. and 40.degree. C. The reaction time may vary
between 1 and 24 hours. The reaction between the antibody and the
cryptophycin payload may be monitored by SEC with a refractometric
and/or ultraviolet detector and/or HRMS in order to determine its
degree of progress. If the degree of substitution is insufficient,
the reaction can be left for longer and/or cryptophycin compound
can be added. Reference may be made to the example section for
further details regarding particular conditions. Particular
embodiments are described in Examples 3, 7, 10, 14, 20 and 23.
[0863] A person skilled in the art has at his disposal various
chromatographic techniques for the separation of step (ii): the
conjugate may be purified, for example, by steric exclusion
chromatography (SEC), by adsorption chromatography (for instance
ion exchange, IEC), by hydrophobic interaction chromatography
(HIC), by affinity chromatography, by chromatography on mixed
supports such as ceramic hydroxyapatite, or by HPLC. Purification
by dialysis or diafiltration may also be used.
[0864] After step (i) or (ii), the solution of the conjugate may
undergo an ultrafiltration and/or diafiltration step (iii). After
these steps, the conjugate in aqueous solution is thus
obtained.
Antibody
[0865] The antibody can be a monoclonal antibody selected from the
group consisting of a murine, chimeric, a humanized and a human
antibody.
[0866] In one embodiment, the antibody is a monospecific antibody,
i.e. an antibody specifically binding to one single target.
Alternatively, it might be a multispecific antibody.
[0867] In one embodiment, the antibody is a IgG antibody, for
instance an IgG.sub.1, an IgG.sub.2, an IgG.sub.3 or an IgG.sub.4
antibody.
[0868] The antibody according to the invention specifically binds
to a target, thereby directing the biologically active compound as
a cytotoxic compound towards said target, As used herein,
"specifically binds" or "binds specifically to" or "binds to" or
the like, means that an antibody or antigen-binding fragment
thereof forms a complex with an antigen that is relatively stable
under physiological conditions. Specific binding can be
characterized by an equilibrium dissociation constant (K.sub.D) of
at least about 1.times.10.sup.-8 M or less (e.g., a smaller K.sub.D
denotes a tighter binding).
[0869] Methods for determining whether two molecules specifically
bind are well known in the art and include, for example,
equilibrium dialysis, surface plasmon resonance, and the like. As
described herein, antibodies have been characterized, for example,
by their specific binding to target and/or target antigen using
surface plasmon resonance, e.g., BIACORE.TM. The target typically
corresponds to a protein expressed at the cell surface, e.g. a
protein expressed at the surface of tumour cells.
[0870] In one embodiment, the target is the EphA2 receptor. The
EphA2 receptor is an Ephrin receptor, and is also referred to as
"EPH receptor A2" or "Epithelial Cell Receptor Protein-Tyrosine
kinase" (see e.g. OMIM Entry *176946, available at the
omim.org/entry/176946 world wide web site, version updated on Jul.
21, 2016). The antibody specifically binding to the EphA2 receptor
might for instance correspond to one of the antibodies described in
WO2008/010101 or WO2011/039724.
[0871] In another embodiment, the target is CD19. CD19 is a cell
surface molecule specifically expressed by B lymphocytes and
follicular dendritic cells of the hematopoietic system, and is also
referred to as "B-lymphocyte antigen CD19" (see e.g. OMIM Entry
*107265, available at the omim.org/entry/107265 world wide web
site, version last updated on May 11, 2015). The antibody
specifically binding to CD19 might for instance correspond to
Coltuximab, i.e. the antibody part (moiety) of Coltuximab
Ravtansin.
[0872] The antibody may optionally be modified with a modifying
agent so as to promote the attachment of the cryptophycin payloadas
previously described. The antibody may especially be monoclonal,
polyclonal or multispecific. It may also be an antibody fragment.
It may also be a murine, human, humanized or chimeric antibody. The
antibody used in the examples of the present invention is
hu2H11_R.sub.3574, an antagonist antibody against EphA2 receptor.
The sequence of hu2H11_R.sub.3574 is described in WO2011/039724
(SEQ ID NO: 18 for the heavy chain and SEQ ID NO: 16 for the light
chain).
Conjugate
[0873] A conjugate generally comprises from about 1 to 10
cryptophycin compounds covalently attached to the antibody (this is
the degree of grafting or "drug-to-antibody ratio" or "DAR"). This
number varies as a function of the nature of the antibody and of
the cryptophycin compound, and also of the operating conditions
used in the conjugation process (for example the number of
equivalents of cryptophycin compound relative to the antibody, the
reaction time, the nature of the solvent and of any cosolvent).
Placing of the antibody and the cryptophycin compound in contact
leads to a mixture comprising several conjugates that are
individually distinguished from each other by different DARs;
optionally the unreacted antibody; optionally aggregates. The DAR
that is determined on the final solution thus corresponds to an
average DAR. The DAR may be calculated from the deconvolution of
the SEC-HRMS spectrum of the conjugate. The DAR (HRMS) is
preferably greater than 0.5, more particularly between 1 and 10 and
even more particularly between 2 and 7.
[0874] The conjugate may be used as an anticancer agent. Owing to
the presence of the antibody, the conjugate is made highly
selective towards tumor cells rather than healthy cells. This makes
it possible to direct the cryptophycin compound in an environment
similar thereto or directly therein; (in this respect, see the
following publications that describe the use of monoclonal antibody
conjugates in cancer treatment: "Antibody-drug conjugates for
cancer therapy" Carter P. J., et al., Cancer J. 2008, 14, 154-169;
"Targeted cancer therapy: conferring specificity to cytotoxic
drugs" Chari R., Acc. Chem. Res. 2008, 41, 98-107). It is possible
to treat solid or liquid cancers. The conjugate may be used alone
or in combination with at least one other anticancer agent.
[0875] The conjugate is formulated in the form of a buffered
aqueous solution at a concentration generally of between 1 and 10
mg/mL. This solution may be injected in perfusion form per se or
may be rediluted to form a perfusion solution.
EXAMPLES
[0876] The examples which follow describe the preparation of
certain compounds in accordance with the invention. These examples
are not limitative, and merely illustrate the present
invention.
Analytical Methods Used
High Pressure Liquid Chromatography--Mass Spectrometry (LCMS)
Method A1
[0877] Spectra have been obtained on a Waters UPLC-SQD system in
positive and/or negative electrospray mode (ES+/-) using ELSD and
UV (210-400 nm) detection. Chromatographic conditions were the
following:
[0878] column: ACQUITY BEH C18-1.7 .mu.m-2.1.times.50 mm; solvents:
A: H.sub.2O (0.1% formic acid), B: CH.sub.3CN (0.1% formic acid);
column temperature: 50.degree. C.; flow rate: 0.8 mL/min; gradient
(2.5 min): from 5 to 100% of B in 1.8 min; 2.4 min: 100% of B; 2.45
min: from 100 to 5% of B in 0.05 min.
Method A2
[0879] Spectra have been obtained on a Waters XeVo-QT of system in
positive electrospray mode (ES+) using ELSD and UV (210-400 nm)
detection. Chromatographic conditions were the following: column:
ACQUITY BEH C18-1.7 .mu.m-2.1.times.100 mm; solvents: A: H.sub.2O
(0.1% formic acid), B: CH.sub.3CN (0.1% formic acid); column
temperature: 70.degree. C.; flow rate: 0.55 mL/min; gradient (11
min): from 5 to 97% of B in 8.3 min; 8.6 min: 97% of B; 9 min: from
97 to 5% of B in 0.7 min and 5% of B during 2 min.
Method A3
[0880] Spectra have been obtained on a Waters XeVo-QT of system in
positive electrospray mode (ES+). Chromatographic conditions were
the following:
[0881] column: ACQUITY BEH C18-1.7 .mu.m-2.1.times.100 mm;
solvents: A: H.sub.2O (0.1% formic acid), B: CH.sub.3CN (0.1%
formic acid); column temperature: 45.degree. C.; flow rate: 0.6
mL/min; gradient (5.3 min): 5% of B during 0.3 min; from 5 to 100%
of B in 3.7 min; 4.6 min: 100% of B; 5.3 min 5% of B.
Method A4
[0882] Spectra have been obtained on a Waters UPLC-SQD system in
positive and/or negative electrospray mode (ES+/-) using ELSD and
UV (210-400 nm) detection. Chromatographic conditions were the
following:
[0883] column: ACQUITY BEH C18-1.7 .mu.m-2.1.times.50 mm; solvents:
A: H.sub.2O (0.1% formic acid), B: CH.sub.3CN (0.1% formic acid);
column temperature: 45.degree. C.; flow rate: 0.8 mL/min; gradient
(10 min): from 5 to 100% of B in 8.6 min; 9.6 min: 100% of B; 9.8
min: 5% of B.
Method A5
[0884] Spectra have been obtained on a Waters UPLC-SQD system in
positive and/or negative electrospray mode (ES+/-) using ELSD and
UV (210-400 nm) detection. Chromatographic conditions were the
following:
[0885] column: ACQUITY CSH C18-1.7 .mu.m-2.1.times.50 mm; solvents:
A: H.sub.2O (0.1% formic acid), B: CH.sub.3CN (0.1% formic acid);
column temperature: 40.degree. C.; flow rate: 0.85 mL/min; gradient
(2.5 min): from 5 to 100% of B in 1.8 min; 2.4 min: 100% of B; 2.45
min: from 100 to 5% of B in 0.05 min.
.sup.1H Nuclear Magnetic Resonance (NMR)
[0886] The .sup.1H NMR spectra were acquired on a Bruker Avance
spectrometer, either of model DRX-300, DRX-400 or DRX-500. The
chemical shifts (6) are given in ppm.
Size Exclusion Chromatography--High Resolution Mass Spectrometry
(SEC-HRMS)
[0887] The chromatographic analysis was performed on an Agilent
HP1100 machine and a Waters BEH SEC 200 1.7 .mu.m (2.1.times.150
mm) column at 30.degree. C. with a flow rate of 0.5 mL/min and an
isocratic elution of (A) 25 mM ammonium formate+1% formic acid/(B)
CH.sub.3CN+0.1% formic acid 70/30 for 15 minutes. The mass
spectrometry was performed on a Waters QTOF-II machine with
electrospray ionization in positive mode (ES+). The mass spectra
were deconvoluted with the Waters MaxEnt1 software.
Analytical Size Exclusion Chromatography (SEC)
[0888] The analysis was performed on a Waters Alliance HPLC system
or a Hitachi Lachrom system equipped with a photodiode array
detector and a Tosoh Bioscience TSKgel G3000 SWXL 5 .mu.m
(7.8.times.300 mm) column with a flow rate of 0.5 mL/min and an
isocratic elution of 30 minutes with a pH 7 buffer containing 0.2 M
of KCl, 0.052 M of KH.sub.2PO.sub.4, 0.107 M of K.sub.2HPO.sub.4
and 20% by volume of isopropanol.
Buffers
[0889] Buffer A (pH 6.5): NaCl (50 mM), potassium phosphate (50
mM), EDTA (2 mM) [0890] Buffer B (pH 6.5): NaCl (140 mM), potassium
and sodium phosphate (9.6 mM) [0891] PBS (pH 7.4): KH.sub.2PO.sub.4
(1.06 mM), NaC (155.17 mM), Na.sub.2HPO.sub.4-7H.sub.2O (2.97 mM)
[0892] DPBS: KCl (2.67 mM), KH.sub.2PO.sub.4 (1.47 mM), NaCl (136.9
mM), Na.sub.2HPO.sub.4 (8.10 mM) adjusted at pH 6.5 with HCl 5N (1
mL per 1000 mL of buffer)
General Method Used for the Preparation of Antibody-Drug Conjugate
(ADC)
[0893] A solution of antibody in an aqueous buffer composed of a
96:4 mixture of buffer A and 1 N HEPES was treated with an excess
of a solution at approximatively 10 mM of cryptophycin payload in
DMA such that the final antibody concentration is 3 mg/mL and the
percentage of DMA in the aqueous buffer is 20%. After stirring for
2 hours, the mixture was analysed by SEC-HRMS to determine the DAR
on the population of monomeric antibodies. If the DAR was found
insufficient, the mixture was treated with a further excess (1 to 5
equivalents) of cryptophycin solution in DMA for 2 additional hours
at RT under stirring. The mixture was purified by gel filtration
using a Superdex 200 .mu.g matrix (HiLoad 16/60 or 26/60 desalting
column, GEHealthcare) pre-equilibrated in aqueous buffer pH 6.5
(buffer B or DPBS) containing 10 to 20% of NMP. The fractions
containing the monomeric conjugated antibody were pooled and
concentrated on Amicon Ultra-15 (10 k or 50 k Ultracel membrane,
Millipore) to a concentration of between 2 and 5 mg/mL. A buffer
exchange or a dilution in the appropriate buffer was then performed
to formulate the conjugate in the final buffer. In the case of a
buffer exchange, it was realized by gel filtration using a
Sephadex.TM. G25 matrix (NAP-5, NAP-10, NAP-25/PD-10 or Hiprep
26/10 desalting columns, GEHealthcare) pre-equilibrated with the
final aqueous buffer whose composition and pH are suited to each
conjugate. The conjugate was finally filtered through a Steriflip@
filter unit (0.22 .mu.m Durapore@ PVDF membrane, Millipore). The
final conjugate was assayed by UV spectrometry or SEC-HPLC so as to
measure the conjugate concentration, by SEC-HPLC so as to determine
the monomeric purity and by SEC-HRMS so as to determine the DAR
from the deconvolution of the mass spectrum of the conjugate.
Synthesis of Fragment A: (2E,5S,6R,7E)-tert-butyl
8-(4-formylphenyl)-5-hydroxy-6-methylocta-2,7-dienoate
##STR00715##
Compound 1: (2E,5S,6R)-tert-butyl
5-hydroxy-7-((4-methoxybenzyl)oxy)-6-methylhept-2-enoate
[0894] Under argon, to a solution of
(2R,3S)-1-[(4-methoxyphenyl)methoxy]-2-methyl-5-hexen-3-ol or
Sakurai alcohol (CAS number [203926-55-0], 100 g, 399.5 mmol) in
DCM (350 mL) were added tert-butyl acrylate (354.7 mL, 2.435 mol)
and Grubbs catalyst (4.849 g, 2.435 mol). After stirring for 17 h
at RT, the reaction mixture was filtered on 230 g of silica and
eluted with a mixture of heptane/AcOEt (50/50, 6.times.300 mL).
After concentration, the residue was purified by flash
chromatography on 1.2 kg of silica gel (gradient elution
heptane/EtOAc) to give 140.8 g of a brown oil. The oil was
dissolved in anhydrous DCM (550 mL), 10 g of quadraPure.TM. TU
resin was added to remove the excess of catalyst. The mixture was
stirred for 3 h at 35.degree. C. The resin was filtered and washed
with DCM, the filtrate was concentrated and dried in vacuo to give
135.75 g of compound 1 as a brown oil (97%).
[0895] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 0.85 (d,
J=7.0 Hz, 3H); 1.42 (s, 9H); 1.72 (m, 1H); 2.18 (m, 1H); 2.30 (m,
1H); 3.24 (dd, J=7.0 and 9.3 Hz, 1H); 3.46 (dd, J=7.7 and 9.3 Hz,
1H); 3.49 (m, 1H); 3.73 (s, 3H); 4.35 (s, 2H); 4.65 (d, J=5.8 Hz,
1H); 5.76 (td, J=1.5 and 15.6 Hz, 1H); 6.83 (td, J=7.4 and 15.6 Hz,
1H); 6.90 (d, J=8.8 Hz, 2H); 7.23 (d, J=8.8 Hz, 2H).
Compound 2: (2E,5S,6R)-tert-butyl
5,7-dihydroxy-6-methylhept-2-enoate
[0896] To a solution of compound 1 in CH.sub.3CN (910 mL), H.sub.2O
(90 mL) was added and the mixture was cooled at 12.degree. C.
before adding in 25 min a solution of CAN (196.7 g, 358.9 mmol) in
H.sub.2O (300 mL). Stirring was continued for 1 h at RT. Additional
CAN (18.83 g, 34.36 mmol) dissolved in a mixture of CH.sub.3CN (70
mL) and H.sub.2O (30 mL) was added and stirred for 1 h at RT to
complete the reaction. The mixture was quenched with NaCl until
saturation of the aq. layer, then MTBE (400 mL) was added. After
decantation, the aq. layer was extracted with MTBE (2.times.80 mL).
The combined organic layers were washed with a 3:1 mixture of 5%
NaHCO.sub.3/H.sub.2O (3.times.200 mL), sat. brine (2.times.130 mL),
dried over MgSO.sub.4, filtered and concentrated. The aq. layer was
acidified with 2N HCl until pH 4, then saturated with NaCl and
extracted with MTBE (2.times.150 mL). This second organic layer was
washed with 5% NaHCO.sub.3 (60 mL), sat. brine (60 mL), dried over
MgSO.sub.4, concentrated and combined with the first organic layer
to give an brown orange oil.
[0897] The mixture was dissolved in MeTHF (300 mL), then were added
1,2-ethanedithiol (22 mL, 0.260 mol) and p-TsOH (1.651 g, 8.590
mmol). After stirring at 60.degree. C. for 5 h, MTBE (200 mL) was
added to the reaction mixture and it was washed with 5% NaHCO.sub.3
(2.times.120 mL), sat. brine (120 mL), dried over MgSO.sub.4,
filtered, concentrated in vacuo and purified by flash
chromatography on 520 g of silica gel (gradient elution DCM/MTBE)
to give 29.48 g of compound 2 as a yellow oil (75%).
Compound 3: (2E,5S,6R)-tert-butyl
6-methyl-5,7-bis((triethylsilyl)oxy)hept-2-enoate
[0898] Under argon to a solution of compound 2 (39.38 g, 0.171 mol)
in anhydrous DCM (500 mL) was added imidazole (51.540 g, 0.749
mol). The yellow mixture was cooled at 0.degree. C., then was added
triethylchlorosilane (63.99 mL, 0.374 mol) and the solution was
allowed to warm up to RT overnight. The reaction mixture was
quenched with sat. NH.sub.4Cl (400 mL), MTBE (300 mL) and ice. The
pH was adjusted at 4 with 2M NaHSO.sub.4, the layers were separated
after vigorous stirring. The aq. layer was extracted with MTBE (200
mL). The combined organic layers were washed with half-sat.
NH.sub.4Cl (2.times.250 mL), phosphate buffer pH 7 (150 mL), sat.
brine (150 mL), dried over MgSO.sub.4, filtered, concentrated in
vacuo and purified by flash chromatography on 490 g of silica gel
(gradient elution heptane/Et.sub.2O) to give 74.52 g of compound 3
as a pale yellow oil (95%).
Compound 4: (2E,5S,6S)-tert-butyl
6-methyl-7-oxo-5-((triethylsilyl)oxy)hept-2-enoate
[0899] Under argon, to a solution of DMSO (102.400 mL, 1.427 mol)
in DCM (300 mL) was dropwise added at -75.degree. C. oxalyl
chloride (63 mL, 0.719 mol) in 1 h and the stirring was continued
for 15 min before adding, at -75.degree. C., a solution of compound
3 in DCM (150 mL) while keeping the temperature below -70.degree.
C. The reaction mixture was allowed to warm up to -40.degree. C.
and the stirring continued for 2 h. The reaction mixture was cooled
again at -75.degree. C., then DIEA (425 mL, 2.432 mol) was added in
75 minutes while keeping the temperature below -65.degree. C. The
reaction mixture was allowed to warm up to RT and then quenched
with MTBE (500 mL), ice, sat. NH.sub.4Cl (200 mL) and 2M
NaHSO.sub.4 to reach pH 4. The layers were separated after vigorous
stirring. The aq. layer was extracted with MTBE (200 mL). The
combined organic layers were washed with NH.sub.4Cl (3.times.300
mL), phosphate buffer pH 7 (300 mL), sat. brine (300 mL), dried
over MgSO.sub.4, filtered, concentrated in vacuo and purified by
flash chromatography on 1.25 kg of silica gel (gradient elution
heptane/Et.sub.2O) to give 51.74 g of compound 4 as an orange oil
(93%).
Compound 5: (2E,5S,6R,7E)-tert-butyl
5-hydroxy-8-(4-(hydroxymethyl)phenyl)-6-methylocta-2,7-dienoate
[0900] Under argon, to a suspension of phosphonium bromide
(synthesis described in WO2011/001052, 147 g, 0.237 mol) in
anhydrous THE (1.5 L) was added at -50.degree. C. a 2.5 M solution
of n-BuLi in hexane (90 mL, 0.225 mol). The temperature was allowed
to warm up to -40.degree. C. and the stirring was continued for 15
min. After warming to RT, the red mixture was stirred for 1 h. The
reaction medium was cooled at -70.degree. C. before adding a
solution of compound 4 (51.63 g, 126.6 mmol) in THE (200 mL) while
keeping the temperature below -65.degree. C. When the addition was
complete, the reaction mixture was allowed to warm up to RT and the
stirring was continued overnight. The reaction mixture was filtered
to remove the insoluble that was washed with MTBE (500 mL). The
filtrate was partially concentrated at 42.degree. C. (1/3), then
quenched with ice, NH.sub.4Cl (500 mL), MTBE (500 mL) and 2M
NaHSO.sub.4 to reach pH 4. The layers were separated and the aq.
layer was extracted with MTBE (200 mL). The combined organic layers
were washed with half-sat. NH.sub.4Cl (250 mL), phosphate buffer pH
7 (250 mL), sat. brine (250 mL), dried over MgSO.sub.4, filtered
and half-concentrated in vacuo until 250 mbar. The suspension was
diluted with 50:50 heptane/MTBE (600 mL) cooled with an ice bath,
filtered off and washed with 50:50 heptane/MTBE. The filtrate was
concentrated in vacuo to give 100.05 g as a brown oil.
[0901] The crude compound was dissolved in anhydrous THE (320 mL),
then was added TBAF trihydrate (90 g, 282.40 mmol) and the reaction
mixture was stirred for 3 h. After concentration in vacuo, the
crude was diluted with 10:1 MTBE/THF (770 mL), washed with a
half-sat. NH.sub.4Cl (3.times.200 mL), 1M NaHSO.sub.4 (200 mL),
phosphate buffer pH 7 (200 mL), sat. brine (200 mL), dried over
MgSO.sub.4, filtered and concentrated. The aq. layer was extracted
with MTBE. After decantation, the organic layer was washed with
phosphate buffer pH 7 (30 mL), sat. brine (30 mL), dried over
MgSO.sub.4 and filtered. After concentration, the combined organic
layers were purified by flash chromatography on 1.25 kg of silica
gel (gradient elution heptane/Et.sub.2O) to give 36.91 g of
compound 5 as a brown-red oil (88%).
Fragment A: (2E,5S,6R,7E)-tert-butyl
8-(4-formylphenyl)-5-hydroxy-6-methylocta-2,7-dienoate
[0902] Under argon, to a solution of compound 5 (30.3 g, 91.7 mmol)
in anhydrous DCM (600 mL) was added, at 10.degree. C., manganese
oxide (175 g, 3.013 mol) and the reaction mixture was stirred for 4
h at 35.degree. C. The oxidant was filtered through a plug of
celite and washed with warm aceton. The filtrate was concentrated
to give 30.43 g of a red-orange oil.
[0903] Under argon, the oil was diluted with benzene (800 mL) and
refluxing in the presence of AIBN (880 mg, 4.58 mmol), and
thiophenol (2.81 mL, 27.51 mmol) for 1 h. Additional AIBN (530 mg,
0.03 eq) and thiophenol (1.03 mL, 10.087 mmol) were added and
refluxing continued for an additional 1 h. Additional AIBN (530 mg,
0.03 eq) and thiophenol (1.03 mL, 10.087 mmol) were added and
refluxing continued for 3 h. Additional AIBN (353 mg, 1.834 mmol)
and thiophenol (468 .mu.L, 4.58 mmol) were added and refluxing
continued for 1 h. The conversion E/Z was 92/8, 352.6 mg of AIBN
was added and refluxing continued for 1 h. The reaction mixture was
cooled to RT and concentrated in vacuo to give 28.03 g of fragment
A as an orange oil (92%) with a E/Z ratio superior to 98/2.
Synthesis of fragment B:
(R)-2-((tert-butoxycarbonyl)amino)-3-(3-chloro-4-methoxy-phenyl)propanoic
Acid
##STR00716##
[0905] To a solution of methyl
(R)-2-((tert-butoxycarbonyl)amino)-3-(3-chloro-4-methoxyphyl)-propanoate
(CAS number [162465-44-3], 30 g, 87.26 mmol) in THE (225 mL), were
added H.sub.2O (30 mL) and LiOH monohydrate (4.4 g, 104.85 mmol).
The reaction medium was stirred 2 h at RT. After this time, the
reaction medium was diluted with H.sub.2O (200 mL) then acidified
at pH 2 with 5N HCl (20 mL) and extracted by EtOAc (2.times.250
mL). The combined organic phases were washed with H.sub.2O (500
mL), dried over MgSO.sub.4, filtered, concentrated in vacuo,
diluted with Et.sub.2O and concentrated in vacuo to give 26.9 g of
fragment B as a white solid (94%).
[0906] RMN .sup.1H (300 MHz, .delta. in ppm, DMSO-d6): 1.21 to 1.37
(m, 9H); 2.74 (dd, J=11.0 and 14.3 Hz, 1H); 2.96 (dd, J=5.0 and
14.3 Hz, 1H); 3.81 (s, 3H); 4.04 (m, 1H); 6.99 to 7.09 (m, 2H);
7.18 (dd, J=2.3 and 8.7 Hz, 1H); 7.29 (d, J=2.3 Hz, 1H); 12.60
(broad m, 1H).
Synthesis of fragment C.sub.1: methyl
3-amino-2,2-dimethylpropanoate Hydrochloride
##STR00717##
[0907] Compound 6: methyl
3-((tert-butoxycarbonyl)amino)-2,2-dimethylpropanoate
[0908] Under argon, to a solution of
3-([(tert-butoxy)carbonyl]amino)-2,2-dimethylpropanoic acid (CAS
number [180181-02-6], 250 mg, 1.09 mmol) in DCM (6 mL) and MeOH (2
mL) was added, dropwise at 0.degree. C.,
(trimethylsilyl)diazomethane (819.86 .mu.L, 1.64 mmol) until yellow
persistent color. Then AcOH was added until complete discoloration.
The reaction mixture was concentrated in vacuo then diluted with
H.sub.2O and extracted with DCM twice. The combined organic phases
were washed with sat. brine, dried over MgSO.sub.4, filtered and
concentrated in vacuo to give 260 mg of compound 6 as a colorless
oil (quant.).
Fragment C.sub.1: methyl 3-amino-2,2-dimethylpropanoate
Hydrochloride
[0909] To a solution of compound 6 (260 mg, 1.12 mmol) in
1,4-dioxane (10 mL) was added 4N HCl in 1,4-dioxane (2.81 mL, 11.24
mmol). The reaction mixture was stirred at RT overnight then
concentrated in vacuo to give 200 mg of fragment C1 (quant.).
Synthesis of fragment C2: methyl 3-amino-2,2-dimethylbutanoate
Hydrochloride
##STR00718##
[0910] Compound 7: 3-((tert-butoxycarbonyl)amino)butanoic Acid
[0911] To a solution of DL-3-aminobutyric acid (CAS number
[541-48-02], 18.72 g, 176.09 mmol) in H.sub.2O (96 mL) were added
di-tert-butyl dicarbonate (39.62 g, 176.09 mmol) and NaOH (8.03 g,
200.74 mmol) in H.sub.2O (76 mL) then tert-butyl alcohol (132 mL).
The reaction mixture was stirred at RT overnight. After this time,
the reaction medium was concentrated in vacuo then diluted with
EtOAc (200 mL) and acidified at pH 3 with diluted HCl. After
settling, the aq. phase was extracted with EtOAc (200 mL). The
combined organic phases were dried over MgSO.sub.4, filtered and
concentrated in vacuo to give 34.5 g of compound 7 as a colorless
oil (82%).
[0912] RMN .sup.1H (300 MHz, .delta. in ppm, CDC.sub.3-d1): 1.25
(d, J=7.0 Hz, 3H); 1.45 (s, 9H); 2.55 (m, 2H); 4.04 (m, 1H); 4.93
(broad m, 1H); 8.41 (broad m, 1H).
Compound 8: methyl 3-((tert-butoxycarbonyl)amino)butanoate
[0913] Under argon, a solution of compound 7 (10 g, 49.20 mmol) in
toluene (350 mL) and MeOH (100 mL) was stirred at +5.degree. C.
Between +5.degree. C. and +10.degree. C.,
(trimethylsilyl)diazomethane (73.81 mL, 147.61 mmol) was added
dropwise. The reaction mixture was stirred 3 h then evaporated in
vacuo to give 10.8 g of compound 8 as a pale yellow oil
(quant.).
[0914] RMN .sup.1H (300 MHz, .delta. in ppm, CDC.sub.3-d1): 1.20
(d, J=7.0 Hz, 3H); 1.45 (s, 9H); 2.50 (m, 2H); 3.69 (s, 3H); 4.03
(m, 1H); 4.90 (broad m, 1H).
Compound 9: methyl
3-((tert-butoxycarbonyl)amino)-2-methylbutanoate
[0915] Under argon, to a solution of LDA (2M in THF, 25.32 mL,
50.63 mmol) in THE (48 mL) at -70.degree. C. was added dropwise a
solution of compound 8 (5 g, 23.01 mmol) in THE (62 mL). The
reaction mixture was stirred 1 h at -75.degree. C. then iodomethane
(5.79 mL, 92.05 mmol) was added dropwise at -70.degree. C. The
reaction mixture was stirred 3 h at -75.degree. C. then at RT
overnight. After this time, an aq. solution of 20% NH.sub.4Cl (100
mL) and Et.sub.2O (125 mL) were added. After settling, the organic
phase was washed with sat. NaHCO.sub.3 (80 mL) then sat. NaCl (80
mL). The combined aq. phases were extracted with Et.sub.2O (125
mL). The combined organic phases were dried over MgSO.sub.4,
filtered and concentrated in vacuo to give 5.49 g of crude oil.
Cristallization with pentane (15 mL) gave 2.65 g of compound 9
after drying in vacuo. The pentane solution was concentrated in
vacuo and purified by flash chromatography on 100 g of silica gel
(gradient elution heptane/Et.sub.2O) to give 1.98 g of compound 9.
The two batches were pooled (87%) and used as such in the following
step.
Compound 10: methyl
3-((tert-butoxycarbonyl)amino)-2-,2-dimethylbutanoate
[0916] Under argon, THE (46 mL) was cooled at -72.degree. C. then
were added LDA (2M in THF, 22 mL, 44.0 mmol) and dropwise at
-72.degree. C. (+/-2.degree. C.) a solution of compound 9 (4.60 g,
19.89 mmol) in THE (64 mL). The reaction mixture was stirred 1 h15
at -75.degree. C. then iodomethane (5 mL, 79.55 mmol) was added
dropwise at -72.degree. C. (+/-2.degree. C.). The reaction medium
was stirred 3 h at -75.degree. C. then overnight at RT. After this
time, an aq. solution of 20% NH.sub.4Cl (50 mL) and Et.sub.2O (80
mL) were added. After settling, the organic phase was washed with
sat. NaHCO.sub.3 (50 mL) and sat. brine (50 mL). The combined aq.
phases were extracted with Et.sub.2O (80 mL). The combined organic
phases were dried over MgSO.sub.4, filtered and concentrated in
vacuo to give 6.5 g of crude oil that was purified by flash
chromatography on 200 g of silica gel (gradient elution
heptane/iPr.sub.2O) to give 1.9 g of compound 10 as a colorless oil
(39%).
[0917] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.92 (d,
J=7.1 Hz, 3H); 1.02 (s, 3H); 1.04 (s, 3H); 1.48 (s, 9H); 3.58 (s,
3H); 3.88 (m, 1H); 6.62 (broad d, J=10.5 Hz, 1H). LCMS (A1): ES
m/z=146, m/z=246 [M+H].sup.+; t.sub.R=1.2 min.
Fragment C.sub.2: methyl 3-amino-2,2-dimethylbutanoate
Hydrochloride
[0918] In a round bottom flask, under magnetic stirring, compound
10 (0.3 g, 1.22 mmol) was introduced, followed by 1,4-dioxane (5
mL) and 4N HCl in 1,4-dioxane (5 mL). The reaction mixture was
stirred at RT overnight then concentrated in vacuo. The crude solid
obtained was precipitated in iPr.sub.2O (15 mL), filtered and dried
to give 210 mg of fragment C2 as a white solid (95%).
[0919] LCMS (A1): ES m/z=146 [M+H].sup.+; t.sub.R=0.8 min.
Synthesis of fragment C.sub.3: ethyl
2-(1-aminocyclopropyl)-2,2-dimethylpropanoate
##STR00719##
[0921] Under argon, to a solution of ethyl
2-cyano-2-methylpropionate (CAS number [1572-98-1], 2 g, 13.88
mmol) in Et.sub.2O (48 mL) was added titanium (IV) isopropoxide
(4.63 g, 15.97 mmol). The reaction mixture was stirred 10 min at RT
then cooled at -5.degree. C. A solution of ethylmagnesium bromide
3M in Et.sub.2O (9.72 mL, 29.16 mmol) was added dropwise at
-5.degree. C.-0.degree. C. in 25 min, the reaction mixture was then
stirred 40 min without the cooling bath. At this time, a TLC showed
than the reaction was complete. The reaction medium was cooled at
0.degree. C. and boron trifluoride diethyl etherate (3M in
Et.sub.2O, 3.6 mL, 29.16 mmol) was added dropwise at 0.degree. C.
The reaction mixture was stirred 30 min without the cooling bath.
After this time, 1N HCl was added at 0.degree. C. until pH 1-2 (8
mL) then 2N NaOH until pH 8 (28 mL), the reaction mixture was
extracted with EtOAc (3.times.150 mL). The combined organic phases
were dried over MgSO.sub.4, filtered and concentrated in vacuo to
give 2.4 g of a crude yellow oil that was purified by flash
chromatography on 70 g of silica gel (gradient elution DCM/MeOH) to
give 915 mg of fragment C3 as a pale yellow oil (39%).
[0922] RMN .sup.1H (400 MHz, .delta. in ppm, CDC.sub.3-d1): 0.52
(m, 2H); 0.70 (m, 2H); 1.11 (s, 6H); 1.27 (t, J=7.2 Hz, 3H); 1.64
(broad s, 2H); 4.18 (q, J=7.2 Hz, 2H).
Synthesis of fragment C4: methyl
3-amino-2-(hydroxymethyl)-2-methylpropanoate Hydrochloride
##STR00720##
[0923] Compound 11:
3-((tert-butoxycarbonyl)amino)-2-methylpropanoic Acid
[0924] To a solution of DL-3-aminoisobutyric acid (CAS number
[10569-72-9], 5 g, 47.52 mmol) in 2 N NaOH (24.7 mL) was added
dropwise a solution of Boc.sub.2O (11.73 g, 53.22 mmol) in THE (75
mL) while keeping the reaction medium temperature below 30.degree.
C. with a cold water bath. The reaction medium was stirred at RT
for 18 h then concentrated in vacuo, diluted in H.sub.2O (75 mL)
and washed with MTBE (3.times.150 mL). The aqueous phase was
acidified to pH 3 by addition of citric acid at 100 g/L (150 mL)
and extracted with EtOAc (3.times.150 mL). The combined organic
phases were washed with H.sub.2O (3.times.45 mL), dried over
MgSO.sub.4, filtered and concentrated in vacuo to give 9.4 g of
compound 11 as a colorless oil (97%).
[0925] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 1.01 (d,
J=7.1 Hz, 3H); 1.38 (s, 9H); 2.48 (m, 1H); 2.91 (dt, J=6.1, 6.5 and
13.5 Hz, 1H); 3.15 (ddd, J=6.1, 7.4 and 13.5 Hz, 1H); 6.80 (t,
J=6.1 Hz, 1H); 12.15 (broad s, 1H).
Compound 12: methyl
3-((tert-butoxycarbonyl)amino)-2-methylpropanoate
[0926] To a solution of compound 11 (9.4 g, 46.25 mmol) in acetone
(300 mL) were added K.sub.2CO.sub.3 (16.14 g, 115.63 mmol) and
CH.sub.3I (13.26 g, 92.5 mmol). The reaction medium, a yellow
suspension, was stirred at RT for 20 h then filtered over Clarcel.
The cake thus obtained was washed with acetone, the filtrate
concentrated in vacuo, diluted with DCM (100 mL), filtered over
Clarcel, the cake thus obtained was washed with DCM and the
filtrate concentrated in vacuo to give 9.4 g of compound 12 as a
yellow liquid (93%).
[0927] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 1.01 (d,
J=7.1 Hz, 3H); 1.37 (s, 9H); 2.54 (m, 1H); 2.91 (dt, J=6.2 and 13.5
Hz, 1H); 3.15 (ddd, J=6.2, 6.9 and 13.5 Hz, 1H); 3.59 (s, 3H); 6.90
(t, J=6.2 Hz, 1H).
Compound 13: methyl
3-((tert-butoxycarbonyl)amino)-2-(((4-methoxybenzyl)oxy)methyl)-2-methylp-
ropanoate
[0928] To a solution of DIEA (3.2 mL, 22.45 mmol) in THE (10 mL)
cooled at -75.degree. C. was added dropwise a solution of 1.6 M
n-BuLi in THE (14 mL, 22.4 mmol). The reaction medium was stirred
at -75.degree. C. for 20 min; then was added dropwise at
-75.degree. C. a solution of compound 12 (2 g, 9.21 mmol) in THE
(16 mL) and the reaction mixture was stirred at -75.degree. C. for
10 min. A solution of 1-((chloromethoxy)methyl)-4-methoxybenzene
(1.72 g, 9.21 mmol) in THE (16 mL) was then quickly added to the
reaction mixture and the stirring carried on at -25.degree. C. for
4 h. The reaction medium was diluted with DCM (100 mL) before the
addition of a citric acid solution at 100 g/L (50 mL) while keeping
the temperature below 5.degree. C. The reaction medium was stirred
at RT for 15 min. The organic phase was washed with a citric acid
solution at 100 g/L (2.times.50 mL), H.sub.2O (3.times.50 mL),
dried over MgSO.sub.4, filtered and concentrated in vacuo to give
4.08 g of a yellow-orange oil that was purified by flash
chromatography on 150 g of silica gel (gradient elution
heptane/EtOAc) to provide 2.05 g of compound 13 as a colorless oil
(60%).
[0929] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 1.03 (s,
3H); 1.37 (s, 9H); 3.14 (d, J=6.8 Hz, 2H); 3.31 (d, J=9.1 Hz, 1H);
3.48 (d, J=9.1 Hz, 1H); 3.58 (s, 3H); 3.73 (s, 3H); 4.38 (s, 2H);
6.76 (t, J=7.1 Hz, 1H); 6.90 (d, J=8.9 Hz, 2H); 7.20 (m, 2H).
Fragment C4: methyl 3-amino-2-(hydroxymethyl)-2-methylpropanoate
Hydrochloride
[0930] Compound 13 (1.5 g, 4.08 mmol) was treated with a 4 M HCl
solution in dioxane (24 mL) at R.T. for 1 h. The reaction medium
was then concentrated in vacuo and co-evaporated in the presence of
toluene to give 794 mg of fragment C4 as a viscous oil
(quant.).
Synthesis of AD1: (2E,5S,6R,7E)-tert-butyl
5-(((S)-2-amino-4-methylpentanoyl)oxy)-8-(4-(azidomethyl)phenyl)-6-methyl-
octa-2,7-dienoate
##STR00721##
[0932] Compound 14: (2E,5S,6R,7E)-tert-butyl
5-(((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-methylpentanoyl)o-
xy)-8-(4-formylphenyl)-6-methylocta-2,7-dienoate
[0933] Under argon, in a round bottom flask under magnetic
stirring, Fmoc-Leu-OH (4.9 g, 13.86 mmol) was introduced, followed
by fragment A (3.5 g, 10.59 mmol) in DCM (100 mL) and DIEA (6.6 mL,
38.13 mmol). Then MNBA (5 g, 14.52 mmol) and DMAP (620 mg, 5.07
mmol) were added and the reaction mixture stirred overnight at RT.
After this time, the reaction medium was washed with H.sub.2O (100
mL) and sat. brine (100 mL). The organic phase was dried over
MgSO.sub.4, filtered and concentrated in vacuo to give 9.1 g of
crude orange oil that was purified by flash chromatography on 400 g
of silica gel (gradient elution heptane/AcOEt) to give 5 g of
compound 14 as a pale yellow oil (71%).
[0934] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.77 (d,
J=6.8 Hz, 6H); 1.05 (d, J=7.0 Hz, 3H); 1.33 to 1.64 (m, 4H); 1.38
(s, 9H); 2.39 to 2.63 (partially masked m, 2H); 4.01 (m, 1H); 4.13
to 4.31 (m, 3H); 4.95 (m, 1H); 5.81 (d, J=15.9 Hz, 1H); 6.37 (dd,
J=8.8 and 16.2 Hz, 1H); 6.52 (d, J=16.2 Hz, 1H); 6.70 (td, J=7.3
and 15.9 Hz, 1H); 7.29 (t, J=7.9 Hz, 2H); 7.40 (t, J=7.9 Hz, 2H);
7.56 (d, J=8.4 Hz, 2H); 7.67 (dd, J=7.9 Hz, 2H); 7.74 to 7.82 (m,
3H); 7.87 (d, J=7.9 Hz, 2H); 9.93 (s, 1H). LCMS (A1): ES m/z=666
[M+H]+, m/z=689 [M+Na].sup.+; t.sub.R=1.92 min.
Compound 15: (2E,5S,6R,7E)-tert-butyl
5-(((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-methylpentanoyl)o-
xy)-8-(4-(hydroxymethyl)phenyl)-6-methylocta-2,7-dienoate
[0935] Under argon, to a solution of compound 14 (5 g, 7.51 mmol)
in MeTHF (60 mL), was added sodium trimethoxyborohydride (1.2 g,
8.91 mmol) portionwise. The reaction medium was stirred 5 h at RT.
After this time, sat. NH.sub.4Cl (100 mL) and acetone (20 mL) were
added. The reaction medium was stirred 1 h at RT. After settling,
the organic phase was washed with H.sub.2O then with sat. brine (50
mL), dried over MgSO.sub.4, filtered and concentrated in vacuo to
give 5.3 g of crude yellow oil that was purified by flash
chromatography on 300 g of silica gel (gradient elution
heptane/AcOEt) to give 3.15 g of compound 15 as a white semi-solid
(63%).
[0936] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.80 (m,
6H); 1.02 (d, J=7.0 Hz, 3H); 1.35 to 1.66 (m, 4H); 1.38 (s, 9H);
2.35 to 2.56 (partially masked m, 2H); 4.02 (m, 1H); 4.15 to 4.32
(m, 3H); 4.43 (d, J=5.5 Hz, 2H); 4.92 (m, 1H); 5.12 (t, J=5.5 Hz,
1H); 5.80 (d, J=15.9 Hz, 1H); 6.10 (dd, J=8.8 et 16.2 Hz, 1H); 6.39
(d, J=16.2 Hz, 1H); 6.69 (m, 1H); 7.20 (d, J=8.4 Hz, 2H); 7.28 to
7.33 (m, 4H); 7.41 (t, J=7.9 Hz, 2H); 7.69 (t, J=7.9 Hz, 2H); 7.80
(d, J=8.2 Hz, 1H); 7.88 (d, J=7.9 Hz, 2H). LCMS (A1): ES m/z=668
[M+H].sup.+; m/z=690 [M+Na].sup.+; m/z=712 [M-H+HCO.sub.2H].sup.-;
t.sub.R=1.84 min.
Compound 16: (2E,5S,6R,7E)-tert-butyl
5-(((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)
amino)-4-methylpentanoyl)oxy)-8-(4-(azidomethyl)phenyl)-6-methylocta-2,7--
dienoate
[0937] Under argon, compound 15 (3.15 g, 4.72 mmol) and DCM (50 mL)
were introduced in a round bottom flask. At 0.degree. C., TEA (987
.mu.L, 7.08 mmol) was added, followed by methanesulfonyl chloride
(438 .mu.L, 5.66 mmol), the reaction medium was stirred 1 h at
0.degree. C. and 13 h at RT. After this time, DCM (50 mL) and water
(50 mL) were added. After settling, the organic phase was washed
with sat. brine (3.times.25 mL), dried over MgSO.sub.4 and
concentrated in vacuo. Under argon, the crude product thus obtained
was dissolved in DMF (50 mL) and sodium azide (644 mg, 9.91 mmol)
was added. The reaction medium was stirred overnight at RT. After
this time, DMF was concentrated in vacuo and AcOEt was added. The
mixture obtained was washed with 0.1N HCl (25 mL), with sat.
NaHCO.sub.3 (25 mL) and sat. brine (25 mL), dried over MgSO.sub.4,
filtered and concentrated in vacuo to give 3.3 g of crude that was
purified by flash chromatography on 200 g of silica gel (gradient
elution heptane/AcOEt) to give 1.8 g of compound 16 as a colorless
gum (55%) and 740 mg of compound AD1 (33%).
[0938] LCMS (A2): ES m/z=715 [M+Na].sup.+; t.sub.R=8.95 min.
Compound AD1: (2E,5S,6R,7E)-tert-butyl
5-(((S)-2-amino-4-methylpentanoyl)oxy)-8-(4-(azidomethyl)phenyl)-6-methyl-
octa-2,7-dienoate
[0939] Under argon, in a round bottom flask under magnetic
stirring, compound 16 (1.8 g, 2.6 mmol) and DCM (50 mL) were
introduced, followed by piperidine (1.6 mL, 16.2 mmol). The
reaction medium was stirred overnight at RT. After this time, it
was washed with 1N HCl then with sat. NaHCO.sub.3, sat. brine,
dried over MgSO.sub.4, filtered and concentrated in vacuo to give 2
g of crude that was purified by flash chromatography on 130 g of
silica gel (gradient elution heptane/AcOEt) to give 1.48 g of
compound AD1 as a pale yellow oil (quant.).
[0940] LCMS (A3): ES m/z=471 [M+H].sup.+; t.sub.R=2.65 min.
Synthesis of AD2: (2E,5S,6R,7E)-tert-butyl
5-(((S)-2-amino-4,4-dimethylpentanoyl)oxy)-8-(4-(hydroxymethyl)phenyl)-6--
methylocta-2,7-dienoate Hydrochloride
##STR00722##
[0941] Compound 17: (2E,5S,6R,7E)-tert-butyl
5-(((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4,4-dimethylpentano-
yl)oxy)-8-(4-formylphenyl)-6-methylocta-2,7-dienoate
[0942] Under argon, in a round bottom flask to a solution of
compound A (1.633 g, 4.94 mmol) in DCM (60 mL) were added
L-Fmoc-tert-Leu-OH (1.82 g, 4.94 mmol), DIEA (2.57 mL, 14.83 mmol),
MNBA (1.70 g, 4.94 mmol) and DMAP (241.51 mg, 1.98 mmol). After
stirring for 2 h at RT, the reaction medium was diluted with
H.sub.2O (50 mL) and extracted twice with DCM. The combined organic
phases were washed with citric acid (2.times.50 mL), sat.
NaHCO.sub.3 (50 mL) and sat. brine (50 mL), dried over MgSO.sub.4,
filtered and concentrated in vacuo to give 3.24 g of crude compound
17 used directly in the subsequent reduction (96%).
Compound 18: (2E,5S,6R,7E)-tert-butyl
5-(((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4,4-dimethylpentano-
yl)oxy)-8-(4-(hydroxymethyl)phenyl)-6-methylocta-2,7-dienoate
[0943] Under argon, in a round bottom flask to a solution of
compound 17 (3.24 g, 4.77 mmol) in MeTHF (60 mL) was added sodium
trimethoxyborohydride (670.56 mg, 5.24 mmol) at 0.degree. C. After
stirring for 1 h at RT, additional sodium trimethoxyborohydride
(304 mg, 2.38 mmol) was added and stirred for 2 h. Then the
reaction medium was cooled at 0.degree. C., diluted with acetone
(18 mL) and sat. NH.sub.4Cl (36 mL) and extracted with AcOEt. The
combined organic phases were washed with sat. brine, dried over
MgSO.sub.4, filtered, concentrated in vacuo and purified by flash
chromatography on 100 g of silica gel (gradient Heptane/AcOEt) to
give 2.61 g of compound 18 as a colorless amorphous solid
(80%).
[0944] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.80 (s,
9H); 1.02 (d, J=7.0 Hz, 3H); 1.35 to 1.60 (m, 4H); 1.38 (s, 9H);
2.37 to 2.58 (partially masked m, 2H); 4.04 (m, 1H); 4.16 to 4.33
(m, 3H); 4.45 (d, J=5.7 Hz, 2H); 4.91 (m, 1H); 5.12 (t, J=5.7 Hz,
1H); 5.80 (d, J=16.0 Hz, 1H); 6.10 (dd, J=8.8 and 16.2 Hz, 1H);
6.39 (d, J=16.2 Hz, 1H); 6.69 (m, 1H); 7.21 (d, J=8.4 Hz, 2H); 7.25
to 7.33 (m, 4H); 7.40 (t, J=7.9 Hz, 2H); 7.68 (t, J=7.9 Hz, 2H);
7.78 (d, J=8.3 Hz, 1H); 7.88 (d, J=7.9 Hz, 2H). LCMS (A1): ES
m/z=608; m/z=682 [M+H].sup.+; m/z=726 [M-H+HCO.sub.2H].sup.-;
t.sub.R=1.85 min.
Compound AD2: (2E,5S,6R,7E)-tert-butyl
5-(((S)-2-amino-4,4-dimethylpentanoyl)oxy)-8-(4-(hydroxymethyl)phenyl)-6--
methylocta-2,7-dienoate Hydrochloride
[0945] Under argon, in a round bottom flask, to a solution of
compound 18 (2.61 g, 3.83 mmol) in DCM (40 mL) was added piperidine
(7.60 mL, 76.56 mmol) and the reaction medium was stirred for 1 h
at RT. Then it was concentrated and extracted with AcOEt. The
combined organic layers were washed with 1N HCl, H.sub.2O and sat.
brine, dried over MgSO.sub.4, filtered and concentrated in vacuo.
The residue was diluted with iPr.sub.2O (50 mL) and stirred for 40
h at RT. The crude product was filtered, washed with iPr.sub.2O and
dried in vacuo 3 h at 40.degree. C. to provide 1.706 g of compound
AD2 as a colorless amorph solid (90%).
[0946] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.88 (s,
9H); 1.10 (d, J=7.0 Hz, 3H); 1.39 to 1.49 (m, 1H); 1.42 (s, 9H);
1.75 (dd, J=6.1 and 15.1 Hz, 1H); 2.47 to 2.64 (partially masked m,
2H); 3.92 (t, J=5.5 Hz, 1H); 4.47 (d, J=5.7 Hz, 2H); 5.02 (m, 1H);
5.15 (t, J=5.7 Hz, 1H); 5.90 (d, J=15.9 Hz, 1H); 6.15 (dd, J=8.3
and 16.1 Hz, 1H); 6.44 (d, J=16.1 Hz, 1H); 6.77 (td, J=7.3 and 15.9
Hz, 1H); 7.26 (d, J=8.4 Hz, 2H); 7.34 (d, J=8.4 Hz, 2H); 8.10
(broad m, 3H). LCMS (A1): ES m/z=460 [M+H].sup.+; t.sub.R=0.95
min.
Synthesis of AD3:
(2R,3S)-1-((4-methoxybenzyl)oxy)-2-methylhex-5-en-3-yl(S)-2-amino-4,4-dim-
ethylpentanoate
##STR00723##
[0947] Compound 19:
(2R,3S)-1-((4-methoxybenzyl)oxy)-2-methylhex-5-en-3-yl(S)-2-((((9H-fluore-
n-9-yl)methoxy)carbonyl)amino)-4,4-dimethylpentanoate
[0948] To a solution of Sakurai alcohol (1.02 g, 4.08 mmol) and
(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4,4-dimethylpentanoic
acid (1.5 g, 4.08 mmol) in THE (15 mL) were added
2,4,6-trichlorobenzoyl chloride (1.02 g, 4.08 mmol), dropwise TEA
(1.14 mL, 8.16 mmol) and DMAP (126.0 mg, 1.02 mmol). The reaction
medium was stirred at RT for 5 h, then cooled using an ice bath
before the addition of 1N HCl (60 mL) while keeping the temperature
below 10.degree. C. The resulting medium was stirred at RT for 15
min and extracted with EtOAc (3.times.50 mL). The combined organic
phases were washed with sat. NaHCO.sub.3 (15 mL), sat. brine
(3.times.15 mL), dried over MgSO.sub.4, filtered, concentrated in
vacuo and purified by three successive flash chromatographies on
silica gel (150 g, gradient elution heptane/EtOAc; 150 g and 20 g,
gradient elution DCM/MeOH) to give 1.78 g of compound 19 as a
colorless oil (72%).
[0949] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.85 (d,
J=7.1 Hz, 3H); 0.89 (s, 9H); 1.51 (dd, J=2.8 and 14.3 Hz, 1H); 1.61
(dd, J=9.0 and 14.3 Hz, 1H); 1.95 (m, 1H); 2.21 (m, 1H); 2.31 (m,
1H); 3.20 (dd, J=6.5 and 9.6 Hz, 1H); 3.35 (m, 1H); 3.73 (s, 3H);
4.04 (m, 1H); 4.18 to 4.34 (m, 5H); 4.83 (m, 1H); 5.00 (dq, J=2.1
and 10.3 Hz, 1H); 5.05 (dq, J=2.1 and 7.3 Hz, 1H); 5.70 (m, 1H);
6.87 (d, J=8.7 Hz, 2H); 7.17 (d, J=8.7 Hz, 2H); 7.30 (m, 2H); 7.41
(t, J=7.8 Hz, 2H); 7.70 (d, J=7.8 Hz, 2H); 7.75 (d, J=8.3 Hz, 1H);
7.90 (d, J=7.8 Hz, 2H). LCMS (A5): ES m/z=600 [M+H].sup.+; m/z=617
[M+H+NH.sub.3].sup.+; m/z=644 [M-H+HCO.sub.2H].sup.-; t.sub.R=1.86
min.
Compound AD3:
(2R,3S)-1-((4-methoxybenzyl)oxy)-2-methylhex-5-en-3-yl(S)-2-amino-4,4-dim-
ethylpentanoate
[0950] To a solution of compound 19 (1.78 g, 2.98 mmol) in DCM (63
mL) was added dropwise piperidine (1.77 mL, 17.9 mmol). The
reaction medium was stirred at R.T. for 4 h, diluted with DCM (150
mL), washed with 1 N HCl (2.times.20 mL), sat. NaHCO.sub.3 (20 mL),
sat. brine (3.times.20 mL), dried over MgSO.sub.4, filtered,
concentrated in vacuo and purified by flash chromatography on 50 g
of silica gel (gradient elution heptane/EtOAc) to give 644 mg of
compound AD3 as a colorless oil (57%).
[0951] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.88 (s,
9H); 0.89 (d, J=7.1 Hz, 3H); 1.21 (dd, J=6.9 and 13.9 Hz, 1H); 1.56
(dd, J=5.0 and 13.9 Hz, 1H); 1.66 (broad s, 2H); 2.00 (m, 1H); 2.24
(m, 1H); 2.33 (m, 1H); 3.26 (m, 2H); 3.38 (dd, J=5.5 and 9.4 Hz,
1H); 3.74 (s, 3H); 4.36 (s, 2H); 4.84 (m, 1H); 5.00 to 5.10 (m,
2H); 5.72 (m, 1H); 6.89 (d, J=8.8 Hz, 2H); 7.22 (d, J=8.8 Hz, 2H).
LCMS (A5): ES m/z=378 [M+H].sup.+; t.sub.R=0.88 min.
Synthesis of BC1:
3-((R)-2-((tert-butoxycarbonyl)amino)-3-(3-chloro-4-methoxyphenyl)-propan-
amido)-2,2-dimethylpropanoic Acid
##STR00724##
[0952] Compound 20: methyl
3-((R)-2-((tert-butoxycarbonyl)amino)-3-(3-chloro-4-methoxyphenyl)-propan-
amido)-2,2-dimethylpropanoate
[0953] Under argon, in a round bottom flask were introduced
fragment C1 (981.45 mg, 4.00 mmol) and DCM (50 mL), followed by
DIEA (1.84 mL, 10.92 mmol), fragment B (1.2 g, 3.64 mmol), HOBt
(563.40 mg, 4.00 mmol) and EDC (1.45 mL, 8.01 mmol). The reaction
medium was stirred overnight at RT. After this time, the reaction
medium was diluted with H.sub.2O (30 mL) and extracted twice with
DCM. The combined organic phases were washed with sat. brine, dried
over MgSO.sub.4, filtered and concentrated in vacuo to give 2.5 g
of crude oil that was purified by flash chromatography on 110 g of
silica gel (gradient elution heptane/AcOEt) to give 1.06 g of
compound 20 as a white meringue (66%).
[0954] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 1.06 (s,
3H); 1.07 (s, 3H); 1.30 (s, 9H); 2.65 (dd, J=11.6 and 13.9 Hz, 1H);
2.82 (dd, J=4.0 and 13.9 Hz, 1H); 3.18 (dd, J=6.1 and 13.4 Hz, 1H);
3.29 (partially masked m, 1H); 3.60 (s, 3H); 3.81 (s, 3H); 4.11 (m,
1H); 6.90 (d, J=8.7 Hz, 1H); 7.04 (d, J=8.6 Hz, 1H); 7.19 (dd,
J=2.3 and 8.6 Hz, 1H); 7.33 (broad s, 1H); 7.75 (large t, J=6.1 Hz,
1H).
Compound BC1:
3-((R)-2-((tert-butoxycarbonyl)amino)-3-(3-chloro-4-methoxyphenyl)-propan-
amido)-2,2-dimethylpropanoic Acid
[0955] Under argon, in a round bottom flask were introduced
compound 20 (1.06 g, 2.39 mmol) and THE (25 mL) followed by LiOH
(70.18 mg, 2.87 mmol) and H.sub.2O (1 mL). The reaction medium was
stirred few hours before adding 70 mg of LiOH and stirred overnight
at RT. After this time, Amberlit resin was added until pH 4,
filtered then washed with THE and concentrated in vacuo to give 1 g
of compound BC1 as a white solid (97%).
Synthesis of BC2:
3-((R)-2-((tert-butoxycarbonyl)amino)-3-(3-chloro-4-methoxyphenyl)-propan-
amido)-2,2-dimethylbutanoic Acid
##STR00725##
[0956] Compound 21: methyl
3-((R)-2-((tert-butoxycarbonyl)amino)-3-(3-chloro-4-methoxyphenyl)-propan-
amido)-2,2-dimethylbutanoate
[0957] Under argon, in a round bottom flask were introduced
fragment B (1.02 g, 2.78 mmol) and DCM (25 mL), followed by EDC
(592 mg, 3.03 mmol) and HOBt (478 mg, 3.03 mmol). The reaction
medium was stirred 15 min then fragment C2 (0.5 g, 2.75 mmol) and
DIEA (1.7 mL, 9.73 mmol) were added. The reaction medium was
stirred overnight at RT. After this time, the reaction medium was
concentrated in vacuo then diluted with AcOEt. The organic layer
was washed with sat. brine, dried over MgSO.sub.4, filtered and
concentrated in vacuo to give 1.45 g of crude oil that purified by
flash chromatography on 100 g of silica gel (gradient elution
heptane/AcOEt) to give 845 mg of compound 21 as a white foam
(67%).
[0958] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6):
diastereoisomer mixture 50:50; 0.87 (d, J=6.8 Hz, 1.5H); 0.97 (d,
J=6.8 Hz, 1.5H); 1.01 (s, 1.5H); 1.03 (s, 1.5H); 1.07 (s, 3H); 1.31
(s, 9H); 2.58 to 2.87 (m, 2H); 3.59 (s, 1.5H); 3.60 (s, 1.5H); 3.81
(s, 3H); 3.99 to 4.20 (m, 2H); 6.90 (d, J=9.0 Hz, 0.5H); 6.97 (d,
J=9.0 Hz, 0.5H); 7.05 (broad d, J=8.6 Hz, 1H); 7.19 (split dd,
J=2.4 and 8.6 Hz, 1H); 7.32 (d, J=2.4 Hz, 0.5H); 7.34 (d, J=2.4 Hz,
0.5H); 7.54 (d, J=10.1 Hz, 0.5H); 7.62 (d, J=10.1 Hz, 0.5H). LCMS
(A3): diastereoisomer mixture 50:50; ES m/z=457 [M+H].sup.+;
m/z=479 [M+Na].sup.+; t.sub.R=3.19-3.2 min.
Compound 21 Stereomers 1 and 2: methyl
3-((R)-2-((tert-butoxycarbonyl)amino)-3-(3-chloro-4-methoxyphenyl)-propan-
amido)-2,2-dimethylbutanoate Stereomers 1 and 2
[0959] Under argon, in a round bottom flask to a solution of
fragment B (1.17 g, 3.55 mmol) in DCM (30 mL) were added EDC
(741.75 mg, 3.87 mmol), HOBt (592.57 mg, 3.87 mmol). After stirring
15 min at RT, fragment C2 (639 mg, 3.52 mmol) and DIEA (2.17 mL,
12.31 mmol) were added. The reaction medium was stirred for 4 h,
then concentrated and diluted with AcOEt (100 mL). The organic
layers were washed with H.sub.2O (2.times.10 mL) and sat. brine
(2.times.10 mL), dried over MgSO.sub.4, filtered and concentrated
in vacuo. The crude product was purified by flash chromatography on
50 g of silica gel (gradient elution heptane/AcOEt) to give 1.306 g
of mixture of diastereoisomers (81%) that were separated by two
successive flash chromatographies, the first one on 100 g of silica
gel (gradient elution DCM/MeOH) to give 376 mg of compound 21
stereomer 1 (23%), the second one on 70 g of silica gel (gradient
elution DCM/MeOH) to give 181 mg of compound 21 stereomer 1 (11%),
279 mg of compound 21 stereomer 2 (17%) and 476 mg of mixture of
diasteroisomers.
Compound 21 Stereomer 1
[0960] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.85 (d,
J=6.8 Hz, 3H); 1.07 (s, 6H); 1.31 (s, 9H); 2.57 (m, 1H); 2.80 (dd,
J=5.2 and 13.8 Hz, 1H); 3.60 (s, 3H); 3.81 (s, 3H); 4.05 (m, 1H);
4.16 (m, 1H); 6.99 (d, J=8.7 Hz, 1H); 7.05 (d, J=8.6 Hz, 1H); 7.20
(dd, J=2.0 and 8.6 Hz, 1H); 7.34 (d, J=2.0 Hz, 1H); 7.57 (d, J=10.1
Hz, 1H). LCMS (A1): ES m/z=381; m/z=401; m/z=455 [M-H].sup.-;
m/z=457 [M+H].sup.+; t.sub.R=1.29 min.
Compound 21 Stereomer 2
[0961] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.95 (d,
J=6.8 Hz, 3H); 1.00 (s, 3H); 1.03 (s, 3H); 1.31 (s, 9H); 2.55 (m,
1H); 2.80 (dd, J=5.0 and 14.3 Hz, 1H); 3.59 (s, 3H); 3.81 (s, 3H);
4.09 to 4.22 (m, 2H); 6.92 (d, J=8.8 Hz, 1H); 7.05 (d, J=8.6 Hz,
1H); 7.20 (dd, J=2.0 and 8.6 Hz, 1H); 7.34 (d, J=2.0 Hz, 1H); 7.64
(d, J=10.1 Hz, 1H). LCMS (A1): ES m/z=381; m/z=401; m/z=455
[M-H].sup.-; m/z=457 [M+H].sup.+; t.sub.R=1.29 min.
Compound BC2:
3-((R)-2-((tert-butoxycarbonyl)amino)-3-(3-chloro-4-methoxyphenyl)-propan-
amido)-2,2-dimethylbutanoic Acid
[0962] Compound 21 (0.845 g, 1.85 mmol) and MeOH (20 mL) were
introduced in a round bottom flask followed by 1.8 mL of 10M NaOH.
The solution was stirred and heated at 50.degree. C. overnight. The
reaction medium was evaporated in vacuo then diluted with H.sub.2O
(20 mL) and neutralized with 5N HCl. The solution was extracted
twice with AcOEt. The combined organic layers were washed with sat.
brine, dried avec MgSO.sub.4, filtered and concentrated in vacuo to
give 800 mg of compound BC2 as a white foam (97%).
[0963] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6):
diastereoisomer mixture 50:50; 0.91 (d, J=6.8 Hz, 1.5H); 0.97 (d,
J=6.8 Hz, 1.5H); 1.00 (s, 3H); 1.03 (s, 1.5H); 1.07 (s, 1.5H); 1.31
(s, 9H); 2.57 (m, 1H); 2.83 (m, 1H); 3.81 (s, 3H); 4.01 to 4.16 (m,
2H); 6.90 (d, J=9.0 Hz, 0.5H); 6.95 (d, J=9.0 Hz, 0.5H); 7.03 (d,
J=8.6 Hz, 1H); 7.20 (broad, J=8.6 Hz, 1H); 7.31 (broad s, 1H); 7.49
(d, J=10.1 Hz, 0.5H); 7.54 (d, J=10.1 Hz, 0.5H); 11.94 (broad m,
1H). LCMS (A1): diastereoisomer mixture 50:50; ES m/z=387; m/z=443
[M+H].sup.+; t.sub.R=1.20-1.21 min.
Compound BC2 stereomer 1:
3-((R)-2-((tert-butoxycarbonyl)amino)-3-(3-chloro-4-methoxy
phenyl)propanamido)-2,2-dimethylbutanoic Acid Stereomer 1
[0964] Compound 21 stereomer 1 (0.325 g, 1.85 mmol) and MeOH (8 mL)
were introduced in a round bottom flask followed by 0.692 mL of 10M
NaOH. The yellow solution was stirred and heated at 50.degree. C.
overnight. The reaction medium was evaporated in vacuo then diluted
with H.sub.2O (20 mL) and extracted with AcOEt (3.times.5 mL). The
aq. layers were acidified with 5N HCl and extracted with AcOEt
(3.times.30 mL). The combined organic phases were washed with sat.
brine (5 mL), dried over MgSO.sub.4, filtered and concentrated in
vacuo to give 303 mg of compound BC2 stereomer 1 as a white foam
(96%) used directly in the subsequent reaction.
Compound BC2 stereomer 2:
3-((R)-2-((tert-butoxycarbonyl)amino)-3-(3-chloro-4-methoxy
phenyl)propanamido)-2,2-dimethylbutanoic Acid Stereomer 2
[0965] Compound 21 stereomer 2 (1.094 g, 2.39 mmol), THE (5 mL) and
H.sub.2O (5 mL) were introduced in a round bottom flask followed by
LiOH (301 mg, 7.18 mmol). The solution was stirred for 44 h at RT.
The reaction was not complete, LiOH (301 mg) was added. The mixture
was stirred for 48 h, then 301 mg of LiOH was added in THE (10 mL)
and H.sub.2O (5 mL) and the reaction medium stirred 40 h at
60.degree. C. The reaction medium was evaporated in vacuo. 1M
citric acid was added until pH 2 and the mixture was extracted with
AcOEt (2.times.20 mL). The combined organic layers were washed with
H.sub.2O, dried over MgSO.sub.4, filtered and concentrated in vacuo
to give 1.096 g of compound BC2 stereomer 2 as a white amorph solid
(quant.) used directly in the subsequent reaction.
Synthesis of BC3: ethyl
2-((R)-1-(2-((tert-butoxycarbonyl)amino)-3-(3-chloro-4-methoxyphenyl)-pro-
panamido)cyclopropyl)-2-methylpropanoic Acid
##STR00726##
[0966] Compound 22: ethyl
2-((R)-1-(2-((tert-butoxycarbonyl)amino)-3-(3-chloro-4-methoxyphenyl)-pro-
panamido)cyclopropyl)-2-methylpropanoate
[0967] Under argon, in a round bottom flask were introduced
fragment C3 (1.2 g, 7.01 mmol) and THE (16.5 mL), followed by
fragment B (2.54 g, 7.71 mmol), HOBt (1.77 g, 8.76 mmol), EDC (1.23
g, 8.06 mmol) and DIEA (1.35 mL, 7.71 mmol). The reaction medium
was stirred for 2 h at RT. After this time, the reaction medium was
diluted with H.sub.2O (25 mL) and extracted with AcOEt (250 mL).
The organic layers were washed with H.sub.2O (2.times.25 mL), sat.
brine (2.times.25 mL), dried over MgSO.sub.4, filtered,
concentrated and purified by flash chromatography, the first one on
200 g of silica gel (gradient elution heptane/AcOEt) to give 2.16 g
of compound 22 as a colorless foam (64%) and 343 mg of mixture
containing the expected compound that was further purified on 30 g
of silica gel (gradient elution heptane/AcOEt) to give 160 mg of
compound 22 as a colorless foam (4.7%).
[0968] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.62 (m,
1H); 0.74 to 0.99 (m, 3H); 1.03 (s, 3H); 1.10 (s, 3H); 1.24 (t,
J=7.2 Hz, 3H); 1.42 (s, 9H); 2.90 (m, 2H); 3.88 (s, 3H); 4.08 (m,
1H); 4.10 (q, J=7.2 Hz, 2H); 4.96 (m, 1H); 6.33 (broad s, 1H); 6.85
(d, J=8.5 Hz, 1H); 7.03 (dd, J=2.4 and 8.5 Hz, 1H); 7.17 (d, J=2.4
Hz, 1H).
Compound BC3:
2-((R)-1-(2-((tert-butoxycarbonyl)amino)-3-(3-chloro-4-methoxyphenyl)-pro-
panamido)cyclopropyl)-2-methylpropanoic Acid
[0969] Compound 22 (2.09 g, 4.33 mmol), THE (10 mL) and H.sub.2O (8
mL) were introduced in a round bottom flask followed by LiOH
(726.33 mg, 17.31 mmol). The solution was stirred and heated at
65.degree. C. After 16 h, the reaction was not completed, 726.33 mg
of LiOH in 10 mL H.sub.2O were added. The mixture was stirred for
48 h at 65.degree. C. After cooling, the reaction medium was
diluted with H.sub.2O (20 mL) then extracted with AcOEt (3.times.40
mL). The organic layers were washed with H.sub.2O (2.times.10 mL),
dried over MgSO.sub.4, filtered and concentrated in vacuo to give
1.29 g of mixture ester/acid. The aq. layer was acidified with 5N
HCl until pH 3, then extracted with AcOEt (3.times.50 mL). The
organic layers were washed with H.sub.2O (2.times.10 mL), dried
over MgSO.sub.4, filtered and concentrated in vacuo to give 787 mg
of compound BC3 as a beige foam (40%).
[0970] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.50 to 0.90
(m, 4H); 1.03 (s, 6H); 1.30 (s, 9H); 2.60 (dd, J=10.5 and 14.1 Hz,
1H); 2.78 (dd, J=5.0 and 14.1 Hz, 1H); 3.81 (s, 3H); 3.97 (m, 1H);
6.80 (d, J=8.7 Hz, 1H); 7.03 (d, J=8.5 Hz, 1H); 7.18 (dd, J=2.0 and
8.5 Hz, 1H); 7.31 (d, J=2.0 Hz, 1H); 7.86 (s, 1H); 12.11 (broad m,
1H).
Synthesis of BC4:
(S)-3-((R)-2-acrylamido-3-(3-chloro-4-methoxyphenyl)propanamido)-2,2-dime-
thylbutanoic Acid
##STR00727##
[0971] Compound 23:
methyl(S)-3-((R)-2-((tert-butoxycarbonyl)amino)-3-(3-chloro-4-methoxyphen-
yl)-propanamido)-2,2-dimethylbutanoate
[0972] To a solution of fragment B (2 g, 6.06 mmol) in DCM (60 mL)
were added EDC (1.13 mL, 7.06 mmol) and HOBt (948 mg, 6.67 mmol).
The reaction medium was stirred at RT for 15 min then were added
methyl(S)-3-amino-2,2-dimethylbutanoate (881 mg, 6.06 mmol) and
DIEA (1.53 mL, 9.10 mmol). The reaction medium was stirred at RT
for 4 h, concentrated in vacuo and diluted with EtOAc (100 mL) and
H.sub.2O (20 mL). The aqueous phase was extracted with EtOAc (20
mL); the combined organic phases were washed with sat. brine
(2.times.20 mL), dried over MgSO.sub.4, filtered, concentrated in
vacuo and purified by flash chromatography on 150 g of silica gel
(gradient elution heptane/EtOAc) to give 2.21 g of compound 23 as a
colorless lacquer (79%).
[0973] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.88 (d,
J=7.0 Hz, 3H); 1.08 (s, 6H); 1.32 (s, 9H); 2.67 (dd, J=9.9 and 13.6
Hz, 1H); 2.82 (dd, J=5.2 and 13.6 Hz, 1H); 3.62 (s, 3H); 3.83 (s,
3H); 4.06 (m, 1H); 4.77 (m, 1H) 6.97 (d, J=8.6 Hz, 1H); 7.05 (d,
J=8.6 Hz, 1H); 7.20 (dd, J=2.4 and 8.6 Hz, 1H); 7.33 (d, J=2.4 Hz,
1H); 7.55 (d, J=9.8 Hz, 1H).
Compound 24:
methyl(S)-3-((R)-2-amino-3-(3-chloro-4-methoxyphenyl)propanamido)-2,2-dim-
ethylbutanoate 2,2,2-trifluoroacetate
[0974] To a solution of compound 23 (2.2 g, 4.81 mmol) in DCM (25
mL) was added TFA (3.6 mL, 48.1 mmol). The reaction medium was
stirred at RT overnight, concentrated in vacuo and co-evaporated in
the presence of toluene to provide 2.0 g of compound 24 as a
diastereoisomer mixture (88%).
[0975] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.80 (d,
J=6.9 Hz, 3H); 1.04 (s, 3H); 1.10 (s, 3H); 2.95 (d, J=7.0 Hz, 2H);
3.62 (s, 3H); 3.84 (s, 3H); 4.00 (m, 1H); 4.15 (m, 1H); 7.10 to
7.30 (m, 3H); 8.00 (d, J=9.5 Hz, 1H); 8.22 (broad s, 3H).
Compound 25:
methyl(S)-3-((R)-2-acrylamido-3-(3-chloro-4-methoxyphenyl)propanamido)-2,-
2-dimethylbutanoate
[0976] To a solution of compound 24 (2.0 g, 4.25 mmol) in DCM (20
mL) were added acryloyl chloride (536 .mu.L, 6.37 mmol) and DIEA
(2.5 mL, 12.74 mmol). The reaction medium was stirred at RT for 2 h
then diluted with H.sub.2O (20 mL). The aqueous phase was extracted
with DCM (2.times.20 mL), the combined organic phases were washed
with sat. brine (2.times.20 mL), dried over MgSO.sub.4, filtered,
concentrated in vacuo and purified by flash chromatography on 100 g
of silica gel (gradient elution heptane/EtOAc) to give 850 mg of
compound 25 as a 85:15 diastereoisomer mixture (68%).
[0977] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.85 (d,
J=6.9 Hz, 3H); 1.03 (s, 3H); 1.04 (s, 3H); 2.72 (dd, J=9.7 and 13.9
Hz, 1H); 2.86 (dd, J=5.8 and 13.9 Hz, 1H); 3.58 (s, 3H); 3.80 (s,
3H); 4.15 (m, 1H); 4.56 (m, 1H); 5.56 (dd, J=2.3 and 10.2 Hz, 1H);
6.03 (dd, J=2.3 and 17.2 Hz, 1H); 6.28 (dd, J=10.2 and 17.2 Hz,
1H); 7.02 (d, J=8.5 Hz, 1H); 7.17 (dd, J=2.2 and 8.5 Hz, 1H); 7.31
(d, J=2.2 Hz, 1H); 7.72 (d, J=9.8 Hz, 1H); 8.36 (d, J=8.6 Hz,
1H).
Compound BC4:
(S)-3-((R)-2-acrylamido-3-(3-chloro-4-methoxyphenyl)propanamido)-2,2-dime-
thylbutanoic Acid
[0978] To a solution of tBuOK (1.11 g, 9.86 mmol) in THE (4 mL)
cooled at 0.degree. C. were added H.sub.2O (47 .mu.L) and compound
25 (450 mg, 1.10 mmol). The reaction medium was stirred at RT for 3
h, then acidified with 1N HCl (5 mL). The aqueous phase was
extracted with DCM (2.times.20 mL); the combined organic phases
were washed with H.sub.2O (30 mL), sat. brine (20 mL), dried over
MgSO.sub.4, filtered and concentrated in vacuo. The two
diastereoisomers were separated by supercritical fluid
chromatography on a Chiralpak AS 10 .mu.m column (isocratic elution
at 85/15 CO.sub.2/[MeOH+0.1% TEA] to give 385 mg of compound BC4 as
an amorphous solid (89%).
[0979] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.88 (d,
J=6.9 Hz, 3H); 0.99 (s, 3H); 1.00 (s, 3H); 2.71 (dd, J=9.4 and 13.7
Hz, 1H); 2.88 (dd, J=5.3 and 13.7 Hz, 1H); 3.80 (s, 3H); 4.10 (m,
1H); 4.54 (m, 1H); 5.55 (dd, J=2.3 and 10.2 Hz, 1H); 6.01 (dd,
J=2.3 and 17.1 Hz, 1H); 6.28 (dd, J=10.2 and 17.1 Hz, 1H); 7.02 (d,
J=8.7 Hz, 1H); 7.17 (dd, J=2.4 and 8.7 Hz, 1H); 7.32 (d, J=2.4 Hz,
1H); 7.80 (d, J=9.8 Hz, 1H); 8.39 (d, J=8.8 Hz, 1H); 12.00 (broad
s, 1H). LCMS (A5): ES m/z=395 [M-H].sup.-; m/z=397 [M+H].sup.+;
t.sub.R=0.92 min.
Synthesis of BC5:
(S)-3-((R)-2-((tert-butoxycarbonyl)amino)-3-(3-chloro-4-methoxyphenyl)-pr-
opanamido)-2,2-dimethylbutanoic Acid
##STR00728##
[0981] Compound BC5 was prepared starting from
methyl(3S)-3-amino-2,2-dimethylbutanoate (MFCD09256689) and
following general synthesis of building block BC depicted in Scheme
32 and described for compounds BC1 and BC2.
[0982] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.89 (d,
J=7.0 Hz, 3H); 1.02 (s, 3H); 1.04 (s, 3H); 1.30 (s, 9H); 2.68 (dd,
J=13.6 and 10.2 Hz, 1H); 2.82 (dd, J=5.2 and 13.6 Hz, 1H); 3.80 (s,
3H); 4.05 (m, 1H); 4.12 (m, 1H); 7.00 (d, J=8.7 Hz, 1H); 7.05 (d,
J=8.7 Hz, 1H); 7.20 (dd, J=2.2 and 8.7 Hz, 1H); 7.32 (d, J=2.2 Hz,
1H); 7.52 (d, J=9.9 Hz, 1H); 12.35 (broad s, 1H). LCMS (A1): ES
m/z=441 [M-H].sup.-; m/z=443 [M+H].sup.+; m/z=883 [2M-H].sup.-;
t.sub.R=1.16 min.
Synthesis of BC6:
3-((R)-2-acrylamido-3-(3-chloro-4-methoxyphenyl)propanamido)-2-(hydroxyme-
thyl)-2-methylpropanoic Acid
##STR00729##
[0983] Compound 26: methyl
3-((R)-2-((tert-butoxycarbonyl)amino)-3-(3-chloro-4-methoxyphenyl)-propan-
amido)-2-(hydroxymethyl)-2-methylpropanoate
[0984] To a solution of fragment C4 (1.059 g, 5.77 mmol) in THE (60
mL) were added DIEA (2.06 mL, 11.76 mmol), fragment B (1.90 g, 5.77
mmol), HOBt (935 mg, 6.92 mmol) and EDC (1.23 mL, 6.92 mmol). The
reaction medium was stirred at RT for 48 h, concentrated in vacuo
and purified by flash chromatography on 200 g of silica gel
(isocratic elution heptane/EtOAc) to give 1.05 g of compound 26 as
a colorless oil (39%).
[0985] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.98 (s,
3H); 1.30 (s, 9H); 2.63 (m, 1H); 2.83 (m, 1H); 3.18 to 3.48 (m,
4H); 3.60 (s, 3H); 3.80 (s, 3H); 4.10 (m, 1H); 4.81 (m, 1H); 6.98
(d, J=8.9 Hz, 1H); 7.04 (d, J=8.7 Hz, 1H); 7.20 (dd, J=2.1 and 8.7
Hz, 1H); 7.35 (d, J=2.1 Hz, 1H); 7.83 (m, 1H). LCMS (A5): ES
m/z=457 [M-H].sup.-; m/z=459 [M+H].sup.+; m/z=503
[M-H+HCO.sub.2H].sup.-; t.sub.R=1.1 min.
Compound 27: methyl
3-((R)-2-amino-3-(3-chloro-4-methoxyphenyl)propanamido)-2-(hydroxymethyl)-
-2-methylpropanoate Hydrochloride
[0986] Compound 26 (1.05 g, 2.29 mmol) was treated with HCl 4M in
dioxane (16 mL, 64 mmol) for 1 h at RT. The reaction medium was
concentrated in vacuo and co-evaporated twice in the presence of
toluene. The crude product was triturated with iPr.sub.2O (10 mL),
filtered and washed twice with iPr.sub.2O (5 mL). The cake was then
dissolved in DCM, filtered and concentrated in vacuo to give 809 mg
of compound 27 as a white foam (90%) that was used without further
purification.
[0987] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.92 (s,
1.5H); 0.97 (s, 1.5H); 2.88 (m, 1H); 3.00 (m, 1H); 3.19 to 3.47 (m,
4H); 3.60 (s, 3H); 3.85 (s, 3H); 4.05 (m, 1H); 4.89 (m, 1H); 7.11
(split d, J=8.6 Hz, 1H); 7.19 (split dd, J=2.0 and 8.6 Hz, 1H);
7.38 (split d, J=2.0 Hz, 1H); 8.15 (broad s, 3H); 8.39 (m, 1H).
Compound 28: methyl
3-((R)-2-amino-3-(3-chloro-4-methoxyphenyl)propanamido)-2-methyl-2-(((tri-
ethylsilyl)oxy)methyl)propanoate
[0988] To a solution of compound 27 (809 mg, 2.05 mmol) in DCM (4
mL) cooled with an ice bath were added TEA (1.43 mL, 10.23 mmol)
and chlorotriethylsilane (1.37 mL, 8.19 mmol) while keeping the
temperature below 4.degree. C. Stirring at 4.degree. C. was carried
on for 10 min then the reaction medium was stirred at RT for 20 h.
Sat. brine (20 mL) and DCM were added to the medium that was
stirred for 10 min. The organic phase was washed with sat. brine
(3.times.10 mL), dried over MgSO.sub.4, filtered, concentrated in
vacuo and purified by flash chromatography on 70 g of silica gel
(gradient elution DCM/MeOH) to give 706 mg of compound 28 as a pale
yellow oil (73%).
[0989] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.52 (q,
J=8.0 Hz, 6H); 0.89 (t, J=8.0 Hz, 9H); 0.98 (s, 3H); 1.70 (broad s,
2H); 2.54 (m, 1H); 2.82 (m, 1H); 3.18 to 3.45 (m, 3H); 3.58 (m,
2H); 3.60 (s, 3H); 3.80 (s, 3H); 7.03 (d, J=8.7 Hz, 1H); 7.14 (dd,
J=2.3 and 8.7 Hz, 1H); 7.28 (split d, J=2.3 Hz, 1H); 7.78 (m, 1H).
LCMS (A5): ES m/z=471 [M-H].sup.-; m/z=473 [M+H].sup.+; m/z=517
[M-H+HCO.sub.2H].sup.-; t.sub.R=0.97 min.
Compound 29: methyl
3-((R)-2-acrylamido-3-(3-chloro-4-methoxyphenyl)propanamido)-2-methyl-2-(-
((triethylsilyl)oxy)methyl)propanoate
[0990] To a solution of compound 28 (704 mg, 1.49 mmol) in DCM (19
mL) cooled with an ice/acetone bath were added DIEA (780 .mu.L,
4.46 mmol) and dropwise acryloyl chloride (181 .mu.L, 2.23 mmol).
The reaction medium was stirred at 0-5.degree. C. for 1 h then
EtOAc was added (38 mL) and the medium washed with 1N HCl (5 mL),
sat. NaHCO.sub.3 (5 mL), sat. brine (3.times.15 mL), dried over
MgSO.sub.4, filtered, concentrated in vacuo and purified by flash
chromatography on 30 g of silica gel (gradient elution DCM/MeOH) to
give 742 mg of compound 29 as a colorless oil (94%).
[0991] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.52 (split
q, J=8.0 Hz, 6H); 0.89 (split t, J=8.0 Hz, 9H); 0.99 (s, 1.5H);
1.01 (s, 1.5H); 2.69 (m, 1H); 2.87 (m, 1H); 3.20 (m, 1H); 3.28 (m,
1H); 3.50 (dd, J=3.1 and 9.9 Hz, 1H); 3.58 (s, 3H); 3.68 (d, J=9.9
Hz, 1H); 3.80 (s, 3H); 4.59 (m, 1H); 5.55 (d, J=10.3 Hz, 1H); 6.00
(d, J=17.3 Hz, 1H); 6.25 (split dd, J=10.3 and 17.3 Hz, 1H); 7.02
(d, J=8.5 Hz, 1H); 7.18 (split dd, J=2.0 and 8.5 Hz, 1H); 7.31
(split d, J=2.0 Hz, 1H); 7.96 (m, 1H); 8.39 (d, J=8.9 Hz, 1H). LCMS
(A5): ES m/z=525 [M-H].sup.-; m/z=527 [M+H].sup.+; m/z=571
[M-H+HCO.sub.2H].sup.-; t.sub.R=1.54 min.
Compound BC6:
3-((R)-2-acrylamido-3-(3-chloro-4-methoxyphenyl)propanamido)-2-(hydroxyme-
thyl)-2-methylpropanoic Acid
[0992] To a suspension of tBuOK (1.42 g, 12.65 mmol) in THE (7 mL)
cooled with an ice/acetone bath was added H.sub.2O (50 .mu.L), the
medium was stirred for 10 min before the addition of a solution of
compound 29 (741 mg, 1.41 mmol) in THE (7 mL). Stirring was carried
on at 0.degree. C. for 10 min then at RT for 1 h. The reaction
medium was cooled with an ice bath before the addition of 1N HCl
(16.9 mL). After 15 min of stirring, the reaction medium was
extracted with DCM (3.times.25 mL). The combined organic phases
were washed with sat. brine (2.times.15 mL), H.sub.2O (15 mL),
dried over MgSO.sub.4, filtered and concentrated in vacuo to give
656 mg of compound BC6 as a yellow foam (quant.).
[0993] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.91 (s,
3H); 2.69 (m, 1H); 2.90 (dd, J=4.8 and 13.6 Hz, 1H); 3.18 to 3.42
(m, 4H); 3.80 (s, 3H); 4.59 (m, 1H); 4.73 (broad, 1H); 5.55 (d,
J=2.3 and 10.3 Hz, 1H); 6.00 (dd, J=2.3 and 17.2 Hz, 1H); 6.24 (dd,
J=10.3 and 17.2 Hz, 1H); 7.03 (d, J=8.7 Hz, 1H); 7.19 (dd, J=2.0
and 8.7 Hz, 1H); 7.35 (d, J=2.0 Hz, 1H); 8.00 (m, 1H); 8.39 (d,
J=8.8 Hz, 1H); 12.30 (broad s, 1H). LCMS (A5): ES m/z=397
[M-H].sup.-; m/z=399 [M+H].sup.+; t.sub.R=0.77 min.
Synthesis of Examples 1 to 3: benzylic amine of aza-C52, NHS ester
of glutaryl-Val-Ala-aza-C52 Benzylic Amine and Corresponding
ADC
##STR00730## ##STR00731##
[0994] Compound 30:
(6R,13S)-(1E,3R,4S,6E)-1-(4-(azidomethyl)phenyl)-8-(tert-butoxy)-3-methyl-
-8-oxoocta-1,6-dien-4-yl
6-(3-chloro-4-methoxybenzyl)-13-isobutyl-2,2,10,10-tetramethyl-4,7,11-tri-
oxo-3-oxa-5,8,12-triazatetradecan-14-oate
[0995] Under argon, in a round bottom flask were introduced
compound BC1 (899.55 mg, 2.10 mmol) in DMF (25 mL), HATU (861 mg,
2.20 mmol) and HOAt (302 mg, 2.20 mmol). The mixture was stirred
for 30 minutes at RT. After that, compound AD1 (940 mg, 2 mmol) and
DIEA (1.05 mL, 5.99 mmol) were added. The reaction medium was
stirred for 4 h at RT. After this time, the reaction medium was
diluted with H.sub.2O (50 mL) and extracted with AcOEt (2.times.40
mL). The organic layers were washed with sat. brine (25 mL), dried
over MgSO.sub.4, filtered, concentrated and purified by flash
chromatography on 80 g of silica gel (gradient elution
heptane/AcOEt) to give 1.011 g of compound 30 as a yellow
semi-solid (57%).
[0996] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.76 (d,
J=6.7 Hz, 3H); 0.78 (d, J=6.7 Hz, 3H); 1.03 (d, J=7.0 Hz, 3H); 1.07
(s, 6H); 1.39 (s, 9H); 1.37 to 1.63 (m, 3H); 1.41 (s, 9H); 2.36 to
2.60 (partially masked m, 3H); 2.64 (dd, J=9.5 and 14.1 Hz, 1H);
2.86 (dd, J=5.6 and 14.1 Hz, 1H); 3.18 (dd, J=6.1 and 13.5 Hz, 1H);
3.25 (dd, J=6.9 and 13.5 Hz, 1H); 3.79 (s, 3H); 4.09 (m, 1H); 4.26
(m, 1H); 4.40 (s, 2H); 4.92 (m, 1H); 5.81 (d, J=15.9 Hz, 1H); 6.17
(dd, J=8.4 and 16.1 Hz, 1H); 6.44 (d, J=15.9 Hz, 1H); 6.70 (m, 1H);
6.94 (d, J=8.9 Hz, 1H); 7.02 (d, J=8.7 Hz, 1H); 7.18 (dd, J=2.3 and
8.9 Hz, 1H); 7.31 (m, 3H); 7.42 (d, J=8.5 Hz, 2H); 7.59 (t, J=6.3
Hz, 1H); 7.77 (d, J=7.9 Hz, 1H). LCMS (A1): ES m/z=879 [M-H].sup.-;
m/z=881 [M+H].sup.+; m/z=925 [M-H+HCO.sub.2H].sup.-; t.sub.R=1.89
min.
Compound 31:
(3S,10R,16S,E)-16-((R,E)-4-(4-(azidomethyl)phenyl)but-3-en-2-yl)-10-(3-ch-
loro-4-methoxybenzyl)-3-isobutyl-6,6-dimethyl-1-oxa-4,8,11-triazacyclohexa-
dec-13-ene-2,5,9,12-tetraone
[0997] Compound 31 was prepared in two steps.
[0998] Step 1: in a round bottom flask were introduced compound 30
(1.011 g, 1.15 mmol) in DCM (10 mL). After cooling to 0.degree. C.,
TFA (1.72 mL, 22.94 mmol) and 100 .mu.L of H.sub.2O were added. The
reaction medium was stirred for 72 h at RT. Upon completion,
toluene was added to the medium and it was concentrated in vacuo to
give 900 mg of amino/acid intermediate (quant.).
[0999] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.76 (d,
J=6.7 Hz, 3H); 0.78 (d, J=6.7 Hz, 3H); 1.03 (d, J=7.0 Hz, 3H); 1.07
(s, 3H); 1.08 (s, 3H); 1.38 to 1.62 (m, 3H); 2.35 to 2.58
(partially masked m, 3H); 2.79 (dd, J=11.0 and 13.8 Hz, 1H); 3.00
(dd, J=4.1 and 13.8 Hz, 1H); 3.16 (dd, J=5.9 and 13.5 Hz, 1H); 3.28
to 3.39 (masked m, 1H); 3.81 (s, 3H); 4.03 (m, 1H); 4.26 (m, 1H);
4.40 (s, 2H); 4.92 (m, 1H); 5.82 (d, J=16.1 Hz, 1H); 6.16 (dd,
J=8.8 and 16.4 Hz, 1H); 6.42 (d, J=16.4 Hz, 1H); 6.73 (m, 1H); 7.09
(d, J=8.6 Hz, 1H); 7.18 (dd, J=2.0 and 8.6 Hz, 1H); 7.32 (d, J=8.6
Hz, 2H); 7.37 (d, J=2.0 Hz, 1H); 7.41 (d, J=8.6 Hz, 2H); 7.84 (d,
J=7.9 Hz, 1H); 8.01 (broad s large, 3H); 8.10 (t, J=6.4 Hz, 1H);
12.2 (broad s, 1H). LCMS (A1): ES m/z=723 [M-H].sup.-; m/z=725
[M+H].sup.+; t.sub.R=1.09 min.
[1000] Step 2: in a round bottom flask, to a solution of amino/acid
intermediate (840 mg, 1.16 mmol) in 200 mL of CH.sub.3CN were added
DIEA (1.95 mL, 11.58 mmol), HOAt (159.23 mg, 1.16 mmol) and HATU
(499.40 mg, 1.27 mmol). The reaction medium was stirred for 3 h at
RT. After concentration in vacuo, the crude was diluted with AcOEt
(200 mL), neutralized with 0.5M citric acid (12 mL) and 1N HCl (6
mL). The organic layer was separated, washed with sat. NaHSO.sub.3,
sat. NaHCO.sub.3, sat. brine, dried over MgSO.sub.4, filtered,
concentrated and purified by flash chromatography on 40 g of silica
gel (gradient elution DCM/MeOH) to give 558 mg of compound 31 as a
white solide (68%).
[1001] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.60 (d,
J=6.7 Hz, 3H); 0.61 (d, J=6.7 Hz, 3H); 0.97 (s, 3H); 1.07 (s, 3H);
1.09 (d, J=7.0 Hz, 3H); 1.15 (m, 1H); 1.33 to 1.48 (m, 2H); 2.24
(m, 1H); 2.53 to 2.70 (m, 2H); 2.88 (large d, J=13.6 Hz, 1H); 3.01
(dd, J=3.5 and 14.5 Hz, 1H); 3.23 to 3.32 (masked m, 1H); 3.80 (s,
3H); 4.18 (m, 1H); 4.35 (m, 1H); 4.40 (s, 2H); 4.95 (m, 1H); 5.86
(dd, J=1.7 and 15.8 Hz, 1H); 6.13 (dd, J=8.8 and 16.1 Hz, 1H); 6.40
(m, 1H); 6.47 (d, J=16.1 Hz, 1H); 7.04 (d, J=8.6 Hz, 1H); 7.18 (dd,
J=2.0 and 8.6 Hz, 1H); 7.29 (d, J=2.0 Hz, 1H); 7.32 (d, J=8.6 Hz,
2H); 7.41 (broad d, J=8.6 Hz, 3H); 7.89 (d, J=8.9 Hz, 1H); 8.1 (d,
J=8.2 Hz, 1H). LCMS (A1): ES m/z=705 [M-H].sup.-; m/z=707
[M+H].sup.+; t.sub.R=1.58 min.
Compound 32:
(3S,10R,16S,E)-16-((S)-1-((2R,3R)-3-(4-(azidomethyl)phenyl)oxiran-2-yl)et-
hyl)-10-(3-chloro-4-methoxybenzyl)-3-isobutyl-6,6-dimethyl-1-oxa-4,8,11-tr-
iazacyclohexadec-13-ene-2,5,9,12-tetraone
[1002] In a round bottom flask, to a solution of compound 31 (410
mg, 0.579 mmol) in DCM (50 mL) was added, at 0.degree. C., m-CPBA
(259 mg, 1.16 mmol). After stirring for 16 h at RT, m-CPBA (130 mg)
was added twice in 24 h. Once the reaction completed, the crude
mixture was stirred for 1 h with sat. NaHCO.sub.3 (15 mL) and sat.
Na.sub.2S2O.sub.3 (15 mL) then extracted with DCM (3.times.15 mL).
The organic layers were washed with sat. brine (15 mL), dried over
MgSO.sub.4, filtered and concentrated to give 440 mg of a mixture
of alpha and beta epoxides as a yellow semi-solid. Alpha and beta
epoxides were separated by chiral liquid chromatography that was
carried out on a 76.times.350 mm column packed with 1.1 kg of 10
.mu.m Chiralpak AD (amylose tris-3,5-dimethylphenylcarbamate coated
on a silica gel support, Chiral Technologies Europe) using
isocratic elution with 80:20 heptane/EtOH. After concentration, 185
mg of compound 32 were obtained as a white solid (44%) and 118 mg
of the alpha epoxide were obtained as a white solid (28%).
[1003] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.72 (d,
J=6.7 Hz, 3H); 0.74 (d, J=6.7 Hz, 3H); 0.96 (s, 3H); 1.04 (d, J=7.0
Hz, 3H); 1.08 (s, 3H); 1.11 (m, 1H); 1.40 to 1.55 (m, 2H); 1.79 (m,
1H); 2.26 (m, 1H); 2.64 (m, 2H); 2.85 (broad d, J=13.2 Hz, 1H);
3.00 (m, 2H); 3.25 (dd, J=10.2 and 13.2 Hz, 1H); 3.80 (s, 3H); 3.90
(d, J=2.0 Hz, 1H); 4.17 (m, 1H); 4.35 (m, 1H); 4.46 (s, 2H); 5.12
(m, 1H); 5.80 (dd, J=1.7 and 16.0 Hz, 1H); 6.39 (ddd, J=3.8, 11.6
and 16.0 Hz, 1H); 7.04 (d, J=8.6 Hz, 1H); 7.18 (dd, J=2.0 and 8.6
Hz, 1H); 7.29 (d, J=2.0 Hz, 1H); 7.31 to 7.40 (m, 5H); 7.94 (d,
J=9.1 Hz, 1H); 8.40 (d, J=8.1 Hz, 1H). LCMS (A1): ES m/z=723
[M+H].sup.+; t.sub.R=1.48 min.
Example 1:
(3S,10R,16S,E)-16-((S)-1-((2R,3R)-3-(4-(aminomethyl)phenyl)oxir-
an-2-yl)ethyl)-10-(3-chloro-4-methoxybenzyl)-3-isobutyl-6,6-dimethyl-1-oxa-
-4,8,11-triazacyclohexadec-13-ene-2,5,9,12-tetraone
[1004] In a round bottom flask, to a solution of compound 32 (185
mg, 255.79 .mu.mol) in DCM (6 mL), MeOH (6 mL) and H.sub.2O (0.8
mL), was added TCEP (81.47 mg, 281, 37 .mu.mol). The solution was
stirred 16 h at RT. Once the reaction complete, the crude mixture
was diluted with sat. NaHCO.sub.3 (15 mL) and extracted with DCM
(2.times.30 mL). The organic layers were washed with sat. brine,
dried over MgSO.sub.4, filtered, concentrated and purified by two
successive flash chromatographies, on 15 g of silica gel (gradient
elution DCM/MeOH) to give 90 mg of example 1 as a white solid
(51%).
[1005] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.72 (d,
J=6.6 Hz, 3H); 0.75 (d, J=6.6 Hz, 3H); 0.97 (s, 3H); 1.03 (d, J=7.1
Hz, 3H); 1.07 (s, 3H); 1.14 (m, 1H); 1.42 to 1.57 (m, 2H); 1.77 (m,
1H); 1.92 (broad m, 2H); 2.26 (m, 1H); 2.64 (m, 2H); 2.86 (broad d,
J=13.0 Hz, 1H); 2.94 (dd, J=2.0 and 8.0 Hz, 1H); 3.00 (dd, J=3.6
and 14.4 Hz, 1H); 3.27 (dd, J=10.2 and 13.0 Hz, 1H); 3.70 (s, 2H);
3.80 (s, 3H); 3.84 (d, J=2.0 Hz, 1H); 4.18 (m, 1H); 4.34 (m, 1H);
5.11 (m, 1H); 5.79 (dd, J=1.7 and 15.6 Hz, 1H); 6.38 (ddd, J=4.1,
11.6 and 15.6 Hz, 1H); 7.05 (d, J=8.6 Hz, 1H); 7.16 (dd, J=2.0 and
8.6 Hz, 1H); 7.22 (d, J=8.5 Hz, 2H); 7.28 (d, J=2.0 Hz, 1H); 7.31
(d, J=8.5 Hz, 2H); 7.35 (d, J=10.2 Hz, 1H); 7.91 (d, J=9.0 Hz, 1H);
8.38 (d, J=8.0 Hz, 1H). LCMS (A1): ES m/z=695 [M-H].sup.-; m/z=697
[M+H].sup.+; t.sub.R=0.83 min.
Compound 33:
(S)-2-amino-N--((S)-1-((4-((2R,3R)-3-((S)-1-((3S,10R,16S,E)-10-(3-chloro--
4-methoxybenzyl)-3-isobutyl-6,6-dimethyl-2,5,9,12-tetraoxo-1-oxa-4,8,11-tr-
iazacyclohexadec-13-en-16-yl)ethyl)oxiran-2-yl)benzyl)amino)-1-oxopropan-2-
-yl)-3-methylbutanamide
[1006] Under argon, in a round bottom flask to a solution of
example 1 (90 mg, 129.01 .mu.mol) in DCM (20 mL), were added
(S)-2-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-methylbutan-am-
ido)propanoic acid or FmocValAla (CAS number [150114-97-9], 79.47
mg, 193.61 .mu.mol), EDC (34.27 .mu.L, 193.61 .mu.mol) and HOBt
(20.93 mg, 154.9 .mu.mol). The reaction medium was stirred
overnight at RT. After this time, piperidine (129 .mu.L, 1.29 mmol)
was added and stirred for 2 h. The solvent was removed and the
crude residue was purified by flash chromatography on 15 g of
silica gel (gradient elution DCM/MeOH) to give 50 mg of compound 33
(45%) as a white solid.
[1007] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.75 (m,
9H); 0.88 (d, J=7.1 Hz, 3H); 0.96 (s, 3H); 1.03 (d, J=7.1 Hz, 3H);
1.08 (s, 3H); 1.18 (m, 1H); 1.23 (d, J=7.0 Hz, 3H); 1.42 to 1.57
(m, 2H); 1.70 (broad m, 2H); 1.79 (m, 1H); 1.92 (m, 1H); 2.26 (m,
1H); 2.63 (m, 2H); 2.86 (broad d, J=13.0 Hz, 1H); 2.99 (m, 3H);
3.22 to 3.33 (partially masked m, 1H); 3.80 (s, 3H); 3.86 (d, J=2.0
Hz, 1H); 4.18 (m, 1H); 4.28 (d, J=6.3 Hz, 2H); 4.33 (m, 2H); 5.11
(m, 1H); 5.79 (dd, J=1.7 and 15.6 Hz, 1H); 6.39 (ddd, J=4.1, 11.6
and 15.6 Hz, 1H); 7.03 (d, J=8.6 Hz, 1H); 7.16 (dd, J=2.0 and 8.6
Hz, 1H); 7.24 (s, 4H); 7.28 (d, J=2.0 Hz, 1H); 7.37 (d, J=10.2 Hz,
1H); 7.92 (d, J=9.1 Hz, 1H); 8.07 (broad d, J=8.3 Hz, 1H); 8.38 (d,
J=8.1 Hz, 1H); 8.42 (t, J=6.3 Hz, 1H). LCMS (A1): ES m/z=434
[M+2H].sup.2+; m/z=865 [M-H].sup.-; m/z=867 [M+H].sup.+; m/z=911
[M-H+HCO.sub.2H].sup.-; t.sub.R=0.88 min.
Compound 34:
5-(((S)-1-(((S)-1-((4-((2R,3R)-3-((S)-1-((3S,10R,16S,E)-10-(3-chloro-4-me-
thoxybenzyl)-3-isobutyl-6,6-dimethyl-2,5,9,12-tetraoxo-1-oxa-4,8,11-triaza-
cyclohexadec-13-en-16-yl)ethyl)oxiran-2-yl)benzyl)amino)-1-oxopropan-2-yl)-
amino)-3-methyl-1-oxobutan-2-yl)amino)-5-oxopentanoic Acid
[1008] Under argon, in a round bottom flask, to a solution of
compound 33 (54 mg, 57.64 .mu.mol) in DMF (5 mL) was added glutaric
anhydride (8 mg, 69.17 .mu.mol). The reaction medium was stirred
for 3.5 h at RT. After this time, the solvent was removed and the
crude residue was purified by flash chromatography on 1.8 g of
silica gel (gradient elution DCM/MeOH) to give 51 mg of compound 34
as a white solid (90%).
[1009] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 0.73 (d,
J=6.7 Hz, 3H); 0.76 (d, J=6.7 Hz, 3H); 0.81 (d, J=7.0 Hz, 3H); 0.84
(d, J=7.0 Hz, 3H); 0.97 (s, 3H); 1.03 (d, J=7.2 Hz, 3H); 1.05 (s,
3H); 1.15 (m, 1H); 1.22 (d, J=7.2 Hz, 3H); 1.43 to 1.52 (m, 2H);
1.70 (m, 2H); 1.77 (m, 1H); 1.97 (m, 1H); 2.17 (m, 2H); 2.24 (m,
1H); 2.55 to 2.68 (m, 2H); 2.85 (broad d, J=12.7 Hz, 1H); 2.96 (dd,
J=1.8 and 7.7 Hz, 1H); 2.99 (dd, J=3.0 and 14.6 Hz, 1H); 3.23 to
3.40 (partially masked m, 1H); 3.80 (s, 3H); 3.85 (d, J=1.8 Hz,
1H); 4.22 to 4.38 (m, 4H); 5.11 (m, 1H); 5.79 (d, J=14.9 Hz, 1H);
6.37 (ddd, J=4.1, 11.3 and 14.9 Hz, 1H); 7.04 (d, J=8.7 Hz, 1H);
7.15 (dd, J=2.0 et 8.7 Hz, 1H); 7.23 (broad s, 4H); 7.28 (d, J=2.0
Hz, 1H); 7.37 (broad d, J=10.7 Hz, 1H); 7.87 (d, J=8.7 Hz, 1H);
7.93 (d, J=9.2 Hz, 1H); 8.06 (m large, 1H); 8.37 (broad m, 1H);
8.41 (broad m, 1H); 12.03 (broad m, 1H). LCMS (A1): ES m/z=979
[M-H].sup.-; m/z=981 [M+H].sup.+; t.sub.R=1.17 min.
Example 2: 2,5-dioxopyrrolidin-1-vi
5-(((S)-1-(((S)-1-((4-((2R,3R)-3-((S)-1-((3S,10R,16S,E)-10-(3-chloro-4-me-
thoxybenzyl)-3-isobutyl-6,6-dimethyl-2,5,9,12-tetraoxo-1-oxa-4,8,11-triaza-
cyclohexadec-13-en-16-yl)ethyl)oxiran-2-yl)benzyl)amino)-1-oxopropan-2-yl)-
amino)-3-methyl-1-oxobutan-2-yl)amino)-5-oxopentanoate
[1010] Under argon, in a round bottom flask, to a solution of
compound 34 (30 mg, 30.56 .mu.mol) in THE (5 mL) were added DIEA
(5.34 .mu.L, 30.56 .mu.mol) and DSC (16.31 mg, 61.13 .mu.mol). The
reaction medium was stirred for 2 h at RT. After this time, the
solvent was removed and the crude residue was purified by flash
chromatography on 1.3 g of silica gel (gradient elution DCM/iPrOH)
to give 9 mg of example 2 as a white solid. A second batch
containing the expected compound as well as an impurity was diluted
with MeTHF, washed twice with H.sub.2O, sat. brine, dried over
MgSO4, filtered and concentrated to give 15 mg of example 2 as a
white solid (global yield of 73%).
[1011] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 0.73 (d,
J=6.7 Hz, 3H); 0.77 (d, J=6.7 Hz, 3H); 0.82 (d, J=7.0 Hz, 3H); 0.84
(d, J=7.0 Hz, 3H); 0.96 (s, 3H); 1.03 (d, J=7.2 Hz, 3H); 1.07 (s,
3H); 1.15 (m, 1H); 1.23 (d, J=7.2 Hz, 3H); 1.43 to 1.56 (m, 2H);
1.78 (m, 1H); 1.81 (m, 1H); 1.97 (m, 1H); 2.20 to 2.33 (m, 3H);
2.58 to 2.69 (m, 4H); 2.80 (s, 4H); 2.85 (broad d, J=12.7 Hz, 1H);
2.98 (dd, J=2.1 and 7.9 Hz, 1H); 3.00 (dd, J=3.2 and 14.7 Hz, 1H);
3.22 to 3.34 (partially masked m, 1H); 3.80 (s, 3H); 3.85 (d, J=2.1
Hz, 1H); 4.15 (m, 2H); 4.22 to 4.38 (m, 4H); 5.11 (m, 1H); 5.79 (d,
J=15.1 Hz, 1H); 6.38 (ddd, J=3.9, 11.2 and 15.1 Hz, 1H); 7.04 (d,
J=8.7 Hz, 1H); 7.15 (dd, J=2.2 and 8.7 Hz, 1H); 7.22 (broad s, 4H);
7.29 (d, J=2.2 Hz, 1H); 7.36 (broad d, J=10.3 Hz, 1H); 7.89 (d,
J=8.7 Hz, 1H); 7.92 (d, J=8.9 Hz, 1H); 8.04 (d, J=7.4 Hz, 1H); 8.32
(t, J=6.1 Hz, 1H); 8.39 (d, J=8.0 Hz, 1H). LCMS (A1): ES m/z=540;
m/z=1076 [M-H].sup.-; m/z=1078 [M+H].sup.+; m/z=1122
[M-H+HCO.sub.2H].sup.-; t.sub.R=1.23 min.
Example 3: mAb-Ex2
[1012] The general method described previously was used for the
preparation of example 3. 60 mg of hu2H11_R35-74 were reacted with
161 .mu.L of a 9.96 mM solution of example 2 in DMA (1.733 mg, 4
eq.) for 2 h. At that time, 121 .mu.L of the solution of example 2
(3 eq.) were added and the medium stirred for 2 h. At that time,
121 .mu.L of the solution of example 2 (3 eq.) were added and
stirred for 2 h. After purification on Superdex 200 .mu.g in DPBS
pH 6.5+20% NMP, concentration on Amicon Ultra-15, buffer exchange
on PD-10 in buffer B pH 6.5+5% NMP and filtration on Steriflip,
39.9 mg of example 3 were obtained as a colorless limpid solution
at a concentration of 2.28 mg/mL with a DAR of 4.6 (HRMS), a
monomeric purity of 99% and a global yield of 66%.
[1013] SEC-HRMS: spectrum for intact ADC in FIG. 1; m/z=150346
(D1); m/z=151307 (D2); m/z=152274 (D3); m/z=153240 (D4); m/z=154200
(D5); m/z=155165 (D6); m/z=156133 (D7); m/z=157095 (D8).
Synthesis of Examples 4 to 7: Benzylic Amine of
(S)-3-neopentyle-aza-C52, NHS Ester of
Glutaryl-Val-Ala-(S)-3-neopentyle-aza-C52 Benzylic Amine and
Corresponding ADC
##STR00732## ##STR00733##
[1014] Compound 35:
(6R,13S)-(1E,3R,4S,6E)-8-(tert-butoxy)-1-(4-(hydroxymethyl)phenyl)-3-meth-
yl-8-oxoocta-1,6-dien-4-yl
6-(3-chloro-4-methoxybenzyl)-2,2,10,10-tetramethyl-13-neopentyl-4,7,11-tr-
ioxo-3-oxa-5,8,12-triazatetradecan-14-oate
[1015] Under argon, in a round bottom flask, to a solution of
fragment BC1 (1.32 g, 3.08 mmol) in DCM (60 mL) were added DIEA
(1.53 mL, 9.25 mmol), HOAt (503.75 mg, 3.70 mmol) and HATU (1.41 g,
3.70 mmol). The yellow suspension was stirred for 30 min at RT,
then fragment AD2 (1.7 g, 3.08 mmol) was added. The reaction medium
was stirred for 2 h at RT. After this time, 1.53 mL of DIEA were
added and stirred for 1 h. The mixture was neutralized with 1M
citric acid (50 mL) and extracted with AcOEt (2.times.80 mL). The
organic layers were washed with 1M NaHSO.sub.4, H.sub.2O, dried
over MgSO.sub.4, filtered, concentrated and purified by flash
chromatography on 100 g of silica gel (gradient elution
heptane/AcOEt) to give 1.475 g of compound 35 as a colorless solid
(57%).
Compound 36:
(2E,5S,6R,7E)-5-(((S)-2-(3-((R)-2-amino-3-(3-chloro-4-methoxyphenyl)-prop-
anamido)-2,2-dimethylpropanamido)-4,4-dimethylpentanoyl)oxy)-8-(4-(hydroxy-
methyl)-phenyl)-6-methylocta-2,7-dienoic Acid
[1016] In a round bottom flask, to a solution of compound 35 (1.475
g, 1.69 mmol) in DCM (20 mL), were added TFA (8 mL, 52.27 mmol) and
H.sub.2O (2 mL). The reaction medium was stirred for 5 h at RT. The
solvent was removed. The residue was diluted with H.sub.2O (20 mL)
and AcOEt (20 mL) and treated with 2M NaOH (2 mL) for 2 h at RT.
The organic layer was separated and the aq. layer was extracted
with AcOEt (2.times.10 mL), dried over MgSO.sub.4, filtered and
concentrated to give 1.24 g of a colorless solid. The solid was
dissolved in AcOEt (10 mL) and H.sub.2O (10 mL) and treated with 2M
NaOH (400 .mu.L) for 2 h at RT. The organic layer was separated,
the aq. layers were extracted with AcOEt (2.times.10 mL), dried
over MgSO.sub.4, filtered, concentrated and purified by flash
chromatography on 100 g of silica gel (gradient elution
heptane/AcOEt) to give 990 mg of compound 36 as a white solid
(82%).
[1017] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.80 (s,
9H); 0.99 (s, 3H); 1.02 (d, J=7.0 Hz, 3H); 1.05 (s, 3H); 1.52 (dd,
J=2.0 and 14.8 Hz, 1H); 1.69 (dd, J=9.9 and 14.8 Hz, 1H); 2.36 to
2.61 (partially masked m, 4H); 2.84 (dd, J=5.0 and 13.9 Hz, 1H);
3.18 (d, J=7.5 Hz, 2H); 3.40 (dd, J=5.1 and 8.1 Hz, 1H); 3.80 (s,
3H); 4.29 (m, 1H); 4.45 (s, 2H); 4.90 (m, 1H); 5.12 (broad m, 1H);
5.81 (d, J=15.5 Hz, 1H); 6.10 (dd, J=8.4 and 15.9 Hz, 1H); 6.40 (d,
J=15.9 Hz, 1H); 6.70 (td, J=7.5 and 15.5 Hz, 1H); 7.01 (d, J=8.7
Hz, 1H); 7.11 (dd, J=2.4 and 8.7 Hz, 1H); 7.25 (m, 3H); 7.32 (d,
J=8.2 Hz, 2H); 7.72 (t, J=6.5 Hz, 1H); 7.79 (d, J=7.8 Hz, 1H). LCMS
(A1): ES m/z=712 [M-H].sup.-; m/z=714 [M+H].sup.+; t.sub.R=0.94
min.
Compound 37:
(3S,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-16-((R,E)-4-(4-(hydroxymethy-
l)-phenyl)but-3-en-2-yl)-6,6-dimethyl-3-neopentyl-1-oxa-4,8,11-triazacyclo-
hexadec-13-ene-2,5,9,12-tetraone
[1018] Under argon, in a round bottom flask, were introduced
compound 36 (990 mg, 1.39 mmol) and CH.sub.3CN (150 mL), heated
with a water bath at 50.degree. C. until complete solubilization
and stirred for 10 min. After that, DIEA (687.20 .mu.L, 4.16 mmol),
HOAt (207.51 mg, 1.52 mmol) and HATU (579.7 mg, 1.52 mmol) were
added and stirred for 30 min at RT. The reaction medium was
neutralized with 1M citric acid (30 mL). The solvent was removed
and the aq. layer was extracted with AcOEt (2.times.40 mL). The
organic layers were washed with 1M NaHSO.sub.4, H.sub.2O, dried
over MgSO.sub.4, filtered and concentrated. The crude solid was
diluted with H.sub.2O (200 mL) and stirred for 1 h. The solid was
filtered then diluted with AcOEt, dried over MgSO.sub.4, filtered
and concentrated to give a mixture of compound 37 and HATU. The
solid was stirred with MeTHF (50 mL) and H.sub.2O (50 mL). The
organic layer was separated, washed with H.sub.2O (4.times.20 mL),
dried over MgSO.sub.4, filtered, concentrated and purified by flash
chromatography on 10 g of silica gel (gradient elution
heptane/AcOEt) to give 680 mg of compound 37 as a colorless solid
(70%).
[1019] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.68 (s,
9H); 0.98 (s, 3H); 1.03 (s, 3H); 1.09 (d, J=6.9 Hz, 3H); 1.19
(broad d, J=14.5 Hz, 1H); 1.58 (dd, J=10.3 and 14.5 Hz, 1H); 2.23
(m, 1H); 2.52 to 2.70 (m, 3H); 2.86 (broad d, J=12.7 Hz, 1H); 3.00
(dd, J=3.3 and 14.8 Hz, 1H); 3.22 to 3.33 (partially masked m, 1H);
3.80 (s, 3H); 4.18 (m, 1H); 4.42 (m, 1H); 4.46 (d, J=6.0 Hz, 2H);
4.91 (m, 1H); 5.13 (t, J=6.0 Hz, 1H); 5.85 (broad d, J=15.0 Hz,
1H); 6.05 (dd, J=8.4 and 15.9 Hz, 1H); 6.40 (m, 2H); 7.03 (d, J=8.7
Hz, 1H); 7.18 (dd, J=2.2 and 8.7 Hz, 1H); 7.25 (d, J=8.5 Hz, 2H);
7.29 (d, J=2.2 Hz, 1H), 7.31 (d, J=8.5 Hz, 2H); 7.42 (d, J=10.6 Hz,
1H); 7.94 (d, J=9.1 Hz, 1H); 8.41 (d, J=8.2 Hz, 1H). LCMS (A1): ES
m/z=694 [M-H].sup.-; m/z=696 [M+H].sup.+; t.sub.R=1.36 min.
Compound 38:
(3S,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-6,6-dimethyl-3-neopentyl-16--
((R,E)-4-(4-(((triisopropylsilyl)oxy)methyl)phenyl)but-3-en-2-yl)-1-oxa-4,-
8,11-triazacyclohexadec-13-ene-2,5,9,12-tetraone
[1020] Under argon, at 0.degree. C. in a round bottom flask, to a
solution of compound 37 (680 mg, 0.976 mmol) in CHCl.sub.3 (10 mL)
were added 1H-imidazole (305.84 mg, 4.49 mmol) and
chlorotriisopropylsilane (480.13 .mu.l, 2.25 mmol). The reaction
medium was stirred for 5 h at RT then diluted with sat. NH.sub.4Cl
and MTBE (30 mL). The organic layer was washed with 1M NaHSO.sub.4,
sat. NaHCO.sub.3, sat. brine, dried over MgSO.sub.4, filtered and
concentrated to give 970 mg of compound 38 as an orange amorph
solid (quant.).
[1021] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 0.63 (s,
9H); 0.87 a 1.17 (m, 31H); 1.53 (dd, J=10.9 and 14.3 Hz, 1H); 2.22
(m, 1H); 2.51 to 2.70 (m, 3H); 2.86 (broad d, J=13.0 Hz, 1H); 3.00
(dd, J=3.2 and 14.9 Hz, 1H); 3.24 to 3.35 (partially masked m, 1H);
3.80 (s, 3H); 4.18 (m, 1H); 4.41 (m, 1H); 4.76 (s, 2H); 4.91 (m,
1H); 5.87 (broad d, J=15.4 Hz, 1H); 6.06 (dd, J=8.9 and 15.9 Hz,
1H); 6.40 (m, 2H); 7.03 (d, J=8.5 Hz, 1H); 7.18 (broad d, J=8.5 Hz,
1H); 7.25 (d, J=8.3 Hz, 2H); 7.28 (d, J=8.3 Hz, 2H); 7.30 (broads,
1H); 7.42 (d, J=10.5 Hz, 1H); 7.93 (d, J=9.2 Hz, 1H); 8.42 (d,
J=8.1 Hz, 1H). LCMS (A1): ES m/z=850 [M-H].sup.-; m/z=852
[M+H].sup.+; m/z=896 [M-H+HCO.sub.2H].sup.-; t.sub.R=2.15 min.
Example 4:
(3S,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-16-((S)-1-((2R,3R)-
-3-(4-(hydroxy-methyl)phenyl)oxiran-2-yl)ethyl)-6,6-dimethyl-3-neopentyl-1-
-oxa-4,8,11-triazacyclohexadec-13-ene-2,5,9,12-tetraone
[1022] Example 4 was prepared in 2 steps.
[1023] Step 1: under argon, in a round bottom flask, to a solution
of compound 38 (832 mg, 0.976 mmol) in DCM (10 mL) was added, in
three times, m-CPBA (339.15 mg, 1.51 mmol). The reaction mixture
was stirred for 50 h at RT then diluted with DCM (10 mL) and
stirred for 15 min with sat. NaHCO.sub.3 (30 mL) and
Na.sub.2S.sub.2O.sub.3 (30 mL). The organic layer was separated,
washed with sat. brine, dried over MgSO.sub.4, filtered and
concentrated to give 1.1 g of mixture of alpha and beta epoxides as
a colorless foam (quant.).
[1024] Step 2: the mixture of alpha and beta epoxides was diluted
in THE (30 mL) and 1M TBAF (952.32 .mu.L) was added. After stirring
for 2 h, 952 .mu.L of TBAF were added. After stirring for 1 h, the
mixture was diluted with H.sub.2O (50 mL) and extracted with AcOEt
(3.times.50 mL). The organic layers were washed with sat. brine,
dried over MgSO.sub.4, filtered and concentrated to give 770 mg of
a mixture of alpha and beta epoxides as a yellow solid (quant.).
Alpha and beta epoxides were separated by chiral liquid
chromatography that was carried out on a 76.times.350 mm column
packed with 1.1 kg of 10 .mu.m Chiralpak AD (amylose
tris-3,5-dimethylphenylcarbamate coated on a silica gel support,
Chiral Technologies Europe) using isocratic elution with 75:25
heptane/EtOH. After concentration, 190 mg of example 4 were
obtained as a white solid (31%) and 125 mg of the alpha epoxide
were obtained as a white solid (20%).
[1025] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 0.81 (s,
9H); 0.98 (s, 3H); 1.03 (d, J=7.0 Hz, 3H); 1.05 (s, 3H); 1.26 (m,
1H); 1.71 (dd, J=10.4 and 14.5 Hz, 1H); 1.82 (m, 1H); 2.26 (m, 1H);
2.52 (m, 2H); 2.84 (d, J=12.8 Hz, 1H); 2.92 (dd, J=2.1 and 7.8 Hz,
1H); 3.00 (dd, J=3.1 and 14.5 Hz, 1H); 3.24 to 3.36 (partially
masked m, 1H); 3.81 (s, 3H); 3.90 (d, J=2.1 Hz, 1H); 4.17 (ddd,
J=3.4, 8.0 and 11.7 Hz, 1H); 4.42 (m, 1H); 4.50 (d, J=6.0 Hz, 2H);
5.10 (m, 1H); 5.20 (t, J=6.0 Hz, 1H); 5.79 (dd, J=1.8 and 15.4 Hz,
1H); 6.39 (ddd, J=3.8, 11.5 and 15.4 Hz, 1H); 7.05 (d, J=8.6 Hz,
1H); 7.16 (dd, J=2.1 and 8.6 Hz, 1H); 7.26 (d, J=8.3 Hz, 2H); 7.29
(d, J=2.1 Hz, 1H); 7.32 (d, J=8.3 Hz, 2H); 7.41 (d, J=10.3 Hz, 1H);
8.02 (d, J=9.2 Hz, 1H); 8.38 (d, J=8.2 Hz, 1H). LCMS (A1): ES
m/z=710 [M-H].sup.-; m/z=712 [M+H].sup.+; t.sub.R=1.28 min.
Compound 39:
(3S,10R,16S,E)-16-((S)-1-((2R,3R)-3-(4-(azidomethyl)phenyl)oxiran-2-yl)et-
hyl)-10-(3-chloro-4-methoxybenzyl)-6,6-dimethyl-3-neopentyl-1-oxa-4,8,11-t-
riazacyclohexadec-13-ene-2,5,9,12-tetraone
[1026] Under argon, in a round bottom flask, to a solution of
example 4 (100 mg, 140 .mu.mol) in THE (5 mL) were added DPPA
(156.82 .mu.l, 701.98 .mu.mol) and DBU (110.22 .mu.l, 701.98
.mu.mol). The solution was stirred for 6 h at RT then diluted with
H.sub.2O and extracted with AcOEt (3.times.30 mL).
[1027] The organic layer was separated, washed with sat. brine,
dried over MgSO.sub.4, filtered, concentrated and purified on 15 g
of silica gel (gradient elution DCM/iPrOH) to give 100 mg of
compound 39 as a white solid (40%).
[1028] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.80 (s,
9H); 0.97 (s, 3H); 1.03 (d, J=7.0 Hz, 3H); 1.04 (s, 3H); 1.28 (d,
J=14.5 Hz, 1H); 1.69 (dd, J=10.7 and 14.5 Hz, 1H); 1.84 (m, 1H);
2.28 (m, 1H); 2.62 (m, 2H); 2.84 (d, J=12.8 Hz, 1H); 2.93 to 3.03
(m, 2H); 3.22 to 3.34 (partially masked m, 1H); 3.80 (s, 3H); 3.92
(broad s, 1H); 4.17 (m, 1H); 4.40 to 4.49 (m, 3H); 5.10 (m, 1H);
5.80 (d, J=15.8 Hz, 1H); 6.39 (ddd, J=3.8, 11.7 and 15.8 Hz, 1H);
7.03 (d, J=8.7 Hz, 1H); 7.16 (dd, J=2.2 and 8.7 Hz, 1H); 7.28 (d,
J=2.1 Hz, 1H); 7.32 (d, J=8.3 Hz, 2H); 7.39 (d, J=8.3 Hz, 2H); 7.41
(m, 1H); 8.00 (d, J=9.1 Hz, 1H); 8.36 (d, J=8.2 Hz, 1H). LCMS (A1):
ES m/z=735 [M-H].sup.-; m/z=737 [M+H].sup.+; t.sub.R=1.54 min.
Example 5:
(3S,10R,16S,E)-16-((S)-1-((2R,3R)-3-(4-(aminomethyl)phenyl)oxir-
an-2-yl)ethyl)-10-(3-chloro-4-methoxybenzyl)-6,6-dimethyl-3-neopentyl-1-ox-
a-4,8,11-triazacyclohexadec-13-ene-2,5,9,12-tetraone
[1029] In a round bottom flask, to a solution of compound 39 (100
mg, 122.07 .mu.mol) in DCM (2.5 mL) and MeOH (2.5 mL) was added
dropwise a solution of TCEP (38.88 mg, 134.28 .mu.mol) in H.sub.2O
(500 .mu.L). The reaction medium was stirred for 24 h at RT. The
reaction mixture was diluted with H.sub.2O and sat. NaHCO.sub.3,
extracted with DCM (3.times.10 mL). The organic layer was
separated, washed with sat. brine, dried over MgSO.sub.4, filtered
and concentrated to give 73 mg of example 5 as a white solid (84%)
used without further purification in the next step.
[1030] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 0.82 (s,
9H); 0.97 (s, 3H); 1.03 (d, J=7.0 Hz, 3H); 1.04 (s, 3H); 1.29 (d,
J=14.4 Hz, 1H); 1.70 (dd, J=10.2 and 14.4 Hz, 1H); 1.80 (m, 1H);
2.02 (broad m, 2H); 2.25 (m, 1H); 2.62 (m, 2H); 2.83 (d, J=13.0 Hz,
1H); 2.93 (dd, J=2.2 and 7.8 Hz, 1H); 2.99 (dd, J=3.4 and 14.5 Hz,
1H); 3.23 to 3.35 (partially masked m, 1H); 3.71 (s, 2H); 3.80 (s,
3H); 3.88 (d, J=2.2 Hz, 1H); 4.17 (ddd, J=3.5, 8.5 and 11.5 Hz,
1H); 4.41 (m, 1H); 5.09 (m, 1H); 5.79 (d, J=15.7 Hz, 1H); 6.39
(ddd, J=3.7, 11.4 and 15.7 Hz, 1H); 7.05 (d, J=8.7 Hz, 1H); 7.16
(dd, J=2.3 and 8.7 Hz, 1H); 7.22 (d, J=8.4 Hz, 2H); 7.28 (d, J=2.3
Hz, 1H); 7.34 (d, J=8.4 Hz, 2H); 7.40 (d, J=10.3, 1H); 8.02 (d,
J=8.9 Hz, 1H); 8.38 (d, J=8.2 Hz, 1H). LCMS (A1): ES m/z=709
[M-H].sup.-; m/z=711 [M+H].sup.+; t.sub.R=0.86 min.
Compound 40:
(9H-fluoren-9-yl)methyl((S)-1-(((S)-1-((4-((2R,3R)-3-((S)-1-((3S,10R,16S,-
E)-10-(3-chloro-4-methoxybenzyl)-6,6-dimethyl-3-neopentyl-2,5,9,12-tetraox-
o-1-oxa-4,8,11-triazacyclohexadec-13-en-16-yl)ethyl)oxiran-2-yl)benzyl)ami-
no)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate
[1031] Under argon, in a round bottom flask were introduced example
5 (73 mg, 82.10 .mu.mol) and DMF (1 mL), followed by FmocValAla
(50.55 mg, 123.16 .mu.mol), HOBt (17.75 mg, 131.37 .mu.mol), DCM
(10 mL) and EDC (14.53 .mu.l, 82.10 .mu.mol). The solution was
stirred for 4 h at RT then diluted with H.sub.2O (10 mL) and
extracted with DCM (3.times.20 mL). The organic layer was
separated, washed with H.sub.2O, dried over MgSO.sub.4, filtered,
concentrated and purified on 15 g of silica gel (gradient elution
DCM/iPrOH) to give 90 mg of compound 40 as a colorless solid
(99%).
[1032] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 0.80 (s,
9H); 0.84 (d, J=7.1 Hz, 3H); 0.86 (d, J=7.1 Hz, 3H); 0.93 (s, 3H);
1.02 (d, J=7.1 Hz, 3H); 1.04 (s, 3H); 1.24 (d, J=7.3 Hz, 3H); 1.29
(d, J=14.5 Hz, 1H); 1.70 (dd, J=10.5 and 14.5 Hz, 1H); 1.81 (m,
1H); 1.99 (m, 1H); 2.25 (m, 1H); 2.60 (m, 2H); 2.82 (d, J=13.0 Hz,
1H); 2.91 (dd, J=1.9 and 7.6 Hz, 1H); 2.99 (dd, J=3.4 and 14.5 Hz,
1H); 3.29 (m, 1H); 3.80 (s, 3H); 3.88 (d, J=1.9 Hz, 1H); 3.90 (m,
1H); 4.16 (ddd, J=3.4, 8.0 and 11.8 Hz, 1H); 4.20 to 4.35 (m, 6H);
4.41 (m, 1H); 5.09 (m, 1H); 5.79 (d, J=15.7 Hz, 1H); 6.39 (ddd,
J=3.7, 11.6 and 15.7 Hz, 1H); 7.05 (d, J=8.6 Hz, 1H); 7.15 (dd,
J=2.5 and 8.6 Hz, 1H); 7.21 (d, J=8.5 Hz, 2H); 7.24 (d, J=8.5 Hz,
2H); 7.28 (d, J=2.5 Hz, 1H); 7.32 (t, J=7.9 Hz, 2H); 7.38 to7.47
(m, 4H); 7.73 (t, J=7.9 Hz, 2H); 7.89 (d, J=7.9 Hz, 2H); 8.03 (d,
J=9.1 Hz, 1H); 8.05 (d, J=7.9 Hz, 1H); 8.39 (m, 2H). LCMS (A1): ES
m/z=1103 [M+H].sup.+; m/z=1147 [M-H+HCO.sub.2H].sup.-; t.sub.R=1.71
min.
Compound 41:
(S)-2-amino-N--((S)-1-((4-((2R,3R)-3-((S)-1-((3S,10R,16S,E)-10-(3-chloro--
4-methoxybenzyl)-6,6-dimethyl-3-neopentyl-2,5,9,12-tetraoxo-1-oxa-4,8,11-t-
riazacyclohexadec-13-en-16-yl)ethyl)oxiran-2-yl)benzyl)amino)-1-oxopropan--
2-yl)-3-methylbutanamide
[1033] Under argon, in a round bottom flask, were introduced
compound 40 (104 mg, 76.65 .mu.mol) in DCM (5 mL) followed by
piperidine (138.87 .mu.l, 1.40 mmol). The solution was stirred for
5 h at RT then concentrated and purified on 10 g of silica gel
(gradient elution DCM/MeOH/H.sub.2O) to give 50 mg of compound 41
as a colorless solid (60%).
[1034] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 0.76 (d,
J=7.0 Hz, 3H); 0.81 (s, 9H); 0.88 (d, J=7.0 Hz, 3H); 0.97 (s, 3H);
1.02 (d, J=7.1 Hz, 3H); 1.04 (s, 3H); 1.22 (d, J=7.3 Hz, 3H); 1.29
(d, J=14.6 Hz, 1H); 1.66 (broad m, 2H); 1.70 (dd, J=10.6 and 14.6
Hz, 1H); 1.81 (m, 1H); 1.92 (m, 1H); 2.25 (m, 1H); 2.60 (m, 2H);
2.83 (d, J=13.0 Hz, 1H); 2.93 (dd, J=1.9 and 7.4 Hz, 1H); 2.99 (m,
2H); 3.28 (dd, J=10.4 and 13.0 Hz, 1H); 3.80 (s, 3H); 3.89 (d,
J=1.9 Hz, 1H); 4.16 (ddd, J=3.2 and 8.2 et 11.8 Hz, 1H); 4.29 (d,
J=6.0 Hz, 2H); 4.34 (m, 1H); 4.41 (m, 1H); 5.09 (m, 1H); 5.79 (dd,
J=1.7 and 15.5 Hz, 1H); 6.38 (ddd, J=3.8, 11.3 and 15.5 Hz, 1H);
7.04 (d, J=8.7 Hz, 1H); 7.16 (dd, J=2.2 and 8.7 Hz, 1H); 7.25 (m,
4H); 7.29 (d, J=2.2 Hz, 1H); 7.40 (d, J=10.4 Hz, 1H); 8.02 (d,
J=9.1 Hz, 1H); 8.08 (d large, J=7.7 Hz, 1H); 8.39 (d, J=8.2 Hz,
1H); 8.45 (t, J=6.0 Hz, 1H). LCMS (A1): ES m/z=441 [M+2H].sup.2+;
m/z=879 [M-H].sup.-; m/z=881 [M+H].sup.+; m/z=925
[M-H+HCO.sub.2H].sup.-; t.sub.R=0.99 min.
Compound 42:
5-(((S)-1-(((S)-1-((4-((2R,3R)-3-((S)-1-((3S,10R,16S,E)-10-(3-chloro-4-me-
thoxy-benzyl)-6,6-dimethyl-3-neopentyl-2,5,9,12-tetraoxo-1-oxa-4,8,11-tria-
zacyclohexadec-13-en-16-yl)ethyl)oxiran-2-yl)benzyl)amino)-1-oxopropan-2-y-
l)amino)-3-methyl-1-oxobutan-2-yl)amino)-5-oxopentanoic Acid
[1035] Under argon, in a round bottom flask, were introduced
compound 41 (50 mg, 51.05 .mu.mol) in DCM (10 mL) followed by
glutaric anhydride (10.48 mg, 91.89 .mu.mol). The reaction medium
was stirred for 2 h at RT, concentrated and purified on 10 g of
silica gel (gradient elution DCM/MeOH/H.sub.2) to give 42 mg of
compound 42 as a colorless solid (82%).
[1036] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 0.80 (s,
9H); 0.82 (d, J=7.0 Hz, 3H); 0.85 (d, J=7.0 Hz, 3H); 0.97 (s, 3H);
1.02 (d, J=7.0 Hz, 3H); 1.04 (s, 3H); 1.23 (d, J=7.2 Hz, 3H); 1.29
(d, J=14.2 Hz, 1H); 1.70 (m, 3H); 1.81 (m, 1H); 1.96 (m, 1H); 2.18
to 2.25 (m, 5H); 2.61 (m, 2H); 2.83 (d, J=13.0 Hz, 1H); 2.93 (dd,
J=2.0 and 7.4 Hz, 1H); 3.00 (dd, J=3.1 and 14.5 Hz, 1H); 3.29 (dd,
J=10.4 and 13.0 Hz, 1H); 3.80 (s, 3H); 3.89 (d, J=2.0 Hz, 1H); 4.16
(m, 2H); 4.25 to 4.31 (m, 3H); 4.42 (m, 1H); 5.09 (m, 1H); 5.79
(dd, J=1.9 and 15.5 Hz, 1H); 6.39 (ddd, J=3.8, 11.6 et 15.5 Hz,
1H); 7.05 (d, J=8.7 Hz, 1H); 7.15 (dd, J=2.1 and 8.7 Hz, 1H); 7.23
(m, 4H); 7.28 (d, J=2.1 Hz, 1H); 7.40 (d, J=10.4 Hz, 1H); 7.83 (d,
J=8.7 Hz, 1H); 8.02 (m, 2H); 8.35 (t, J=6.1 Hz, 1H); 8.39 (d, J=8.0
Hz, 1H); 12.04 (broad m, 1H). LCMS (A1): ES m/z=498 [M+2H].sup.2+;
m/z=993 [M-H].sup.-; m/z=995 [M+H].sup.+; t.sub.R=1.27 min.
Example 6: 2,5-dioxopyrrolidin-1-Vi
5-(((S)-1-(((S)-1-((4-((2R,3R)-3-((S)-1-((3S,10R,16S,E)-10-(3-chloro-4-me-
thoxybenzyl)-6,6-dimethyl-3-neopentyl-2,5,9,12-tetraoxo-1-oxa-4,8,11-triaz-
acyclohexadec-13-en-16-yl)ethyl)oxiran-2-yl)benzyl)amino)-1-oxopropan-2-yl-
)amino)-3-methyl-1-oxobutan-2-yl)amino)-5-oxopentanoate
[1037] Under argon, in a round bottom flask, were introduced
compound 42 (23 mg, 23.10 .mu.mol) in DCM (5 mL), followed by DSC
(8.29 mg, 32.34 .mu.mol) and DIEA (5.63 .mu.L, 32.34 .mu.mol). The
reaction medium was stirred for 2 h at RT. After this time, 2 mg of
DSC, 1 .mu.L of DIEA and DCM (2 mL) were added and stirred for 1 h
at RT. The solvent was removed and the crude residue was purified
by flash chromatography on 10 g of silica gel (gradient elution
DCM/iPrOH) to give 20 mg of example 6 as a colorless solid
(79%).
[1038] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 0.80 (s,
9H); 0.82 (d, J=7.0 Hz, 3H); 0.85 (d, J=7.0 Hz, 3H); 0.97 (s, 3H);
1.02 (d, J=7.0 Hz, 3H); 1.04 (s, 3H); 1.23 (d, J=7.2 Hz, 3H); 1.30
(d, J=14.2 Hz, 1H); 1.70 (dd, J=10.7 and 14.7 Hz, 1H); 1.81 (m,
3H); 1.97 (m, 1H); 2.21 to 2.32 (m, 3H); 2.61 (m, 2H); 2.68 (t,
J=7.8 Hz, 2H); 2.80 (broad s, 4H); 2.83 (d, J=13.0 Hz, 1H); 2.94
(dd, J=2.0 et 7.6 Hz, 1H); 3.00 (dd, J=3.4 and 14.9 Hz, 1H); 3.28
(dd, J=10.5 and 13.0 Hz, 1H); 3.80 (s, 3H); 3.88 (d, J=2.0 Hz, 1H);
4.16 (m, 2H); 4.23 to 4.31 (m, 3H); 4.42 (m, 1H); 5.10 (m, 1H);
5.79 (dd, J=1.9 and 15.3 Hz, 1H); 6.39 (ddd, J=3.8, 11.4 and 15.3
Hz, 1H); 7.05 (d, J=8.8 Hz, 1H); 7.16 (dd, J=2.2 and 8.8 Hz, 1H);
7.23 (m, 4H); 7.28 (d, J=2.2 Hz, 1H); 7.40 (d, J=10.5 Hz, 1H); 7.89
(d, J=8.7 Hz, 1H); 8.02 (d, J=9.1 Hz, 1H); 8.06 (d, J=7.5 Hz, 1H);
8.34 (t, J=6.1 Hz, 1H); 8.39 (d, J=8.1 Hz, 1H). LCMS (A1): ES
m/z=546.5 [M+2H].sup.2+; m/z=1090 [M-H].sup.-; m/z=1092
[M+H].sup.+; m/z=1136 [M-H+HCO.sub.2H].sup.-; t.sub.R=1.34 min.
Example 7: mAb-Ex6
[1039] The general method described previously was used for the
preparation of example 7. 60 mg of hu2H11_R35-74 were reacted with
233 .mu.L of a 10.6 mM solution of example 6 in DMA (5 eq.) for 2
h. After purification on Superdex 200 .mu.g in DPBS pH 6.5+20% NMP,
concentration on Amicon Ultra-15, buffer exchange on NAP-25 in
buffer B pH 6.5+5% NMP and filtration on Steriflip, 39 mg of
example 7 were obtained as a colorless limpid solution at a
concentration of 1.98 mg/mL with a DAR of 4.1 (HRMS), a monomeric
purity of 100% and a global yield of 66%. SEC-HRMS: spectrum for
intact ADC in FIG. 2; m/z=149370 (naked mAb); m/z=150357 (D1);
m/z=151330 (D2); m/z=152307 (D3); m/z=153285 (D4); m/z=154262 (D5);
m/z=155238 (D6); m/z=156222 (D7).
Synthesis of Examples 8 to 10: Benzylic Amine of 7-Me-aza-C52
Stereomer 1, NHS Ester of Glutaryl-Val-Ala-7-Me-aza-C52 Benzylic
Amine Stereomer 1 and Corresponding ADC
##STR00734## ##STR00735## ##STR00736##
[1040] Compound 43:
(6R,13S)-(1E,3R,4S,6E)-1-(4-(azidomethyl)phenyl)-8-(tert-butoxy)-3-methyl-
-8-oxoocta-1,6-dien-4-yl
6-(3-chloro-4-methoxybenzyl)-13-isobutyl-2,2,9,10,10-pentamethyl-4,7,11-t-
rioxo-3-oxa-5,8,12-triazatetradecan-14-oate
[1041] Under argon, in a round bottom flask, were introduced
fragment BC2 (1.10 g, 2.48 mmol) in DMF (5 mL), followed by HATU
(950 mg, 2.5 mmol) and HOAt (340 mg, 2.5 mmol). The mixture was
stirred for 30 min at RT, then fragment AD1 (1.24 g, 2.18 mmol) and
DIEA (1.2 mL, 6.87 mmol) were added. The yellow solution was
stirred for 16 h at RT, quenched with H.sub.2O and extracted with
AcOEt (3.times.30 mL). The organic layers were washed with
H.sub.2O, sat. brine, dried over MgSO.sub.4, filtered, concentrated
and purified on 200 g of silica gel (gradient elution
heptane/AcOEt) to give 1.55 g of compound 43 as a white meringue
(77%).
[1042] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 55/45
diastereoisomer mixture; 0.82 to 0.89 (m, 6H); 0.85 (d, J=7.0 Hz,
1.65H); 0.91 (d, J=7.0 Hz, 1.35H); 0.99 to 1.09 (m, 9H); 1.30 (s,
9H); 1.40 (s, 10H); 1.50 to 1.70 (m, 2H); 2.38 to 2.59 (partially
masked m, 3H); 2.68 (m, 1H); 2.84 (m, 1H); 3.79 (s, 1.35H); 3.81
(s, 1.65H); 4.00 to 4.18 (m, 2H); 4.30 (m, 1H); 4.40 (broad s, 2H);
4.92 (m, 1H); 5.81 (d, J=15.7 Hz, 1H); 6.18 (dd, J=8.3 and 16.1 Hz,
1H); 6.45 (d, J=16.1 Hz, 1H); 6.71 (td, J=7.3 and 15.7 Hz, 1H);
6.94 (d, J=8.1 Hz, 0.45H); 6.96 (d, J=8.1 Hz, 0.55H); 7.04 (split
d, J=8.7 Hz, 1H); 7.19 (broad d, J=8.7 Hz, 1H); 7.30 (d, J=7.8 Hz,
2H); 7.32 (broad s, 1H); 7.41 (d, J=8.7 Hz, 2H); 7.52 (d, J=10.1
Hz, 0.45H); 7.59 (d, J=10.1 Hz, 0.55H); 7.74 (m, 1H). LCMS (A1):
55/45 diastereoisomer mixture; ES m/z=895 [M+H].sup.+; m/z=917
[M+Na].sup.+; t.sub.R=6.94-6.98 min.
Compounds 44 & 45:
(3S,10R,16S,E)-16-((R,E)-4-(4-(azidomethyl)phenyl)but-3-en-2-yl)-10-(3-ch-
loro-4-methoxybenzyl)-3-isobutyl-6,6,7-trimethyl-1-oxa-4,8,11-triazacycloh-
exadec-13-ene-2,5,9,12-tetraone
[1043] Compounds 44 & 45 were obtained in two steps.
[1044] Step 1: at 0.degree. C., in a round bottom flask, to a
solution of compound 43 (1.50 g, 1.67 mmol) in 11 mL of DCM were
added TFA (2.6 mL, 34.65 mmol) and 100 .mu.L of H.sub.2O. The
mixture was stirred for 15 min at 0.degree. C. and at RT for 6.5 h.
The reaction medium was then evaporated in vacuo and co-evaporated
in the presence of toluene to give 1.7 g of deprotected
intermediate as an orange solid.
[1045] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 55/45
diastereoisomer mixture; 0.70 to 0.80 (m, 7.65H); 0.90 (s, 1.35H);
0.95 (m, 3H); 1.01 to 1.09 (m, 6H); 1.38 to 1.68 (m, 3H); 2.40 to
2.60 (partially masked m, 3H); 2.80 to 3.02 (m, 2H); 3.81 (s,
1.35H); 3.82 (s, 1.65H); 3.96 to 4.08 (m, 1H); 4.18 (m, 1H); 4.28
(m, 1H); 4.41 (s, 2H); 4.91 (m, 1H); 5.83 (d, J=15.7 Hz, 0.45H);
5.85 (d, J=15.7 Hz, 0.55H); 6.18 (m, 1H); 6.43 (d, J=16.1 Hz,
0.45H); 6.46 (d, J=16.1 Hz, 0.55H); 6.74 (m, 1H); 7.08 to 7.20 (m,
2H); 7.30 (masked m, 0.45H); 7.32 (d, J=7.8 Hz, 2H); 7.37 (d, J=2.0
Hz, 0.55H); 7.42 (m, 2H); 7.76 (d, J=8.00 Hz, 0.45H); 7.79 (d,
J=8.00 Hz, 0.55H); 7.86 (d, J=10.1 Hz, 0.55H); 8.00 (d, J=10.1 Hz,
0.45H); 8.11 (broad m, 3H); 12.22 (broad m, 1H). LCMS (A1): 55/45
diastereoisomer mixture; ES m/z=737 [M-H].sup.-; m/z=739
[M+H].sup.+; t.sub.R=1.07-1.09 min.
[1046] Step 2: in a round bottom flask, to a solution of
deprotected intermediate (1.43 g, 1.68 mmol) in 25 mL of CH.sub.3CN
were added DIEA (3 mL, 16.23 mmol), HOAt (250.91 mg, 1.84 mmol) and
HATU (700.91 mg, 1.84 mmol). The mixture was stirred for 1 h at RT.
Then the solvent was removed, the medium diluted with AcOEt (200
mL), neutralized with 0.5 M citric acid and HCl. The organic layer
was separated, washed with sat. NaHSO.sub.3, sat. NaHCO.sub.3, sat.
brine, dried over MgSO.sub.4, filtered, concentrated and purified
on 100 g of silica gel (gradient elution DCM/MeOH) to give 640 mg
of compounds 44 & 45 as a yellow solid (53%).
[1047] Diastereoisomers at C7 were separated by chiral liquid
chromatography that was carried out on a 76.5.times.350 mm column
packed with 1.1 kg of 10 .mu.m Whelk 01 SS
(4-(3,5-dinitrobenzamido) tetrahydrophenanthrene, Regis
Technologies) using isocratic elution with 50:50 heptane/EtOH.
After concentration, 210 mg of compound 44 (stereomer 1) were
obtained as a white solid (17%) and 236 mg of compound 45
(stereomer 2) were obtained as a white solid (19%).
Compound 44 (Stereomer 1)
[1048] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 0.60 (d,
J=6.7 Hz, 3H); 0.62 (d, J=6.7 Hz, 3H); 0.98 (s, 3H); 1.05 (d, J=7.0
Hz, 3H); 1.10 (d, J=7.0 Hz, 3H); 1.14 (s, 3H); 1.18 (m, 1H); 1.40
to 1.54 (m, 2H); 2.24 (m, 1H); 2.48 to 2.61 (partially masked m,
2H); 2.65 (dd, J=11.8 and 14.5 Hz, 1H); 3.04 (dd, J=3.2 and 14.5
Hz, 1H); 3.55 (m, 1H); 3.81 (s, 3H); 4.19 (m, 2H); 4.40 (s, 2H);
4.96 (m, 1H); 5.91 (dd, J=1.4 and 15.5 Hz, 1H); 6.13 (dd, J=8.9 and
16.1 Hz, 1H); 6.40 (ddd, J=3.9, 11.3 and 15.5 Hz, 1H); 6.46 (d,
J=16.1 Hz, 1H); 7.03 (d, J=8.7 Hz, 1H); 7.19 (dd, J=2.1 and 8.7 Hz,
1H); 7.30 (d, J=2.1 Hz, 1H); 7.32 (d, J=8.4 Hz, 2H); 7.41 (d, J=8.4
Hz, 2H); 7.87 (d, J=8.9 Hz, 1H); 8.36 (d, J=9.9 Hz, 1H); 8.40 (d,
J=8.0 Hz, 1H). LCMS (A1): ES m/z=719 [M-H].sup.-; m/z=721
[M+H].sup.+; t.sub.R=1.61 min Compound 45 (stereomer 2): RMN
.sup.1H (in ppm, DMSO-d6): 0.59 (d, J=6.7 Hz, 3H); 0.67 (d, J=6.7
Hz, 3H); 0.88 (d, J=6.7 Hz, 3H); 1.03 (s, 3H); 1.10 (d, J=7.0 Hz,
3H); 1.19 (s, 3H); 1.21 (m, 1H); 1.49 to 1.60 (m, 2H); 2.23 (m,
1H); 2.46 to 2.61 (partially masked m, 2H); 2.71 (dd, J=11.3 and
14.5 Hz, 1H); 2.98 (dd, J=3.7 and 14.5 Hz, 1H); 3.48 (m, 1H); 3.80
(s, 3H); 4.05 (m, 1H); 4.11 (ddd, J=3.7, 7.6 and 11.3 Hz, 1H); 4.40
(s, 2H); 4.90 (m, 1H); 5.93 (d, J=15.7 Hz, 1H); 6.14 (dd, J=8.7 and
16.1 Hz, 1H); 6.47 (d, J=16.1 Hz, 1H); 6.51 (ddd, J=5.2, 10.3 and
15.5 Hz, 1H); 7.02 (d, J=8.7 Hz, 1H); 7.21 (dd, J=2.4 and 8.7 Hz,
1H); 7.31 (d, J=8.4 Hz, 2H); 7.37 (d, J=2.4 Hz, 2H); 7.41 (d, J=8.4
Hz, 2H); 7.87 (d, J=6.9 Hz, 1H); 7.89 (d, J=9.0 Hz, 1H); 8.51 (d,
J=7.6 Hz, 1H). LCMS (A1): ES m/z=719 [M-H].sup.-; m/z=721
[M+H].sup.+; t.sub.R=1.61 min.
Compound 46:
(3S,10R,16S,E)-16-((S)-1-(3-(4-(azidomethyl)phenyl)oxiran-2-yl)ethyl)-10--
(3-chloro-4-methoxybenzyl)-3-isobutyl-6,6,7-trimethyl-1-oxa-4,8,11-triazac-
yclohexadec-13-ene-2,5,9,12-tetraone
[1049] At 0.degree. C., under argon, in a round bottom flask to a
solution of compound 44 (154 mg, 213.51 .mu.mol) in DCM (10 mL) was
added m-CPBA (80 mg, 324.51 .mu.mol). The reaction medium was
stirred at RT for 5 d. The reaction mixture was diluted with DCM
(15 mL) and stirred 15 min with sat. NaHCO.sub.3 (6 mL) and
Na.sub.2S.sub.2O.sub.3 (6 mL). The organic layer was separated,
washed with sat. brine (2.times.3 mL), dried over MgSO.sub.4,
filtered and concentrated to give 150 mg of compound 46 as a white
solid (quant.).
[1050] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 60/40
diastereoisomer mixture; 0.75 (d, J=6.8 Hz, 1.8H); 0.79 (d, J=6.8
Hz, 3H); 0.85 (d, J=6.8 Hz, 1.2H); 0.95 to 0.99 (m, 4.2H); 1.02 to
1.09 (m, 4.8H); 1.15 (s, 1.8H); 1.18 (s, 1.2H); 1.20 (m, 0.6H);
1.38 (m, 0.4H); 1.59 to 1.62 (m, 2H); 1.80 (m, 0.6H); 1.89 (m,
0.4H); 2.25 (m, 0.6H); 2.40 to 2.71 (partially masked m, 2.4H);
2.96 to 3.08 (m, 2H); 3.54 (m, 1H); 3.80 (s, 3H); 3.82 (d, J=1.9
Hz, 0.4H); 3.92 (d, J=1.9 Hz, 0.6H); 4.14 to 4.29 (m, 2H); 4.40 to
4.50 (m, 2H); 5.11 (m, 1H); 5.85 (dd, J=2.0 and 15.5 Hz, 0.6H);
5.95 (dd, J=2.0 and 15.5 Hz, 0.4H); 6.38 (m, 1H); 7.04 (split d,
J=8.8 Hz, 1H); 7.16 (dd, J=2.2 and 8.8 Hz, 0.6H); 7.19 (dd, J=2.2
and 8.8 Hz, 0.4H); 7.28 (d, J=2.2 Hz, 0.6H); 7.30 (d, J=2.2 Hz,
0.4H); 7.30 to 7.40 (m, 4H); 7.89 (d, J=8.1 Hz, 0.6H); 7.92 (d,
J=8.1 Hz, 0.4H); 8.29 (d, J=10.0 Hz, 0.6H); 8.32 (d, J=8.1 Hz,
0.6H); 8.35 (d, J=10.0 Hz, 0.4H); 8.40 (d, J=8.1 Hz, 0.4H). LCMS
(A1): ES m/z=735 [M-H].sup.-; m/z=737 [M+H].sup.+; t.sub.R=1.52
min.
Example 8:
(3S,10R,16S,E)-16-((S)-1-(3-(4-(aminomethyl)phenyl)oxiran-2-yl)-
ethyl)-10-(3-chloro-4-methoxybenzyl)-3-isobutyl-6,6,7-trimethyl-1-oxa-4,8,-
11-triazacyclohexadec-13-ene-2,5,9,12-tetraone
[1051] At 0.degree. C., in a round bottom flask, to a solution of
compound 46 (60 mg, 81.38 .mu.mol) in DCM (3 mL) and MeOH (3 mL)
was dropwise added a solution of TCEP (38.9 mg, 134.3 .mu.mol) in 1
mL of H.sub.2O. The reaction mixture was stirred at RT for 35 h,
then diluted with DCM (15 mL) and sat. NaHCO.sub.3. After stirring
for 10 min, the organic layer was separated, washed with sat.
brine, dried over MgSO.sub.4, filtered, concentrated in vacuo and
purified on 5 g of silica gel (gradient elution DCM/MeOH) to give
23 mg of example 8 as a white solid (40%).
[1052] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 60/40
diastereoisomer mixture; 0.77 (d, J=7.0 Hz, 1.8H); 0.81 (split d,
J=7.0 Hz, 3H); 0.88 (d, J=7.0 Hz, 1.4H); 0.95 (d, J=7.0 Hz, 1.2H);
0.98 (s, 1.8H); 1.00 (s, 1.2H); 1.02 to 1.09 (m, 4.8H); 1.17 (s,
1.8H); 1.19 (s, 1.2H); 1.22 (m, 0.6H); 1.40 (m, 0.4H); 1.51 to 1.64
(m, 2H); 1.78 (m, 0.6H); 1.89 (m, 0.4H); 2.28 (m, 0.6H); 2.40 to
2.71 (partially masked m, 2.4H); 2.96 (dd, J=2.2 and 7.5 Hz, 0.6H);
2.99 (dd, J=2.2 and 7.5 Hz, 0.4H); 3.03 (m, 1H); 3.55 (m, 1H); 3.70
(s, 1.2H); 3.72 (s, 1.8H); 3.78 (d, J=2.2 Hz, 0.4H); 3.81 (s, 3H);
3.88 (d, J=2.2 Hz, 0.6H); 4.12 to 4.30 (m, 2H); 5.12 (m, 1H); 5.84
(dd, J=1.8 and 15.6 Hz, 0.6H); 5.96 (dd, J=1.8 and 15.6 Hz, 0.4H);
6.39 (m, 1H); 7.05 (d, J=8.7 Hz, 1H); 7.16 to 7.38 (m, 6H); 7.90
(d, J=8.1 Hz, 0.6H); 7.93 (d, J=8.1 Hz, 0.4H); 8.28 (d, J=10.0 Hz,
0.6H); 8.32 (d, J=8.1 Hz, 0.6H); 8.37 (d, J=10.0 Hz, 0.4H); 8.41
(d, J=8.1 Hz, 0.4H). LCMS (A1): ES m/z=709 [M-H].sup.-; m/z=711
[M+H].sup.+; t.sub.R=0.86 min.
Compound 47:
(9H-fluoren-9-yl)methyl((S)-1-(((S)-1-((4-(3-((S)-1-((3S,10R,16S,E)-10-(3-
-chloro-4-methoxybenzyl)-3-isobutyl-6,6,7-trimethyl-2,5,9,12-tetraoxo-1-ox-
a-4,8,11-triazacyclohexadec-13-en-16-yl)ethyl)oxiran-2-yl)benzyl)amino)-1--
oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate
[1053] Under argon, in a round bottom flask were introduced example
8 (110 mg, 154.65 .mu.mol) and DMF (2 mL), followed by FmocValAla
(90 mg, 219 .mu.mol), HOBt (30 mg, 222 .mu.mol), DCM (10 mL) and
EDC (35 .mu.l, 197.52 .mu.mol). The solution was stirred at RT for
3 h30 then quenched with H.sub.2O (10 mL) and extracted by DCM
(3.times.10 mL). The organic layer was separated, washed with sat.
NaHCO.sub.3, sat. brine, dried over MgSO.sub.4, filtered,
concentrated in the presence of toluene and purified on 15 g of
silica gel (gradient elution DCM/MeOH) to give 49 mg of compound 47
as a white solid (46%).
[1054] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 60/40
diastereoisomer mixture; 0.76 (d, J=7.0 Hz, 1.8H); 0.80 (m, 3H);
0.82 to 0.89 (m, 6.4H); 0.95 (d, J=7.0 Hz, 1.2H); 0.98 (s, 1.8H);
1.00 (s, 1.2H); 1.02 to 1.09 (m, 4.8H); 1.17 (s, 1.8H); 1.19 (s,
1.2H); 1.20 to 1.32 (m, 3.6H); 1.40 (m, 0.4H); 1.51 to 1.63 (m,
2H); 1.78 (m, 0.6H); 1.85 (m, 0.4H); 2.00 (m, 1H); 2.27 (m, 0.6H);
2.40 to 2.72 (partially masked m, 2.4H); 2.96 (m, 1H); 3.04 (m,
1H); 3.55 (m, 1H); 3.77 (d, J=2.2 Hz, 0.4H); 3.81 (s, 3H); 3.88 (d,
J=2.2 Hz, 0.6H); 3.90 (m, 1H); 4.15 to 4.38 (m, 6H); 5.12 (m, 1H);
5.85 (dd, J=1.8 and 15.6 Hz, 0.6H); 5.95 (dd, J=1.8 and 15.6 Hz,
0.4H); 6.39 (m, 1H); 7.05 (split d, J=8.7 Hz, 1H); 7.15 to 7.48 (m,
19H); 7.73 (t, J=8.1 Hz, 2H); 7.90 (d, J=8.1 Hz, 2.6H); 7.92 (d,
J=8.1 Hz, 0.4H); 8.05 (d, J=8.1 Hz, 1H); 8.25 to 8.45 (m, 3H). LCMS
(A1): ES m/z=552 [M+2H].sup.2+; m/z=1103 [M+H].sup.+; m/z=1147
[M-H+HCO.sub.2H].sup.-; t.sub.R=1.55-1.57 min.
Compound 48:
(2S)-2-amino-N-((2S)-1-((4-((2R,3R)-3-((1S)-1-((3S,10R,16S,E)-10-(3-chlor-
o-4-methoxybenzyl)-3-isobutyl-6,6,7-trimethyl-2,5,9,12-tetraoxo-1-oxa-4,8,-
11-triazacyclohexadec-13-en-16-yl)ethyl)oxiran-2-yl)benzyl)amino)-1-oxopro-
pan-2-yl)-3-methylbutanamide
[1055] In a round bottom flask, piperidine (60 .mu.L, 600.6
.mu.mol) was added to a solution of compound 47 (50 mg, 45.30
.mu.mol) in DCM (5 mL). The resulting mixture was stirred for 24 h
at RT, concentrated in vacuo and purified on 5 g of silica gel
(gradient elution DCM/MeOH) to give 70 mg of alpha and beta
epoxides.
[1056] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 60/40
diastereoisomer mixture; 0.75 (d, J=7.0 Hz, 1.8H); 0.80 (m, 3H);
0.82 to 0.92 (m, 6.4H); 0.96 (d, J=7.0 Hz, 1.2H); 0.98 (s, 1.8H);
1.00 (s, 1.2H); 1.02 to 1.09 (m, 4.8H); 1.15 (s, 1.8H); 1.19 (s,
1.2H); 1.20 to 1.42 (m, 4H); 1.50 to 1.70 (masked m, 2H); 1.78 (m,
0.6H); 1.85 (m, 0.4H); 2.00 (m, 1H); 2.25 (m, 0.6H); 2.40 to 2.72
(partially masked m, 2.4H); 2.92 to 3.08 (m, 3H); 3.54 (m, 1H);
3.79 (d, J=2.1 Hz, 0.4H); 3.81 (s, 3H); 3.88 (d, J=2.1 Hz, 0.6H);
4.13 to 4.41 (m, 6H); 5.12 (m, 1H); 5.85 (d, J=15.4 Hz, 0.6H); 5.93
(d, J=15.4 Hz, 0.4H); 6.38 (m, 1H); 7.05 (d, J=8.7 Hz, 1H); 7.15 to
7.32 (m, 6H); 7.90 (d, J=8.3 Hz, 0.6H); 7.93 (d, J=8.3 Hz, 0.4H);
8.10 to 8.55 (m, 7H). LCMS (A1): ES m/z=441 [M+2H].sup.2+; m/z=879
[M-H].sup.-; m/z=881 [M+H].sup.+; m/z=925 [M-H+HCO.sub.2H].sup.-;
t.sub.R=0.92 min.
[1057] Alpha and beta epoxides were separated by chiral liquid
chromatography that was carried out on a 76.times.350 mm column
packed with 1.1 kg of 10 .mu.m Chiralpak AD (amylose
tris-3,5-dimethylphenylcarbamate coated on a silica gel support,
Chiral Technologies Europe) using isocratic elution with 70:30
heptane/EtOH. After concentration, 28 mg of compound 48 were
obtained as a white solid (70%) and 19 mg of the alpha epoxide were
obtained as a white solid.
[1058] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 0.75 (d,
J=7.0 Hz, 6H); 0.80 (d, J=7.0 Hz, 3H); 0.88 (d, J=7.0 Hz, 3H); 0.98
(s, 3H); 1.03 (d, J=7.0 Hz, 6H); 1.17 (s, 3H); 1.23 (d, J=7.0 Hz,
3H); 1.35 (m, 1H); 1.50 to 1.68 (m, 2H); 1.78 (m, 1H); 1.91 (m,
1H); 2.26 (m, 1H); 2.58 to 2.70 (m, 2H); 2.96 (dd, J=1.9 and 7.7
Hz, 1H); 2.99 (d, J=4.8 Hz, 1H); 3.02 (dd, J=3.3 and 14.8 Hz, 1H);
3.53 (m, 1H); 3.80 (s, 3H); 3.89 (d, J=1.9 Hz, 1H); 4.10 to 4.23
(m, 3H); 4.28 (d, J=6.1 Hz, 2H); 4.35 (m, 1H); 5.11 (m, 1H); 5.83
(dd, J=1.9 and 15.2 Hz, 1H); 6.37 (ddd, J=4.0, 11.2 and 15.2 Hz,
1H); 7.03 (d, J=8.8 Hz, 1H); 7.18 (dd, J=2.4 and 8.8 Hz, 1H); 7.26
(s, 4H); 7.29 (d, J=2.4 Hz, 1H); 7.90 (d, J=8.2 Hz, 1H); 8.08
(broad d, J=7.7 Hz, 1H); 8.29 (d, J=10.1 Hz, 1H); 8.33 (d, J=8.2
Hz, 1H); 8.46 (t, J=6.7 Hz, 1H). LCMS (A1): ES m/z=441
[M+2H].sup.2+; m/z=879 [M-H].sup.-; m/z=881 [M+H].sup.+; m/z=925
[M-H+HCO.sub.2H].sup.-; t.sub.R=0.92 min.
Compound 49:
5-(((S)-1-(((S)-1-((4-((2R,3R)-3-((S)-1-((3S,10R,16S,E)-10-(3-chloro-4-me-
thoxybenzyl)-3-isobutyl-6,6,7-trimethyl-2,5,9,12-tetraoxo-1-oxa-4,8,11-tri-
azacyclohexadec-13-en-16-yl)ethyl)oxiran-2-yl)benzyl)amino)-1-oxopropan-2--
yl)amino)-3-methyl-1-oxobutan-2-yl)amino)-5-oxopentanoic Acid
[1059] Under argon, in a round bottom flask, a solution of glutaric
anhydride (3.78 mg, 32.44 .mu.mol) in DCM (4 mL) was added to a
solution of compound 48 (26 mg, 29.5 .mu.mol) in DCM (9 mL). The
resulting mixture was stirred 2 h at RT, concentrated in vacuo and
purified on 2.5 g of silica gel (gradient elution DCM/MeOH/H.sub.2)
to give 18 mg of compound 49 as a white solid (61%).
[1060] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 0.78 (d,
J=7.0 Hz, 3H); 0.80 (d, J=7.0 Hz, 3H); 0.82 (d, J=7.0 Hz, 3H); 0.84
(d, J=7.0 Hz, 3H); 0.97 (s, 3H); 1.03 (d, J=7.0 Hz, 6H); 1.15 (s,
3H); 1.23 (broad d, J=7.0 Hz, 4H); 1.49 to 1.61 (m, 2H); 1.70 (m,
2H); 1.78 (m, 1H); 1.97 (m, 1H); 2.20 (m, 4H); 2.25 (m, 1H); 2.62
(m, 2H); 2.95 (m, 1H); 3.02 (m, 1H); 3.53 (m, 1H); 3.80 (s, 3H);
3.88 (s, 1H); 4.10 to 4.22 (m, 3H); 4.24 to 4.31 (m, 3H); 5.11 (m,
1H); 5.83 (d, J=15.7 Hz, 1H); 6.36 (m, 1H); 7.03 (d, J=8.7 Hz, 1H);
7.19 (broad d, J=8.7 Hz, 1H); 7.23 (m, 4H); 7.29 (broad s, 1H);
7.87 (d, J=8.9 Hz, 1H); 7.90 (d, J=8.1 Hz, 1H); 8.06 (d large,
J=7.3 Hz, 1H); 8.29 (d, J=10.1 Hz, 1H); 8.37 (m, 2H); 12.0 (broad
m, 1H). LCMS (A1): ES m/z=993 [M-H].sup.-; m/z=995 [M+H].sup.+;
t.sub.R=1.21 min.
Example 9: 2,5-dioxopyrrolidin-1-vi
5-(((S)-1-(((S)-1-((4-((2R,3R)-3-((S)-1-((3S,10R,16S,E)-10-(3-chloro-4-me-
thoxybenzyl)-3-isobutyl-6,6,7-trimethyl-2,5,9,12-tetraoxo-1-oxa-4,8,11-tri-
azacyclohexadec-13-en-16-yl)ethyl)oxiran-2-yl)benzyl)amino)-1-oxopropan-2--
yl)amino)-3-methyl-1-oxobutan-2-yl)amino)-5-oxopentanoate
[1061] Under argon, in a round bottom flask, to a solution of
compound 49 (15 mg, 15.07 .mu.mol) in DCM (5 mL) were added DSC
(5.63 mg, 21.09 .mu.mol) and DIEA (3.56 .mu.L, 21.09 .mu.mol). The
resulting mixture was stirred for 1 h at RT, concentrated in vacuo
and purified on 2.5 g of silica gel (gradient elution DCM/MeOH) to
give 7.7 mg of example 9 as a white solid (47%).
[1062] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 0.78 (d,
J=6.7 Hz, 3H); 0.80 (d, J=6.7 Hz, 3H); 0.82 (d, J=7.0 Hz, 3H); 0.85
(d, J=7.0 Hz, 3H); 0.99 (s, 3H); 1.04 (d, J=7.2 Hz, 6H); 1.18 (s,
3H); 1.26 (m, 4H); 1.57 (m, 2H); 1.79 (m, 1H); 1.83 (m, 2H); 1.99
(m, 1H); 2.22 to 2.33 (m, 3H); 2.6062.71 (m, 4H); 2.82 (s, 4H);
2.97 (dd, J=2.1 and 7.7 Hz, 1H); 3.04 (dd, J=3.4 and 14.7 Hz, 1H);
3.55 (m, 1H); 3.81 (s, 3H); 3.89 (d, J=2.1 Hz, 1H); 4.19 (m, 3H);
4.26 to 4.34 (m, 3H); 5.12 (m, 1H); 5.86 (dd, J=2.0 and 15.7 Hz,
1H); 6.38 (ddd, J=3.8, 11.2 and 15.7 Hz, 1H); 7.05 (d, J=8.7 Hz,
1H); 7.19 (dd, J=2.2 and 8.7 Hz, 1H); 7.26 (m, 4H); 7.29 (d, J=2.2
Hz, 1H); 7.91 (m, 2H); 8.09 (m, 1H); 8.29 (d, J=9.9 Hz, 1H); 8.35
(m, 2H). LCMS (A1): ES m/z=1092 [M+H].sup.+; m/z=1136
[M-H+HCO.sub.2H].sup.-; t.sub.R=1.26 min.
Example 10: mAb-Ex9
[1063] The general method described previously was used for the
preparation of example 10. 60 mg of hu2H11_R35-74 were reacted with
198 .mu.L of a 10.78 mM solution of example 9 in DMA (5 eq.) for 2
h. At that time, 120 .mu.L of the solution of example 9 (3 eq.)
were added and the medium stirred for 2 h. After purification on
Superdex 200 .mu.g in DPBS pH 6.5+20% NMP, concentration on Amicon
Ultra-15, buffer exchange on PD-10 in buffer B pH 6.5+5% NMP and
filtration on Steriflip, 46 mg of example 10 were obtained as a
colorless limpid solution at a concentration of 2.23 mg/mL with a
DAR of 4.7 (HRMS), a monomeric purity of 99.2% and a global yield
of 78%. SEC-HRMS: spectrum for intact ADC in FIG. 3; m/z=150345
(D1); m/z=151319 (D2); m/z=152297 (D3); m/z=153274 (D4); m/z=154251
(D5); m/z=155222 (D6); m/z=156202 (D7); m/z=157183 (D8).
Synthesis of Examples 11 to 14: Benzylic Amine of
3-(S)-neopentyl-7-Me-aza-C52 Stereomer 1, NHS Ester of
Glutaryl-Val-Ala-3-(S)-neopentyl-7-Me-aza-C52 Benzylic Amine
Stereomer 1 and Corresponding ADC
##STR00737## ##STR00738## ##STR00739##
[1064] Compound 50:
(6R,13S)-(1E,3R,4S,6E)-8-(tert-butoxy)-1-(4-(hydroxymethyl)phenyl)-3-meth-
yl-8-oxoocta-1,6-dien-4-yl
6-(3-chloro-4-methoxybenzyl)-2,2,9,10,10-pentamethyl-13-neopentyl-4,7,11--
trioxo-3-oxa-5,8,12-triazatetradecan-14-oate
[1065] Under argon, in a round bottom flask, to a solution of
fragment BC2 (742 mg, 1.68 mmol) in DMF (20 mL) were added HATU
(716 mg, 1.83 mmol) and HOAt (251 mg, 1.83 mmol). The mixture was
stirred 30 min at RT. Then a solution of fragment AD (730 mg, 1.59
mmol) in DMF (10 mL) and DIEA (981 .mu.L, 5.56 mmol) were added.
The reaction medium was stirred for 24 h at RT. After this time,
the reaction medium was diluted with ice (200 g), extracted with
AcOEt (4.times.200 mL). The organic layers were washed with
H.sub.2O (80 mL), sat. brine (2.times.80 mL), dried over
MgSO.sub.4, filtered, concentrated and purified by two successive
flash chromatographies, the first one on 300 g of silica gel
(gradient elution DCM/MeOH) and the second one on 70 g of silica
gel (gradient elution DCM/MeOH) to give 428 mg of compound 50 as a
colorless foam (30%).
Compound 51:
(2E,5S,6R,7E)-5-(((2S)-2-(3-((R)-2-amino-3-(3-chloro-4-methoxyphenyl)-pro-
panamido)-2,2-dimethylbutanamido)-4,4-dimethylpentanoyl)oxy)-8-(4-(hydroxy-
methyl)phenyl)-6-methylocta-2,7-dienoic Acid
[1066] In a round bottom flask, were introduced compound 50 (428
mg, 483.87 .mu.mol) and DCM (27 mL). The solution was cooled at
0.degree. C. then TFA (8 mL, 106.62 mmol) was added. The mixture
was stirred for 1.5 h at RT. The solvent was removed and
co-evaporated under reduced pressure with toluene (3.times.100 mL).
The crude oil was diluted with 1:1 AcOEt/H.sub.2O (75 mL) and
neutralized with 2M NaOH (250 .mu.L) until pH 6-7. The mixture was
stirred for 6 h at RT. The layers were separated. The aq. layer was
extracted with AcOEt (3.times.50 mL). The organic layers were
washed with sat. brine (2.times.15 mL), dried over MgSO.sub.4,
filtered and concentrated to give 374 mg of compound 51 as a
colorless foam (quant.).
Compound 52:
(3S,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-16-((R,E)-4-(4-(hydroxymethy-
l)-phenyl)but-3-en-2-yl)-6,6,7-trimethyl-3-neopentyl-1-oxa-4,8,11-triazacy-
clohexadec-13-ene-2,5,9,12-tetraone
[1067] Under argon, in a round bottom flask, to a solution of
compound 51 (352 mg, 483.31 .mu.mol) in CH.sub.3CN (60 mL) were
added HATU (208 mg, 531.64 mmol), HOAt (73.09 mg, 531.64 .mu.mol)
and DIEA (244.52 .mu.L, 1.45 mmol). The reaction medium was stirred
for 45 min at RT. After this time, the reaction medium was
neutralized with 0.5 N citric acid until pH 4, concentrated
partially in vacuo and extracted with AcOEt (150 mL). The organic
layer was washed with sat. NaHCO.sub.3 (10 mL), sat. brine
(3.times.10 mL), dried over MgSO.sub.4, filtered, concentrated and
purified by flash chromatography on 15 g of silica gel (gradient
elution DCM/MeOH) to give 188 mg of compound 52 as a colorless foam
(54%).
Compound 53:
(3S,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-6,6,7-trimethyl-3-neopentyl--
16-((R,E)-4-(4-(((triisopropylsilyl)oxy)methyl)phenyl)but-3-en-2-yl)-1-oxa-
-4,8,11-triazacyclohexadec-13-ene-2,5,9,12-tetraone
[1068] At 0.degree. C., under argon, in a round bottom flask, to a
solution of compound 52 (188 mg, 264.68 .mu.mol) in DCM (7 mL),
were added 1H-imidazole (83.72 mg, 1.2 mmol) and 1M
chlorotriisopropylsilane (134.15 .mu.l). The reaction medium was
stirred for 5 h at RT, then quenched with sat. NH.sub.4Cl and
stirred for 15 min. The layers were separated. The aq. layer was
extracted with DCM (3.times.25 mL). The organic layers were washed
with 1M NaHSO.sub.4 (10 mL), sat. NaHCO.sub.3 (10 mL), sat. brine,
dried over MgSO.sub.4, filtered, concentrated and purified by flash
chromatography on 10 g of silica gel (gradient elution DCM/MeOH) to
give 137 mg of compound 53 as a colorless foam (59%).
Example 11:
(3S,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-16-((S)-1-((2R,3R)-3-(4-(hyd-
roxymethyl)phenyl)oxiran-2-yl)ethyl)-6,6,7-trimethyl-3-neopentyl-1-oxa-4,8-
,11-triazacyclohexadec-13-ene-2,5,9,12-tetraone
[1069] Example 11 was prepared in two steps.
[1070] Step 1: at 0.degree. C. under argon, in a round bottom
flask, to a solution of compound 53 (137 mg, 158.08 .mu.mol) in DCM
(5.5 mL) was added a solution of m-CPBA (50.66 mg, 205.51 .mu.mol)
in DCM (2 mL) and the reaction medium was stirred for 2 h. Then 39
mg of m-CPBA were added twice after 2 h of stirring. After 16 h of
stirring, the mixture was quenched with sat. NaHCO.sub.3 (30 mL)
and Na.sub.2S.sub.2O.sub.3 (30 mL), stirred for 15 min and diluted
with DCM (40 mL). The layers were separated. The aq. layer was
extracted with DCM (2.times.20 mL). The organic layers were washed
with sat. brine (2.times.8 mL), dried over MgSO.sub.4, filtered and
concentrated to give 160 mg of alpha and beta epoxides as a
colorless solid (quant.).
[1071] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 60/40
diastereoisomer mixture; 0.80 to 0.91 (m, 12H); 0.97 to 1.09 (m,
24H); 1.12 to 1.21 (m, 6H); 1.32 (d, J=14.7 Hz, 0.6H); 1.40 (d,
J=14.7 Hz, 0.4H); 1.70 to 1.87 (m, 1H); 1.90 (dd, J=10.1 and 14.7
Hz, 0.4H); 1.97 (dd, J=10.1 and 14.7 Hz, 0.6H); 2.28 (m, 0.6H);
2.40 (m, 0.4H); 2.55 to 2.79 (m, 2H); 2.90 to 3.00 (m, 2H); 3.44
(m, 1H); 3.79 (d, J=2.1 Hz, 0.4H); 3.80 (s, 3H); 3.90 (d, J=2.1 Hz,
0.6H); 4.03 to 4.22 (m, 2H); 4.78 (s, 0.8H); 4.80 (s, 1.2H); 5.03
(m, 1H); 5.90 (dd, J=1.5 and 15.5 Hz, 0.6H); 5.99 (dd, J=1.5 and
15.5 Hz, 0.4H); 6.40 to 6.55 (m, 1H); 7.02 to 7.07 (m, 1H); 7.13 to
7.38 (m, 6H); 7.85 to 7.93 (m, 2H); 8.40 (d, J=7.3 Hz, 0.6H); 8.51
(d, J=7.3 Hz, 0.4H). LCMS (A1): ES m/z=880 [M-H].sup.-; m/z=882
[M+H].sup.+; m/z=926 [M-H+HCO.sub.2H].sup.-; t.sub.R=2.05-2.06
min.
[1072] Step 2: at 0.degree. C. under argon, in a round bottom
flask, to a solution of alpha and beta epoxides (177 mg, 200.53
.mu.mol) in THE (7.5 mL) was dropwise added 1M TBAF (221 .mu.L, 221
.mu.mol). After stirring for 2 h at RT, 50 .mu.L of TBAF were added
and stirred for 3.5 h. The reaction medium was diluted with
H.sub.2O (9 mL), stirred for 10 min and extracted with DCM
(3.times.25 mL). The combined organic layers were washed with sat.
brine (3.times.8 mL), dried over MgSO.sub.4, filtered and
concentrated to give 210 mg of alpha and beta epoxides as a
colorless solid (quant.).
[1073] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 60/40
diastereoisomer mixture; 0.82 to 1.25 (m, 21H); 1.32 (d, J=14.5 Hz,
0.6H); 1.42 (d, J=14.5 Hz, 0.4H); 1.80 (m, 1H); 1.91 (dd, J=10.0
and 14.5 Hz, 0.4H); 1.98 (dd, J=10.0 and 14.5 Hz, 0.6H); 2.22 to
2.48 (m, 1H); 2.55 to 2.78 (m, 2H); 2.89 to 3.03 (m, 2H); 3.44 (m,
1H); 3.79 (d, J=2.2 Hz, 0.4H); 3.80 (s, 3H); 3.90 (d, J=2.2 Hz,
0.6H); 4.04 to 4.22 (m, 2H); 4.48 (d, J=5.8 Hz, 0.8H); 4.50 (d,
J=5.8 Hz, 1.2H); 5.03 (m, 1H); 5.16 (t, J=5.8 Hz, 0.4H); 5.19 (t,
J=5.8 Hz, 0.6H); 5.89 (dd, J=1.9 and 15.6 Hz, 0.6H); 5.99 (dd,
J=1.9 and 15.6 Hz, 0.4H); 6.40 to 6.52 (m, 1H); 7.02 (d, J=8.7 Hz,
0.6H); 7.04 (d, J=8.7 Hz, 0.4H); 7.16 to 7.37 (m, 6H); 7.83 to 7.94
(m, 2H); 8.39 (d, J=7.4 Hz, 0.6H); 8.50 (d, J=7.4 Hz, 0.4H). LCMS
(A1): ES m/z=724 [M-H].sup.-; m/z=726 [M+H].sup.+; t.sub.R=1.29
min.
[1074] Alpha and beta epoxides were separated by chiral liquid
chromatography that was carried out on a 76.times.350 mm column
packed with 1.1 kg of 10 .mu.m Chiralpak AD (amylose
tris-3,5-dimethylphenylcarbamate coated on a silica gel support,
Chiral Technologies Europe) using isocratic elution with 75:25
heptane/EtOH. After concentration, 66 mg of example 11 were
obtained as a white solid (45%) and 45 mg of the alpha epoxide were
obtained as a white solid (31%).
[1075] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 0.82 to 0.89
(m, 12H); 0.99 (s, 3H); 1.03 (d, J=6.9 Hz, 3H); 1.19 (s, 3H); 1.34
(d, J=14.6 Hz, 1H); 1.80 (m, 1H); 1.98 (dd, J=10.1 and 14.6 Hz,
1H); 2.26 (m, 1H); 2.61 (m, 1H); 2.69 (dd, J=11.1 and 14.6 Hz, 1H);
2.91 (dd, J=2.1 and 7.8 Hz, 1H); 2.94 (dd, J=3.7 and 14.6 Hz, 1H);
3.42 (m, 1H); 3.80 (s, 3H); 3.91 (d, J=2.1 Hz, 1H); 4.03 to 4.14
(m, 2H); 4.50 (d, J=5.8 Hz, 2H); 5.03 (m, 1H); 5.19 (t, J=5.8 Hz,
1H); 5.89 (dd, J=2.1 and 15.5 Hz, 1H); 6.43 (ddd, J=4.7, 10.9 and
15.5 Hz, 1H); 7.03 (d, J=8.7 Hz, 1H); 7.20 (dd, J=2.3 and 8.7 Hz,
1H); 7.23 (d, J=8.4 Hz, 2H); 7.30 (d, J=2.3 Hz, 1H); 7.33 (d, J=8.4
Hz, 2H); 7.86 (d, J=8.4 Hz, 1H); 7.92 (d, J=7.1 Hz, 1H); 8.39 (d,
J=9.1 Hz, 1H). LCMS (A1): ES m/z=724 [M-H].sup.-; m/z=726
[M+H].sup.+; t.sub.R=1.29 min.
Compound 54:
(3S,10R,16S,E)-16-((S)-1-((2R,3R)-3-(4-(azidomethyl)phenyl)oxiran-2-yl)et-
hyl)-10-(3-chloro-4-methoxybenzyl)-6,6,7-trimethyl-3-neopentyl-1-oxa-4,8,1-
1-triazacyclohexadec-13-ene-2,5,9,12-tetraone
[1076] Under argon, in a round bottom flask, to a solution of
example 11 (66 mg, 90.87 .mu.mol) in THE (5 mL) were added, at
0.degree. C., DPPA (100.23 .mu.l, 454.36 .mu.mol) and DBU (69.27
.mu.l, 454.36 .mu.mol). The solution was stirred for 5 h at RT then
diluted with H.sub.2O and extracted with AcOEt (2.times.15 mL). The
organic layer was separated, washed with sat. brine (2.times.5 mL),
dried over MgSO.sub.4, filtered, concentrated and purified on 15 g
of silica gel (gradient elution DCM/iPrOH) to give 64 mg of
compound 54 as a colorless solid (94%).
Example 12:
(3S,10R,16S,E)-16-((S)-1-((2R,3R)-3-(4-(aminomethyl)phenyl)oxiran-2-yl)et-
hyl)-10-(3-chloro-4-methoxybenzyl)-6,6,7-trimethyl-3-neopentyl-1-oxa-4,8,1-
1-triazacyclohexadec-13-ene-2,5,9,12-tetraone
[1077] In a round bottom flask, to a solution of compound 54 (64
mg, 85.18 .mu.mol) in DCM (3 mL), MeOH (3 mL) and H.sub.2O (400
.mu.L) was added TCEP (26.86 mg, 93.70 .mu.mol). The reaction
medium was stirred for 24 h at RT. The reaction mixture was diluted
with DCM (15 mL) and sat. NaHCO.sub.3, stirred for 10 min and
extracted with DCM (3.times.15 mL). The combined organic layers
were washed with sat. brine, dried over MgSO.sub.4, filtered,
concentrated and purified by flash chromatography on 4.5 g of
amino-propyl modified silica gel (gradient elution DCM/MeOH) to
give 42 mg of example 12 as a white solid (68%).
Compound 55:
(9H-fluoren-9-yl)methyl((2S)-1-(((2S)-1-((4-((2R,3R)-3-((1S)-1-((3S,10R,1-
6S,E)-10-(3-chloro-4-methoxybenzyl)-6,6,7-trimethyl-3-neopentyl-2,5,9,12-t-
etraoxo-1-oxa-4,8,11-triazacyclohexadec-13-en-16-yl)ethyl)oxiran-2-yl)benz-
yl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate
[1078] Under argon, in a round bottom flask, were introduced
example 12 (42 mg, 57.91 .mu.mol) and DMF (1 mL), followed by
FmocValAla (34.44 mg, 86.86 .mu.mol), HOBt (13.20 mg, 93.81
.mu.mol), DCM (10 mL) and EDC (10.36 .mu.l, 57.91 .mu.mol). The
reaction medium was stirred for 3 h at RT and then diluted with
H.sub.2O (15 mL), stirred for 10 min at RT and extracted with DCM
(3.times.20 mL). The combined organic layers were dried over
MgSO.sub.4, filtered and concentrated to give 83 mg of compound 55
as a white solid (quant.).
Compound 56:
(2S)-2-amino-N-((2S)-1-((4-((2R,3R)-3-((1S)-1-((3S,10R,16S,E)-10-(3-chlor-
o-4-methoxybenzyl)-6,6,7-trimethyl-3-neopentyl-2,5,9,12-tetraoxo-1-oxa-4,8-
,11-triazacyclohexadec-13-en-16-yl)ethyl)oxiran-2-yl)benzyl)amino)-1-oxopr-
opan-2-yl)-3-methylbutanamide
[1079] In a round bottom flask, piperidine (57.8 .mu.L, 579.10
.mu.mol) was added to a solution of compound 55 (64.73 mg, 57.91
.mu.mol) in DCM (10 mL). After stirring 5 h, 57.8 .mu.L of
piperidine were added and the medium was stirred overnight at RT.
The reaction medium was concentrated in vacuo and purified on 15 g
of silica gel (gradient DCM/MeOH/H.sub.2) to give 30 mg of compound
56 as a colorless solid (58%).
[1080] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 0.86 (d,
J=7.0 Hz, 3H); 0.82 to 0.90 (m, 15H); 1.00 (s, 3H); 1.03 (d, J=7.0
Hz, 3H); 1.19 (s, 3H); 1.24 (d, J=7.0 Hz, 3H); 1.34 (d, J=14.6 Hz,
1H); 1.66 (broad m, 2H); 1.80 (m, 1H); 1.91 (m, 1H); 1.98 (dd,
J=10.2 and 14.6 Hz, 1H); 2.27 (m, 1H); 2.60 (m, 1H); 2.69 (dd,
J=11.1 and 14.6 Hz, 1H); 2.91 (dd, J=2.0 and 7.7 Hz, 1H); 2.94 (dd,
J=3.7 and 14.6 Hz, 1H); 2.99 (d, J=4.9 Hz, 1H); 3.43 (m, 1H); 3.80
(s, 3H); 3.91 (d, J=2.0 Hz, 1H); 4.03 to 4.12 (m, 2H); 4.29 (d,
J=6.2 Hz, 2H); 4.34 (m, 1H); 5.03 (m, 1H); 5.89 (dd, J=1.8 and 15.6
Hz, 1H); 6.43 (ddd, J=4.8, 10.9 and 15.6 Hz, 1H); 7.02 (d, J=8.6
Hz, 1H); 7.20 (dd, J=2.2 and 8.6 Hz, 1H); 7.22 (d, J=8.4 Hz, 2H);
7.26 (d, J=8.4 Hz, 2H); 7.32 (d, J=2.2 Hz, 1H); 7.86 (d, J=8.4 Hz,
1H); 7.92 (d, J=7.2 Hz, 1H); 8.07 (broad d, J=7.9 Hz, 1H); 8.40 (d,
J=7.3 Hz, 1H); 8.45 (t, J=6.2 Hz, 1H). LCMS (A1): ES m/z=448
[M+2H].sup.2+; m/z=893 [M-H].sup.-; m/z=895 [M+H].sup.+; m/z=939
[M-H+HCO.sub.2H].sup.-; t.sub.R=1.29 min.
Compound 57:
5-(((2S)-1-(((2S)-1-((4-((2R,3R)-3-((1S)-1-((3S,10R,16S,E)-10-(3-chloro-4-
-methoxybenzyl)-6,6,7-trimethyl-3-neopentyl-2,5,9,12-tetraoxo-1-oxa-4,8,11-
-triazacyclohexadec-13-en-16-yl)ethyl)oxiran-2-yl)benzyl)amino)-1-oxopropa-
n-2-yl)amino)-3-methyl-1-oxobutan-2-yl)amino)-5-oxopentanoic
Acid
[1081] Under argon, in a round bottom flask, a solution of glutaric
anhydride (4.29 mg, 36.85 .mu.mol) in DCM (2 mL) was added to a
solution of compound 56 (30 mg, 33.5 .mu.mol) in DCM (6 mL). The
reaction medium was stirred for 2 h at RT, concentrated partially
in vacuo and purified on 2.5 g of silica gel (gradient elution
DCM/MeOH/H.sub.2) to give 34 mg of compound 57 as a colorless
lacquer (quant.).
[1082] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 0.80 to 0.89
(m, 18H); 0.99 (s, 3H); 1.03 (d, J=7.0 Hz, 3H); 1.19 (s, 3H); 1.24
(d, J=7.0 Hz, 3H); 1.34 (d, J=14.6 Hz, 1H); 1.70 (m, 2H); 1.80 (m,
1H); 1.97 (m, 2H); 2.19 (m, 4H); 2.26 (m, 1H); 2.60 (m, 1H); 2.70
(dd, J=11.2 and 14.6 Hz, 1H); 2.90 (dd, J=2.2 and 7.8 Hz, 1H); 2.95
(dd, J=3.7 and 14.6 Hz, 1H); 3.43 (m, 1H); 3.80 (s, 3H); 3.91 (d,
J=2.2 Hz, 1H); 4.03 to 4.18 (m, 3H); 4.22 to 4.33 (m, 3H); 5.03 (m,
1H); 5.90 (d, J=15.5 Hz, 1H); 6.43 (ddd, J=4.9, 11.0 and 15.5 Hz,
1H); 7.02 (d, J=8.6 Hz, 1H); 7.19 to 7.28 (m, 5H); 7.32 (d, J=2.2
Hz, 1H); 7.85 (broad d, J=8.9 Hz, 2H); 7.91 (d, J=7.2 Hz, 1H); 8.06
(broad d, J=7.5 Hz, 1H); 8.36 (broad t, J=6.6 Hz, 1H); 8.42 (d,
J=7.8 Hz, 1H); 12.10 (broad m, 1H). LCMS (A1): ES m/z=1007
[M-H].sup.-; m/z=1009 [M+H].sup.+; t.sub.R=1.21 min.
Example 13: 2,5-dioxopyrrolidin-1-yl
5-(((2S)-1-(((2S)-1-((4-((2R,3R)-3-((1S)-1-((3S,10R,16S,E)-10-(3-chloro-4-
-methoxybenzyl)-6,6,7-trimethyl-3-neopentyl-2,5,9,12-tetraoxo-1-oxa-4,8,11-
-triazacyclohexadec-13-en-16-yl)ethyl)oxiran-2-yl)benzyl)amino)-1-oxopropa-
n-2-yl)amino)-3-methyl-1-oxobutan-2-yl)amino)-5-oxopentanoate
[1083] Under argon, in a round bottom flask, to a solution of
compound 57 (33 mg, 32.69 .mu.mol) in DCM (8 mL) were added DSC
(11.72 mg, 45.76 .mu.mol) and DIEA (7.7 .mu.L, 45.76 .mu.mol). The
reaction medium was stirred for 1 h at RT, concentrated in vacuo
and purified by two successive flash chromatographies on 2.5 g of
silica gel (gradient elution DCM/iPrOH) to give 17.9 mg of example
13 as a colorless solid (49%).
[1084] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 0.80 to 0.90
(m, 18H); 1.00 (s, 3H); 1.04 (d, J=7.0 Hz, 3H); 1.19 (s, 3H); 1.24
(d, J=7.0 Hz, 3H); 1.34 (d, J=14.6 Hz, 1H); 1.80 (m, 1H); 1.83 (m,
2H); 1.98 (m, 2H); 2.26 (m, 1H); 2.29 (m, 2H); 2.60 (m, 1H); 2.68
(t, J=7.5 Hz, 2H); 2.70 (dd, J=11.2 and 14.6 Hz, 1H); 2.80 (s, 4H);
2.91 (dd, J=2.2 and 7.6 Hz, 1H); 2.95 (dd, J=3.7 and 14.6 Hz, 1H);
3.43 (m, 1H); 3.80 (s, 3H); 3.90 (d, J=2.2 Hz, 1H); 4.06 to 4.15
(m, 2H); 4.18 (dd, J=6.9 and 8.7 Hz, 1H); 4.21 to 4.33 (m, 3H);
5.03 (m, 1H); 5.89 (d, J=15.5 Hz, 1H); 6.43 (ddd, J=4.9, 10.9 and
15.5 Hz, 1H); 7.02 (d, J=8.7 Hz, 1H); 7.20 (dd, J=2.3 and 8.7 Hz,
1H); 7.23 (d, J=8.4 Hz, 2H); 7.25 (d, J=8.4 Hz, 2H); 7.31 (d, J=2.3
Hz, 1H); 7.84 (d, J=8.6 Hz, 1H); 7.89 (m, 2H); 8.04 (d, J=7.5 Hz,
1H); 8.33 (t, J=6.5 Hz, 1H); 8.39 (d, J=7.6 Hz, 1H). LCMS (A1): ES
m/z=796; m/z=1104 [M-H].sup.-; m/z=1106 [M+H].sup.+; m/z=1150
[M-H+HCO.sub.2H].sup.-; t.sub.R=1.26 min.
Example 14: mAb-Ex13
[1085] The general method described previously was used for the
preparation of example 14. 60 mg of hu2H11_R35-74 were reacted with
200 .mu.L of a 10.05 mM solution of example 13 in DMA (5 eq.) for 2
h. At that time, 180 .mu.L of the solution of example 13 (4.5 eq.)
were added and the medium stirred for 2 h. After purification on
Superdex 200 .mu.g in buffer B pH 6.5+10% NMP, concentration on
Amicon Ultra-15, buffer exchange on PD-10 in buffer B pH 6.5+5% NMP
and filtration on Steriflip, 46 mg of example 14 were obtained as a
colorless limpid solution at a concentration of 2 mg/mL with a DAR
of 3.5 (HRMS), a monomeric purity of 99.7% and a global yield of
77%.
[1086] SEC-HRMS: spectrum for intact ADC in FIG. 4; m/z=149336
(naked mAb); m/z=150328 (D1); m/z=151319 (D2); m/z=152311 (D3);
m/z=153302 (D4); m/z=154295 (D5); m/z=155290 (D6); m/z=156282
(D7).
Example 15:
(3S,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-16-((S)-1-(3-(4-(hydroxy-met-
hyl)phenyl)oxiran-2-yl)ethyl)-3,6,6-trimethyl-1-oxa-4,8,11-triazacyclohexa-
dec-13-ene-2,5,9,12-tetraone
##STR00740##
[1088] Example 15 was prepared following general route B depicted
in Scheme 2 and described for examples 4 and 11.
[1089] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 65/35
diastereoisomer mixture; 0.93 to 1.26 (m, 12H); 1.75 (m, 0.65H);
1.83 (m, 0.35H); 2.22 (m, 0.65H); 2.41 (m, 0.35H); 2.55 to 2.70 (m,
2H); 2.81 (d, J=13.7 Hz, 0.65H); 2.88 (d, J=13.7 Hz, 0.35H); 2.93
(dd, J=2.1 and 8.2 Hz, 0.65H); 3.00 (m, 1.35H); 3.22 to 3.35
(partially masked m, 1H); 3.77 (d, J=2.1 Hz, 0.35H); 3.81 (s, 3H);
3.88 (d, J=2.1 Hz, 0.65H); 4.25 to 4.39 (m, 1.65H); 4.34 (m,
0.35H); 4.48 (d, J=6.0 Hz, 0.7H); 4.50 (d, J=6.0 Hz, 1.3H); 5.08
(m, 1H); 5.17 (t, J=6.0 Hz, 0.35H); 5.20 (t, J=6.0 Hz, 0.65H); 5.78
(dd, J=1.9 and 15.5 Hz, 0.65H); 5.89 (dd, J=1.9 and 15.5 Hz,
0.35H); 6.40 (m, 1H); 7.04 (d, J=8.7 Hz, 1H); 7.16 (dd, J=2.2 and
8.7 Hz, 0.65H); 7.19 (dd, J=2.2 and 8.7 Hz, 0.35H); 7.20 to 7.34
(m, 5H); 7.58 (broad d, J=10.2 Hz, 0.65H); 7.64 (broad d, J=10.2
Hz, 0.35H); 8.00 (d, J=8.4 Hz, 0.65H); 8.07 (d, J=8.4 Hz, 0.35H);
8.35 (d, J=8.3 Hz, 0.65H); 8.44 (d, J=8.3 Hz, 0.35H). LCMS (A1): ES
m/z=654 [M-H].sup.-; m/z=656 [M+H].sup.+; t.sub.R=1.06 min.
Example 16:
(3S,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-16-((S)-1-(3-(4-(hydroxy-met-
hyl)phenyl)oxiran-2-yl)ethyl)-6,6-dimethyl-3-isopropyl-1-oxa-4,8,11-triaza-
cyclohexadec-13-ene-2,5,9,12-tetraone
##STR00741##
[1091] Example 16 was prepared following general route B depicted
in Scheme 2 and described for examples 4 and 11.
[1092] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 60/40
diastereoisomer mixture; 0.72 (d, J=7.0 Hz, 1.8H); 0.82 (d, J=7.0
Hz, 1.2H); 0.84 (d, J=7.0 Hz, 1.8H); 0.87 (d, J=7.0 Hz, 1.2H); 0.98
(s, 1.8H); 0.99 (d, J=7.0 Hz, 1.8H); 1.01 (s, 1.2H); 1.05 (d, J=7.0
Hz, 1.2H); 1.09 (s, 1.8H); 1.11 (s, 1.2H); 1.82 (m, 1H); 1.91 (m,
0.6H); 2.01 (m, 0.4H); 2.30 (m, 1H); 2.52 to 2.72 (m, 2H); 2.88 to
3.04 (m, 3H); 3.25 to 3.35 (masked m, 1H); 3.79 (d, J=2.2 Hz,
0.4H); 3.80 (s, 3H); 3.88 (d, J=2.2 Hz, 0.6H); 4.09 to 4.21 (m,
2H); 4.48 (d, J=5.8 Hz, 0.8H); 4.50 (d, J=5.8 Hz, 1.2H); 5.14 to
5.29 (m, 2H); 5.79 (dd, J=1.7 and 15.4 Hz, 0.6H); 5.90 (dd, J=1.7
and 15.4 Hz, 0.4H); 6.40 to 6.52 (m, 1H); 7.05 (d, J=8.7 Hz, 1H);
7.10 (dd, J=2.0 and 10.2 Hz, 1H); 7.17 (m, 1H); 7.21 to 7.35 (m,
5H); 7.70 (d, J=9.3 Hz, 0.6H); 7.80 (d, J=9.3 Hz, 0.4H); 8.39 (d,
J=8.0 Hz, 0.6H); 8.44 (d, J=8.0 Hz, 0.4H). LCMS (A1): ES m/z=682
[M-H].sup.-; m/z=684 [M+H].sup.+; t.sub.R=1.16 min.
Example 17:
(3S,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-16-((S)-1-(3-(4-(hydroxy-met-
hyl)phenyl)oxiran-2-yl)ethyl)-3-tert-butyl-6,6-dimethyl-1-oxa-4,8,11-triaz-
acyclohexadec-13-ene-2,5,9,12-tetraone
##STR00742##
[1094] Example 17 was prepared following general route B depicted
in Scheme 2 and described for examples 4 and 11.
[1095] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 50/50
diastereoisomer mixture; 0.90 (s, 4.5H); 0.91 (s, 4.5H); 1.00 (d,
J=7.0 Hz, 1.5H); 1.03 (s, 1.5H); 1.05 (s, 1.5H); 1.06 (d, J=7.0 Hz,
1.5H); 1.10 (s, 1.5H); 1.12 (s, 1.5H); 1.85 (m, 1H); 2.32 (m, 1H);
2.55 to 2.72 (m, 2H); 2.90 to 3.03 (m, 3H); 3.25 to 3.35 (masked m,
1H); 3.81 (s, 3H); 3.90 (d, J=2.2 Hz, 1H); 4.15 (m, 1H); 4.36 (d,
J=10.0 Hz, 0.5H); 4.43 (d, J=10.0 Hz, 0.5H); 4.49 (d, J=5.9 Hz,
1H); 4.51 (d, J=5.9 Hz, 1H); 5.15 (t, J=5.9 Hz, 0.5H); 5.18 (t,
J=5.9 Hz, 0.5H); 5.29 (m, 1H); 5.79 (dd, J=2.0 and 15.4 Hz, 0.5H);
5.90 (d, J=15.4 Hz, 0.5H); 6.39 (m, 1H); 6.91 (dd, J=2.5 and 10.4
Hz, 0.5H); 6.98 (dd, J=2.5 and 10.4 Hz, 0.5H); 7.05 (split d, J=8.7
Hz, 1H); 7.15 (split dd, J=2.4 and 8.7 Hz, 1H); 7.20 to 7.39 (m,
6H); 8.32 (d, J=7.9 Hz, 0.5H); 8.40 (d, J=7.9 Hz, 0.5H). LCMS (A4):
ES m/z=696 [M-H].sup.-; m/z=698 [M+H].sup.+; t.sub.R=4.13-4.16
min.
Example 18:
(3S,10R,16S,E)-16-((S)-1-((2R,3R)-3-(4-(aminomethyl)phenyl)oxiran-2-yl)et-
hyl)-10-(3-chloro-4-methoxybenzyl)-3-isobutyl-6,6,7-trimethyl-1-oxa-4,8,11-
-triazacyclohexadec-13-ene-2,5,9,12-tetraone
##STR00743##
[1097] Example 18 was prepared following general route A depicted
in Scheme 1 and described for example 8.
[1098] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 0.78 (d,
J=7.0 Hz, 3H); 0.84 (d, J=7.0 Hz, 3H); 0.87 (d, J=7.0 Hz, 3H); 1.00
(s, 3H); 1.03 (d, J=7.0 Hz, 3H); 1.19 (s, 3H); 1.30 (m, 1H); 1.50
to 1.90 (m, 5H); 2.28 (m, 1H); 2.55 to 2.76 (m, 2H); 2.90 to 3.00
(m, 2H); 3.48 (m, 1H); 3.70 (s, 2H); 3.80 (s, 3H); 3.89 (s, 1H);
4.02 to 4.15 (m, 2H); 5.06 (m, 1H); 5.88 (d, J=15.5 Hz, 1H); 6.47
(m, 1H); 7.03 (d, J=8.7 Hz, 1H); 7.20 (m, 3H); 7.31 (m, 3H); 7.80
(d, J=8.7 Hz, 1H); 7.89 (d, J=7.3 Hz, 1H); 8.41 (d, J=8.2 Hz,
1H).
Example 19: 2,5-dioxopyrrolidin-1-yl
5-(((S)-1-(((S)-1-((4-((2R,3R)-3-((S)-1-((3S,10R,16S,E)-10-(3-chloro-4-me-
thoxybenzyl)-3-isobutyl-6,6,7-trimethyl-2,5,9,12-tetraoxo-1-oxa-4,8,11-tri-
azacyclohexadec-13-en-16-yl)ethyl)oxiran-2-yl)benzyl)amino)-1-oxopropan-2--
yl)amino)-3-methyl-1-oxobutan-2-yl)amino)-5-oxopentanoate
##STR00744##
[1100] Example 19 was prepared as depicted in Scheme 3 and
described for examples 2, 6, 9 and 13. RMN .sup.1H (500 MHz,
.delta. in ppm, DMSO-d6): 0.79 (d, J=7.0 Hz, 3H); 0.81 to 0.89 (m,
18H); 1.01 (s, 3H); 1.03 (d, J=7.0 Hz, 3H); 1.20 (s, 3H); 1.24 (d,
J=7.0 Hz, 3H); 1.31 (m, 1H); 1.60 to 1.74 (m, 2H); 1.78 to 1.86 (m,
3H); 1.96 (m, 1H); 2.21 to 2.31 (m, 3H); 2.55 to 2.72 (m, 4H); 2.80
(s, 4H); 2.96 (m, 2H); 3.47 (m, 1H); 3.80 (s, 3H); 3.89 (d, J=2.2
Hz, 1H); 4.03 to 4.14 (m, 2H); 4.17 (dd, J=6.8 and 8.6 Hz, 1H);
4.21 to 4.33 (m, 3H); 5.06 (m, 1H); 5.89 (d, J=15.5 Hz, 1H); 6.47
(ddd, J=5.2, 10.5 and 15.5 Hz, 1H); 7.02 (d, J=8.7 Hz, 1H); 7.20
(dd, J=2.3 and 8.7 Hz, 1H); 7.23 (m, 4H); 7.32 (d, J=2.3 Hz, 1H);
7.80 (d, J=8.3 Hz, 1H); 7.89 (m, 2H); 8.04 (d, J=7.6 Hz, 1H); 8.32
(t, J=6.3 Hz, 1H); 8.42 (d, J=7.6 Hz, 1H). LCMS (A1): ES m/z=1092
[M+H].sup.+; m/z=1136 [M-H+HCO.sub.2H].sup.-; t.sub.R=1.23 min.
Example 20: mAb-Ex19
##STR00745##
[1102] Example 20 was prepared in a similar way to examples 3, 7,
10 and 14. 45 mg of example 20 were obtained as a colorless limpid
solution at a concentration of 2.55 mg/mL with a DAR of 4.4 (HRMS),
a monomeric purity of 99.1% and a global yield of 78%.
[1103] SEC-HRMS: spectrum for intact ADC in FIG. 5; m/z=150368
(D1); m/z=151350 (D2); m/z=152327 (D3); m/z=153304 (D4); m/z=154281
(D5); m/z=155255 (D6); m/z=156237 (D7); m/z=157217 (D8).
Example 21:
(3S,10R,16S,E)-16-((S)-1-(3-(4-(aminomethyl)phenyl)oxiran-2-yl)ethyl)-10--
(3-chloro-4-methoxybenzyl)-7-cyclopropyl-3-isobutyl-6,6-dimethyl-1-oxa-4,8-
,11-triazacyclo-hexadec-13-ene-2,5,9,12-tetraone
##STR00746##
[1105] Example 21 was prepared following general route A depicted
in Scheme 1 and described for examples 1 and 8.
Example 22: 2,5-dioxopyrrolidin-1-vi
5-(((S)-1-(((S)-1-((4-((2R,3R)-3-((S)-1-((3S,10R,16S,E)-10-(3-chloro-4-me-
thoxybenzyl)-7-cyclopropyl-3-isobutyl-6,6-dimethyl-2,5,9,12-tetraoxo-1-oxa-
-4,8,11-triazacyclohexadec-13-en-16-yl)ethyl)oxiran-2-yl)benzyl)amino)-1-o-
xopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)amino)-5-oxopentanoate
##STR00747##
[1107] Example 22 was prepared as depicted in Scheme 3 and
described for examples 2, 6, 9 and 13. RMN .sup.1H (500 MHz,
.delta. in ppm, DMSO-d6): 0.34 (m, 1H); 0.66 (m, 1H); 0.74 (d,
J=7.0 Hz, 3H); 0.76 (d, J=7.0 Hz, 3H); 0.78 (s, 3H); 0.80 (m, 1H);
0.82 (d, J=7.0 Hz, 3H); 0.85 (d, J=7.0 Hz, 3H); 1.04 (d, J=7.0 Hz,
3H); 1.08 (s, 3H); 1.11 (m, 1H); 1.20 (m, 1H); 1.23 (d, J=7.0 Hz,
3H); 1.43 to 1.54 (m, 2H); 1.78 (m, 1H); 1.82 (m, 2H); 1.98 (m,
1H); 2.22 (m, 1H); 2.28 (m, 2H); 2.65 (m, 3H); 2.79 (m, 1H); 2.81
(s, 4H); 2.97 (dd, J=2.2 and 7.9 Hz, 1H); 3.80 (s, 3H); 3.89 (d,
J=2.2 Hz, 1H); 4.02 (m, 1H); 4.17 (dd, J=6.7 and 8.7 Hz, 1H); 4.27
(d, J=6.3 Hz, 2H); 4.30 (m, 1H); 4.37 (m, 1H); 5.10 (m, 1H); 5.79
(dd, J=1.8 and 15.5 Hz, 1H); 6.39 (ddd, J=4.0, 11.6 and 15.5 Hz,
1H); 7.02 (d, J=8.7 Hz, 1H); 7.11 (dd, J=2.3 and 8.7 Hz, 1H); 7.20
(d, J=2.3 Hz, 1H); 7.22 (m, 4H); 7.46 (s, 1H); 7.77 (d, J=9.0 Hz,
1H); 7.89 (d, J=8.6 Hz, 1H); 8.05 (d, J=7.5 Hz, 1H); 8.29 (d, J=7.6
Hz, 1H); 8.32 (t, J=6.3 Hz, 1H).
Example 23: mAb-Ex22
##STR00748##
[1109] Example 23 was prepared in a similar way to examples 3, 7,
10 and 14. 45 mg of example 23 were obtained as a colorless limpid
solution at a concentration of 2.14 mg/mL with a DAR of 3.6 (HRMS),
a monomeric purity of 100% and a global yield of 75%.
[1110] SEC-HRMS: spectrum for intact ADC in FIG. 6; m/z=150341
(D1); m/z=151329 (D2); m/z=152317 (D3); m/z=153308 (D4); m/z=154296
(D5); m/z=155287 (D6); m/z=156279 (D7); m/z=157267 (D8).
Example 24:
(3S,7S,10R,16S,E)-16-((S)-1-((2R,3R)-3-(4-(azidomethyl)phenyl)oxiran-2-yl-
)-ethyl)-10-(3-chloro-4-methoxybenzyl)-6,6,7-trimethyl-3-neopentyl-1-oxa-4-
,8,11-triazacyclohexadec-13-ene-2,5,9,12-tetraone
##STR00749##
[1112] Example 24 was prepared following general route C depicted
in Scheme 3 and described for example 32.
[1113] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 0.83 (s,
9H); 0.88 (d, J=6.8 Hz, 3H); 1.00 (s, 3H); 1.03 (d, J=7.1 Hz, 3H);
1.19 (s, 3H); 1.33 (d, J=14.5 Hz, 1H); 1.84 (m, 1H); 1.97 (dd,
J=9.8 and 14.5 Hz, 1H); 2.27 (dd, J=11.1 and 14.5 Hz, 1H); 2.61 (m,
1H); 2.69 (dd, J=11.1 and 14.2 Hz, 1H); 2.92 (dd, J=2.1 and 7.7 Hz,
1H); 2.96 (dd, J=3.6 and 14.2 Hz, 1H); 3.43 (m, 1H); 3.80 (s, 3H);
3.96 (d, J=2.1 Hz, 1H); 4.08 (ddd, J=3.6, 7.1 and 11.1 Hz, 1H);
4.12 (m, 1H); 4.46 (s, 2H); 5.05 (ddd, J=1.3, 3.9 and 11.3 Hz, 1H);
5.90 (dd, J=1.3 and 15.3 Hz, 1H); 6.45 (ddd, J=4.7, 10.7 and 15.3
Hz, 1H); 7.02 (d, J=8.7 Hz, 1H); 7.20 (dd, J=2.4 and 8.7 Hz, 1H);
7.32 (m, 3H); 7.40 (d, J=8.4 Hz, 2H); 7.88 (d, J=8.4 Hz, 1H); 7.92
(d, J=7.1 Hz, 1H); 8.40 (d, J=7.4 Hz, 1H). LCMS (A5): ES m/z=749
[M-H].sup.-; m/z=751 [M+H].sup.+; m/z=795 [M-H+HCO.sub.2H].sup.-;
t.sub.R=1.52 min.
Example 25:
(3S,7S,10R,16S,E)-16-((S)-1-((2R,3R)-3-(4-(aminomethyl)phenyl)oxiran-2-yl-
)ethyl)-10-(3-chloro-4-methoxybenzyl)-6,6,7-trimethyl-3-neopentyl-1-oxa-4,-
8,11-triazacyclohexadec-13-ene-2,5,9,12-tetraone
##STR00750##
[1115] Example 25 was prepared as described for examples 1, 5, 8
and 11.
[1116] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.86 (s,
9H); 0.88 (d, J=6.9 Hz, 3H); 0.98 (s, 3H); 1.02 (d, J=7.1 Hz, 3H);
1.18 (s, 3H); 1.34 (d, J=14.5 Hz, 1H); 1.80 (m, 1H); 1.98 (dd,
J=9.8 and 14.5 Hz, 1H); 2.27 (dd, J=11.1 and 14.5 Hz, 1H); 2.40
(broad m, 2H); 2.62 (m, 1H); 2.68 (dd, J=11.1 and 14.2 Hz, 1H);
2.90 (dd, J=2.1 and 7.7 Hz, 1H); 2.96 (dd, J=3.6 and 14.2 Hz, 1H);
3.43 (m, 1H); 3.76 (s, 2H); 3.80 (s, 3H); 3.91 (d, J=2.1 Hz, 1H);
4.02 to 4.15 (m, 2H); 5.04 (ddd, J=1.3, 3.9 and 11.3 Hz, 1H); 5.88
(dd, J=1.3 and 15.4 Hz, 1H); 6.45 (ddd, J=4.7, 10.7 and 15.3 Hz,
1H); 7.03 (d, J=8.5 Hz, 1H); 7.20 (dd, J=2.2 and 8.5 Hz, 1H); 7.23
(d, J=8.3 Hz, 2H); 7.32 (d, J=2.2 Hz, 2H); 7.36 (d, J=8.3 Hz, 2H);
7.86 (d, J=8.3 Hz, 1H); 7.93 (d, J=6.9 Hz, 1H); 8.40 (d, J=7.1 Hz,
1H). LCMS (A5): ES m/z=723 [M-H].sup.-; m/z=725 [M+H].sup.+;
m/z=769 [M-H+HCO.sub.2H].sup.-; t.sub.R=0.87 min.
Synthesis of Examples 26 to 28: 3-(S)-neopentyl-7-(S)-Me-aza-C52
Benzylic Alcohol, NHS Ester of
Glutaryl-Val-Ala-EDA-3-(S)-neopentyl-7-(S)-Me-aza-C52 Benzylic
Alcohol and Corresponding ADC
##STR00751## ##STR00752## ##STR00753##
[1117] Compound 58:
(2R,3S)-1-((4-methoxybenzyl)oxy)-2-methylhex-5-en-3-yl(S)-2-((S)-3-((R)-2-
-acrylamido-3-(3-chloro-4-methoxyphenyl)propanamido)-2,2-dimethylbutanamid-
o)-4,4-dimethylpentanoate
[1118] To a solution of compound BC4 (365 mg, 919.7 .mu.mol) in DMF
(12 mL) were added HATU (402 mg, 1.06 mmol) and HOAt (144 mg, 1.06
mmol), the reaction medium was stirred at RT for 30 min then were
added a solution of compound AD3 (365 mg, 965.7 .mu.mol) in DMF (5
mL) and DIEA (562 .mu.L, 3.22 mmol). The reaction medium was
stirred at RT for 4 h, then diluted with H.sub.2O (50 mL) and
extracted with EtOAc (3.times.50 mL). The combined organic phases
were washed with H.sub.2O (15 mL), sat. brine (3.times.15 mL),
dried over MgSO.sub.4, filtered, concentrated in vacuo and purified
by two successive flash chromatographies on 30 g of silica gel
(gradient elution DCM/MeOH and heptane/EtOAc) to give 564 mg of
compound 58 as a colorless foam (81%).
[1119] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.83 (d,
J=6.9 Hz, 3H); 0.85 (s, 9H); 0.87 (d, J=6.9 Hz, 3H); 1.00 (s, 3H);
1.03 (s, 3H); 1.55 (dd, J=2.4 and 14.5 Hz, 1H); 1.78 (dd, J=9.5 and
14.5 Hz, 1H); 1.96 (m, 1H); 2.20 (m, 1H); 2.30 (m, 1H); 2.72 (dd,
J=9.6 and 13.9 Hz, 1H); 2.87 (dd, J=5.3 and 13.9 Hz, 1H); 3.20 (dd,
J=6.5 and 9.5 Hz, 1H); 3.37 (dd, J=5.4 and 9.5 Hz, 1H); 3.76 (s,
3H); 3.80 (s, 3H); 4.19 (m, 1H); 4.28 (m, 1H); 4.34 (s, 2H); 4.55
(m, 1H); 4.82 (m, 1H); 5.00 (d, J=10.2 Hz, 1H); 5.07 (d, J=17.4 Hz,
1H); 5.55 (dd, J=2.3 and 10.2 Hz, 1H); 5.71 (m, 1H); 6.01 (dd,
J=2.3 and 17.1 Hz, 1H); 6.28 (dd, J=10.2 and 17.1 Hz, 1H); 6.90 (d,
J=8.7 Hz, 2H); 7.02 (d, J=8.6 Hz, 1H); 7.17 (dd, J=2.3 and 8.6 Hz,
1H); 7.22 (d, J=8.7 Hz, 2H); 7.32 (d, J=2.3 Hz, 1H); 7.65 (d, J=9.5
Hz, 1H); 7.70 (d, J=7.9 Hz, 1H); 8.35 (d, J=8.4 Hz, 1H). LCMS (A5):
ES m/z=754 [M-H].sup.-; m/z=756 [M+H].sup.+; m/z=800
[M-H+HCO.sub.2H].sup.-; t.sub.R=1.62 min.
Compound 59:
(3S,7S,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-16-((R)-1-((4-methoxy-ben-
zyl)oxy)propan-2-yl)-6,6,7-trimethyl-3-neopentyl-1-oxa-4,8,11-triazacycloh-
exadec-13-ene-2,5,9,12-tetraone
[1120] To a solution of compound 58 (560 mg, 740.4 .mu.mol) in DCM
(56 mL) was added under Ar Grubbs I catalyst (31.0 mg, 37.02
.mu.mol). The reaction medium was stirred at RT for 1 h 30 before
the addition of 31.0 mg of catalyst. Stirring was carried on at RT
for 1 h 30 before the addition of 31.0 mg of catalyst. Stirring was
carried on at RT for 1 h 30 before the addition of 31.0 mg of
catalyst and the reaction medium was stirred at RT for 1 h 30. It
was the concentrated in vacuo and purified by flash chromatography
on 25 g of silica gel (gradient elution DCM/MeOH) to give 330 mg of
compound 59 (61%) and 220 mg that were further purified by flash
chromatography on 15 g of silica gel (gradient elution DCM/MeOH) to
give 204 mg of compound 59 (37%) as a mixture with
tricyclohexylphosphine oxide.
[1121] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.85 (s,
9H); 0.88 (d, J=6.9 Hz, 3H); 0.91 (d, J=7.1 Hz, 3H); 1.04 (s, 3H);
1.20 (s, 3H); 1.29 (d, J=14.5 Hz, 1H); 1.95 (dd, J=9.8 and 14.5 Hz,
1H); 1.99 (m, 1H); 2.26 (m, 1H); 2.43 (m, 1H); 2.72 (dd, J=10.1 and
14.3 Hz, 1H); 2.97 (dd, J=3.6 and 14.3 Hz, 1H); 3.27 (dd, J=6.1 and
9.3 Hz, 1H); 3.40 (dd, J=5.8 and 9.3 Hz, 1H); 3.46 (m, 1H); 3.72
(s, 3H); 3.80 (s, 3H); 4.10 (m, 1H); 4.13 (m, 1H); 4.38 (s, 2H);
4.97 (m, 1H); 5.93 (d, J=15.4 Hz, 1H); 6.43 (ddd, J=4.8, 10.7 and
15.4 Hz, 1H); 6.90 (d, J=8.7 Hz, 2H); 7.02 (d, J=8.6 Hz, 1H); 7.17
(d, J=8.6 Hz, 3H); 7.36 (d, J=2.3 Hz, 1H); 7.88 (m, 2H); 8.48 (d,
J=7.5 Hz, 1H). LCMS (A5): ES m/z=726 [M-H].sup.-; m/z=728
[M+H].sup.+; m/z=772 [M-H+HCO.sub.2H].sup.-; t.sub.R=1.54 min.
Compound 60:
(3S,7S,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-16-((R)-1-hydroxypropan-2-
-yl)-6,6,7-trimethyl-3-neopentyl-1-oxa-4,8,11-triazacyclohexadec-13-ene-2,-
5,9,12-tetraone
[1122] Compound 59 (532 mg, 730.4 .mu.mol) was treated with a
solution of TFA (3.93 mL) in DCM (36 mL) at RT for 30 min. The
reaction medium was poured on 9% aq. NaHCO.sub.3 (130 mL) under
magnetic stirring. Stirring was carried on for 30 min then the
aqueous phase was extracted with DCM (2.times.70 mL). The combined
organic phases were washed with H.sub.2O (3.times.20 mL), dried
over MgSO.sub.4, filtered, concentrated in vacuo and purified by
flash chromatography on 30 g of silica gel (gradient elution
DCM/MeOH) to give 299 mg of compound 60 as a white foam (67%).
[1123] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.88 (d,
J=6.9 Hz, 3H); 0.89 (s, 9H); 0.90 (d, J=7.0 Hz, 3H) 1.03 (s, 3H);
1.20 (s, 3H); 1.36 (dd, J=1.8 and 14.5 Hz, 1H); 1.80 (m, 1H); 1.96
(dd, J=9.6 and 14.5 Hz, 1H); 2.25 (m, 1H); 2.43 (m, 1H); 2.72 (dd,
J=11.1 and 14.3 Hz, 1H); 2.97 (dd, J=3.8 and 14.3 Hz, 1H); 3.25 (m,
1H); 3.45 (m, 2H); 3.80 (s, 3H); 4.10 (m, 1H); 4.16 (m, 1H); 4.57
(t, J=5.3 Hz, 1H); 4.98 (m, 1H); 5.93 (dd, J=1.3 and 15.3 Hz, 1H);
6.45 (ddd, J=4.9, 10.7 and 15.3 Hz, 1H); 7.02 (d, J=8.6 Hz, 1H);
7.22 (dd, J=2.3 and 8.6 Hz, 1H); 7.36 (d, J=2.3 Hz, 1H); 7.89 (m,
2H); 8.48 (d, J=7.3 Hz, 1H). LCMS (A5): ES m/z=606 [M-H].sup.-;
m/z=608 [M+H].sup.+; t.sub.R=1.2 min.
Compound 61:
(S)-2-((3S,7S,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-6,6,7-trimethyl-3--
neopentyl-2,5,9,12-tetraoxo-1-oxa-4,8,11-triazacyclohexadec-13-en-16-yl)pr-
opanal
[1124] To a solution of compound 60 (297 mg, 488.4 .mu.mol) in DCM
(6 mL) cooled with an ice/acetone bath were added at 0.degree. C. a
solution of KBr (58.11 mg, 488.4 .mu.mol) in H.sub.2O (1.18 mL),
TEMPO (1.57 mg, 9.8 .mu.mol) and dropwise an aqueous solution of
1.56M sodium hypochlorite pH 9.5 (467.6 .mu.L, 732.52 .mu.mol).
Stirring was carried on at 0.degree. C. for 15 min then was added
at 0.degree. C. sat. Na.sub.2S.sub.2O.sub.3 (3.56 mL), the ice bath
was removed and the reaction medium stirred for 10 min. It was then
extracted with DCM (3.times.25 mL), the combined organic phases
were washed with H.sub.2O (2.times.10 mL), dried over MgSO.sub.4,
filtered, concentrated in vacuo and purified by flash
chromatography on 15 g of silica gel (gradient elution DCM/MeOH) to
give 139 mg of compound 61 as a white lacquer (47%).
[1125] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.85 (s,
9H); 0.90 (d, J=7.0 Hz, 3H); 1.03 (s, 3H); 1.04 (d, J=6.9 Hz, 3H);
1.20 (s, 3H); 1.26 (d, J=15.3 Hz, 1H); 1.95 (m, 1H); 2.44 (m, 1H);
2.57 (m, 1H); 2.72 (dd, J=11.2 and 14.4 Hz, 1H); 2.80 (m, 1H); 2.98
(dd, J=3.1 and 14.4 Hz, 1H); 3.80 (s, 3H); 4.10 (m, 3H); 5.22 (m,
1H); 5.98 (d, J=15.3 Hz, 1H); 6.47 (ddd, J=4.9, 10.8 and 15.3 Hz,
1H); 7.04 (d, J=8.7 Hz, 1H); 7.22 (dd, J=2.3 and 8.7 Hz, 1H); 7.37
(s, 1H); 7.90 (m, 1H); 7.92 (d, J=8.2 Hz, 1H); 8.53 (d, J=7.6 Hz,
1H); 9.68 (s, 1H). LCMS (A5): ES m/z=604 [M-H].sup.-; m/z=606
[M+H].sup.+; m/z=650 [M-H+HCO.sub.2H].sup.-; t.sub.R=1.28 min.
Compound 62: (4-(((triisopropylsilyl)oxy)methyl)phenyl)methanol
[1126] To a solution of 1,4-benzenedimethanol (2 g, 14.33 mmol) in
THE (100 mL) was added imidazole (1.13 g, 16.48 mmol). The reaction
medium was stirred at RT for 15 min then was added
triisopropylsilyl chloride (3.14 mL, 14.33 mmol) and stirring was
carried on at RT overnight. Et.sub.2O (50 mL) was added to the
reaction mixture and the organic phase was washed twice with sat.
brine (100 mL), filtered over MgSO.sub.4, concentrated in vacuo,
dissolved in DCM, filtered, concentrated in vacuo and purified by
flash chromatography on 200 g of silica gel (isocratic elution 8:2
heptane/EtOAc) to give 1.9 g of compound 62 as a colorless oil
(45%).
[1127] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 1.04 (d,
J=6.7 Hz, 18H); 1.15 (m, 3H); 4.48 (d, J=5.7 Hz, 2H); 4.78 (s, 2H);
5.13 (t, J=5.7 Hz, 1H); 7.29 (s, 4H).
Compound 63: ((4-(bromomethyl)benzyl)oxy)triisopropylsilane
[1128] To a suspension of N-bromosuccinimide (1.29 g, 7.16 mmol) in
DCM (65 mL) cooled at 0.degree. C. was added dropwise dimethyl
sulfide (953 .mu.L, 12.9 mmol). Stirring was carried on at
0.degree. C. for 10 min then the reaction medium was cooled at
-20.degree. C. and stirred at -20.degree. C. for 10 min. A solution
of compound 62 (1.9 g, 6.45 mmol) in DCM (30 mL) cooled at
-20.degree. C. was then added dropwise. Stirring was carried on at
-20.degree. C. for 15 min then at 0.degree. C. for 15 min and at RT
overnight. The reaction medium was washed twice with sat. brine
(100 mL), dried over MgSO.sub.4, filtered, concentrated in vacuo
and purified by two successive flash chromatographies on 40 g of
silica gel (gradient elution heptane/EtOAc). The fractions
containing the expected compound were combined, concentrated in
vacuo and dissolved in heptane (8 mL). The suspension was filtered,
the filtrate concentrated in vacuo, dissolved in Et.sub.2O (5 mL),
cooled at -20.degree. C., filtered, concentrated in vacuo to give
1.18 g of compound 63 as a pale yellow oil (51%).
[1129] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 1.04 (d,
J=6.8 Hz, 18H); 1.15 (m, 3H); 4.70 (s, 2H); 4.81 (s, 2H); 7.29 (d,
J=8.4 Hz, 2H); 7.41 (d, J=8.4 Hz, 2H). LCMS (A5): ES m/z=104;
m/z=356 [M].sup.+; t.sub.R=1.99 min.
Compound 64:
(1R,4S,5R,6S)-4,7,7-trimethyl-6-(4-(((triisopropylsilyl)oxy)methyl)benzyl-
)-6-thiabicyclo[3.2.1]octan-6-ium trifluoromethanesulfonate
[1130] To (1R,4R,5R)-4,7,7-trimethyl-6-thiabicyclo[3.2.1]octane
(CAS number [5718-75-2], 562.3 mg, 3.3 mmol) was added a solution
of compound 63 (1.18 g, 3.3 mmol) in DCM (3.4 mL). A solution of
lithium trifluoromethanesulfonate (2.63 g, 16.51 mmol) in H.sub.2O
(3 mL) was then added dropwise and the reaction medium was stirred
at RT overnight. H.sub.2O (15 mL) and DCM (15 mL) were then added
to the reaction medium and stirring carried on at RT for 10 min.
The aqueous phase was extracted with DCM (3.times.20 mL), the
combined organic phases were washed with sat. brine (3.times.8 mL),
dried over MgSO.sub.4, filtered and concentrated in vacuo. The pale
yellow oil was triturated in iPr.sub.2O (5 mL), the solid thus
obtained was filtered, washed with iPr.sub.2O (2.times.5 mL) and
dried under vacuum to give 1.125 g of compound 64 as a white solid
(57%).
[1131] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 1.04 (m,
21H); 1.15 (m, 3H); 1.45 (m, 1H); 1.60 (m, 2H); 1.68 (s, 3H); 1.71
(m, 1H); 1.74 (s, 3H); 1.98 (m, 1H); 2.40 (d, J=14.6 Hz, 1H); 2.45
(m, 1H); 2.58 (broad d, J=14.6 Hz, 1H); 3.85 (m, 1H); 4.56 (d,
J=12.6 Hz, 1H); 4.83 (s, 2H); 4.90 (d, J=12.6 Hz, 1H); 7.44 (d,
J=8.4 Hz, 2H); 7.57 (d, J=8.4 Hz, 2H).
Compound 65:
(3S,7S,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-6,6,7-trimethyl-3-neopent-
yl-16-((S)-1-((2R,3R)-3-(4-(((triisopropylsilyl)oxy)methyl)phenyl)oxiran-2-
-yl)ethyl)-1-oxa-4,8,11-triazacyclohexadec-13-ene-2,5,9,12-tetraone
[1132] To a solution of compounds 61 (138 mg, 227.7 .mu.mol) and 64
(149.5 mg, 250.4 .mu.mol) in DCM (4 mL) cooled at -70.degree. C.
was added dropwise BEMP (CAS number [98015-45-3], 90.2 .mu.L, 296.0
.mu.mol). The reaction mixture was stirred at -70.degree. C. for 2
h, sat. brine (7 mL) was added to the reaction mixture, the bath
removed and stirring carried on vigorously up to RT. The aqueous
phase was extracted with DCM (3.times.20 mL), the combined organic
phases were dried over MgSO.sub.4, filtered, concentrated in vacuo
and purified by flash chromatography on 10 g of silica gel (gradien
elution DCM/MeOH) to give 163 mg of compound 65 as a colorless oil
(30%) and 60 mg of compound 61 (43%).
[1133] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 0.84 (s,
9H); 0.88 (d, J=6.9 Hz, 3H); 1.00 (s, 3H); 1.04 (d, J=7.1 Hz, 3H);
1.05 (d, J=7.3 Hz, 18H); 1.15 (m, 3H); 1.19 (s, 3H); 1.32 (d,
J=14.8 Hz, 1H); 1.82 (m, 1H); 1.97 (dd, J=9.9 and 14.8 Hz, 1H);
2.28 (dt, J=11.1 and 14.9 Hz, 1H); 2.61 (m, 1H); 2.69 (dd, J=11.2
and 14.3 Hz, 1H); 2.91 (dd, J=2.2 and 7.6 Hz, 1H); 2.95 (dd, J=3.8
and 14.3 Hz, 1H); 3.43 (m, 1H); 3.80 (s, 3H); 3.91 (d, J=2.2 Hz,
1H); 4.08 (ddd, J=3.8, 7.4 and 11.2 Hz, 1H); 4.12 (m, 1H); 4.81 (s,
2H); 5.04 (ddd, J=1.5, 4.5 and 11.1 Hz, 1H); 5.89 (dd, J=1.5 and
15.2 Hz, 1H); 6.44 (ddd, J=4.5, 10.6 and 15.2 (d, J=2.3 Hz, 1H);
7.36 (d, J=8.4 Hz, 2H); 7.88 (d, J=8.4 Hz, 1H); 7.91 (d, J=7.1 Hz,
1H); 8.39 (d, J=7.4 Hz, 1H). LCMS (A4): ES m/z=120; m/z=882
[M+H].sup.+; t.sub.R=7.65 min.
Example 26:
(3S,7S,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-16-((S)-1-((2R,3R)-3-(4-(-
hydroxymethyl)phenyl)oxiran-2-yl)ethyl)-6,6,7-trimethyl-3-neopentyl-1-oxa--
4,8,11-triazacyclohexadec-13-ene-2,5,9,12-tetraone
[1134] To a solution of compound 65 in THE cooled at 0.degree. C.
was added TBAF. The reaction medium was stirred at 0.degree. C. for
1 h 30 then H.sub.2O (5 mL) was added and stirring carried on for
20 min. The reaction medium was extracted with DCM (3.times.20 mL),
the combined organic phase were washed with sat. brine (3.times.5
mL), dried over MgSO.sub.4, filtered, concentrated in vacuo and
purified by flash chromatography on 15 g of silica gel (gradient
elution EtOAc/MeOH/H.sub.2O) to give 69 mg of example 26 as a white
lacquer (91%).
[1135] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.85 (s,
9H); 0.89 (d, J=6.9 Hz, 3H); 1.00 (s, 3H); 1.04 (d, J=7.1 Hz, 3H);
1.19 (s, 3H); 1.35 (d, J=14.8 Hz, 1H); 1.80 (m, 1H); 1.99 (dd,
J=9.9 and 14.8 Hz, 1H); 2.27 (dt, J=11.1 and 14.9 Hz, 1H); 2.61 (m,
1H); 2.69 (dd, J=11.2 and 14.3 Hz, 1H); 2.90 (dd, J=2.2 and 7.6 Hz,
1H); 2.95 (dd, J=3.8 and 14.3 Hz, 1H); 3.43 (m, 1H); 3.80 (s, 3H);
3.91 (d, J=2.2 Hz, 1H); 4.06 to 4.15 (m, 2H); 4.50 (d, J=5.9 Hz,
2H); 5.03 (dd, J=1.5, 3.7 and 11.5 Hz, 1H); 5.20 (t, J=5.9 Hz, 1H);
5.89 (dd, J=1.5 and 15.3 Hz, 1H); 6.43 (ddd, J=4.6, 10.7 and 15.3
Hz, 1H); 7.02 (d, J=8.6 Hz, 1H); 7.20 (dd, J=2.2 and 8.6 Hz, 1H);
7.23 (d, J=8.3 Hz, 2H); 7.32 (m, 3H); 7.87 (d, J=8.3 Hz, 1H); 7.92
(d, J=7.0 Hz, 1H); 8.40 (d, J=7.4 Hz, 1H). LCMS (A5): ES m/z=724
[M-H].sup.-; m/z=726 [M+H].sup.+; m/z=770 [M-H+HCO.sub.2H].sup.-;
t.sub.R=1.29 min.
Compound 66:
4-((2R,3R)-3-((S)-1-((3S,7S,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-6,6,-
7-trimethyl-3-neopentyl-2,5,9,12-tetraoxo-1-oxa-4,8,11-triazacyclohexadec--
13-en-16-yl)ethyl)oxiran-2-yl)benzyl(4-nitrophenyl) Carbonate
[1136] To a solution of example 26 (68 mg, 93.6 .mu.mol) in DCM (5
mL) were added bis(4-nitrophenyl)carbonate (118.7 mg, 374.5
.mu.mol) and dropwise DIEA (49 .mu.L, 281.0 .mu.mol). The reaction
medium was stirred at RT for 6 d then sat. brine was added and it
was extracted with DCM (3.times.10 mL). The combined organic phases
were dried over MgSO.sub.4, filtered, concentrated in vacuo and
purified by flash chromatography on 5 g of silica gel (gradient
elution DCM/MeOH) to give 79 mg of compound 66 as a white lacquer
(94%).
[1137] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.85 (s,
9H); 0.89 (d, J=6.9 Hz, 3H); 1.00 (s, 3H); 1.05 (d, J=7.1 Hz, 3H);
1.19 (s, 3H); 1.34 (d, J=14.6 Hz, 1H); 1.83 (m, 1H); 1.97 (dd,
J=9.9 and 14.6 Hz, 1H); 2.28 (dt, J=11.1 and 14.9 Hz, 1H); 2.61 (m,
1H); 2.69 (dd, J=11.2 and 14.3 Hz, 1H); 2.93 (m, 2H); 3.42 (m, 1H);
3.79 (s, 3H); 3.99 (d, J=2.2 Hz, 1H); 4.09 (m, 2H); 5.05 (dd,
J=1.3, 4.0 and 11.1 Hz, 1H); 5.31 (s, 2H); 5.89 (dd, J=1.3 and 15.3
Hz, 1H); 6.47 (ddd, J=4.8, 10.8 and 15.3 Hz, 1H); 7.01 (d, J=8.6
Hz, 1H); 7.21 (dd, J=2.2 and 8.6 Hz, 1H); 7.31 (d, J=2.2 Hz, 1H);
7.36 (d, J=8.5 Hz, 2H); 7.50 (d, J=8.5 Hz, 2H); 7.59 (d, J=9.3 Hz,
2H); 7.87 (d, J=8.3 Hz, 1H); 7.92 (d, J=7.0 Hz, 1H); 8.32 (d, J=9.3
Hz, 2H); 8.39 (d, J=7.4 Hz, 1H). LCMS (A5): ES m/z=889 [M-H].sup.-;
m/z=891 [M+H].sup.+; m/z=935 [M-H+HCO.sub.2H].sup.-; t.sub.R=1.55
min.
Compound 67:
(9H-fluoren-9-yl)methyl((S)-1-(((S)-1-((2-NBoc-aminoethyl)amino)-1-oxopro-
pan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate
hydrochloride
[1138] To a suspension of Fmoc-Val-Ala-OH (3.5 g, 8.53 mmol) in DCM
(100 mL) were added TEA (3.6 mL, 25.58 mL) leading to complete
dissolution of starting material, N-Boc-EDA (1.62 mL, 10.23 mmol)
and a solution of propylphosphonic anhydride (6.51 g, 10.23 mmol)
50% in DCM. The reaction medium was stirred at RT for 3 h then 1N
NaOH (50 mL) was added and the suspension filtered, washed with
H.sub.2O and DCM. The organic phase of the filtrate was washed with
H.sub.2O. The cake and the organic phase were combined, partially
concentrated in vacuo, filtered, washed with DCM and dried to give
3.952 g of compound 67 as a white powder (84%).
[1139] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.84 (d,
J=7.0 Hz, 3H); 0.86 (d, J=7.0 Hz, 3H); 1.19 (d, J=7.1 Hz, 3H); 1.37
(s, 9H); 1.99 (m, 1H); 2.92 to 3.14 (m, 4H); 3.88 (dd, J=6.9 and
9.1 Hz, 1H); 4.19 to 4.35 (m, 4H); 6.71 (m, 1H); 7.32 (m, 2H); 7.38
(m, 1H); 7.42 (m, 2H); 7.73 (m, 2H); 7.84 (t, J=6.8 Hz, 1H); 7.89
(d, J=7.8 Hz, 2H); 7.92 (d, J=7.8 Hz, 1H).
Compound 68:
(9H-fluoren-9-yl)methyl((S)-1-(((S)-1-((2-aminoethyl)amino)-1-oxopropan-2-
-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate Hydrochloride
[1140] To as suspension of compound 67 (100 mg, 159.5 .mu.mol) in
dioxane (3 mL) was added HCl 4N in dioxane (905 .mu.L, 3.62 mmol).
The reaction medium was stirred at RT for 20 h then concentrated in
vacuo. The crude product was resuspended in iPr.sub.2O (3 mL),
immersed in an ultrasonic bath and filtered. The cake thus obtained
was washed with iPr.sub.2O (2.times.3 mL) and dried under vacuum to
give 78 mg of compound 68 as a white solid (88%).
[1141] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.85 (d,
J=6.9 Hz, 3H); 0.87 (d, J=6.9 Hz, 3H); 1.23 (d, J=7.1 Hz, 3H); 1.99
(m, 1H); 2.83 (m, 2H); 3.29 (m, 2H); 3.89 (dd, J=6.9 and 8.9 Hz,
1H); 4.19 to 4.38 (m, 4H); 7.33 (m, 2H); 7.42 (m, 3H); 7.75 (m,
2H); 7.88 (broad s, 3H); 7.90 (d, J=7.6 Hz, 2H); 8.08 (d, J=7.3 Hz,
1H); 8.14 (d, J=5.9 Hz, 1H).
Compound 69:
4-((2R,3R)-3-((S)-1-((3S,7S,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-6,6,-
7-trimethyl-3-neopentyl-2,5,9,12-tetraoxo-1-oxa-4,8,11-triazacyclohexadec--
13-en-16yl)ethyl)oxiran
2-yl)benzyl(2-((S)-2-((S)-2-amino-3-methylbutanamido)propanamido)ethyl)ca-
rbamate
[1142] To a suspension of compounds 66 (78 mg, 87.5 .mu.mol) and 68
(51.4 mg, 105.0 .mu.mol) in DCM was added DIEA (44.0 .mu.L, 262.5
.mu.mol). The reaction medium is stirred at RT overnight then were
added compound 68 (24 mg, 49 .mu.oml) and DIEA (15 .mu.L) and
stirring was carried on at RT for 1 d. Piperidine (87.0 .mu.L,
875.0 .mu.mol) was added and stirring carried on at RT overnight.
The reaction medium was concentrated in vacuo and purified by two
successive flash chromatrographies on 5 g of silica gel (gradient
elution EtOAc/MeOH/H2O) to give 57 mg of compound 69 as a white
lacquer (66%).
[1143] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 0.75 (d,
J=7.0 Hz, 3H); 0.85 (s, 9H); 0.86 (d, J=7.0 Hz, 3H); 0.87 (d, J=6.7
Hz, 3H); 0.99 (s, 3H); 1.04 (d, J=7.0 Hz, 3H); 1.18 (m, 6H); 1.33
(d, J=14.5 Hz, 1H); 1.75 (broad s, 2H); 1.81 (m, 1H); 1.92 (m, 1H);
1.98 (dd, J=10.0 and 14.5 Hz, 1H); 2.28 (m, 1H); 2.61 (m, 1H); 2.69
(dd, J=11.3 and 14.7 Hz, 1H); 2.90 (dd, J=2.0 and 7.5 Hz, 1H); 2.96
(m, 1H); 2.98 (d, J=4.7 Hz, 1H); 3.05 (m, 2H); 3.12 (m, 2H); 3.43
(m, 1H); 3.81 (s, 3H); 3.93 (d, J=2.0 Hz, 1H); 4.09 (m, 2H); 4.26
(m, 1H); 5.01 (s, 2H); 5.04 (m, 1H); 5.89 (dd, J=1.5 and 15.2 Hz,
1H); 6.45 (ddd, J=4.5, 10.4 and 15.2 Hz, 1H); 7.02 (d, J=8.8 Hz,
1H); 7.20 (dd, J=2.4 and 8.8 Hz, 1H); 7.26 (t, J=6.0 Hz, 1H); 7.29
(d, J=8.4 Hz, 2H); 7.32 (d, J=2.5 Hz, 1H); 7.37 (d, J=8.4 Hz, 2H);
7.88 (d, J=8.4 Hz, 1H); 7.93 (d, J=7.1 Hz, 1H); 8.00 (t, J=6.0 Hz,
1H); 8.03 (d, J=8.1 Hz, 1H); 8.41 (d, J=7.2 Hz, 1H). LCMS (A5): ES
m/z=492 [M+2H].sup.2+; m/z=980 [M-H].sup.-; m/z=982 [M+H].sup.+;
m/z=1026 [M-H+HCO.sub.2H].sup.-; t.sub.R=0.91 min.
Compound 70:
(9S,12S)-1-(4-((2R,3R)-3-((S)-1-((3S,7S,10R,16S,E)-10-(3-chloro-4-methoxy-
-benzyl)-6,6,7-trimethyl-3-neopentyl-2,5,9,12-tetraoxo-1-oxa-4,8,11-triaza-
cyclohexadec-13-en-16-yl)ethyl)oxiran-2-yl)phenyl)-12-isopropyl-9-methyl-3-
,8,11,14-tetraoxo-2-oxa-4,7,10,13-tetraazaoctadecan-18-oic Acid
[1144] To a solution of compound 69 (56.0 mg, 56.8 .mu.L) in DCM (8
mL) was added a solution of glutaric anhydride (7.27 mg, 62.5
.mu.mol) in DCM (4 mL). The reaction medium was stirred at RT for 2
h, concentrated in vacuo and purified by flash chromatography on 5
g of silica gel (gradient elution DCM/MeOH/H.sub.2) to give 35.5 mg
of compound 70 as a white lacquer (56%).
[1145] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 0.81 (d,
J=7.0 Hz, 3H); 0.83 (d, J=7.0 Hz, 3H); 0.85 (s, 9H); 0.87 (d, J=6.5
Hz, 3H); 0.99 (s, 3H); 1.04 (d, J=7.1 Hz, 3H); 1.19 (m, 6H); 1.32
(d, J=14.3 Hz, 1H); 1.70 (m, 2H); 1.81 (m, 1H); 1.92 (m, 1H); 1.98
(m, 2H); 2.15 (m, 2H); 2.19 (t, J=7.5 Hz, 2H); 2.27 (m, 1H); 2.61
(m, 1H); 2.69 (dd, J=11.1 and 14.1 Hz, 1H); 2.91 (d, J=7.6 Hz, 1H);
2.95 (m, 1H); 3.04 (m, 2H); 3.10 (m, 2H); 3.41 (m, 1H); 3.80 (s,
3H); 3.93 (s, 1H); 4.03 to 4.16 (m, 3H); 4.19 (m, 1H); 5.01 (s,
2H); 5.04 (m, 1H); 5.89 (d, J=15.6 Hz, 1H); 6.43 (ddd, J=5.3, 11.0
and 15.6 Hz, 1H); 7.02 (d, J=8.7 Hz, 1H); 7.20 (dd, J=2.3 and 8.7
Hz, 1H); 7.28 (d, J=8.4 Hz, 2H); 7.30 (m, 1H); 7.32 (d, J=2.3 Hz,
1H); 7.36 (d, J=8.4 Hz, 2H); 7.88 (m, 2H); 7.93 (d, J=7.4 Hz, 1H);
7.98 (broad s, 1H); 8.06 (broad s, 1H); 8.42 (d, J=7.4 Hz, 1H).
LCMS (A5): ES m/z=549 [M+2H].sup.2+; m/z=1094 [M-H].sup.-; m/z=1096
[M+H].sup.+; t.sub.R=1.21 min.
Example 27:
2,5-dioxopyrrolidin-1-yl(9S,12S)-1-(4-((2R,3R)-3-((S)-1-((3S,7S,10R,16S,E-
)-10-(3-chloro-4-methoxybenzyl)-6,6,7-trimethyl-3-neopentyl-2,5,9,12-tetra-
oxo-1-oxa-4,8,11-triazacyclo-hexadec-13-en-16-yl)ethyl)oxiran-2-yl)phenyl)-
-12-isopropyl-9-methyl-3,8,11,14-tetraoxo-2-oxa-4,7,10,13-tetraazaoctadeca-
n-18-oate
[1146] To a solution of compound 70 (14.6 mg, 13.3 .mu.mol) in DCM
(5 mL) under Ar were added DSC (4.3 mg, 16.0 .mu.mol) and DIEA (2.8
.mu.L, 16.0 .mu.mol). The reaction medium was stirred at RT for 3 h
then were added DSC (1.5 mg, 5.6 .mu.mol) and DIEA (1 .mu.L, 5.7
.mu.mol) and stirring was carried on at RT for 1 h. The reaction
medium was concentrated in vacuo and purified by flash
chromatography on 16.4 g of diol-modified silica gel (gradient
elution DCM/iPrOH) to give 11.4 mg of example 27 as a white lacquer
(72%).
[1147] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 0.81 (d,
J=7.0 Hz, 3H); 0.83 (d, J=7.0 Hz, 3H); 0.85 (s, 9H); 0.88 (d, J=6.5
Hz, 3H); 0.99 (s, 3H); 1.04 (d, J=7.1 Hz, 3H); 1.19 (m, 6H); 1.34
(d, J=14.4 Hz, 1H); 1.83 (m, 3H); 1.98 (m, 2H); 2.26 (m, 1H); 2.29
(m, 2H); 2.60 (m, 1H); 2.68 (t, J=7.6 Hz, 2H); 2.70 (dd, J=11.2 and
14.3 Hz, 1H); 2.80 (s, 4H); 2.91 (dd, J=2.3 and 7.6 Hz, 1H); 2.95
(dd, J=3.7 and 14.3 Hz, 1H); 2.99 to 3.20 (m, 4H); 3.43 (m, 1H);
3.80 (s, 3H); 3.93 (d, J=2.2 Hz, 1H); 4.05 to 4.25 (m, 4H); 5.01
(m, 2H); 5.03 (m, 1H); 5.89 (dd, J=1.6 and 15.4 Hz, 1H); 6.44 (ddd,
J=4.6, 10.9 and 15.4 Hz, 1H); 7.02 (d, J=8.5 Hz, 1H); 7.20 (m, 2H);
7.28 (d, J=8.5 Hz, 2H); 7.31 (d, J=2.3 Hz, 1H); 7.37 (d, J=8.5 Hz,
2H); 7.86 (m, 3H); 7.91 (d, J=7.1 Hz, 1H); 7.95 (d, J=7.6 Hz, 1H);
8.39 (d, J=7.3 Hz, 1H). LCMS (A5): ES m/z=311; m/z=1191
[M-H].sup.-; m/z=1193 [M+H].sup.+; m/z=1237 [M-H+HCO.sub.2H].sup.-;
t.sub.R=1.26 min.
Example 28: mAb-Ex27
[1148] Example 28 was prepared in a similar way to examples 3, 7,
10 and 14. 1.56 mg of example 28 were obtained as a colorless
limpid solution at a concentration of 0.78 mg/mL with a DAR of 4
(HRMS), a monomeric purity of 100% and a global yield of 13%.
[1149] SEC-HRMS: m/z=149405 (naked mAb); m/z=150486 (D1);
m/z=151568 (D2); m/z=152645 (D3); m/z=153725 (D4); m/z=154802 (D5);
m/z=155882 (D6); m/z=156961 (D7); m/z=158039 (D8).
Synthesis of Example 29:
Maleimido-mc-vc-PABA-3-(S)-neopentyl-7-(S)-Me-aza-C52 Benzylic
Amine
##STR00754##
[1150] Compound 71:
4-((S)-2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-me-
thylbutanamido)-5-ureidopentanamido)benzyl(4-nitrophenyl)
Carbonate
[1151] Compound 72 was prepared as described by Verma V. A., et
al., in Bioorg Med Chem Lett 2015, 25, 864-868.
[1152] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.83 (d,
J=7.0 Hz, 3H); 0.87 (d, J=7.0 Hz, 3H); 1.18 (m, 2H); 1.31 to 1.75
(m, 8H); 1.96 (m, 1H); 2.10 (m, 1H); 2.18 (m, 1H); 2.96 (m, 1H);
3.01 (m, 1H); 3.37 (t, J=7.2 Hz, 2H); 4.19 (dd, J=7.0 and 8.6 Hz,
1H); 4.38 (m, 1H); 5.24 (s, 2H); 5.42 (s, 2H); 5.98 (t, J=6.0 Hz,
1H); 7.00 (s, 2H); 7.40 (d, J=8.7 Hz, 2H); 7.57 (d, J=9.2 Hz, 2H);
7.66 (d, J=8.7 Hz, 2H); 7.81 (d, J=8.6 Hz, 1H); 8.12 (d, J=7.9 Hz,
1H); 8.31 (d, J=9.2 Hz, 2H); 10.08 (s, 1H). LCMS (A5): ES m/z=738
[M+H].sup.+; m/z=782 [M-H+HCO.sub.2H].sup.-; t.sub.R=1.1 min.
Example 29:
4-((S)-2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-me-
thyl-butanamido)-5-ureidopentanamido)benzyl(4-((2R,3R)-3-((S)-1-((3S,7S,10-
R,16S,E)-10-(3-chloro-4-methoxybenzyl)-6,6,7-trimethyl-3-neopentyl-2,5,9,1-
2-tetraoxo-1-oxa-4,8,11-triazacyclohexadec-13-en-16-yl)ethyl)oxiran-2-yl)b-
enzyl)carbamate
[1153] To compound 71 (16.0 mg, 21.7 .mu.mol) were added a solution
of example 25 (14.3 mg, 19.7 .mu.mol) in DCM (2.5 mL) and DIEA (3.4
.mu.L, 19.7 .mu.mol). The reaction medium was stirred at RT
overnight then was added DMF (1 mL) and stirring was carried on at
RT for 1 d. H.sub.2O (8 mL) was added to the reaction medium,
stirring carried on for 15 min then the aqueous phase was extracted
with DCM (3.times.10 mL). The combined organic phases were dried
over MgSO.sub.4, filtered, concentrated in vacuo, co-evaporated
twice with toluene and purified by flash chromatography on 5 g on
silica gel (gradient elution DCM/MeOH) to give 15.8 mg of example
29 as a white solid (60%).
[1154] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.81 (d,
J=7.0 Hz, 3H); 0.85 (d, J=7.0 Hz, 3H); 0.86 (s, 9H); 0.89 (d, J=6.8
Hz, 3H); 0.99 (s, 3H); 1.04 (d, J=7.0 Hz, 3H); 1.18 (s, 3H); 1.19
(m, 2H); 1.31 to 1.75 (m, 9H); 1.80 (m, 1H); 1.96 (m, 2H) 2.10 (m,
1H); 2.18 (m, 1H); 2.27 (m, 1H); 2.61 (m, 1H); 2.69 (dd, J=10.8 and
14.3 Hz, 1H); 2.90 (dd, J=2.1 and 7.6 Hz, 1H); 2.96 (m, 2H); 3.01
(m, 1H); 3.37 (t, J=7.2 Hz, 2H); 3.42 (m, 1H); 3.80 (s, 3H); 3.90
(d, J=2.1 Hz, 1H); 4.08 (m, 1H); 4.11 (m, 1H); 4.20 (m, 3H); 4.39
(m, 1H); 4.97 (s, 2H); 5.04 (m, 1H); 5.40 (s, 2H); 5.89 (dd, J=1.7
and 15.5 Hz, 1H); 5.97 (t, J=6.2 Hz, 1H); 6.45 (ddd, J=4.8, 10.7
and 15.5 Hz, 1H); 6.99 (s, 2H); 7.01 (d, J=8.7 Hz, 1H); 7.20 (dd,
J=2.2 and 8.7 Hz, 1H); 7.21 to 7.30 (m, 6H); 7.31 (d, J=2.2 Hz,
1H); 7.59 (d, J=8.7 Hz, 2H); 7.78 (m, 2H); 7.85 (d, J=8.5 Hz, 1H);
7.90 (d, J=6.9 Hz, 1H); 8.07 (d, J=7.8 Hz, 1H); 8.39 (d, J=7.3 Hz,
1H); 9.97 (s, 1H). LCMS (A5): ES m/z=662 [M+2H].sup.2+; m/z=1322
[M-H].sup.-; m/z=1324 [M+H].sup.+; m/z=1368 [M-H+HCO.sub.2H].sup.-;
t.sub.R=1.3 min.
Synthesis of Examples 30 & 31: NHS Ester of Non-Cleavable
Triazole-3-(S)-neopentyl-7-(S)-Me-aza-C52 and Corresponding ADC
##STR00755##
[1155] Compound 72: tert-butyl 3-(prop-2-yn-1-yloxy)propanoate
[1156] To a solution of propargyl alcohol (1.362 mL, 23.4 mmol) in
THE (23 mL) was added sodium (20.08 mg, 0.874 mmol), the reaction
medium was heated at 60.degree. C. until complete solubilization of
sodium then cooled down at RT before the addition of tert-butyl
acrylate (2.286 mL, 15.6 mmol). The reaction medium was stirred at
RT overnight then H.sub.2O (25 mL) was added and the aqueous phase
was extracted with EtOAc (3.times.25 mL). The combined organic
phase were dried over Na.sub.2SO.sub.4, filtered and concentrated
in vacuo to give 2 g of compound 72 as a colorless oil (70%).
Compound 73: 3-(prop-2-yn-1-yloxy)propanoic Acid
[1157] To a solution of compound 72 (2.0 g, 10.86 mmol) in DCM (50
mL) was added TFA (8.065 mL, 108.6 mmol). The reaction medium was
stirred at RT overnight, concentrated in vacuo, co-evaporated with
toluene and purified by flash chromatography on 80 g of silica gel
(gradient elution DCM/MeOH) to give 1.1 g of compound 73 as an oil
(80%).
[1158] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 2.46 (t,
J=6.4 Hz, 2H); 3.43 (t, J=2.4 Hz, 1H); 3.63 (t, J=6.4 Hz, 2H); 4.11
(d, J=2.4 Hz, 2H); 12.20 (broad, 1H).
Compound 74:
3-((1-(4-((2R,3R)-3-((S)-1-((3S,7S,10R,16S,E)-10-(3-chloro-4-methoxybenzy-
l)-6,6,7-trimethyl-3-neopentyl-2,5,9,12-tetraoxo-1-oxa-4,8,11-triazacycloh-
exadec-13-en-16-yl)ethyl)oxiran-2-yl)benzyl)-1H-1,2,3-triazol-4-yl)methoxy-
)propanoic Acid
[1159] To a solution of example 24 (50 mg, 66.6 .mu.mol) in THE
(0.5 mL) were added compound 73 (17.05 mg, 113.1 .mu.mol), 0.1M aq.
copper (II) sulfate (266 .mu.L, 26.6 .mu.mol) and 0.2M aq. sodium
ascorbate (266 .mu.L, 53.2 .mu.mol). The reaction medium was
stirred at RT for 1 d then H.sub.2O (1 mL) was added and the
aqueous phase was extracted with EtOAc (3.times.1 mL). The combined
organic phases were washed with sat. brine, dried over MgSO.sub.4,
filtered, concentrated in vacuo and purified by filtration on
Sephadex LH20 (elution DCM) to give 40 mg of an oil that was
further purified by flash chromatography on 5 g of silica gel
(gradient elution DCM/MeOH) to give 20 mg of compound 74 (35%).
[1160] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 0.82 (s,
9H); 0.88 (d, J=6.7 Hz, 3H); 1.00 (s, 3H); 1.04 (d, J=7.1 Hz, 3H);
1.18 (s, 3H); 1.31 (d, J=14.6 Hz, 1H); 1.80 (m, 1H); 1.97 (dd,
J=10.0 and 14.6 Hz, 1H); 2.25 (m, 1H); 2.42 (t, J=6.6 Hz, 2H); 2.60
(m, 1H); 2.70 (dd, J=10.9 and 14.4 Hz, 1H); 2.90 (dd, J=2.2 and 7.6
Hz, 1H); 2.95 (dd, J=3.6 and 14.4 Hz, 1H); 3.44 (m, 1H); 3.62 (t,
J=6.6 2H); 3.80 (s, 3H); 3.94 (d, J=2.2 Hz, 1H); 4.08 (m, 2H); 4.49
(s, 2H); 5.03 (m, 1H); 5.59 (s, 2H); 5.89 (dd, J=1.7 and 15.3 Hz,
1H); 6.43 (ddd, J=4.8, 10.8 and 15.3 Hz, 1H); 7.02 (d, J=8.7 Hz,
1H); 7.20 (dd, J=2.4 and 8.7 Hz, 1H); 7.29 (d, J=8.4 Hz, 2H); 7.32
(d, J=2.4 Hz, 1H); 7.35 (d, J=8.4 Hz, 2H); 7.85 (d, J=8.4 Hz, 1H);
7.90 (d, J=7.0 Hz, 1H); 8.13 (s, 1H); 8.46 (m, 1H); 12.20 (broad,
1H). LCMS (A5): ES m/z=440 [M+2H].sup.2+; m/z=877 [M-H].sup.-;
m/z=879 [M+H].sup.+; t.sub.R=1.24 min.
Example 30: 2,5-dioxopyrrolidin-1-yl
3-((1-(4-((2R,3R)-3-((S)-1-((3S,7S,10R,16S,E)-10-(3-chloro-4-methoxybenzy-
l)-6,6,7-trimethyl-3-neopentyl-2,5,9,12-tetraoxo-1-oxa-4,8,11-triaza-cyclo-
hexadec-13-en-16-yl)ethyl)oxiran-2-yl)benzyl)-1H-1,2,3-triazol-4-yl)methox-
y)propanoate
[1161] To a solution of compound 74 (20 mg, 22.7 .mu.mol) in DCM (5
mL) were added DIEA (5.0 .mu.L, 28.5 .mu.mol) and DSC (6.34 mg,
23.8 .mu.mol). The reaction medium was stirred at RT for 3 h then
were added DSC (3 mg, 11.3 .mu.mol) and DIEA (5 .mu.L, 28.5
.mu.mol) and stirring was carried on at RT for 2 h. The reaction
medium was then concentrated in vacuo and purified by two
successive flash chromatographies on 1.5 g of diol-modified silica
gel (gradient elution DCM/iPrOH) to give 11.5 mg of example 30
(50%).
[1162] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 0.83 (s,
9H); 0.87 (d, J=6.6 Hz, 3H); 0.99 (s, 3H); 1.03 (d, J=7.1 Hz, 3H);
1.04 (d, J=6.6 Hz, 3H); 1.19 (s, 3H); 1.32 (d, J=14.5 Hz, 1H); 1.81
(m, 1H); 1.96 (dd, J=10.2 and 14.5 Hz, 1H); 2.25 (m, 1H); 2.60 (m,
1H); 2.70 (dd, J=11.2 and 14.5 Hz, 1H); 2.80 (s, 4H); 2.90 (dd,
J=2.0 and 7.4 Hz, 1H); 2.94 (t, J=6.1 Hz, 2H); 2.97 (dd, J=3.6 and
14.1 Hz, 1H); 3.42 (m, 1H); 3.74 (t, J=6.1 Hz, 2H); 3.80 (s, 3H);
3.92 (d, J=2.0 Hz, 1H); 4.09 (m, 2H); 4.55 (s, 2H); 5.03 (m, 1H);
5.59 (s, 2H); 5.89 (dd, J=1.6 and 15.2 Hz, 1H); 6.44 (ddd, J=4.7,
10.6 and 15.2 Hz, 1H); 7.02 (d, J=8.6 Hz, 1H); 7.20 (dd, J=2.4 and
8.6 Hz, 1H); 7.29 (d, J=8.3 Hz, 2H); 7.32 (m, 3H); 7.86 (d, J=8.4
Hz, 1H); 7.90 (d, J=6.9 Hz, 1H); 8.14 (s, 1H); 8.39 (d, J=7.5 Hz,
1H). LCMS (A5): ES m/z=120; m/z=974 [M-H].sup.-; m/z=976
[M+H].sup.+; m/z=1020 [M-H+HCO.sub.2H].sup.-; t.sub.R=1.29 min.
Example 31: mAb-Ex.30
[1163] Example 31 was prepared in a similar way to examples 3, 7,
10 and 14. 5.4 mg of example 31 were obtained as a colorless limpid
solution at a concentration of 1.8 mg/mL with a DAR of 4 (HRMS), a
monomeric purity of 98.1% and a global yield of 45%.
[1164] SEC-HRMS: m/z=149399 (naked mAb); m/z=150245 (D1);
m/z=151101 (D2); m/z=151965 (D3); m/z=152831 (D4); m/z=153679 (D5);
m/z=154546 (D6); m/z=155408 (D7); m/z=156273 (D8); m/z=157284
(D9).
Synthesis of Example 32: 3-(S)-neopentyl-6-Me-6-CH.sub.2OH-aza-C52
Benzylic Amine
##STR00756## ##STR00757##
[1165] Compound 75:
(2R,3S)-1-((4-methoxybenzyl)oxy)-2-methylhex-5-en-3-yl(2S)-2-((4-((R)-2-a-
crylamido-3-(3-chloro-4-methoxyphenyl)propanamido)-3-(hydroxymethyl)-3-met-
hyl-2-oxobutyl)amino)-4,4-dimethylpentanoate
[1166] To a solution of compound BC6 (385.6 mg, 773.5 .mu.mol) in
DMF (12 mL) were added HATU (348.7 mg, 889.5 .mu.mol) and HOAt
(122.3 mg, 889.5 .mu.mol). The reaction medium was stirred at RT
for 30 min then were added a solution of compound AD3 (292 mg,
773.5 .mu.mol) in DMF (5 mL) and DIEA (475.2 .mu.L, 2.71 mmol) and
stirring was carried on at RT for 4 h. H.sub.2O (50 mL) was added
and the aqueous phase was extracted with EtOAc (3.times.50 mL). The
combined organic phases were washed with H.sub.2O (15 mL), sat.
brine (3.times.15 mL), dried over MgSO.sub.4, filtered,
concentrated in vacuo and purified by flash chromatography on 30 g
of silica gel (gradient elution DCM/MeOH) to give 383 mg of
compound 75 as a yellow oil (65%).
[1167] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 55/45
diastereoisomer mixture; 0.85 to 0.88 (m, 12H); 0.91 (s, 1.65H);
0.92 (s, 1.35H); 1.56 (m, 1H); 1.60 (m, 1H); 1.98 (m, 1H); 2.21 (m,
1H); 2.30 (m, 1H); 2.71 (m, 1H); 2.92 (m, 1H); 3.19 to 3.45 (m,
6H); 3.73 (s, 3H); 3.80 (s, 3H); 4.29 (m, 1H); 4.33 (m, 2H); 4.58
(m, 1H); 4.82 (m, 1H); 4.95 to 5.09 (m, 3H); 5.55 (dd, J=2.2 and
10.2 Hz, 1H); 5.71 (m, 1H); 6.01 (dd, J=2.2 and 17.2 Hz, 1H); 6.23
(dd, J=10.2 and 17.2 Hz, 1H); 6.89 (m, 2H); 7.01 (d, J=8.6 Hz, 1H);
7.17 (dd, J=2.2 and 8.6 Hz, 1H); 7.21 (m, 2H); 7.34 (d, J=2.2 Hz,
1H); 7.82 (d, J=8.0 Hz, 0.45H); 7.84 (d, J=8.0 Hz, 0.55H); 7.98 (t,
J=6.5 Hz, 0.45H); 8.00 (t, J=6.5 Hz, 0.55H); 8.39 (d, J=8.6 Hz,
1H). LCMS (A5): ES m/z=756 [M-H].sup.-; m/z=758 [M+H].sup.+;
m/z=802 [M-H+HCO.sub.2H].sup.-; t.sub.R=1.54-1.56 min.
Compound 76:
(3S,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-6-(hydroxymethyl)-16-((R)-1--
((4-methoxybenzyl)oxy)propan-2-yl)-6-methyl-3-neopentyl-1-oxa-4,8,11-triaz-
acyclohexadec-13-ene-2,5,9,12-tetraone
[1168] To a solution of compound 75 (380 mg, 501.1 .mu.mol) in DCM
(38 mL) under Ar was added Grubbs I catalyst (20.97 mg, 25.05
.mu.mol). The reaction medium was stirred under Ar at RT for 4 h
then was added Grubbs I catalyst (20.97 mg, 25.05 .mu.mol).
Stirring was carried on at RT for 3 h then was added Grubbs I
catalyst (20.97 mg, 25.05 .mu.mol) and stirring carried on at RT.
After 24 h of reaction, Grubbs I catalyst (20.97 mg, 25.05 .mu.mol)
was added and stirring carried on for 4 h. The reaction medium was
concentrated in vacuo and purified by flash chromatography on 20 g
of silica gel (isocratic elution heptane/EtOAc) to give 170 mg of
compound 76 stereomer 1 (56%) and 138 mg of compound 76 stereomer 2
(37%).
Compound 76 Stereomer 1 RMN .sup.1H (400 MHz, .delta. in ppm,
DMSO-d6): 0.83 (s, 9H); 0.91 (d, J=7.1 Hz, 3H); 1.02 (s, 3H); 1.30
(dd, J=2.4 and 14.6 Hz, 1H); 1.53 (dd, J=9.9 and 14.6 Hz, 1H); 1.99
(m, 1H); 2.28 (m, 1H); 2.45 (m, 1H); 2.67 (m, 1H); 2.91 (dd, J=3.0
and 13.7 Hz, 1H); 2.97 (dd, J=4.0 and 14.5 Hz, 1H); 3.17 to 3.49
(m, 5H); 3.72 (s, 3H); 3.80 (s, 3H); 4.18 (m, 1H); 4.37 (m, 2H);
4.50 (td, J=2.4 and 9.6 Hz, 1H); 5.00 (m, 3H); 5.82 (dd, J=1.9 and
15.4 Hz, 1H); 6.39 (ddd, J=4.2, 11.6 and 15.4 Hz, 1H); 6.90 (d,
J=8.7 Hz, 2H); 7.04 (d, J=8.6 Hz, 1H); 7.12 (m, 1H); 7.15 (dd,
J=2.3 and 8.6 Hz, 1H); 7.21 (d, J=8.7 Hz, 2H); 7.28 (d, J=2.3 Hz,
1H); 8.09 (d, J=9.6 Hz, 1H); 8.38 (d, J=8.0 Hz, 1H). LCMS (A4): ES
m/z=728 [M-H].sup.-; m/z=730 [M+H].sup.+; m/z=774; t.sub.R=5.15
min.
Compound 76 Stereomer 2
[1169] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.83 (s,
9H); 0.88 (s, 3H); 0.91 (d, J=7.1 Hz, 3H); 1.28 (dd, J=2.4 and 14.6
Hz, 1H); 1.67 (dd, J=9.9 and 14.6 Hz, 1H); 1.99 (m, 1H); 2.28 (m,
1H); 2.45 (m, 1H); 2.67 (m, 1H); 3.02 (dd, J=3.3 and 14.2 Hz, 1H);
3.08 (dd, J=1.9 and 13.5 Hz, 1H); 3.25 to 3.42 (m, 4H); 3.55 (dd,
J=5.1 and 11.0 Hz, 1H); 3.73 (s, 3H); 3.81 (s, 3H); 4.17 (m, 1H);
4.37 (m, 2H); 4.44 (td, J=2.1 and 9.3 Hz, 1H); 4.80 (t, J=5.1 Hz,
1H); 5.00 (m, 2H); 5.86 (dd, J=1.6 and 15.1 Hz, 1H); 6.38 (ddd,
J=4.0, 11.4 and 15.3 Hz, 1H); 6.90 (d, J=8.8 Hz, 2H); 7.04 (d,
J=8.7 Hz, 1H); 7.19 (dd, J=2.2 and 8.7 Hz, 1H); 7.22 (d, J=8.8 Hz,
2H); 7.30 (d, J=2.2 Hz, 1H); 7.42 (d, J=10.4 Hz, 1H); 7.92 (d,
J=8.9 Hz, 1H); 8.45 (d, J=8.0 Hz, 1H). LCMS (A4): ES m/z=728
[M-H].sup.-; m/z=730 [M+H].sup.+; m/z=774; t.sub.R=4.79 min.
Compound 77:
(3S,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-16-((R)-1-((4-methoxy-benzyl-
)oxy)propan-2-yl)-6-methyl-3-neopentyl-6-(((triethylsilyl)oxy)methyl)-1-ox-
a-4,8,11-triaza-cyclohexadec-13-ene-2,5,9,12-tetraone
[1170] To a solution of compound 76 stereomer 1 (170 mg, 232.8
.mu.mol) in DCM (3 mL) cooled with an ice bath were added at
4.degree. C. chlorotriethylsilane (159.3 .mu.L, 931.1 .mu.mol) and
dropwise TEA (131.1 .mu.L, 931.1 .mu.mol). The reaction medium was
stirred at 4.degree. C. for 30 min then at RT for 20 h. The
reaction medium was diluted with DCM (50 mL) and brine (10 mL) and
stirring was carried on for 10 min. The organic phase was washed
with sat. brine (2.times.10 mL), dried over MgSO.sub.4, filtered
and concentrated in vacuo. The other diastereoisomer of compound 76
(138 mg, 189.0 .mu.mol) was similarly protected, both batches were
pooled and purified by flash chromatography on 20 g of silica gel
(isocratic elution heptane/EtOAc) to give 139 mg of compound 77
stereomer 1 as a colorless foam (39%) and 107 mg of compound 77
stereomer 2 as a colorless foam (30%).
Compound 77 Stereomer 1
[1171] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.62 (q,
J=8.1 Hz, 6H); 0.83 (s, 9H); 0.91 (d, J=7.1 Hz, 3H); 0.96 (t, J=8.1
Hz, 9H); 1.04 (s, 3H); 1.66 (dd, J=3.4 and 14.4 Hz, 1H); 1.43 (dd,
J=9.3 and 14.4 Hz, 1H); 1.99 (m, 1H); 2.28 (m, 1H); 2.47 (m, 1H);
2.68 (m, 1H); 2.92 (dd, J=3.0 and 13.5 Hz, 1H); 2.99 (dd, J=4.0 and
14.8 Hz, 1H); 3.21 to 3.40 (m, 3H); 3.48 (m, 1H); 3.63 (d, J=10.3
Hz, 1H); 3.73 (s, 3H); 3.81 (s, 3H); 4.17 (m, 1H); 4.36 (m, 2H);
4.51 (td, J=2.9 and 9.4 Hz, 1H); 5.02 (m, 1H); 5.82 (dd, J=1.8 and
15.4 Hz, 1H); 6.39 (ddd, J=4.3, 11.6 and 15.4 Hz, 1H); 6.89 (d,
J=8.7 Hz, 2H); 7.02 (m, 1H); 7.04 (d, J=8.7 Hz, 1H); 7.15 (dd,
J=2.3 and 8.7 Hz, 1H); 7.21 (d, J=8.7 Hz, 2H); 7.29 (d, J=2.3 Hz,
1H); 7.96 (d, J=9.4 Hz, 1H); 8.31 (d, J=8.0 Hz, 1H). LCMS (A4): ES
m/z=842 [M-H].sup.-; m/z=844 [M+H].sup.+; m/z=888
[M-H+HCO.sub.2H].sup.-; t.sub.R=7.08 min.
Compound 77 Stereomer 2
[1172] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.52 (q,
J=8.1 Hz, 6H) 0.84 (s, 9H); 0.88 to 0.93 (m, 15H); 1.29 (dd, J=2.6
and 14.5 Hz, 1H); 1.68 (dd, J=10.1 and 14.5 Hz, 1H); 1.99 (m, 1H);
2.28 (m, 1H); 2.47 (m, 1H); 2.68 (m, 1H); 3.01 (dd, J=3.4 and 14.5
Hz, 1H); 3.15 (d, J=12.8 Hz, 1H); 3.33 (m, 1H); 3.48 (d, J=10.4 Hz,
1H); 3.73 (s, 3H); 3.81 (s, 3H); 3.83 (d, J=10.4 Hz, 1H); 4.17 (m,
1H); 4.36 (m, 2H); 4.45 (td, J=2.4 and 9.2 Hz, 1H); 5.01 (m, 1H);
5.84 (dd, J=1.8 and 15.3 Hz, 1H); 6.39 (ddd, J=3.9, 11.4 and 15.3
Hz, 1H); 6.90 (d, J=8.8 Hz, 2H); 7.05 (d, J=8.6 Hz, 1H); 7.19 (dd,
J=2.2 and 8.6 Hz, 1H); 7.22 (d, J=8.8 Hz, 2H); 7.30 (d, J=2.2 Hz,
1H); 7.47 (d, J=10.4 Hz, 1H); 8.01 (d, J=9.2 Hz, 1H); 8.41 (d,
J=8.0 Hz, 1H). LCMS (A4): ES m/z=842 [M-H].sup.-; m/z=844
[M+H].sup.+; m/z=888 [M-H+HCO.sub.2H].sup.-; t.sub.R=6.88 min.
Compound 78:
3S,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-16-((R)-1-hydroxypropan-2-yl)-
-6-methyl-3-neopentyl-6-(((triethylsilyl)oxy)methyl)-1-oxa-4,8,11-triazacy-
clohexadec-13-ene-2,5,9,12-tetraone
[1173] To a solution of both diastereoisomers of compound 77 (245
mg, 290.1 .mu.mol) in DCM (10 mL) and H.sub.2O (2.5 mL) cooled with
an ice/acetone bath were added DDQ (339.4 mg, 1.45 mmol) and
2,6-di-tert-butylpyridine (171.7 mg, 870.3 .mu.mol). The reaction
medium was stirred at 0.degree. C. for 2 h then was diluted with
aq. NaHCO.sub.3 (10 mL) and DCM (10 mL) and stirring was carried on
for 10 min. The aqueous phase was extracted with DCM (3.times.20
mL), the combined organic phases were washed with sat. brine
(3.times.5 mL), dried over MgSO.sub.4, filtered, concentrated in
vacuo and purified by flash chromatography on 20 g of silica gel
(gradient elution DCM/MeOH) to give 155 mg of compound 78 as a
white foam (74%).
[1174] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 0.49 to 0.65
(m, 6H); 0.80 to 1.07 (m, 24H); 1.35 to 1.71 (m, 2H); 1.83 (m, 1H);
2.28 (m, 1H); 2.47 (m, 1H; 2.68 (m, 1H); 2.90 to 3.50 (m, 5.96H);
3.65 (d, J=10.6 Hz, 0.52H); 3.80 (s, 3H); 3.82 (d, J=10.6 Hz,
0.52H); 4.18 (m, 1H); 4.29 to 4.70 (m, 2H); 5.02 (m, 1H); 5.80 to
5.89 (m, 1H); 6.05 (m, 0.11H); 6.39 (m, 0.89H); 6.98 to 7.31 (m,
3.48H); 7.47 (d, J=10.6 Hz, 0.52H); 7.87 (d, J=9.4 Hz, 0.11H); 7.96
(d, J=9.4 Hz, 0.52H); 8.00 (d, J=9.4 Hz, 0.37H); 8.31 (d, J=8.0 Hz,
0.63H); 8.42 (d, J=8.4 Hz, 0.37H). LCMS (A4): ES m/z=722
[M-H].sup.-; m/z=724 [M+H].sup.+; m/z=768 [M-H+HCO.sub.2H].sup.-;
t.sub.R=5.68-5.78 min.
Compound 79:
2S)-2-((3S,10R,16S,E)-10-(3-chloro-4-methoxybenzyl)-6-methyl-3-neopentyl--
2,5,9,12-tetraoxo-6-(((triethylsilyl)oxy)methyl)-1-oxa-4,8,11-triazacycloh-
exadec-13-en-16-yl)propanal
[1175] To a solution of compound 78 (154 mg, 212.6 .mu.mol) in DCM
(1.5 mL) cooled with an ice/acetone bath were added at 0.degree. C.
a solution of KBr (25.6 mg, 212.6 .mu.mol) in H.sub.2O (612 .mu.L),
a solution of TEMPO at 5 mg/mL in DCM (137 .mu.L, 4.25 .mu.mol) and
dropwise an aqueous solution of 1.56M sodium hypochlorite pH 9.5
(204 .mu.L, 318.9 .mu.mol). Stirring was carried on at 0.degree. C.
for 15 min then was added at 0.degree. C. sat.
Na.sub.2S.sub.2O.sub.3 (1.9 mL), the ice bath was removed and the
reaction medium stirred for 10 min. It was then extracted with DCM
(3.times.20 mL), the combined organic phases were washed with
H.sub.2O (2.times.10 mL), dried over MgSO.sub.4, filtered,
concentrated in vacuo and purified by flash chromatography on 15 g
of silica gel (gradient elution DCM/MeOH) to give 36 mg of compound
61 (23%).
[1176] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 72/28
diastereoisomer mixture: 0.49 to 0.65 (m, 6H); 0.80 to 1.08 (m,
24H); 1.32 to 1.69 (m, 2H); 2.40 (m, 1H); 2.68 (m, 2H); 2.79 (m,
1H); 2.89 to 3.70 (m, 5H); 3.80 (s, 3H); 4.10 to 4.53 (m, 2H); 5.02
(m, 0.28H); 5.28 (m, 0.72H); 5.78 to 5.91 (m, 1H); 6.07 (m, 0.28H);
6.40 (m, 0.72H); 7.00 to 7.51 (m, 4H); 7.90 (d, J=9.4 Hz, 0.28H);
7.98 (d, J=9.4 Hz, 0.72H); 8.34 (m, 1H); 9.59 (d, J=2.5 Hz, 0.28H);
9.63 (d, J=1.8 Hz, 0.72H). LCMS (A5): m/z=722 [M+H].sup.+;
t.sub.R=1.71 min.
Compound 80: 1-(azidomethyl)-4-(bromomethyl)benzene
[1177] To a solution of p-xylene dibromide (2.0 g, 7.2 mmol) in DMF
(20 mL) was added in 20 min a solution of sodium azide (584.9 mg,
8.64 mmol) in DMF (20 mL). The reaction medium was stirred at RT
for 20 h then poured on ice (100 g) and extracted with EtOAc
(3.times.50 mL). The combined organic phase were washed with sat.
brine (3.times.15 mL), dried over MgSO.sub.4, filtered,
concentrated in vacuo, co-evaporated with toluene and purified by
flash chromatography on 70 g of silica gel (elution Et.sub.2O) to
give to give 773 mg of compound 80 as a colorless oil (47%).
[1178] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 4.45 (s,
2H); 4.71 (s, 2H); 7.35 (d, J=8.5 Hz, 2H); 7.47 (d, J=8.5 Hz,
2H).
Compound 81:
(1R,4S,5R,6S)-6-(4-(azidomethyl)benzyl)-4,7,7-trimethyl-6-thiabicyclo[3.2-
.1]octan-6-ium trifluoromethanesulfonate
[1179] To (1R,4R,5R)-4,7,7-trimethyl-6-thiabicyclo[3.2.1]octane
(CAS number [5718-75-2], 580.1 mg, 3.41 mmol) was added a solution
of compound 80 (770 mg, 3.41 mmol) in DCM (2.2 mL). A solution of
lithium trifluoromethanesulfonate (2.71 g, 17.03 mmol) in H.sub.2O
2 mL) was then added dropwise and the reaction medium was stirred
at RT for 2 d. H.sub.2O (15 mL) and DCM (15 mL) were then added to
the reaction medium and stirring carried on at RT for 10 min. The
aqueous phase was extracted with DCM (3.times.15 mL), the combined
organic phases were washed with sat. brine (3.times.8 mL), dried
over MgSO.sub.4, filtered and concentrated in vacuo. The pale
yellow oil was triturated in iPr.sub.2O (5 mL), the solid thus
obtained was filtered, washed with iPr.sub.2O (2.times.5 mL) and
dried under vacuum to give 1.266 g of compound 81 as a white solid
(79%).
[1180] RMN .sup.1H (400 MHz, .delta. in ppm, DMSO-d6): 1.08 (d,
J=7.2 Hz, 3H); 1.45 (m, 1H); 1.55 to 1.80 (m, 3H); 1.69 (s, 3H);
1.75 (s, 3H); 1.99 (m, 1H); 2.40 (d, J=13.8 Hz, 1H); 2.45 (m, 1H);
2.59 (dm, J=13.8 Hz, 1H); 3.88 (t, J=4.6 Hz, 1H); 4.52 (s, 2H);
4.60 (d, J=12.8 Hz, 1H); 4.90 (d, J=12.8 Hz, 1H); 7.47 (d, J=8.5
Hz, 2H); 7.61 (d, J=8.5 Hz, 2H).
Compound 82:
(3S,10R,16S,E)-16-((S)-1-((2R,3R)-3-(4-(azidomethyl)phenyl)oxiran-2-yl)et-
hyl)-10-(3-chloro-4-methoxybenzyl)-6-methyl-3-neopentyl-6-(((triethylsilyl-
)oxy)methyl)-1-oxa-4,8,11-triazacyclohexadec-13-ene-2,5,9,12-tetraone
[1181] To a solution of compounds 79 (35 mg, 48.5 .mu.mol) and 81
(24.8 mg, 53.3 .mu.mol) in DCM (1.5 mL) cooled at -70.degree. C.
was added dropwise BEMP (CAS number [98015-45-3], 18.6 .mu.L, 63.0
.mu.mol). The reaction mixture was stirred at -70.degree. C. for 2
h 30, sat. brine (1.5 mL) was added to the reaction mixture, the
bath removed and stirring carried on vigorously up to RT. The
aqueous phase was extracted with DCM (3.times.10 mL), the combined
organic phases were dried over MgSO.sub.4, filtered, concentrated
in vacuo and purified by flash chromatography on 5 g of silica gel
(gradien elution DCM/MeOH) to give 10.2 mg of compound 82 as a
colorless lacquer (24%).
[1182] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 0.61 (q,
J=8.1 Hz, 6H); 0.80 (s, 9H); 0.98 (t, J=8.1 Hz, 9H); 1.02 (s, 3H);
1.03 (d, J=7.1 Hz, 3H); 1.34 (dd, J=2.5 and 14.4 Hz, 1H); 1.44 (dd,
J=10.0 and 14.4 Hz, 1H); 1.85 (m, 1H); 2.27 (m, 1H); 2.62 (m, 2H);
2.88 (dd, J=2.6 and 13.5 Hz, 1H); 2.97 (dd, J=3.7 and 14.2 Hz, 1H);
3.00 (dd, J=2.3 and 7.3 Hz, 1H); 3.35 (m, 1H); 3.48 (dd, J=9.5 and
14.2 Hz, 1H); 3.61 (d, J=10.3 Hz, 1H); 3.81 (s, 3H); 3.92 (d, J=2.3
Hz, 1H); 4.15 (m, 1H); 4.46 (s, 2H); 4.48 (td, J=2.5 and 9.7 Hz,
1H); 5.10 (m, 1H); 5.78 (dd, J=2.2 and 15.3 Hz, 1H); 6.40 (ddd,
J=4.3, 11.6 and 15.3 Hz, 1H); 7.04 (m, 2H); 7.14 (dd, J=2.3 and 8.6
Hz, 1H); 7.28 (d, J=2.3 Hz, 1H); 7.33 (d, J=8.4 Hz, 2H); 7.39 (d,
J=8.4 Hz, 2H); 7.96 (d, J=9.7 Hz, 1H); 8.28 (d, J=8.0 Hz, 1H). LCMS
(A5): ES m/z=120; m/z=865 [M-H].sup.-; m/z=867 [M+H].sup.+; m/z=911
[M-H+HCO.sub.2H].sup.-; t.sub.R=1.87 min.
Example 32:
(3S,10R,16S,E)-16-((S)-1-((2R,3R)-3-(4-(aminomethyl)phenyl)oxiran-2-yl)et-
hyl)-10-(3-chloro-4-methoxybenzyl)-6-methyl-3-neopentyl-6-(((triethylsilyl-
)oxy)methyl)-1-oxa-4,8,11-triazacyclohexadec-13-ene-2,5,9,12-tetraone
[1183] To a solution of compound 82 (9.4 mg, 10.84 .mu.mol) in DCM
(1.3 mL) and MeOH (0.7 mL) was added a solution of TCEP (3.45 mg,
11.9 .mu.mol) in H.sub.2O (0.7 mL). The reaction medium was stirred
at RT overnight then was added aq. NaHCO.sub.3 (2.5 mL) and
stirring carried on for 10 min. The aqueous phase was extracted
with DCM (3.times.10 mL), the combined organic phases were dried
over MgSO.sub.4, filtered, concentrated in vacuo and purified by
flash chromatography on 5 g of silica gel (gradient elution
DCM/MeOH/H.sub.2) to give 4.55 mg of example 32 as a white lacquer
(57%).
[1184] RMN .sup.1H (500 MHz, .delta. in ppm, DMSO-d6): 0.82 (s,
9H); 1.01 (s, 3H); 1.03 (d, J=7.1 Hz, 3H); 1.33 (dd, J=2.3 and 14.5
Hz, 1H); 1.56 (dd, J=10.1 and 14.5 Hz, 1H); 1.82 (m, 1H); 2.27 (m,
1H); 2.64 (m, 2H); 2.88 (dd, J=2.6 and 13.5 Hz, 1H); 2.92 (dd,
J=2.2 and 7.3 Hz, 1H); 2.96 (dd, J=4.0 and 11.2 Hz, 1H); 3.19 (dd,
J=4.3 and 10.9 Hz, 1H); 3.41 (m, 2H); 3.74 (s, 2H); 3.81 (s, 3H);
3.88 (d, J=2.2 Hz, 1H); 4.18 (m, 1H); 4.47 (td, J=2.1 and 9.4 Hz,
1H); 4.91 (dd, J=4.2 and 6.2 Hz, 1H); 5.08 (m, 1H); 5.76 (dd, J=2.3
and 15.5 Hz, 1H); 6.40 (ddd, J=3.7, 11.5 and 15.5 Hz, 1H); 7.05 (d,
J=8.8 Hz, 1H); 7.11 (m, 1H); 7.14 (dd, J=2.4 and 8.8 Hz, 1H); 7.22
(d, J=8.3 Hz, 2H); 7.25 (d, J=2.4 Hz, 1H); 7.35 (d, J=8.3 Hz, 2H);
8.08 (d, J=9.4 Hz, 1H); 8.31 (d, J=8.0 Hz, 1H). LCMS (A5): ES
m/z=725 [M-H].sup.-; m/z=727 [M+H].sup.+; t.sub.R=0.79 min.
Pharmacological Results
[1185] The compounds of the invention were subjected to
pharmacological tests for determining their antitumoral effect. The
ADC of formula (III) were also assessed in terms of plasmatic
stability.
[1186] For illustrative purposes, two conjugates, ADC1 and ADC2
depicted below, derived from WO2011/001052 were also tested.
##STR00758##
Evaluation of the Inhibition of Proliferation of the HCT116 and
MDA-MB-231 Cell Lines by the Cryptophycin Compounds of Formula
(I)
[1187] HCT116 and MDA-MB-231 cells in their exponential growth
phase were trypsinized and resuspended in their respective culture
medium (DMEM/F12 Gibco #21331, 10% FCS Gibco #10500-056, 2 nM
glutamine Gibco #25030 for the MDA-MB-231 cells; DMEM Gibco #11960,
10% FCS Gibco #10500-056, 2 mM glutamine Gibco #25030 for the
HCT116 cells). The cell suspension was seeded in Cytostar 96-well
culture plates (GE Healthcare Europe, #RPNQ0163) in the whole
culture medium containing serum at a density of 5000 cells/well.
After incubation for 4 h, successive dilutions of the cryptophycin
compounds were added to the wells at concentrations decreasing from
10-7 to 10.sup.-12 M (in triplicate for each concentration). The
cells were cultured at 37.degree. C. in an atmosphere containing 5%
CO.sub.2 in the presence of the cryptophycin compounds for 3 d. On
the 4.sup.th day, 10 .mu.l of a .sup.14C-thymidine solution (0.1
.mu.Ci/well, Perkin Elmer #NEC56825000) were added to each well.
The incorporation of .sup.14C-thymidine was measured 96 h after the
start of the experiment with a microbeta radioactivity counter
(Perkin Elmer). The data were expressed in the form of a percentage
of survival by determining the ratio between the reduced count
obtained with the cells treated with the cryptophycin compound and
the count obtained with the cells of the control wells (treated
with the culture medium alone).
[1188] The inhibitory activity is given by the concentration which
inhibits 50% of the activity.
TABLE-US-00008 TABLE II Structural IC.sub.50 (pM) IC.sub.50 (pM)
comment.sup.1 HCT116 MDA-MD-231 C52 .beta. epoxide 76 90 Ex. 1
.beta. epoxide 163 250 Ex. 4 .beta. epoxide 51 82 Ex. 8
.alpha./.beta. epoxide 3:7 518 564 Ex. 11 .beta. epoxide n.t. 102
Ex. 15 .alpha./.beta. epoxide 35:65 n.t. 511 Ex. 16 .alpha./.beta.
epoxide 4:6 n.t. 2815 Ex. 17 .alpha./.beta. epoxide 5:5 n.t. 856
Ex. 18 .beta. epoxide 179 228 Ex. 21 .alpha./.beta. epoxide 3:7
n.t. 456 Ex. 32 .beta. epoxide n.t. 1777 .sup.1Cryptophycin
compounds of formula (I) were tested either as pure .beta. epoxides
or as a mixture of .alpha. and .beta. epoxides as specified in the
column entitled "structural comment". It is known from the
literature that the .beta. epoxides are usually 50 to 100 times
more potent than the .alpha. epoxide (see for example, Al-Awar R.
S., et al., J Med Chem 2003, 46, 2985-3007).
[1189] Cryptophycin compounds of formula (I) were found to inhibit
the proliferation of HCT116 and MDA-MB-231 cell lines with
IC.sub.50 ranging from 50 pM to 2.815 nM.
Evaluation of the Inhibition of Proliferation of the MDA-MB-231
Cell Line by the ADC of Formula (III)
[1190] MDA-MB-231 cells in their exponential growth phase were
trypsinized and resuspended in their culture medium (DMEM/F12 Gibco
#21331, 10% FCS Gibco #10500-056, 2 nM glutamine Gibco #25030). The
cell suspension was seeded in Cytostar 96-well culture plates (GE
Healthcare Europe, #RPNQ0163) in the whole culture medium
containing serum at a density of 5000 cells/well. After incubation
for 4 h, successive dilutions of the ADC are added to the wells at
concentrations decreasing from 10-7 to 10.sup.-12 M (in triplicate
for each concentration). The cells were cultured at 37.degree. C.
in an atmosphere containing 5% CO.sub.2 in the presence of the ADC
for 3 d. On the 4.sup.th day, 10 .mu.l of a .sup.14C-thymidine
solution (0.1 .mu.Ci/well, Perkin Elmer #NEC56825000) were added to
each well. The incorporation of .sup.14C-thymidine was measured 96
h after the start of the experiment with a microbeta radioactivity
counter (Perkin Elmer). The data were expressed in the form of a
percentage of survival by determining the ratio between the reduced
count obtained with the cells treated with the ADC and the count
obtained with the cells of the control wells (treated with the
culture medium alone). In certain experiments, the naked antibody
was added to the wells at a concentration of 1 .mu.M at the start
of the experiment and the inhibition of proliferation was measured
as described previously.
TABLE-US-00009 TABLE III IC.sub.50 (pM), MDA-MB-231 in the presence
of ADC alone naked antibody ADC1 42 4571 ADC2 46 9377 Ex. 3 20 3738
Ex. 7 38 18042 Ex. 10 35 10367 Ex. 14 53 25887 Ex. 20 43 11871 Ex.
23 129 64270 Ex. 31 72 31784
[1191] Cryptophycin ADC of formula (III), as well as ADC1 and ADC2,
were found to inhibit the proliferation of MDA-MB-231 cell line
with IC.sub.50 ranging from 20 .mu.M to 130 .mu.M and selectivity
ratio ADC alone vs ADC+naked antibody between 185 and 500.
Determination of the MTD of the ADC of Formula (III) Following
Single i.v. Administration in SCID Mice
[1192] MTD was determined as the maximal dose that does not induce
15% body weight loss during 3 consecutive days for an individual
mouse or 20% body weight loss during 1 day or mortality. It was
evaluated after a single intravenous (i.v.) bolus injection in 3
female SCID mice and during a period of 28 days post-treatment.
TABLE-US-00010 TABLE IV Table IV MTD (mg/kg) Ex. 3 20 Ex. 7 30 Ex.
10 40 Ex. 14 .gtoreq.50 Ex. 20 20 Ex. 23 .gtoreq.40
[1193] Cryptophycin ADC of formula (III) displayed MTD in SCID mice
ranging from 20 mg/kg to 50 mg/kg.
Evaluation of the In Vivo Antitumor Activity of ADC of Formula
(III) Against MDA-MB-231 in SCID Mice Following Single i.v.
Administration
[1194] In vivo antitumor activity was evaluated at 3 dose-levels
against measurable breast MDA-MB-231 xenografts implanted s.c. in
female SCID mice. Control groups were left untreated. Conjugates
were administered by a single i.v. bolus injection, the day of the
treatment was indicated on each graph by an arrow ().
[1195] For the evaluation of antitumor activity of conjugates,
animals were weighed twice weekly and tumors were measured twice
weekly by caliper. Animal body weights included the tumor weights.
Tumor volume were calculated using the formula mass
(mm.sup.3)=[length (mm).times.width (mm).sup.2]/2. The primary
efficacy end points were .DELTA.T/.DELTA.C, percent median
regression, partial and complete regressions (PR and CR). Changes
in tumor volume for each treated (T) and control (C) were
calculated for each tumor by subtracting the tumor volume on the
day of first treatment (staging day) from the tumor volume on the
specified observation day. The median .DELTA.T was calculated for
the treated group and the median .DELTA.C was calculated for the
control group. Then the ratio .DELTA.T/.DELTA.C was calculated and
expressed as a percentage: .DELTA.T/.DELTA.C=(delta T/delta
C).times.100.
[1196] The percentage of tumor regression was defined as the % of
tumor volume decrease in the treated group at a specified
observation day (t) compared to its volume on the first day of
first treatment (t0). At a specific time point and for each animal,
% regression was calculated. The median % regression was then
calculated for the group. % regression (at
t)=((Volume.sub.t0-Volume.sub.t)/Volume.sub.t0).times.100.
Regressions were defined as partial (PR) if the tumor volume
decreased to 50% of the tumor volume at the start of treatment and
complete (CR) when tumor volume cannot be measured (0 mm.sup.3).
Tumor free survivor (TFS) was defined as the animals with
undetectable tumors at the end of the study (>100 days post last
treatment).
Evaluation of the In Vivo Antitumor Activity of Ex.3 Against
MDA-MB-231 in SCID Mice Following Single i.v. Administration
TABLE-US-00011 TABLE V Dose Median .DELTA.T/.DELTA.C Median % of
Regressions (mg/kg) in % (day) regression PR CR TFS Control -- --
-- -- -- -- ADC2 2.5 <0 (d 53) 90% 4/6 3/6 0/6 1.25 18 (d 49) --
0/6 0/6 0/6 Ex. 3 2.5 <0 (d 53) 100% 6/6 5/6 0/6 1.25 9 (d 53)
-- 2/6 0/6 0/6 0.625 44 (d 42) -- 0/6 0/6 0/6
Evaluation of the In Vivo Antitumor Activity of Ex.7 Against
MDA-MB-231 in SCID Mice Following Single i.v. Administration
TABLE-US-00012 TABLE V Dose Median .DELTA.T/.DELTA.C Median % of
Regressions (mg/kg) in % (day) regression PR CR TFS Control -- --
-- -- -- -- ADC2 2.5 <0 (d 53) 90% 4/6 3/6 0/6 1.25 18 (d 49) --
0/6 0/6 0/6 Ex. 7 2.5 <0 (d 53) 100% 6/6 6/6 1/6 1.25 <0 (d
53) 64% 5/6 1/6 0/6 0.625 42 (d 42) -- 0/6 0/6 0/6
Evaluation of the In Vivo Antitumor Activity of Ex.10 Against
MDA-MB-231 in SCID Mice Following Single i.v. Administration
TABLE-US-00013 TABLE VI Dose Median .DELTA.T/.DELTA.C Median % of
Regressions (mg/kg) in % (day) regression PR CR TFS Control -- --
-- -- -- -- ADC2 2.5 <0 (d 42) 14% 0/6 0/6 0/6 1.25 6 (d 42) --
0/6 0/6 0/6 Ex. 10 2.5 <0 (d 59) 95% 6/6 3/6 0/6 1.25 <0 (d
46) 32% 0/6 0/6 0/6 0.625 16 (d 42) -- 0/6 0/6 0/6
Evaluation of the In Vivo Antitumor Activity of Ex.14 Against
MDA-MB-231 in SCID Mice Following Single i.v. Administration
TABLE-US-00014 TABLE VII Dose Median .DELTA.T/.DELTA.C Median % of
Regressions (mg/kg) in % (d 34) regression PR CR TFS Control -- --
-- -- -- -- ADC2 2.5 21 -- 0/6 0/6 0/6 1.25 48 -- 0/6 0/6 0/6 Ex.
14 5 <0 100% 6/6 6/6 1/6 2.5 <0 11% 1/6 0/6 0/6 1.25 39 --
0/6 0/6 0/6
Evaluation of the In Vivo Antitumor Activity of Ex.20 Against
MDA-MB-231 in SCID Mice Following Single i.v. Administration
TABLE-US-00015 TABLE VIII Dose Median .DELTA.T/.DELTA.C Median % of
Regressions (mg/kg) in % (day 40) regression PR CR TFS Control --
-- -- -- -- -- ADC2 2.5 <0 49% 4/6 0/6 0/6 1.25 14 -- 0/6 0/6
0/6 Ex. 20 5 <0 100% 6/6 6/6 6/6 2.5 <0 100% 6/6 4/6 1/6 1.25
<0 3% 3/6 1/6 0/6
Evaluation of the In Vivo Antitumor Activity of Ex.23 Against
MDA-MB-231 in SCID Mice Following Single i.v. Administration
TABLE-US-00016 TABLE VIII Dose Median .DELTA.T/.DELTA.C Median % of
Regressions (mg/kg) in % (day 40) regression PR CR TFS Control --
-- -- -- -- -- ADC2 2.5 <0 49% 4/6 0/6 0/6 1.25 14 -- 0/6 0/6
0/6 Ex. 23 5 <0 81% 6/6 3/6 0/6 2.5 16 -- 1/6 0/6 0/6 1.25 36 --
0/6 0/6 0/6
[1197] These results showed that all the tested examples of the
invention, as well as ADC2, displayed antitumor activity at doses
ranging from 0.625 mg/kg to 5 mg/kg.
Determination of PK Parameters of Ex.3 and Ex.7 Following a Single
i.v. Administration in SCID Mice (5 mg/kg)
[1198] In vivo pharmacokinetics of ADC and total antibody were
evaluated in female SCID mice following administration of the
conjugate by a single i.v. bolus injection. Female SCID mice (5-6
weeks of age, weight on average 20-25 g) were housed in a sterile
room, under aseptic conditions in a laminar hood and were fed ad
libitum. The ADC was administered (non-serial design, n=3/sampling
time) as an i.v. bolus at one dose level (10 mL/kg). For each
animal and at each selected time point (i.e. 0.083, 0.25, 24, 72,
96, 168, 240, 336 h), 600 .mu.L of blood were collected via cardiac
puncture and blood samples were then centrifuged (15 min at
4.degree. C. and 3500 tr/min). Quantification of ADC and total
antibody in plasma samples was performed using immunoassays. Plasma
concentration versus time profiles and PK parameters of conjugate
and total antibody in mouse were characterized using
non-compartmental analysis (Phoenix, WinNonLin version 6.3) and are
depicted in FIGS. 15 and 16. The area under the concentration-time
curve, AUC (.mu.gday/mL) was estimated by the trapezoidal rule.
Concentration at t=0 C.sub.0 (.mu.g/mL), Clearance CL (L/(daykg),
and terminal elimination half-life t.sub.1/2 (day) were derived and
calculated from the curve.
TABLE-US-00017 TABLE IX c.sub.0 AUC.sub.last t.sub.last AUC CL
V.sub.ss t.sub.1/2z Table IX Analytes (.mu.g/mL) (.mu.g day/mL)
(day) (.mu.g day/mL) (L/(day kg)) (L/kg) (day) Ex. 3 ADC 62.8 191
14 217.sup. 0.023 0.14 4.8 total 74.9 455 14 791.sup.a 0.0063.sup.a
0.10.sup.a 11.sup.a Ex. 7 ADC 81.8 235 14 266.sup. 0.019 0.12 4.8
total 77.4 368 14 741.sup.b 0.0067.sup.b 0.14.sup.b 16.sup.b
.sup.ainformative data only as AUC.sub.ext >> 30% (i.e. 42%);
.sup.binformative data only as AUC.sub.ext >> 30% (i.e.
50%).
Evaluation by HRMS of Plasmatic Stability of Cryptophycin ADC of
Formula (III) Following Single i.v. Administration in SCID Mice at
5 mg/kg
[1199] Plasma samples from the PK study were also analyzed by
LC-HRMS. The chromatographic analysis was performed on a Waters
Acquity I Class and a Waters Mass Prep Micro Desalting 20 .mu.m
(2.1.times.5 mm) column at 80.degree. C. with a gradient elution of
(A) water+0.1% formic acid/(B) CH.sub.3CN+0.1% formic acid
described below
TABLE-US-00018 Time (min) % B Flow (ml/min) 0.00 5 0.5 0.50 5 0.5
0.51 5 0.2 2.00 90 0.2 2.10 5 0.5 2.70 90 0.5 2.80 5 0.5 3.40 90
0.5 3.50 5 0.5 4.00 5 0.5
[1200] The mass spectrometry was performed on a Waters QTOF Synapt
G2-S machine with electrospray ionization in positive mode (ES+).
The mass spectra were deconvoluted with the Waters Biopharmalynx
software. HRMS spectra were obtained for all tested examples and
are depicted in FIGS. 20 to 25.
[1201] These results showed that all tested examples of the
invention didn't display the metabolization observed with reference
ADC, ADC1 and ADC2.
[1202] It is therefore apparent that the compounds of the invention
have an anticancer activity and that the conjugates of the
invention display an improved stability in mice plasma.
[1203] Accordingly, in another of its aspects, the invention also
relates to the use of cryptophycin compounds of formula (I) or of
the conjugates of formula (III) as anticancer agents.
[1204] The present invention, according to another of its aspects,
also provides medicaments which comprise a conjugate of formula
(III).
[1205] These medicaments are employed therapeutically, especially
in the treatment of cancer.
[1206] According to another of its aspects, the present invention
relates to pharmaceutical compositions comprising as active
principle a conjugate of formula (III) according to the invention.
These pharmaceutical compositions comprise an effective dose of at
least one conjugate of formula (III) according to the invention and
also at least one pharmaceutically acceptable excipient.
[1207] The said excipients are selected, in accordance with the
pharmaceutical form and method of administration desired, from the
customary excipients, which are known to a person skilled in the
art.
[1208] The present invention, according to another of its aspects,
also provides a method of treating the pathologies indicated above,
which comprises administering to a patient an effective dose of a
conjugate of formula (III) according to the invention.
* * * * *